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A series of platinum(II) aminophosphine complexes has been prepared and their 
interactions with nucleotides studied. Such complexes are potential anticancer 
agents combining cytotoxic phosphines with features of platinum am(m)ine drugs. 
Ligands of the form Ph 2P(CH2 ) 3NRR' have been prepared, where R and R' are alkyl 
groups of varying steric bulk. On complexation with platinum the ligands form six-
membered chelate rings bound via P and N and the extent of chelation has been 
shown to be controlled by the bulk of the substituents. Chelate formation is also pH 
dependent with low pH favouring a ring-opened structure due to protonation of the 
amine group. All the complexes formed were fully characterised by the use of 31 P 
NMR and X-ray crystallography. 
Nucleotides are ideal model compounds for studying the interactions of platinum 
complexes with DNA, the target for platinum drugs in vivo. The aminophosphine 
complexes prepared were reacted with four different nucleotides and their binding 
analysed by 'H NMR. Binding was most prominent to the nucleotides guanosine and 
thymidine. The complexes can bind two guanosine per Pt to form bifunctional 
adducts but with the other nucleotides only monofunctional binding was observed. 
The formation of these bound adducts was confirmed by electrospray ionisation mass 
spectrometry. The pH dependence of thymidine binding was investigated since 
binding occurs through the endocyclic N3 site which has a high PK a of Ca. 10. 
Although the extent of binding of the complexes decreased at low pH, the thymidine 
remained fully bound over an unusually wide pH range, 4-12. For the less sterically 
hindered complexes binding also decreased at low pH due to competition from 
chelate ring-closing reactions Competition reactions were carried out with the 
complexes and all four nucleotides together to determine the selectivity of binding by 
capillary electrophoresis. Surprisingly thymidine binding was as prevalent as 
guanosine. This is in contrast to Pt-am(m)ine anticancer complexes which have a 
much higher affinity for the purine bases than pyrimidines. 
0 
The binding of the complex [Pt{Ph2P(CH2 ) 3NMe2-P} 2 C1 2] to calf thymus DNA and 
synthetic polynucleotides was also investigated. The selectivity for thymine seen 
with individual nucleotides was not evident in polymeric DNA structures. The 
binding profile was however distinctly different to Pt(amine) complexes, in particular 
the rate of binding increased greatly. This is due to electrostatic interactions between 
the protonated amines of the ligands in the complex and the phosphate groups on 
DNA. 
In addition, the binding of the complexes to AZT (3'-azido, Y-deoxy thymidine) was 
investigated. AZT is an anti-HIV drug and it is predicted that Pt-AZT complexes 
could act as multifunctional antiviral agents incorporating the cytotoxic properties of 
the platinum complex. The binding profiles observed were similar to those for 
binding thymidine, with a pH dependence due to protonation of the N3 binding site. 
The adducts produced were monofunctional and existed as a mixture of 
diastereomers. 
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1.1.1 Discovery and Extraction 
Platinum (atomic number 78, mass number 195.08) is in Group 10 of the periodic 
table. Platinum-containing objects date back as early as 700 BC although Pt was not 
formally discovered until 1735 by the Spanish astronomer A. de Ulloa, in deposits 
from the Pinto River in Colombia, and brought to Europe. Platinum is typically 
metallic, a face-centred cubic structure with a silver-white appearance, and it is both 
malleable and ductile. Due to its inertness and high melting point (2045 K), platinum 
required complex aqueous chemical processing for isolation and identification. Thus 
few developments were made in its chemistry until the 19th  century, when powder 
metallurgical techniques were developed by Frenchman P. F. Chabeneau and later 
W. H. Wollaston in London. 1 
The abundance of platinum in the earth's crust is approximately 106%  by weight. 
Virtually all platinum comes from nickel or copper sulfide ores and must be 
selectively extracted from other Platinum Group metals (ruthenium, rhodium, 
palladium, osmium, and iridium). The world's major deposits of platinum are in 
Bushfeld-South Africa, Sudbury-Canada, and Norilsk-Talnakah-Russia. These 
deposits are exploited by underground mining and the sulfide ores concentrated by 
flotation separation. Copper and nickel sulfides are then leached out leaving a residue 
that is 15-20% platinum metals. This concentrate is dissolved in aqua regia 
dissolving only platinum and palladium. Platinum is then precipitated from the 
solution with ammonium chloride. The resulting salt is heated to give a crude 
metallic product which is purified by redissolving in aqua regia, reprecipitating with 
ammonium chloride and heating. The world production of platinum is currently 
about 90 tonnes per year. 
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1.1.2 Uses 
Platinum has widespread uses due to its various properties. Its lusterous appearance 
has lead to its use in jewellery for many centuries. It is usually alloyed with 
palladium or ruthenium for extra strength. More recently the most notable use is in 
catalysis, where about 42% of the platinum in the western world is employed. 2 Uses 
include cracking oil to form hydrocarbons, and as catalytic converters in the 
automotive industry. Here the platinum promotes the conversion of unburned 
hydrocarbons, carbon monoxide and nitric oxides to water, carbon dioxide and 
nitrogen. Due to its inertness, platinum also has widespread uses as electrodes, 
thermocouple elements, electrical contacts, wire and crucibles for laboratory use, 
dentistry, and coating for jet engine fuel nozzles. 
1.1.3 Chemistry 
Platinum has 6 isotopes: ' 90Pt and 192Pt account for less than 0.8% and are unstable 
a-emitters. 194Pt (32.9%), ' 95Pt (33.8%), 196Pt (25.3%) and 198Pt (7.2%) are stable 
isotopes. All the isotopes have nuclear spin quantum number of 0, except for 195Pt 
which has 1=1/2 making it useful for NMR observation. The electronic configuration 
of platinum is [Xe] 4f14 5d 6s', and it has an electronegativity of 2.28. 
The principal oxidation states of platinum are +2 and +4, although +1 and +3 are 
known in which M-M bonds are often present. 3 
Platinum(IV) complexes are octahedral and diamagnetic with t2g6  electronic 
configuration. They are thermodynamically stable and kinetically inert. Complexes 
with halide, pseudo-halide and N-donor ligands are especially numerous. K2PtCI 6 is 
the most common commercially available fonn, and is useful as a route into Pt(II) 
chemistry, by reduction with sulphur dioxide to K2PtC14 . 4 
Platinum(II) complexes are d 8 and also diamagnetic. They are principally square- 
planar as the splitting of the d-orbitals in this geometry provides the opportunity to 
2 
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place all 8 d electrons in four lower orbitals leaving the uppermost (dx2y)  orbital 
empty. For a 3rd row transition metal, the d-orbital splitting is sufficient to offset the 
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Figure 1.1 Effect of complexation on d-orbital splitting for Pt(II) 
Platinum(II) shows a low affinity for 0-donor and V ligands preferring heavier 
halogens and ic-bonding ligands. Platinum(II) complexes have played an important 
role in the development of various aspects of coordination chemistry, such as 




An important phenomenon of reactions of square planar complexes is the trans effect 
- the effect of a ligand on the rate of substitution of a ligand trans to it. Ligand 
displacement on Pt(II) occurs almost entirely by an associative pathway, via a 5-
coordinate intermediate. Generally the stereochemistry of the complex is retained 
but if the intermediate is sufficiently long-lived it can undergo pseudorotation 
leading to the opposite isomer (Figure 1.2). 
I'd 
C 	 C;Pt 







trans 	 trans 
Figure 1.2 Associative mechanism of ligand substitution in Pt(II) square-planar 
complexes 
The trans effect series in order of decreasing rate of displacement at trans position 
is5 : 
CO, CN, C2 H4 > PR3 , H - > CH 3 > C6 H 5 , NO2 , 0, SCN> Br, Cr> py, NH3 , 0H, H20 
The ligands exerting the strongest trans effect are those for which the bonding to 
Pt(II) is thought to have the most ic-acceptor character. This removes electron 
density from the metal and the reduced density on the opposite side means that 
nucleophilic attack is more likely to take place. The trans effect is a kinetic 
4 
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phenomenon affecting the rates of reaction and isomer formation. This series is 
useful in rationalising known synthetic procedures and devising new ones. 
A related property of ligands in square planar complexes is the trans influence. This 
is a thermodynamic effect of one ligand on the strength of the bond to the ligand 
trans to it. The series of ligands with decreasing trans influence is5 : 
H - > PR3 > SCN> 1, CH3 , CO, CN> Br> Cr> NH3 > OH 
This effect is greatest for ligands which are strong a-donors producing an axial 
polarisation of the platinum, the lone pair inducing a positive charge on the nearside 
of the metal and a concomitant negative charge on the far side. This will weaken the 
trans bond. The trans influence is apparent in ground state properties such as bond 
lengths, vibrational frequencies and NMR coupling constants. 
iW1tiii.iii 
Cancer is a group of related diseases characterised by uncontrolled multiplication and 
disorganised growth of the affected cells. 6 Normal mammalian cells divide only 20-
50 times before dying whereas cancer cells are said to be "immortal", they can go on 
dividing indefinitely if they have a continual supply of nutrients. Potential problems 
arise when a normal cell is transfomed into a cancer cell. If this cell evades the 
body's immune system it may proliferate to form a tumour, a mass of cancer cells 
within an otherwise normal tissue. If these cells remain at the original site, the 
tumour is said to be benign, such tumours can usually be removed by surgery and do 
not cause serious problems. If however, the tumour becomes invasive enough to 
impair the functions of one or more organs it becomes malignant. Invasiveness 
usually implies an ability to break loose, enter the blood stream or lymphatic vessels 
and form secondary tumours (metastases) at other sites in the body. The more 
widely a cancer metastasises, the harder it becomes to eradicate. 
5 
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It is now known that cancer can be caused by a number of factors 7 including a wide 
variety of chemical substances, various types of ionising radiation, and various 
classes of viruses. Cancer is a genetic disease; either defective genes are passed from 
parent to child, or a mutation occurs by activation of DNA tumour viruses forming 
an onocogene. These genetic mutations can lead to malfunctioning proteins that 
interfere with the cell cycle machinery. For example, the proteins necessary for cell 
division may be activated at the wrong time causing uncontrollable growth, or the 
proteins that halt cell growth may be inactivated or lost. As understanding of the 
causes of cancer increases, better methods of treatment can be developed. 
Cancers are classified according to the tissue and cell type from which they arise. 7 
Carcinomas derive from epithelial cells which comprise skin and the covering and 
lining of the organs and internal passageways. Examples include lung, breast, 
testicular and ovarian cancers. Sarcomas derive from connective or muscle tissue 
such as blood, bone, and cartilage. Other cancers do not fit in either of these broad 
catagories including leukemias, derived from hemopoietic cells in the bone marrow 
and lymph systems. 
1.2.1 Treatment of Cancer 
Successful treatment of cancer requires the complete removal or destruction of all 
cancerous tissue or the disease can recur. Three main types of treatment exist 7 . 
Surgery is the most effective form of treatment, although it is limited in that it 
must be performed before the cancer has spread into organs and tissues that cannot 
safely be removed. Surgery is often used in conjunction with another kind of 
treatment in order to help prevent remission. 
Radiation therapy makes use of ionising radiations - X-rays, electrons, neutrons 
and gamma rays. These generate reactive oxygen species in the body which lead to 
to DNA strand breaks, resulting in cell death. Precautions must be taken to shield 
and protect normal cells, which can also be killed. Some cancers however are not 
responsive to radiation, cells of differing origin have varying sensitivities. In 
addition to this individual cells within the same tumour may also have widely 
6 
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differing susceptibility to irradiation. Radio sensitisers are used to increase the 
damage to localised areas without having to increase the radiation dose. 
3. Chemotherapy uses synthetic chemicals and antibiotics that can differentiate to 
some extent between normal tissue cells and cancer cells. These agents are used to 
interfere at various points in the cell division process of cancer cells, preventing them 
from multiplying. Most drugs are limited in their usefulness by three factors. Firstly, 
most cancer drugs can only destroy the certain proportion of the cell population 
undergoing division at any one time, making it difficult to completely destroy a 
tumour. Another problem is that cancer drugs damage normal, as well as cancer, 
cells and tissues. Since the drugs target rapidly dividing cells (like cancers), healthy 
rapidly dividing cells such as hair follicles, the gastrointestinal lining, and bone 
marrow cells, are also open to attack. This results in the typical side-effects 
experienced with chemotherapy: hair loss, nausea and poor immuno-response. In 
addition, some cancer cells eventually become resistant to drugs. In order to 
overcome these three difficulties, combinations of chemotherapeutic agents that act 
on cells in different ways have been used in treatment programs simultaneously or in 
sequence. 
1.3 Platinum Anticancer Agents 
1.3.1 Discovery of Cisplatin 
Cis-diamminedichloroplatinum(II), cisplatin, is one of the most widely utilized 
antitumour drugs in the world and currently has annual sales of approximately $500 
million (U.S.). 8 ' 9 Although the compound was first synthesised in 184510  and known 
as Peyrone 'S Chloride, its cytotoxic activity was a serendipitous discovery in the 
1960's by Barnett Rosenberg at Michigan State University. Whilst investigating the 
effect of electric field on the growth of E. coli bacteria, Rosenberg noticed strong 
filamentous growth but no cell division." After further investigation, the cause of 
this phenomenon was determined to be the presence of small amounts of certain 
VA 
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platinum compounds formed by slow dissolution of the "inert" platinum electrodes 
used. 
	
electrolysis 	 NH4 
Pt(electrode) 	 Pt 	 Pt"(NH3 )2C14 
hv 
By synthesising and testing various complexes, Pt(NH 3)2C14 was found to be the 
active species. Other similar complexes were synthesised and tested and only 
complexes with a cis-geometry showed filamentous growth (Figure 1.3).12  The Pt 
(II) analogue cis-[Pt(NH 3)2 C12], now known as cisplatin, exhibited the greatest effect. 
H3 N\ /CI 	
H3NiCI 
Pt 	 Pt 
/\  
H3N 	CI 	H3 N/  
Cisplatin 
Figure 1.3 Platinum compounds identified as having antitumour activity 
Further investigations were carried out to test the postulate that if these complexes 
could stop cell division in bacteria at concentrations without marked toxicity, then 
perhaps they would stop cell division in rapidly growing tumours without 
unacceptable toxicity to the host animal. Rosenberg and his co-workers performed 
initial antitumour experiments on mice bearing Sarcoma 180 solid tumours and 
Leukaemia L1210. These demonstrated the potency of these complexes in the 
treatment of tumours.' 3 ' 14 In addition the drugs showed the ability to totally regress 




In 1971 the first clinical trials of cisplatin were initiated. 15  Approval of cisplatin for 
the treatment of testicular and ovarian cancer was given in 1978. Today it is 
routinely used in the clinic and is most effective against testicular and ovarian 
cancers. 16 Until the 1970's, testicular cancer was usually a fatal diagnosis, and fewer 
than 10% of patients enjoyed long-term survival. With the advent of aggressive 
chemotherapy, over 90% of patients can now expect to be cured. The most 
important contribution to this success is the development of cisplatin and its use in 
combination treatments for the disease. The response rates of other solid 
malignancies, such as head, neck, lung and bone tumours can also be improved with 
cisplatin treatment. 17  In combination with other antitumour drugs, such as 5'-
Fluorouracil, synergistic effects have been achieved.' 8 5 '-Fluorouracil interferes 
with excision repair and is thought to reduce the repair of cisplatin-induced DNA 
damage, thereby enhancing the cytotoxicity of cisplatin. 
A severe limitation of the clinical use of cisplatin has been its toxicity. Platinum 
compounds accumulate in the kidney and tubular damage is the major origin of 
cisplatin induced nephrotoxicity.' 9  Saline hydration and diuresis is used to reduce 
this nephrotoxicity, although this makes outpatient treatment impossible. 20  Other 
toxic side-effects, because of the high doses required, are bone marrow suppression, 
neurotoxicity, loss of high frequency hearing and gastrointestinal toxicity (nausea, 
vomiting, and diarrhoea). It is these side-effects which limit the dose of cisplatin 
which can be given to patients; typical doses are 100 mg/day for up to five 
consecutive days . 2 ' Resistance to cisplatin treatment also significantly limits cure 
rates. Some tumours have natural resistance to cisplatin whilst others develop 
acquired resistance after initial treatment. Several mechanisms for this resistance 
have been proposed and are discussed in detail in Section 1.3.2.4. 
These drawbacks associated with an otherwise highly successful drug have provided 
the impetus for the development of an improved platinum anticancer agent. Since 
the introduction of cisplatin, thousands of Pt compounds have been synthesised and 
their cytotoxicity evaluated. 
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1.3.2 Mechanism of Action 
It is generally accepted that it is the interaction of cisplatin with DNA that is 
responsible for its antitumour activity. This was suspected after Rosenberg's early 
experiments, since E. co/i cell division was stopped suggesting inhibition of DNA 
replication. Later biochemical studies measuring the uptake of radiolabelled 
precursors for proteins and nucleic acids confirmed this, showing only inhibition of 
DNA synthesis and not RNA or protein synthesis on administration of cisplatin. 22 
It is still unclear how cisplatin can cross the cell membrane to reach the target DNA. 
1.3.2.1 Hydrolysis 
In considering the in vivo interactions of cisplatin, it was first necessary to consider 
the effect of the biological environment on its structure. Since the dichloro form of 
cisplatin is relatively unreactive, it was soon realised that the hydrolysis of the 
complex to the more reactive aqua forms could be an important step in the action of 
the drug. Furthermore deprotonation of the aqua ligands is also then possible. 
Several studies have been carried out to determine the rate constants for the two-step 
aquation process and the PKa values for the acid-base equilibria of each aqua species. 
A summary of all these reactions is given in Figure 1.4 and the experimentally 
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Figure 1.4 Aquation-anation, and acid-base equilibia of cisplatin 
Rate/Equilibrium Constants 
k 1 [s'] (1.9 ± 0.2) x 10 
k 	[M's] (6.0 ± 1.5) x 102 
KI[M] 3.2x10 3 
k2 [s'] (2.3 ± 0.3) x 10 
k2 [M's] (9.8 ± 1.4) x 10 1 
K2 [M] 2.3 x 10 
Table 1.1 Aquation rate constants (k) and equilibrium constants (K) for cisplatin 23 
(see Figure 1.4) 
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Ref 	24 	25 	26 
pKai 	6.85 ± 0.1 6.41 ± 0.02 
pK.2 	5.93 ± 0.1 5.37 ± 0.09 5.24 ± 0.05 
pK.3 	7.9±0.1 	7.21±0.09 7.42±0.10 
Table 1.2 pKa values for acid-base equilibria of aquation products of cisplatin 24 ' 25 ' 26 
(see Figure 1.4) 
The discrepancies between the pKa values determined by various groups are due to 
differences in experimental conditions such as temperature and ionic strength. For 
this reason a set of "concensus" values can be drawn up for room temperature and 
physiological conditions. These values (pK a i = 6.6, PKa2 = 5.5, pKa3 = 7.3) and the 
rate constants quoted have been used to determine the proportions of each species 
which are present in vivo. 27  (Table 1.3) Two environments must be considered: the 
blood plasma since the drug is administered intavenously, and the cell where the 
drug reaches its target, DNA. The widely differing chloride concentrations in these 
two areas (plasma 104 mM, cell 4 mM) must also be taken into account. 
Ligands 
Plasma 
(104 mM CF) 
Cell 
(4 mM Cl-) 
Cr, Cr 0.67 0.03 
Cr' H20 0.04 0.05 
Cl- , Off 0.26 0.30 
H20 5  H20 1 x 10 0.003 
Off, H20 0.009 0.28 
Off, Off 0.012 0.35 
Table 1.3 Mole fractions of(NH3) 2Pt(II) species at pH 7.4, at plasma and 
intracellular chloride ion concentrations 
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The major species present in the cell are the chioro-hydroxo, aqua-hydroxo and 
dihydroxo complexes. These then are the most likely species that go on to interact 
with DNA. 
1.3.2.2 Platination of DNA 
As previously stated, the major target of cisplatin in the cell is DNA. Since 
platinum(II) behaves as a "class b" metal ion, it is expected to bind preferentially 
with the nitrogen atoms of the nucleobases. 28 Figure 1.5 shows a schematic structure 
of a single-stranded fragment of DNA containing the four common nucleobases with 
indications of their preferred metal binding sites . 2 ' After hydrolysis, binding of 
cisplatin occurs mainly at the N7 position of guanine bases, followed by adenine-N7, 
adenine-NI, and cytosine-N3, although the latter two are not usually accessible in 
double-stranded DNA as they are involved in base pairing to the complementary 
strand. Calculations of electrostatic potentials indicate that the guanine carbonyl 
group enhances the basicity of N7, while the amino group in adenine reduces the 
relative basicity. Also in double-stranded DNA, N7 of guanine is exposed on the 
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Figure 1.5 Schematic structure of 5'-CGAT DNA fragment showing ring numbering 
and metal binding sites (adapted from J. Reedijk, ref. 21) 
Several modes of binding of cisplatin to DNA are possible since the drug has two 
potential binding sites, with labile hydroxo ligands. These include intrastrand 
crosslinks, where the platinum binds to two bases on the same strand of the DNA, 
and interstrand crosslinks where the platinum binds to two bases on opposite strands 
of the DNA. Monofunctional adducts are also possible where binding to only one 
base occurs and the presence of S-donor ligands in the cell also gives the possibility 
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Figure 1.6 Some possible DNA-cisplatin adducts 
In order to determine which adducts of cisplatin are formed on DNA, experiments 
have been carried out using cisplatin-treated salmon sperm DNA. 29  Pt binding was 
studied by enzymatic digestion, chromatographic separation of products, and NMR 
analysis. The major products were 1,2 intrastrand crosslinks between adjacent bases 
(GpG or ApG), and other adducts formed were 1,3 intrastrand crosslinks/interstrand 
crosslinks (not distinguishable by method employed) and monofunctional adducts. 
The proportions of adducts observed are detailed in Table 1.4. 
Adducts % 
cis-[Pt(NH3)2 {dGpG}] 60-65 
cis-[Pt(NH 3)2 {dApG}] 20-25 
cis-[Pt(NH3)2 {dGpNpG} ] 
4-8 
or cis-[Pt(NH3)2 {dG} {dG} 
cis-[Pt(NIH3)2 {dG} Y] 2-3 
(Y = Cl-, H20, Off, protein) 




It is notable that although both d(GpG) and d(ApG) 1,2 intrastrand crosslinks are 
observed, there are no occurrences of d(GpA) crosslinks. Studies using cis-
[Pt(N}{3)2(H 20)2] 2  on various oligonucleotides have shown the following 30: the rate 
constants for platination of A are much lower than for G (this is due to the fact that G 
has the highest electron density on DNA  31 ) 3'-monoadducts chelate up to 10 times 
faster than 5' monoadducts (this could be due to the rigidity of the DNA and the 
relative distances to adjacent bases). These factors mean that in the GA case the rate 
of closure for the less nucleophilic A in the geometrically unfavoured 3' position to 
the Pt would be expected to be very low. This could account for the absence of the 
GA adduct. 
The mechanism of reaction of cisplatin has been investigated using "'Pt NMR 
spectroscopy.  32 -33  The hydrolysis reaction is the rate limiting step for DNA binding, 
the half-life being - 2h. Aquated cisplatin subsequently binds to an N7 atom of a 
guanine base in DNA, which displaces the water molecule in a relatively fast 
reaction step (half-life 0.1 h), forming a monofunctional adduct. Closure of the 
monofunctional adduct to form a bifunctional adduct involves hydrolysis of the 
second chloride ligand with a half-life of -j 2 h. 
By labelling cisplatin with 15NH3 ligands, the DNA adducts and intermediates can be 
characterised by NMR. 34 In the formation of the GG interstrand crosslink, the diaqua 
complex shows little selectivity for 5'G or 3'G in the initial platination step whereas 
the chioro-complex preferentially platinates the 3'G. However replacement of T by 
C at the 3' side of the GG site increases the selectivity of the diaqua by a factor of 6. 
Unexpectedly, the 5'G monoadduct is much longer lived (t1,2 4 h - aqua, t112 80 h 
- chloro) than the 3'G monoadduct 0112 :!~ 45 mm - aqua, t112 6 h - chloro) on a 
double stranded oligonucleotide, but the lifetimes of the two monofunctional adducts 
are the same on the GG single strand  .34  This suggests the three-dimensional 
structure of DNA plays a role in stabilising the 5'-G adduct either by shielding the Cl 
ligand from hydrolysis or, or by constraining the position of the incoming 3'-G N7 
ligand. 
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Since the most prevalent adduct formed on treatment of DNA with cisplatin is the 
1 ,2-intrastrand crosslink it was suggested that these may be important for anticancer 
activity. Many structural studies have since been carried out to determine the nature 
of this cisplatin adduct on double and single-stranded DNA fragments, these have 
recently been reviewed. 35 
The first X-ray crystal structures determined of cis-GG crosslinks were for the 
dinucleotide d(pGpG) 36 and the trinucleotide d(CpGpG). 37 The structures are shown 
in Figure 1.7, (A) and (B) respectively. The dinucleotide structure has the two 
guanine rings in a "head-to-head" configuration, with the two 06 atoms on the same 
side of the platinum coordination plane. The bases are forced to destack with an 
average dihedral angle of 81.10.  A hydrogen bond is also present between one of the 
platinum ammine ligands and an oxygen atom on the 5'-phosphate group. 
(A) 	 (B) 
Figure 1.7 (A) - X-ray crystal structure of d(pGpG) containing a cis-GG Pt adduct 
36 
(B) - X-ray crystal structure of d(CpGpG) containing a cis-GG Pt adduct37 
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To obtain structural information on the cisplatin adduct in longer oligonucleotide 
structures, gel electrophoresis studies were initially employed. 38 These indicated a 
bending and unwinding of the DNA duplex structure. This was then followed by 
several high-resolution X-ray and NMR structural studies. Figure 1.8 shows a 2.6 A 
resolution X-ray structure of a DNA dodecamer duplex containing a 1 ,2-intrastrand 
crosslink. 394° The structure contained two molecules in the asymmetric unit with 
very similar structures. The two duplexes show a significant bend towards the major 
groove (39 0 and 550). The dihedral angle between the guanine bases is 30 0 , 
considerably less than that seen in the d(pGpG) structure. However, the ammine-
phosphate hydrogen bond is conserved. The base pairs at the platination site are 
propeller-twisted, but retain their hydrogen bonds. The platinum is displaced from 
the planes of the guanine rings by 1 A resulting in a strained square-planar 
environment for Pt(II). The conformation of the DNA alters at the site of platination. 
In the 5' direction it adopts the A-form with the sugar rings in a C3' endo 
configuration, while in the 3' direction it is B-form with a C2' endo sugar pucker. 
An overall consequence of the platinum binding is a widened shallow minor groove, 
a feature that may be important for protein recognition and anticancer activity. 
An NMR structure of the same platinated dodecamer duplex has been determined 
allowing comparison of solid and solution phase structures. This structure (Figure 
1.9)41 shows an overall helix bend of 780 and the dihedral angle between adjacent 
guanines was 47° . These values are larger than those observed for the crystal 
structure reflecting the influence of crystal packing. The base pairing is also more 
distorted in the solution structure. The platinum still shows distorted geometry and 
the overall helix structure is similar with a wide flat minor groove. Other NMR 
duplex structures have been determined for a platinated octamer 42 and a palindromic 
dodecamer. 43 The major features of all these structures are compared in Table 35 
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Figure 1.8 X-ray crystal structure of tPt(NH3)2} 
d(CCTCTG*G *TCTCC ).d(GcIAGAccAGAGc), containing a cis-GG adduct where G* 
represents platination site (PDBID I GPG) 394°  
Figure 1.9 NMR solution structure of (Pt(NH3)2) 
d(CCTCTG*G*TCTCC).d(GGAGACCAGAGG), containing a cis-GG adduct where G* 
represents platination site (PDBID 1A84) 4 ' 
19 
Introduction 
Structure reference 39,40 41 42 43 
Sequence d(CCTCTGGTCFCC) d(CCTCTGGTCTCC) d(CCTGQTCC) d(CTCTCGGTCFC) 
d(GGAGACCAGAGG) d(GGAGACCAGAGG) d(GGACCAGG) d(OAGAGCCAGAG) 
Method X-ray NMR NMR NMR 
DNA form A/B junction primarily B primarily B primarily B 
Minor groove width/depth (A) 9.5-11.0 / 3.0 9.4-12.5 /1.4 4.5-7.8 / 3.2 9.0-12/2.1 
Average P-P distance (A) 5.5 6.9 6.8 6.8 
Roll at platinated 
26 49 42 59 
bases (°) 
Pt atom displacement from 1.3 - 5' 0.8 - 5' 1.0 	- 5' 0.5 - 5' 
guanine ring planes (A) 0.8 - 3' 0.8 - 3' 0.8 - 3' 0.65 - 3' 
Average helical twist (°) 32 25 25 26 
DNA bend (0) 39,55 78 58 —81 
Table 1.5 Selected structural parameters of GG cisplatin-DNA adducts 
The octamer structure shows an interesting rearrangement from the 1,2 intrastrand 
crosslink to a more stable interstrand crosslink promoted by the presence of a 
nucleophilic chloride ion .42  Structures of some minor cisplatin-DNA adducts have 
also been determined including an interstrand crosslink44 and a 1,3 intrastrand 
crosslink. 45 
In conclusion these high resolution studies all indicate that the major 1,2 intrastrand 
crosslink of cisplatin affords a bent and unwound duplex with a wide, shallow minor 
groove, unlike any other cisplatin adducts. This specific feature could be significant 
in cisplatin's anticancer activity. 
1.3.2.3 Recognition of Cisplatin-DNA Adducts 
A number of proteins has been identified which show affinity towards cisplatin 
modified DNA and have recently been reviewed. 46 A large family of related proteins 
with the ability to bind to cisplatin adducts is the HMG (High Mobility Group) 
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proteins. The binding ability was discovered 10 years ago during initial screening 
experiments. Two species were identified, of molecular mass --100 kDa and 28 kDa, 
which bind to double-stranded DNA modified with cisplatin. In the same study two 
cDNA clones were isolated from a human B-cell cDNA library which encoded 
portions of a protein that bind specifically to the cisplatin adduct. This ultimately led 
to the isolation and characterisation of a full-length human cDNA clone that coded 
for a structure-specific recognition protein (SSRP). This protein contained a number 
of highly-charged domains, including the 75 amino acid DNA binding region known 
as the HMG domain. Although these domains had been shown to bind specific DNA 
sequences; this work demonstrated that such a domain could also recognise 
specifically DNA having altered structures. These initial experiments suggested that 
HMG-domain proteins were strong candidates for binding preferentially to cisplatin-
modified DNA and perhaps affecting its biological properties. 
Proteins in the family can contain multiple HMG domains. They bind in the minor 
groove of DNA and bend DNA on binding. HMG1 is a chromosomal protein 
containing two prototypical HMG domains, A and B, both have three cc-helices 
forming an L shape with _800  between the arms. The NMR solution structure of 
domain A is shown in Figure 1.10(A). 47  This L-shape seems to be common amongst 
HMG domains and may be necessary for positioning on the DNA. The binding 
affinity of HMG1 towards a series of cisplatin-modified 15-mer DNA duplexes 
d(CCTCTCN 1 G*G*N2TCTTC).d(GAAGAN3CCN4GAGAGG) has been 
investigated and shown to be highly dependent on the bases adjacent to the Pt-
lesion . 48 The affinity for HMG domain A decreases by over two orders of magnitude 
in the order N2 = dA > T > dC. When Ni = N2 = dA, Pt DNA binds 100-fold 
stronger to HMG  domain A then to domain B. Several studies show that binding of 
HMG full-length protein or individual domains can further bend the kinked DNA 
structure by up to 90 0. A recent X-ray crystal structure has been determined of the 
HMG1 domain A bound to a 16-bp DNA probe, containing a cis-GG adduct.49 
(Figure 1.10 (B)) This structure shows that the protein binds through its concave 
surface and bends the DNA by —61 ' The protein bend is offset from the platination 
site, by 2-bp to the 3' side. The protein intercalates a Phe side chain into the DNA, in 
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a hydrophobic section in the minor groove opposite the platinum adduct. The 
geometry of the platinum site is less constrained than in either the X-ray or NMR 
structures of the cisplatin-modified duplex. 
Several mechanisms have been considered for how HMG-domain proteins might 
modulate the sensitivity of cells to cisplatin. Two of the more prominent hypotheses 
are as follows. 
The cisplatin-DNA adducts hijack proteins away from their normal binding sites, 
thereby disrupting cellular function. Since many HMG-domain proteins function 
as transcription factors, their removal from promoter or suppresser sequences by 
binding to cisplatin-DNA adducts could severely alter tumour cell biology. 
HMG-domain proteins block cisplatin-DNA adducts from damage recognition 
needed for repair. This would result in diminished repair of the adducts, and 
persistence of platinum on the DNA would lead to cell death. 
The hypotheses are not mutually exclusive and could both contribute to cisplatin 
cytotoxicity. Although it remains to be proved that HMG proteins are important 
mediators in cisplatin activity, a large body of experimental evidence points to their 
likely importance. 46 Recently S. J. Lippard's group have described work 50 in which 
human cancer cells with steroid hormone receptors, have been treated with the 
appropriate hormone estrogen and/or progesterone. The potency of cisplatin and 
carboplatin to these cells is then increased by causing overexpression of the HMG1 
protein. This could have major implications in the treatment of ovarian and breast 
tumours which carry the hormone receptors. 
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(A) 	 (B) 
Figure 1.10 (A) The NMR refined structure of HMG1 protein domain A (PDBID- 
IAAB)47 (B) The X-ray crystal structure of HMG  domain A bound to a 16-mer 
containing a cis-GG adduct (PDBID- I CKT)49  
In over 35 years of research since the discovery of cisplatin, much has been 
elucidated about the anticancer activity of the complex. Although this research is far 
from complete, the information gathered so far is useful for the design of new more 
powerful drugs with the aims of reducing toxic side-effects, improving the spectrum 
of activity and overcoming resistance. 
1.3.2.4 Resistance to Cisplatin Treatment 
Resistance to cisplatin can be both natural and acquired. Some tissues are inherently 
resistant to cisplatin and do not respond to treatment, whilst other types, such as 
ovarian cancer may respond initially to treatment but acquire resistance over time. 
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Cisplatin-resistant cells can be made through repeated exposure to the drug. 
Comparison between parental and resistant cell lines then provides an insight into the 
mechanism. Three main processes have been proposed for cellular resistance and it 
is likely that a combination of these factors plays a role. These processes have been 
comprehensively reviewed 5 ' and are discussed below. 
Changes in intracellular accumulation of the drug - A number of studies on 
ovarian cell lines have shown significantly reduced accumulation of platinum 
inside resistant cells by up to 50%. This is due to either reduced intake or 
enhanced efflux of cisplatin. This feature is not consistent in all resistant cell 
lines however and cannot be the sole cause of resistance. A P-glycoprotein, found 
in multi-drug resistant cell lines, has been found to act as a pump, which prevents 
the accumulation of drugs in the cell. 
Increased production of intracellular thiols - The affinity of platinum ions for S-
donor ligands suggests that cisplatin may bind to intracellular peptides such as 
glutathione (GSH) and metallothionein (MT), thus preventing or reducing 
binding to DNA. Elevated levels of GSH or MT have been observed in some 
cisplatin-resistant cells. The role of S-peptides in transport of platinum drugs can 
not be ruled out as it has been shown that sulphur-containing ligands (kinetically 
preferred) can be displaced by nucleotide/DNA binding (thermodynamically 
more favoured) in platinum (II) complexes. 52 
Increased capability of cells to repair cisplatin-DNA damage - Numerous 
experiments have revealed enhanced DNA repair in cisplatin-resistant lines, 
however increased repair does not always correlate with the level of cisplatin 
resistance. 
From the experimental results reported so far, the mechanism of cisplatin resistance 
appears to be to be complex and multifactorial. More work must be done to solve 
this important problem if the goal of overcoming cisplatin-resistance is to be realised. 
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1.3.3 Development of New Platinum Drugs 
Since the introduction of cisplatin there have been many attempts to design improved 
platinum anticancer agents. This is because the applicability of cisplatin is still 
limited to a relatively narrow range of tumours, resistance is a major problem and the 
major toxic side-effects are dose limiting. Cisplatin also has limited solubility in 
water and must be administered intravenously making it inconvenient for outpatient 
oral treatment. Although many compounds have been made and their antitumour 
activity tested, very few make it into clinical trials. 
1.3.3.1 	Classical Structure-Activity Rules 
The initial criteria deemed necessary for activity of platinum complexes were derived 
from early systematic studies. Various factors must be considered in the structure of 
an active compound. Firstly the geometry of the complex. This was thought to be 
limited to cis-compounds by Rosenberg's initial results. Secondly, the nature of the 
leaving groups determines the reactivity of the complex. If they are too labile (for 
example nitrate ligands) the complex is too toxic, binding to other biomolecules in 
vivo before reaching the active site. However, if the leaving ligands are too strongly 
coordinating (e.g. iodide), the complex will not bind to DNA and will be inactive. 
The non-leaving groups (amines) also have a large effect in activity as they can exert 
steric hindrance on the platinum centre controlling the rate of substitution. The H-
bonding ability of the amines can also be important as well as their trans effects, in 
controlling the binding properties of the complexes. The oxidation state of the 
platinum is also a factor since platinum(IV) compounds are far more inert in vivo 
than their platinum(II) counterparts. 
The requirements for an active complex were determined to be: 53 
1. A cis-complex of the form PtX 2(amine) 2 for Pt(II), and PtX 2(amine)2Y2 for 
Pt(IV), (with Y ligands trans) 
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The X ligand (leaving group) should be an anion with intermediate binding 
strength such as Cl - , citrate, oxalate, and other carboxylic acid residues. The Y 
ligands can be Cl, Off, or 0(C0)CH 2+ , 
The complex should be uncharged, as it is believed they are taken into the cell by 
passive transport through the lipophilic cell wall, a pathway less available to 
charged compounds. 
The amine should possess at least one N}l moiety, necessary for H-bonding 
interactions with DNA. These H-bonds (to 06 of guanine or the 5'-phosphate 
group) are important thermodynamically to stabilise the DNA adduct, and 
kinetically, directing the platinum to the N7 position. 
1.3.3.2 Second Generation Platinum Anticancer Agents 
Although over 28 complexes have entered human trials the only one to have received 
worldwide approval and achieved routine clinical use apart from cisplatin is 
Carboplatin, {diammine(cyclo-butanedicarboxylato-0,0')platinum(II)], (Figure 1. 11, 
complex 1). The greater chemical stability of this complex, compared to cisplatin, 54 
results in slower hydrolysis reactions. 55  It therefore shows a lower reactivity towards 
biomolecules leading to reduced side-effects in vivo. This means higher doses of up 
to 2000 mg/dose can be administered. 2 ' Other clinically approved compounds are a 
glycolato complex, nedaplatin and an oxalato complex, oxaliplatin (Figure 1. 11, 
complexes 2 and 3). These have been approved for clinical use in Japan and France, 
respectively, and are particularly effective in combination chemotherapy for 
advanced lung, colorectal and ovarian cancers. 56  These classical compounds show 
no major advantages over cisplatin and so the search continues for new active agents. 
One approach is to develop sterically hindered complexes, an example being cis-
amminedichloro(2-methylpyridine)platinum(II) (ZD0473, Figure 1. 11, complex 4). 
This was rationally designed to circumvent resistance by hindering substitution by 
GSH and other cellular thiols while retaining the ability to form cytotoxic lesions 
with DNA. The crystal structure of the complex shows the pyridine ring to be tilted 
out of the platinum plane by 102.7 ° placing the methyl group directly over the square 











the platinum, inhibiting the formation of the five-coordinate intermediate. In vitro 
studies of ZD0473 showed it to be active in cisplatin-resistant cell lines. The 
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Figure 1.11 New platinum anticancer agents, clinically approved or in human trials 
The desire to develop an orally active Pt drug has reinitiated the interest in Pt(IV) 
compounds. The complex JIM2 16 (Figure 1. 11, complex 5), in currently in phase II 
clinical trials and shows increased in vitro and in vivo activity against human 
cervical, small cell lung, and ovarian carcinoma cell lines. 56 Since Pt(IV) 
compounds are much more inert to ligand substitution than Pt(II), it is generally 
believed that they are reduced to Pt(II) by extracellular and intracellular agents prior 
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to reaction with DNA. The electron-withdrawing ability and steric hindrance of the 
axial and carrier ligands have a large influence on the redox process and biological 
activity of these complexes. 
1.3.3.3 New Rule-Breaking Platinum Compounds 
More recently a number of complexes which do not adhere to the classical structure-
activity relationships, has been shown to exhibit antitumour activity. 56 
Since the in vivo behaviour and mechanism of actions of these complexes is expected 
to be completely different from those for cisplatin or carboplatin, it is hoped that they 
could overcome platinum resistance in tumours and be applicable to a broader range 
of cancers. 
Most of the previous work on the design of platinum complexes has concentrated on 
cis complexes since the early discovery, by Rosenberg, that trans-[Pt(NH3)2C12] was 
inactive. However, since the report that trans-[Pt(yridine)2C12] is potently 
cytotoxic, 58 there has been renewed interest in the trans geometry. It is now believed 
that the higher kinetic reactivity of transpiatin compared to cisplatin leads to its 
deactivation by reactions with biomolecules in vivo. It is then possible to design 
complexes using sterically hindered ligands to reduce the reactivity of the Pt. The 
trans complexes are not capable, sterically, of forming the cisplatin-like 1,2-
intrastrand crosslinks, they form mainly interstrand crosslinks. In this way trans 
complexes could overcome cisplatin resistance. Several groups have persued this 
concept of activating the trans geometry. 
Farrell and colleagues have compared the cytotoxicities of three series of trans 
complexes with the general formula [PtC1 2(L)(L')] where: (i) L = L' = pyridine, N-
methylimidazole, thiazole, (ii) L = quinoline, and L' = RR'SO (R = methyl, and R' = 
methyl, phenyl, benzyl), (iii) L = quinoline and L' = NH3. 59  Examples are shown in 
Figure 1. 12, complexes 6, 7 and 8 respectively. The Pt compounds in these three 
series showed comparable activity to cisplatin in sensitive cell lines and also activity 
in cisplatin-resistant cell lines. 59  Interestingly they also showed higher activity than 
their cis counterparts. In particular the complexes showed activity in cisplatin 
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resistant cell lines where the mechanism of resistance was known to be due to 
reduced Pt accumulation and enhanced removal of and/or increased tolerance to Pt-
DNA adducts. Kelland et al.60 have shown that a series of Pt(II) and Pt(IV) 
complexes of the type trans-[Pt(NH3)(RN}1 2)C12] and trans, trans, trans-
[Pt(N1F13)(RNH2)(OH)2 C12] are highly active in vitro, where R = cyclohexyl (JM335) 
activity is comparable to cisplatin (Figure 1.12, complex 9). Coluccia et al. have 
also demonstrated the activity of the trans geometry with a series of Pt(II) complexes 
with iminoether ligands. 6 ' For example, trans- [Pt {E-HN=C(OMe)Me}2C12 (Figure 
1.12, complex 10) has much higher antitumour activity than its cis-analogue. The 
mechanism of action appears to different to that of cisplatin and may be related to the 
properties of the imino ether ligands. 62 Although these trans complexes react with 
DNA more slowly than cisplatin, they achieve the same level of DNA binding after 
24h. The trans EE complex is the most effective in inhibiting DNA synthesis and 
cell proliferation, but does not induce large local DNA conformational changes. 63 
Another approach to the design of complexes that form radically different Pt-DNA 
adducts is the use of multinuclear complexes with bridging linkers. 53, 56 Farrell and 
colleagues have been most active in this area investigating complexes of the form 
[{PtCl m(NH3 )3m}H2N_R_NH2_{PtCln(NH3)3n}1[(2 m) 2  (m or n = 0-3, and R is a 
linear or substituted aliphatic linker). The most successful of these complexes is 
BBR3464.64 (Figure 1. 12, complex 11) The central Pt moiety has no leaving groups 
and is capable only of forming hydrogen bonds with DNA. The high charge greatly 
enhances DNA affinity, with the major adduct formation being long-range 
interstrand crosslinks up to 6 base-pairs apart with significant unwinding and 
efficient, irreversible B- to Z-DNA conversion. These adducts terminate DNA 
synthesis in vitro. In preclinical trials this compound has exhibited a complete lack 
of cross-resistance to cisplatin-resistant cell lines. It is also significantly more potent 
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Figure 1.12 Antitumour-active platinum compounds, not adhering to classical 
structure-activity relationships 
There is good hope that these new classes of compounds may help to expand the 
realm of platinum chemotherapy treatment. 
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1.4 Phosphines in Medicine 
1.4.1 Chemistry of Phosphines 
In mammalian systems, the chemistry of phosphorus is entirely that of the P(V) 
oxidation state and the whole of biology revolves around phosphate and its 
derivatives. The term "phosphine" describes both PH 3 and its substituted derivatives 
PH2R, PHR2, and PR3 . The most dominant characteristic of all phosphine 
compounds is the presence of the lone pair of electrons on P. These compounds can 
therefore act as both nucleophiles and bases. The P atom is larger and less 
electronegative than N and therefore has higher nucleophilic reactivity than the 
analogous nitrogen compounds. This high nucleophilicity and formation of strong 
bonds to C, N, 0, or S, have made them one of the most widely used class of regents 
in organic synthesis. In addition, phosphorus has the ability to expand its valence 
shell to ten electrons and thus trivalent phosphorus compounds can also behave as 
electrophiles. This is generally only seen for PR 3 compounds containing electron-
withdrawing substituents (e.g. Cl, F). One of the most common features of tertiary 
phosphines is the formation of very strong P=O (phosphoryl) bonds, with energies 
lying in the range 534 to 582 kJmol 1 . 65 This bond formation can act as the driving 
force for many phosphine reactions. 
Complexes of phosphines with virtually every transition metal have be shown to 
form, making them one of the most versatile and commonly encountered ligands 
available. 66  The electronic versatility of phosphines, mentioned above, makes it 
possible to bind to metals in both very high and low oxidation states (+IV to —I). The 
biological activity of phosphines may be related to their ability to coordinate to 
metals in critical sites, but whilst the chemistry of phosphines and metal phosphine 
complexes has been well studied their biological properties have not. 
1.4.2 Gold Antiarthritic Drugs 
The chemistry of gold drugs has recently been comprehensively reviewed. 67 Gold 
has been used in the field of medicine from as early as 2500 BC in Chinese and 
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Arabic traditions as a "cure-all" treatment. In 1929, Forestier discovered that gold 
was effective for the treatment of rheumatoid arthritis 68 , but it was not until 1960 that 
controlled clinical trials were able to prove the efficacy of gold therapy. 67  A number 
of injectable gold thiolate compounds are now in clinical use for very difficult 
arthritis cases. (Examples are shown in Figure 1. 13, structures 12 and 13). These 
complexes are now known to be polymeric in the solid state and solution, forming 
ring or chain structures .69' 70  The drugs have some side effects associated with their 
use, the most severe being exfoliative dermatitis, bone marrow suppression, and 
nephrosis. 67 In the mid 1960's a search was undertaken by the Smith Kline and 
French company to find an orally active drug to overcome these problems and those 
associated with painful intramuscular injections of the thiolate compounds. It was 
hoped this would allow blood levels of gold to be maintained with a low daily dose, 
preventing the accumulation of gold in tissues following the large injected doses. 
Several gold(I) phosphines were found to have oral activity in animal models, 
including Et3PAuC1 and (Et3P) 2AuCl, but these had severe side effects . 7 ' Eventually 
a tetraacetylthioglucose derivative, auranofin (Figure 1. 13, structure 14) was 




S—Au I in [ HO 	 OH n 








(14) auranofin (Ridaura) 
Figure 1.13 Clinically approved gold antiarthritic drugs (Tradename) 
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Ligand-exchange reactions of linear gold(I) complexes are facile, via an associative 
mechanism with a 3-coordinate intermediate. The Au-P bond is strong but the thiol 
ligand can easily be displaced in vivo by sulfur containing serum proteins. Over 80% 
of gold in circulation in the body after administration can be found bound to albumin 
at Cys-34 72 (the only one of the 35 Cys residues not oxidised in a disulfide bond). 
The high affinity of Cys-34 for Au(I) is consistent with its reported low pK sH (Ca. 
5.5). Once the gold is bound to the albumin, the phosphine can be displaced by 
another ligand such as CN (this may affect the rate of gold metabolism in smokers). 
The free phosphine can then reduce a disulfide bridge in the albumin to free thiols 
which are then available to bind more drug. 73  This results in a series of gold-albumin 
complexes with variation in the position of gold binding determined by which of the 
disulfide bridges is oxidised. This illustrates the trans effect resulting in labilisation 
of the phosphine. After loss of the phosphine, the products from metabolism of 
auranofin could be similar to the products from gold(I) thiolate drugs. The 
phosphine ligand therefore may influence the distribution of gold in vivo without 
necessarily contributing to the antiarthritic activity of the complex. 
1.4.3 Cytotoxicity of Gold-Phosphine Complexes 
1.4.3.1 	Auranofin and its Analogues 
Lorber and co-workers first demonstrated that auranofin exhibited cytotoxic activity 
to human cell lines in culture and increased the survival time of mice with P388 
leukaemia. 74 Further studies showed that while it has potent cytotoxicity against a 
variety of cell lines in vitro, it is active only against the P388 tumour model in vivo. 75 
It is therefore not useful as an anticancer agent, and a large number of other gold(I) 
phosphine complexes of the form R 3PAuX have had their cytotoxicity evaluated. 76 
These all exhibited potent cytotoxicity in vitro. In vivo the activity was related to the 
leaving group, X, being lowest when X was a good leaving group (e.g. Cl - or NO3). 
These complexes are very reactive to thiols and it is likely the trans ligand will be 
rapidly displaced by —SH groups in vivo so that R3PAu- will bind to proteins and be 
prevented from reaching intracellular targets. Indeed, the cytotoxic potency of 
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auranofin to cultured tumour cells in vitro has been shown to be reduced ten-fold 
when the culture medium contains serum proteins, suggesting gold-protein binding 
can be correlated with loss of activity. 75 
It appears that the phosphine is responsible for the anticancer activity of these 
complexes since replacement of the phosphine with another thiolate group gives 
complexes with at best marginal activity in vivo. Over 150 free tertiary phosphines 
have been tested for anticancer activity but again none showed more than marginal 
activity. 77  It is likely that phosphines will be rapidly oxidised in vivo, since they are 
very good reducing agents, and this could inactivate them. It is possible that 
coordination to gold(I) may protect the phosphine from unfavourable oxidation 
allowing it to be carried to the target site. 
1.4.3.2 Diphosphine Chelated Gold Complexes 
In order to design gold(I) phosphine complexes with increased activity, it was 
therefore necessary to design complexes with increased stability, less reactive to 
ligand exchange reactions. In this way binding to serum proteins can be prevented 
allowing the active component to reach its target. This has been achieved through 
the use of tetrahedral gold(I) complexes. In contrast to linear Au(I) complexes these 
do not undergo ligand exchange via an associative mechanism but by a dissociative 
mechanism, since no 5-coordinate intermediate is observed. The use of a 
diphosphine chelating ligand introduces further stability to the complexes because 
ligand exchange will also require a ring-opening mechanism. 31 P NMR studies 
showed the existence of such a four-coordinate gold complex, [Au(dppe) 2]Cl, (dppe 
= 1 ,2-bis(diphenylphosphino)ethane), along with free dppe in a solution of the 
bridged compound C1Au(Ph2P(CH2)2PPh2)AuC1. 78 Furthermore this complex 
appeared to have high kinetic stability and was stable at room temperature. Since 
this discovery, both five- and six-membered rings have been shown to form readily 
on Au(I) with phenyl-substituted diphosphines 79 whilst bisphosphines with longer 
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chain length prefer to form annular 3-coordinate gold dimers or bridged digold 
species with trigonal and linear coordination geometries respectively. (Figure 1.14) 
[Au(dppe)2]Cl is much less reactive to ligand exchange than auranofin and 
consequently exhibits a wider spectrum of anticancer activity, including activity in a 
cisplatin resistant cell line. Moreover, [Au(dppe) 2]Cl and cisplatin can be 
administered concurrently at their respective maximum tolerated doses to tumour 
bearing mice with no lethality. This combination of treatment is more effective 
against moderately advanced P388 leukaemia than cisplatin alone, 80  indicating that a 
different mechanism or site of action is involved. 
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Figure 1.14 Structures of cytotoxic Au(I) diphosphine complexes: 
(A) tetrahedral gold bisdiphosphine, (B) annular digold bisdiphosphine, 
(C) bridged linear digold diphosphine 
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The series of free ligands, Ph2P(CH2)PPh 2 , and dppe-bridged digold complexes of 
diphosphine ligands exhibit a pattern of activity towards P388 leukaemia similar to 
that of [Au(dppe) 2]Cl, although the complexes are much more potent (lower doses 
for same activity) than the free ligands. 8 ' Again this can be attributed to oxidation of 
the free phosphines, reducing their activity. The cytotoxicities of all the Au-
phosphine complexes studied have been compiled and reviewed in references 67 and 
77. In general the most active complexes seem to be those where the phosphines 
contain 2 or 3 carbon atoms in the bridge or where the bridge is cis-ethylene. These 
ligands are all capable of forming 5- or 6-membered chelate rings suggesting the 
mechanism of action may involve chelation of metal ions in vivo. Activity is lost if 
the phenyl groups on the phosphines are replaced by ethyl groups, but is retained if 
the gold(I) is replaced by silver(I) or copper (I). [Au(dppe) 2]Cl was the most potent 
diphosphine compound of those tested. 
1.4.3.3 Mechanism of Action 
[Au(dppe) 2]C1 shows very different cytotoxic effects to auranofin indicating a 
different mechanism of action. The complex is known to induce DNA-protein 
crosslinks and DNA single strand breaks when incubated with L 1210 cells. 80  The 
strand breaks are only significant at lethal concentrations but the crosslinks occur 
within the cytotoxic concentration range of the complex. The mechanism of action 
for these complexes is still not well understood but many have been postulated. The 
high kinetic and thermodynamic stability of these complexes along with their high 
lipophilicity is likely to mean that they can penetrate cells intact. It is still believed 
that the phosphine is the active component in the compound so the Au-P bond must 
be sufficiently labile to allow release of the phosphine at the target site. Since 
chelation of metals also appears to be involved in the mechanism of action, binding 
to copper may have an important role. Indeed, the cytotoxic potency of 
[Au(dppe) 2]Cl is significantly increased in the presence of Cu-salts whereas Mg(II), 
Fe(II), Co(II) and Cd(II) have no effect. 82 Since phosphines readily reduce Cu(II) 
salts to Cu(I), chelation of copper could have major implications in Cu metabolism in 
the cell. Copper has previously been implicated in the anticancer activity of several 
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other chelating agents. Since Au is a soft metal, it has a high affinity for sulfur-
containing ligands so many proteins could be bound in vivo. It is notable that many 
nucleic-binding and gene-regulatory proteins contain sites with multiple Cys 
residues, these could receive Au(I) or Cu(I) ions with functional consequences to the 
cell. It is possible that diphosphines could even remove metal ions from 
metalloproteins and metalloenzymes or act as inhibitors by binding to metal ions in 
active sites. 
1.4.3.4 Development of New Phosphine Drugs 
In preclinical trials [Au(dppe) 2]Cl exhibited cardiac, hepatic and vascular toxicity. 83 
For this reason no diphosphine gold(I) complex has entered full clinical trials as yet. 
These side effects have been attributed to the ability of the complex to uncouple 
oxidative phosphorylation in mitochondria and rapidly destroy the electrochemical 
potentials across the inner mitochondria membrane. 84  This has the effect of 
2+ 	+ increasing the permeability of the mitochondrial membrane to cations (e.g. Ca , K ) 
disrupting the function of the mitochondria. 
This toxicity towards mitochondria can be utilised in the design of new anticancer 
agents. Gold-diphenylphosphine complexes are extremely lipophilic and so non-
selectively target mitochondria in all cells leading to the unwanted side effects 
described above. Recent work has been undertaken with the aim of modifying the 
ligands in metal complexes related to [Au(dppe) 2]Cl, in order to vary the hydrophilic 
character of the complex and achieve greater selectivity for tumour cells versus 
normal cells. Such lipophilic cations still target mitochondria but exhibit preferential 
cytotoxicity in carcinoma cells with hyperpolarised membranes. Recent results with 
[Au(dppe) i]Cl analogues, in which some or all the aromatic groups have been 
replaced by hydrophobic pyridyl groups, have shown that the position of the N atom 
in the pyridyl ring finely modulates this lipophilic-hydrophilic balance and greatly 
affects the cytotoxicity of the complex. 85 
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Aminophosphine complexes of platinum(II) combine two important characteristics - 
platinum bound amino groups of classical am(m)ine anticancer agents, and aryl 
phosphines as in the previously described cytotoxic gold complexes. In this manner 
it is possible to envisage complexes of this kind acting as multifunctional drugs 
which can exhibit antitumour activity via two different mechanisms. 
1.5.2 Chemistry of Aminophosphine Complexes 
Aminophosphines are mixed donor ligands containing a soft phosphorus donor and a 
hard nitrogen donor. They can therefore be chelating ligands conferring high 
stability to a metal complex. In complexes with platinum(II), a soft metal, the 
nitrogen atom binds more weakly than the phosphorus especially when the N is in a 
trans position to a P, which exerts a high trans influence. 86  Furthermore the strength 
of the M-N bond is affected much more by steric factors than that of the 
corresponding M-P bond .87  Variation of the chain length in the ligand (and hence 
size of chelate ring) along with the substituents on the nitrogen can lead to 
displacement of the amino group from the metal to form ring-opened complexes with 
ligands bound only through phosphorus. This leaves a potential binding site on the 
metal, thereby increasing its inherent biological or catalytic activity. It is possible to 
form a series of complexes varying from bis-chelate to non-chelate by changing the 
ligand and the solution conditions. There have been many previous reports relating 
the potential use of aminophosphine complexes in catalysis including asymmetric 
hydroformylation of olefins or acetylenes. 88,89  The utility of these ligands in 
homogeneous catalysis lies in the susceptibility of the weak donor N to displacement 
by a substrate molecule, whereas the chelate effect confers additional stability on the 
catalyst precursor in the absence of the substrate. Another potential catalytic use is 
carbonylation, for example in hydroformylation, alkoxylation and polyketone 
production. 90 '9 ' In contrast very few studies have explored the potential biological 
activity of these complexes. 92 
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1.5.2 Biological Activity of Aminophosphine Platinum(U) Complexes 
Recent studies involving complexes with ligands of the type: 
R2N (C H 2) 2  PP h 2 
(R = H, Me) have established that chelate ring-opening can be controlled under 
biologically relevant conditions of pH and chloride concentration .93  The primary-
amino ligand H 2N(CH2)2PPh2 formed a bis-chelated structure (Figure 1. 15, complex 
15), in the solid state and solution, due to the lack of steric bulk on the N 
substituents. However when the tertiary-amino ligand Me 2N(CH2 ) 2PPh2 was used, a 
mono-chelate product (Figure 1.15, complex 16b) was formed. On dissolution in 
D 20 , 31 P NMR showed evidence of both this product and the bis-chelate, fully ring-
closed form (Figure 1.15, complex 16a). The equilibrium between the two was 
shown to be pH*  dependent, with the ring-opened species being favoured at low pH*, 
and reversible. The pK value for this ring-opening reaction was determined to be 
6.9. The equilibrium is also dependent on chloride concentration as would be 
expected. When all the Cl - was removed by precipitation with AgNO 3 , it was much 
harder to ring-open the chelate and a pH*  of Ca. 2 was required. Conversely when 
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Figure 1.15 Aminophosphine platinum(II) complexes: (15) bis-chelate, (16) ring- 
opening equilibrium controllable by pH and [Cl] 
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The binding of these complexes to 5'-guanosine monophosphate (GMP) was 
investigated as a model nucleotide since the DNA base guanine is the most 
prominent binding site for platinum drugs in cells. The bis chelate complex 15 does 
not undergo facile reactions with 5'-GMP. Complex 16 reacts rapidly with 5'-GMP, 
(minutes) forming two isomers of the product cis- [Pt {Me 2(CH2)2PPh2-N,P}-
{Me2(CH2)2PPh2-P)(5'-GMP-N7)] 2 identified by 31 P and 'H NMR. The bound 5'-
GMP can easily be displaced by chloride which appears to be unprecedented. 
Surprisingly no reaction was observed between this complex and 5'-adenosine 
monophosphate (AMP) the second most prevalent base for platinum binding on 
DNA (see Section 1.3.2.2). 
The bis-chelated and ring-opened complexes exhibit contrasting cytotoxicities 
towards cancer cell lines. The ring-closed complex 15 is relatively non-cytotoxic to 
LXFL non-small cell lung carcinoma and OVXF ovarian adenocarcinoma cells in 
culture whereas the ring-opened complex 16b is only slightly less potent than 
cisplatin. In contrast both 15 and 16b are active against A2780 cells and are as 
potent as cisplatin. However complex 16b has a much lower resistance factor 
against an A2780 cell line which has acquired resistance to cisplatin, than either 
complex 15 or cisplatin itself. Therefore it seems likely that ring-opened and ring-
closed aminophosphine complexes can act via different mechanisms in different 
types of cells. This could involve attack on DNA by platinum (like cisplatin-type 
complexes, section 1.3.2), interference with mitochondrial membrane potentials 
(since they are lipophilic cations like cytotoxic gold complexes, section 1.4.3.3) 
and/or redox reactions of the phosphine ligand (section 1.4.3.3). 
Further investigation into reactions of complex 16b with nucleotides showed an 
unexpected ability to bind strongly and reversibly to thymine and uracil under 
physiological conditions. 94  The N3 atom of thymine should provide a strong binding 
site for platinum 95  but has a high pKa value (ca. 10)96  and is usually inaccessible in 
double-stranded DNA due to involvement in AT base pairs. Complex 16b reacts 
with the nucleotide deoxythymine 5'-monophosphate (5'-dTMP) rapidly, within 
minutes, to form two diastereomers of the product cis- [Pt {Me2(CH 2)2PPh2-N,P}- 
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{Me2(CH2)2PPh 2-P}(5'-dTMP-N3)] 2t (Figure 1. 16, complex 17) These differ by 
1800 rotation around the Pt-N3 bond giving head and tail conformations of 
coordinated 5'-dTMP. Formation of this product may be influenced by the ability of 
the non-coordinated "dangling arm" amino group to accept a proton, aiding the 
deprotonation of the N3 site. Interactions of this dangling arm and the dTMP may 
help to stabilise these isomers. Reaction with the RNA nucleotide 5'-UMP was 
shown to follow a similar course. The pH-dependent stability of the 5'-dTMP 
complex was investigated and it was shown to exist over a wide range (pH*  3-8) with 
a pK of 5.1. The binding of 5'dTMP although strong is also reversible in the 
presence of chloride ions. 
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Figure 1.16 Binding of deoxythymine 5'-monophosphate to complex 16 
Following these discoveries, the binding of the complex to thymine in double 
stranded DNA was investigated using the self-complementary octamer 
oligonucleotide d(TTGGCCAA) which has previously been used to study the 
mechanism of formation of intrastrand crosslinks by cisplatin 97 but no thymine 
binding was reported to occur. The appearance of new singlet 'H NMR peaks for 
thymine CH3 groups shifted to high field, suggested direct binding of platinum to the 
N3 site as with 5'-dTMP. Some binding to N7 of guanine was also indicated 
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although the spectrum was too complex to assign fully. This is because binding to G 
and T on both strands is possible giving a large number of possible products. 
The unusual binding of Pt to thymine is most likely to be due to a combination of the 
strong trans influence of the P and the role of the dangling arm amino group. This 
specificity of attack on DNA and control of chelate ring-opening could prove to be 
useful in the design of new anticancer platinum complexes with improved 
therapeutic properties, in particular overcoming factors which limit the use of current 
drugs: narrow spectrum of activity, resistance and toxic side effects. 
1.6 Platinum(ll) Complexes Containing Antiviral Nucleoside 
Analogues 
1.6.1 Nucleoside Analogues as Antiviral Agents 
Although there has always been much scepticism in the pharmaceutical industry 
about the development of nucleosides as antiviral agents, the majority of the drugs 
currently licensed in this field are nucleoside analogues. Nucleosides containing a 
free primary hydroxyl group or a phosphonate function in the sugar moiety are 
always good candidates for enzymatic phosphorylation potentially leading to 
incorporation of the modified nucleotide into the DNA. This incorporation may lead 
to mutagenesis subsequently followed by cell proliferation. This is a danger for host 
cells as well as viruses. 
The enzymes used by virus and host to activate nucleosides and incorporate them in 
DNA are very similar. A nucleoside accepted as a substrate for a viral enzyme is 
therefore also a potential substrate for host enzymes. Moreover, the enzymatic 
machinery used to activate the nucleoside so that it becomes an antiviral agent and/or 
a toxic compound is often the same. In order to achieve an active antiviral agent a 
selectivity between virus and host must be achieved. 
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The range of nucleotide analogue classes having therapeutic potential has increased 
significantly in recent years. 98  In addition to modifications of conventional 
nucleosides, acyclic nucleosides have received a lot of attention and the success of 
acyclovir (Figure 1.17, complex 18) has been a major influence in promoting this 
area. Other areas of interest are in carbocyclic nucleoside analogues, 4'-
thionucleosides and L-nucleosides. 
1.6.1.1 	Acyclovir 
The leading antiviral nucleoside agent to date is acyclovir which was discovered in 
1974 (Zovirax - Figure 1.17, complex 18). The antiviral activity, pharmacokinetic 
properties and therapeutic efficacy of acyclovir have recently been reviewed. 99 It 
was first launched for treatment of the herpes simplex virus (HSV), but its 
effectiveness and clinical safety profile have made it the drug of choice for a wide 
range of viral infections including varicella zoster virus (VZV) in both the primary 
infection (chicken pox) and recurrent infections (shingles). More than 30 million 
people have taken oral acyclovir and no serious side-effect has yet been identified. 
This is particularly due to the fact that acyclovir is taken up into virally-infected cells 
much more efficiently than into normal cells and is selectively monophosphorylated 
by the virally-encoded thymidine kinase. It is however a very poor substrate for the 
cellular enzyme. After further phosphorylation by host enzymes the resultant 
triphosphate is a substrate for and selective inhibitor of viral DNA polymerase. 
Incorporation of acyclovir into the growing DNA strand blocks elongation and 
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Figure 1.17 Acyclovir, a potent antiviral guanosine analogue, and analogues 
There are only two significant disadvantages associated with acyclovir. The drug is 
only approximately 20% bioavailable after oral administration and is absorbed 
through the gastrointestinal tract. Acyclovir-resistant strains of both HSV and VZV 
have been found and whilst resistance to acyclovir is not a problem for 
immunocompetent people, it may be for immunocompromised individuals who are 
prone to recurrent disease. As a result there has been a search for further acyclic 
analogues resulting in new compounds such as pencyclovir and famcyclovir 98 
(Figure 1.17, complexes 19 and 20). The antiviral activity of pencyclovir is similar 
to that of acyclovir but has a number of advantages such as faster onset, increased 
potency and longer duration of action, attributed to the increased half-life of its 
triphosphate relative to acyclovir. Famcyclovir is a prodrug for pencyclovir and has 
improved oral absorption. 
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1.6.1 .2 AZT - an anti HIV agent 
The emergence of the human immunodeficiancy virus (HIV) which is the causative 
agent of AIDS, further intensified efforts to identify active antiviral agents and 2',3'-
dideoxy analogues of conventional 13-D nucleosides have featured prominently. 3'-
Azido-3'-deoxythymine (AZT, zidovudine - Figure 1.18, complex 21) was the first 
agent approved for use against HIV. HIV is a retrovirus, containing an RNA-
directed DNA polymerase (reverse transcriptase) which catalyses the synthesis of a 
double-stranded DNA copy of the viral RNA, the first step in viral replication. The 
pharmacodymanic and pharmacokinetic properties, and therapeutic efficacy of AZT 
have been comprehensively reviewed. 100 AZT is taken up by T lymphocytes, 
immune system cells that are particularly vulnerable to HIV infection, and converted 
to AZT triphosphate (AZTTP) by thymidine kinase (the triphosphate cannot be 
administered directly as it cannot cross the plasma membrane). The HIV reverse 
transcriptase has a higher affinity for AZT triphosphate than deoxythymidine 
triphosphate (dTTP)' ° ' so the AZT acts as an inhibitor of dTTP binding. AZTTP can 
then be added to the 3' end of the growing RNA/DNA chain, but because it contains 
no 3' hydroxyl the RNA/DNA synthesis is terminated. The compound is not toxic to 
the T lymphocytes themselves as the cellular DNA polymerases have a low affinity 
for AZTTP compared to dTTP. Unfortunately the drug appears to be toxic to the 
bone marrow cells that are the progenitors of erythrocytes, and patients often develop 
anaemia. AZT can increase the survival time of patients with advanced AIDS by 
about a year and has also been shown to delay the onset of AIDS in individuals in the 
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Figure 1.18 Anti-HIV agent, AZT and a prodrug derivative 
Chronic administration of AZT is associated with haematological toxicity and the 
emergence of resistant strains of the virus.  102  A number of strategies are being 
employed to overcome these problems. Clear advantages have been demonstrated in 
the clinic by using the approach of combination therapy with other nucleoside 
analogues and other agents. Another novel strategy is to devise a prodrug allowing 
intracellular delivery of AZT monophosphate to overcome the first highly 
demanding phosphorylation step. For example a phosphotriester derivative' 03 
(Figure 1.18, complex 22) has been shown to undergo sequential intracellular 
carboxyesterase-mediated decomposition processes leading to the parent nucleotide. 
1.6.2 Platinum Nucleoside Complexes 
Cisplatin is known to be effective against virally-induced cancer. This coupled to the 
fact that it has a high affinity for guanine have lead to the rationale that cisplatin and 
related platinum antitumour agents may by effective in treating herpes simplex virus 
(HSV) infections. HSV viral DNA has a much higher GC (guanine-cytosine) content 
(66-70%) than normal human DNA (GC-40%). It was hypothesised that the viral 
DNA might be more susceptible to binding of cisplatin because of this and hence 
cisplatin might inhibit viral-DNA replication. Initially the in vitro activity of 
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cisplatin and several related species was evaluated against HSV-1 and HSV-2 
viruses. 104  Cisplatin was the most active of the complexes tested with an activity 
comparable to that of acyclovir. The in vivo activity of cisplatin was then evaluated 
in an HSV-2 genital mouse model. The drug was found to have some effect when 
applied topically to the site of infection and no abnormal side effects were observed. 
Following these promising results on the antiherpes activity of platinum drugs, a 
broad-based research project was initiated to investigate the antiviral activities of 
other inorganic and organometallic complexes.' 05  Studies have initially been 
confined to complexes with known carcinostatic properties. Organotin complexes of 
the form R 2 SnX2 L2 (where R = CH 3 , C2 1­1 5 , C6 1 ­1 5 ; X = Cl - , Bf, L2 = phenanthroline, 
or 1 -(2-pyridyl)benzimidazole), were tested but showed only weak activity at most 
towards a range of DNA and RNA viruses and were non-inhibitory towards HIV-1. 
A range of metallocene and metallocenium complexes showed more promising 
results, [(C2H5)2Ti(bipy)]{CF3S0 3 1 2 having distinct activity against selected strains of 
the DNA virus herpes simplex. 
A new strategy that emerged was the discovery that a number of platinum(II) square 
planar complexes containing selected antiviral nucleosides as part of the coordination 
sphere were, in many instances, less toxic to normal cells than either component and 
had similar or enhanced antiviral activities.' 05  This strategy is based on the idea of 
combination treatment commonly used in cancer chemotherapy. Synergistic 
interactions between agents with different mechanisms of action can occur and the 
development of resistant cell lines is prevented. This has spawned the idea of 
multifunctional drugs, 106  i.e. combining two different cytotoxic moieties in the same 
drug. In contrast, investigation into antiviral drug combinations is relatively non-
existent. 
The complexes initially studied were (NH 3) 2PtNu2 and (dach)PtNu 2 with the antiviral 
nucleosides acyclovir, DHPG (9- { 1,3 -dihydroxy- 1 -propoxy-methyl } -guanine), and 
DHBG (9-{3,4-dihydroxybutylguanine}). All the complexes were active against 
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HSV-1 and HSV-2 and showed a dramatic decrease in toxicity compared to the 
platinum precursor complexes for reasons not yet understood. 
More recently, the complex [PtC1(NH 3 )2(acyclovir)]NO 3 has been synthesised and 
tested for antiviral and anticancer activity.' 07  The multifunctional compound 
maintained the antiviral activity of the parent drug acyclovir, in vitro against HSV- 1. 
Although, as an anticancer agent, it was markedly less potent than cisplatin on a 
mole-equivalent basis, it was as effective as cisplatin when administered in equitoxic 
doses in vivo to P388 leukaemia bearing mice. The complex was also active against 
a cisplatin-resistant subline of the P388 leukaemia suggesting that it acts via a 
different mechanism of action. The DNA binding properties of the complex have 
been investigated in more detail 108  and the major DNA adduct was identified as a 
monofunctional adduct of {Pt(NH3) 2(acyc1ovir)} with a guanine residue. In contrast 
to DNA adducts of other monodentate and clinically inactive platinum(II) 
compounds, the adducts terminated in vitro DNA and RNA synthesis. The lack of 
bifunctional adducts confirms the difference in mechanism of action from cisplatin. 
On the basis of these studies, multifunctional complexes consisting of platinum(II) 
complexes coupled with antiviral nucleosides present a novel strategy for attacking 
viral diseases. 
1.7 Nucleotides 
Nucleotides are the monomer building blocks of DNA and RNA and as such are 
ideal models for investigating interactions of platinum and its biological target. 
DNA comprises four different heterocyclic bases: the bi-cyclic purines guanine (G) 
and adenine (A), and the mono-cyclic pyrimidines cytosine (C) and thymine (T). 
These bases are connected to a pentose sugar ring, D-ribose for RNA and 2-deoxy-D-
ribose for DNA, by a bond from the C-i' of the sugar to the N-i of C or T and N-9 of 
A or G. In the polymeric structure of DNA these nucleoside units are linked together 
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via a phospo-diester linkage from the 5' site on one nucleoside to the 3' site on the 
next. This forms a chain-like structure which can bind a complementary strand via 
hydrogen bonds between the bases. The usual Watson —Crick base pairs are GC 














Figure 1.19 Watson-Crick hydrogen bonding between DNA bases 
A nucleotide is the phosphate ester of a nucleoside and so consists of three 
components: a nucleobase (G,C,A,T), a pentose ring, and a phosphate group (mono-, 
di- or tn-) at the 3' or 5' site. For the purpose of this thesis the nucleotides used have 
been monophosphates and have all been ribonucleotides (5'-GMP, 5'-AMP, 5'-CMP) 
with the exception of the thymine monophosphate which was in the 2-deoxyribose 
form (5'-dTMP) since T does not occur in RNA. The structures with full numbering 


































Figure 1.20 Structures and numbering schemes of mononucleotides used in this 
thesis 
The acid-base behaviour of a nucleotide is its most important physical characteristic 
since it determines its charge, tautomeric structure and its ability to accept and 
donate hydrogen bonds. The PK a values of the four nucleosides and 5'-nucleotides 
are given in Table 1.6. All the bases are neutral in the physiological range 5 <pH < 
9. The same is true for the pentoses where the D-ribose loses a proton only above pH 
12 and the deoxy-ribose only above pH 15. The monophosphate group loses its first 
proton at pH 1 and a second proton at about pH 7. The three amino bases G, A, and 
C all become protonated on one of the ring nitrogens rather than the exocyclic amino 
group since this does not interfere with delocalisation of the NH 2 electron lone pair 
into the aromatic system. 
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Base (site of protonation) Nucleoside 5'-Nucleotide 
Adenine (N-I) 3.52 3.88 
Cytosine (N-3) 4.17 4.56 
Guanine (N-7) 3.30 3.60 
Guanine (N- 1) 9.42 10.00 
Thymine (N-3) 9.93 10.47 
Table 1.6 PKa values for bases in nucleosides and nucleotides at 20°C and zero salt 
concentration 96 
1.7.1 Metal Binding Sites 
As discussed for cisplatin, the N7 purine sites provide major binding sites for Pt due 
to their accessibility in the major groove of DNA. In addition guanine has been 
shown to be the most electron rich site on DNA in studies on photoinduced DNA 
cleavage via electron transfer. 3 ' However, when looking at model bases such as 
nucleotides virtually any site on the base can be a potential binding site. A number 
of methods have been employed to study platinum-nucleobase binding such as 'H 
NMR, IR, Raman, UV, CD, and X-ray crystallography. The results of these studies 
95,109,110 have been comprehensively 
Guanine 
A number of factors make G-N7 the most common metal binding site on all the 
nucleobases. Primarily its accessibility in DNA and the fact that it is not involved in 
the major Watson-Crick base pairing. There is also the possibility of H bonding 
between the 06 on guanine and auxiliary ligands on the platinum. The N7 of 
guanine has a somewhat higher basicity than adenine N7 and a favourable 
electrostatic potential. Another possible binding site on guanine is the N  site, this 
can be deprotonated in an N7-metallated species at high pH. In kinetically labile 
complexes a competition between the Pt(II) ion and the proton exists and a Pt bound 




In all the bases exocyclic amine groups are metal binding sites only following 
removal the removal of one or both protons, i.e. after deprotonation or shift of a 
proton to another site of the base corresponding to a change in tautomeric structure. 
This is because the N lone pair of electrons is not free for donation but delocalised 
into the hetrocyclic ring. 
Adenine 
At physiological pH, adenine provides three unprotonated endocyclic nitrogen 
atoms: Ni, N7 and N3. The order of basicity of the sites is NI > N7 > N3, and while 
in duplex DNA the N7 site is preferred due to its accessibility, in nucleotides there is 
strong competition between N7 and NI binding. Only at strongly acidic pH when 
the Ni site is fully protonated, is metal binding preferentially through the N7. 
Binding at N3 can only be achieved by blocking both the N7 and N  sites. 
Cytosine 
Cytosine can have many different binding motifs for metal ions including through 
N3, 02, N4, and C5. In isolated cytosine base the binding is predominantly through 
N3 and 02 depending on the softness/hardness of the metal ion and possible steric 
effects. For this reason platinum generally prefers the N3 site. Coordination of a 
second platinum through the deprotonated Ni site has also been observed by NMR 
coupling." Bridging and chelating via N3 and N4 has also been observed.' 12 
Thym me 
The nucleobase thymine has not been identified in any of the established cisplatin 
crosslinks with DNA. This is a consequence of the kinetic preference of Pt for other 
sites such as N7 of purines and the unfavourable location of the N3 site in the helix 
interior due to its involvement in H bonding. Platinum binding is possible in model 
nucleotides and in single stranded DNA, for example aquated cisplatin reacts with 
polyU (U is the RNA analogue of T, differing by loss of the methyl group at the C5 
position) at pH to give a platinum-blue species. 113  Platinum blues are a class of 
intensely-coloured platinum antitumour compounds derived form cis-
[Pt(NH 3 )2(H20)2 ] 2 and uracil, thymine or related ligands, first discovered by 
Rosenberg's group in 1975. N3 is the major binding site for platinum on thymine and 
numerous X-ray crystal structures have been determined of Pt bound to an Ni 
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blocked model base (1-MeT) showing N-3 binding." 4 (The Ni site is blocked to 
mimic nucleotide/DNA binding since this site is where the sugar ring would be 
bound.) 
Binding of platinum to one of the exocyclic oxygens in thymine is not uncommon 
since replacement of the N3 proton by less electron-attracting Pt(II) causes an 
increase in electron density at the oxygens, and allows easy formation of 0-bound 
species. " 5 In particular thymine can form N,0 bridged dimer species bound through 
the N3 and 04 sites.' 6 These dimers are termed head-tail dimers due to the opposed 
orientations of the two thymines and were first observed by Rosenberg and co 
workers "7' 118  with [Pt(NH 3 ) 2 ] 2 and later crystallised by Lippert's group using 1-
methyl thymine" 9 (Figure 1.2 1, complex 23). 
2+ 
7CH3 
H3N\ / O / NH3 
Pt 	 Pt 
H3 N 
O,zr N 	0/  NH3 
H 3C7 
(23) 
Figure 1.21 1-Methyl thymine N3,04 bridged dimer species' 9 
The reaction of platinum with DNA can be modelled at various levels of complexity 
from cyclic DNA or short double or single-stranded oligomers, to tn-, di- or 
mononucleotides or even just nucleosides or nucleobases. The use of the 
mononucleotides in this work allows a variety of spectroscopic techniques to be 
employed and information about the rate and base specificity of binding to be 
determined. The effect of the negatively charged phosphate may also play a role in 
the complex binding so can not be ignored. 
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iLl "i'i .ili fl flhiiI*ir! 
The overall aim of this thesis is to synthesis a range of Pt(II) aminophosphine 
complexes and investigate their interactions with nucleotides. Such complexes could 
have potential as new anticancer agents with improved therapeutic properties, in 
particular overcoming factors which limit the use of current drugs: narrow spectrum 
of activity, resistance and toxic side effects 
The initial challenge is to synthesise a series of ligands of the type: R2N(CH2)3PPh 2 . 
These are similar to the ligands discussed in Section 1.5.2 but with a three carbon 
backbone giving the potential to form six-membered chelate rings. The alkyl groups 
(R) on the amine of the ligand will be varied, in order to investigate the influence of 
these groups on chelation. The ligands produced will then be used in the synthesis of 
Pt(II) aminophosphine complexes. The compounds formed will be characterised by 
use of NMR, mass spectrometry and X-ray crystallography techniques. The ring-
opening equilibria of the complexes under different conditions will also be 
investigated. 
Since DNA is the major target for Pt(II) complexes in the body, the interactions of 
the aminophosphine complexes with nucleotides (models for DNA binding) will also 
be studied. NMR will be used to study individual complex-nucleotide reactions 
whilst CE and HPLC will be employed to study competition reactions between the 
complexes and a mixture of nucleotides to determine the selectivity in binding site. 
The effect of pH on the binding to nucleotides will also be considered. The results 
for the Pt(II) aminophosphine complexes will be compared to those for cisplatin-
nucleotide binding in order to determine if the mode of action is likely to be the 
same. 
The effect of binding these complexes to polynucleotides will also be studied as the 




Since it has been indicated that complexes of this type may have an affinity for 
thymine binding, the reactions of the complexes with the anti-HIV drug AZT (a 
thymine analogue) will be investigated. Pt-AZT adducts have the potential to act as 
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21 Materials 
The reagents used in this work were purchased from the following companies listed 
in Table 2.1. 
Reagent Company 
ethyl formate, methylene oxide, Acros 
tert-butylamine, lithium aluminium hydride, lithium 
tetrafluoroborate, 
guanosine 5'-monophosphate (sodium salt) - 5'-GMP 
Me2N(CH2)3 C1.HC1, H 2N(CH2)3 C1.HC1, Aldrich 
potassium tert-butoxide, thionyl chloride, 
1,5-cyclooctadiene - COD, Pt(COD)C1 2 , tetramethyl tin 
sodium phosphate, potassium phosphate Sigma 
adenosine 5'-monophosphate (sodium salt) - 5'-AMP, 
cytidine 5'-monophosphate (sodium salt) - 5'-CMP, 
deoxythymidine 5'-monophosphate (sodium salt) - 5'-dTMP, 
3'-azido,3'-deoxythymidine - AZT 
Pt(COD)C1 2 Strem 
tetrabutyl ammonium hydrogen sulfate - TBAHS Fluka 
diphenyl phosphine Flurochem 
3-amino-l-propanol Lancaster 
potassium tetrachloroplatinate Johnson Matthey 
Table 2.1 Materials and sources 
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22 Methods 
2.2.1 Nuclear Magnetic Resonance Spectroscopy 
NMR signals were first recorded in 1946 and can now routinely be detected for 
almost any magnetic nucleus. Many textbooks have been published describing the 
theory and applications of NMR." 2 '3 
Angular Momentum and Nuclear Magnetism 
Nuclear magnetic moments are very sensitive to their surroundings yet interact very 
weakly with them making them ideal tools to investigate the structures and motions 
of molecules. 
Magnetic nuclei possess an intrinsic angular momentum known as spin, arising 
largely from the number of unpaired protons and neutrons they contain. The spin 
quantum number of a nucleus (I) may have one of the following values 
I = 0, 112, 1, 312, 2...., 
with quantum numbers greater than 4 being very rare. Nuclei having spins greater 
than V2 are called quadrupolar and normally give broad NMR lines making them 
difficult to study. The spinning of a nucleus (a charged body) generates a magnetic 
moment, the nuclear magnetic moment, p (p is a vector quantity). The moment is 
proportional to the spin with a constant of proportionality, y, called the gyromagnetic 
ratio. Every isotope has a different characteristic value of y. 
The number of m j states (energy levels) for a nucleus with spin I is 21 + 1. In the 
absence of a magnetic field the m j states are all degenerate. When a nucleus is placed 
in an applied field, different states will have different energies depending on how the 
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nuclear magnetic moment is orientated relative to the applied field. For a spin- Y2 
nucleus such as 'H there are two energy levels which correspond to nuclei having 
their spins aligned with or opposed to the magnetic field. 
The energies (E) of the allowed orientations of the nuclear magnetic moment depend 
on the strength of the applied field (B o), the size of the nuclear magnetic moment (y), 
and on the orientation of the moment in the applied field (m i) 
E = mjyB o 
Resonance Frequencies 
Transitions of nuclei between different levels is possible by irradiation with 
electromagnetic radiation of the correct frequency. This is known as the resonance 
frequency (v). Since the separation of energy levels will also be dependent on the 
magnetic field strength and the gyromagnetic ratio, each different isotope will 
resonate at a characteristic, distinct frequency. 
ziE=hv = yB 0 
v = yB o 12ir 
(h = Plank's constant) 
The selection rule for NMR is i\m j = ± 1, i.e. transitions are allowed only between 
adjacent levels. Since all energy levels are equally spaced only a single resonance 
will be observed in the spectrum. 
Irradiation of a sample at the resonance frequency causes the nuclear spins to both be 
excited from lower to higher energy levels (absorption) and relax from the higher to 
lower states (emission). Since these are both transitions of the same energy, the  
NMR signal depends on the difference between the numbers of absorptions and 
emissions that occur. This is in turn dependent on the population difference between 
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the two levels which is very small (approx. 1 in 10) so NMR signals are therefore 
very weak. One way to improve the sensitivity of NMR as a technique is to make B0, 
the field strength as large as possible so the separation of the energy levels is large. 
NMR spectrometers are usually classified by their proton frequencies (since this is 
the most popular NMR nucleus) rather than their magnetic field, e.g. in 9.4 T field 
v('H) = 400 MHz. 
The magnetic properties of some useful NMR active nuclei are displayed in Table 
2.2. 
Relative 
Spin Gyromagnetic Resonance Natural 
Magnetic sensitivity 
Nucleus Quantum ratio, 	' Frequency, Abundance 
Moment, p (versus 'H at 
Number, I (10 8radT's') v (MHz) % 
constant field) 
'H '/2 2.798 2.675 42.577 1.000 99.98 
13c '/2 0.702 0.673 10.705 0.016 1.108 
' 5N V2 -0.283 -0.271 4.315 0.001 0.365 
V2 1.132 1.083 17.235 0.066 100.00 
'/2 0.606 0.580 9.238 0.003 33.8 
Table 2.2 Selected NMR properties of common nuclei (in a 1 T magnetic field) 
Experimental Methods 
An NMR spectrum is measured by applying a radio frequency as a powerful pulse 
for a certain time over a range of frequencies. This excites all the resonances within 
a sample and as a result the macroscopic magnetisation of the sample is displaced by 
an angle 0. The intensity of the excitation pulse determines how much the 
magnetisation is tipped. A pulse producing 0 = 90 ° will give the maximum intensity 
of NMR signal. The tipped magnetisation precesses around its axis and a receiver 
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coil picks up the resultant oscillation which decays away to zero during the 
acquisition period a process known as free induction decay (FID). Fourier 
transformation then converts the FID in the time domain into a spectrum in the 
frequency domain resulting in a spectrum of signal intensity versus frequency. 
Integration 
The intensity of an NMR signal is proportional to the number of nuclei resonating at 
that frequency so we can quantify the relative numbers of nuclei in different 
chemical environments by comparing the areas under peaks. This area is measured 
by integration. 
Chemical Shifts 
As well as depending on yand B 0 the frequency at which a nucleus resonates is also 
dependent, to a lesser extent, on the local electron distribution within the molecule. 
This distinguishes individual nuclei according to their position in a molecule. 
The external magnetic field applied to a sample causes the electrons to circulate in 
their atomic orbitals, generating a small magnetic field B' which reinforces or 
opposes the existing magnetic field. A nucleus in a molecule then experiences a 
different magnetic field (B) depending on its surrounding electron distribution. 
This effect is referred to as nuclear shielding. The resonance frequency of the 
nucleus is then shifted from that for a bare nucleus with no electrons. The chemical 
shielding is reported as the shift of the resonance line from that of a resonance 
compound, the chemical shift. This is given as a fraction of the applied magnetic 
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field, in parts per million, on the ö scale which is then independent of the applied 
field. öincreases as the amount of shielding increases. Conventionally the 5 scale 
increases from right to left in an NMR spectrum. The left-hand side is known as the 
downfield end and is the high frequency end. The opposite is true for the right-hand 
side. 
Several factors influence the shielding of nuclei in complexes and hence their 
chemical shift. 4 It is however difficult to establish general trends for these effects as 
often many independent factors with competing effects are present in a single 
complex. 
Geometry - geometric factors can make otherwise equivalent nuclei distinct e.g. 
cis or trans, fac or mer. The position of a nucleus in a complex determines its 
electronic environment and hence its chemical shift. 
Electronegativity, charge and oxidation state - all of these factors affect the 
electron density around the nucleus and so alter the chemical shift. The shielding 
becomes smaller as the electron density decreases and the chemical shift 
produced is larger. Thus electronegative substituents, positive charge or an 
increase in oxidation state all result in a downfield shift. 
Co-ordination number - The chemical shift can be diagnostic of the co-
ordination number of a nucleus in a complex, shifting upfield as the co-ordination 
number increases. This is well illustrated in work by J. Errington using 17 
NMR to distinguish between terminal and bridging oxygen atoms in W60 1 92 
structures. 5 
Spin-Spin Coupling 
Coupling arises because the nuclear magnetic moments of other NMR active nuclei 
surrounding the nucleus under observation produce small magnetic fields in addition 
to those due to the spectrometer magnet and the chemical shift. Thus the observed 
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nucleus sees not one resultant field but several depending on the number and nature 
of the surrounding NMR active nuclei. 
If the neighbouring nucleus is aligned with the field, the total effective field will be 
larger than the applied field of the spectrometer causing the resonance frequency to 
be higher. Conversely if the nucleus is aligned opposed to the field, the effective 
field will be reduced and the resonance will be at a lower frequency. Since there is 
an almost equal probability of the nucleus being in either spin state, this results in 
two lines of equal intensity in the NMR spectrum instead of a single resonance. The 
same principle of splitting can be applied to larger numbers of nuclei in the same 
molecule resulting in multiplet patterns of resonances. 
The difference between resonance frequencies of the split lines is called the coupling 
constant (J). This is independent of the spectrometer field used and so is measured 
in Hertz (Hz). The size of J diminishes as the number of bonds between the two 
active nuclei increases. 
Many factors, discussed below, affect the coupling constant, 4 some general trends 
can be identified allowing structural and chemical information to be determined. In 
general it is the s-character of the bond(s) between the coupling nuclei that controls 
the magnitude J. The coupling between nuclei is transmitted via the bonding 
electrons rather than directly through space. Only s-electrons have a finite density at 
the nucleus so the amount of s-character in the valence hybrids used to form the 
chemical bond influences the strength of the coupling. Percentage s-character is 
determined by the following: 
Hybridisation - coupling constants increase in the order of sp 3 < sp2 < sp 
hybridised nuclei as s-character increases 
Co-ordination number - increasing co-ordination number leads to a decrease in 
coupling constant, the s-character of the bond to any given ligand decreases as 
the number of ligands increases 
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Electronegativity - Coupling constants increase with increasing electronegativity 
of the substituents 
Trans influence - The magnitude of couplings between a ligand and acceptor is 
strongly influenced by the other ligands in the complex. The nature of the trans 
group affects the covalency or s-character of the metal-ligand bond. A ligand 
with a high trans influence will weaken the bond trans to it and lower the 
coupling constant, conversely a ligand with low trans influence will produce a 
higher J value. 
Interbond angles - as the bond angle increases between coupling nuclei the s-
character of the bonds increases until a maximum at 1800.  Hence the magnitude 
of the coupling constant can be correlated to the interbond angle between nuclei, 
e.g. trans couplings will normally be larger than cis couplings. 
Natural Abundance 
Elements can exist as more than one isotope. These isotopes need not all have the 
same spin so will not necessarily all be NMR active. Even those which are active 
will have different gyromagnetic ratios, 'y, and hence different resonance frequencies. 
The different isotopes will therefore show different coupling constants and different 
coupling patterns. To understand the NMR spectra of compounds containing an 
element possessing more than one NMR active isotope it must be considered as a 
combination of the spectrum containing only inactive isotopes of the element and 
spectra containing each of the active isotopes. 
2.2.1.1 NMR of Platinum(11) Complexes with Phosphine Ligands 
Platinum Satellites 
A number of the NMR effects described above can be used to great effect in the 
study of platinum complexes. Platinum contains only one NMR active isotope - 
195Pt, which is only 33.8% abundant. When coupling to other active nuclei this 
produces a distinctive pattern of satellites. (Figure 2.1) The central unsplit line is 
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due to molecules containing the non-active Pt isotopes. This is flanked by a doublet 
of peaks from molecules containing the 1 95p spin-1/2 molecule. 
-1 
Figure 2.1 Satellites produced by coupling of 195Pt to an NMR active nucleus 
Phosphorus-31 NMR 
Due to its favourable nuclear properties (1 = Y2, high NMR frequency and high 
receptivity), 	the 	31 P nucleus is 	easy to observe and very useful 	in structure 
determination. 
The properties of the 31 P nucleus are described in Table 2.3. 
Natural abundance, % 
	
100 
Nuclear spin, I 
	
V2 
Magnetic moment, ,u 	 1.1316 
Gyromagnetic ratio, y (107  radT- 1 s - 1 ) 	 10.8394 
NMR frequency at 2.35 T (MHz) 	 40.480 
Receptivity relative to that of 'H 	 6.63 x 10.2 
Table 2.3 NMR Properties of 31 p 6 
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Phosphorus-31 chemical shifts have been observed over a range exceeding 1000 
ppm. 7 The chemical shift can be indicative of the coordination number of the 
phosphorus atom as it is determined by the bond angles to the neighbouring nuclei, 
the electronegativity of the substituents and the extent of t-bonding. Phosphorus-31 
shifts are reported relative to the signal for 85% phosphoric acid as an external 
reference. Being present in 100% abundance, and having a spin quantum number of 
½, 31 P imparts spin-spin coupling information analogous to a proton. Coupling 
information such as multiplicity and J value are useful aids in the identification of 
compound structures from spectra. 
Phosphorus-Platinum Coupling 
In transition metal complexes coupling of 31 P to platinum is one of the most widely 
studied NMR interactions. As previously discussed the magnitude of the coupling 
constant is seen to depend on the trans influence of the ligand opposite to P. A 
combination of calculations and experimental data have shown that contributions 
from the interaction of the nuclear spins of the atoms (P and Pt) are negligible in 
determining the magnitude of the coupling constant, while the Fermi contact 
interaction at the nucleus, between the nuclear spin and s-electrons, makes the 
dominant contribution. 8,9 
The coupling constant J( 31 P-' 95Pt) is then given by: 
J(3 'P- '95Pt) a )7ps  c€p2 apf I P(3s)(0) 2 	 2  (34Ej' 
where 'yx  is the gyromagnetic ratio for the nucleus, cL x2 is the s-character of the 
bonding hybrid orbital used by X in the P-Pt bond, the I ns) (0)I 2  terms describe the 
electron density of the indicated orbital evaluated at the parent nuclei and 3 A is an 
average singlet-triplet excitation energy. 
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The variation of J( 31 P.) 95Pt) according to the ligand in the trans position can then be 
accounted for by the effect of this ligand on the degree of covalency/s-character of 
the Pt-P bond and hence the coupling. This is very useful in the characterisation of 
platinum phosphine compounds indicating the nature of the coordinated ligands and 
cis/trans geometry. 10-14 
A trans influence series (according to increase of coupling constant) has been 
obtained by combining several sets of data ' 5 : 
SiMeP11 2 > Ph > Me > PEt 3 , PBu'1 3 > PMe2Ph> PPh3 > P(OPh) 3 , CN >NO2_ > 
EtNH2 > Et2NH > py, N 3 , NCO, NCS, Cl - , Br, 1> 0NO 2 
Table 2.4 shows a rule of thumb correlation between phosphorus-platinum coupling 
constant and various trans donor atoms relevant to platinum compounds in this 
thesis. 
increasing trans influence 
trans ligand P N Cl 0 
'J ("P-"'Pt) I Hz 2400-3000 3200-3600 3500-3800 >4000 
Table 2.3 Effect of trans ligand on the 'J ("P-"'Pt) coupling in square-planar Pt(II) 
complexes 
In addition to coupling to platinum, phosphorus can also couple to other P ligands in 
a square-planar Pt(II) complex. This coupling again indicates the geometry of a 
complex since it is only observed for two phosphorus atoms with a cis relationship 
and not with a trans relationship. The 2J(31 P- 31 P) coupling is of the order of 20 Hz. 
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Chelate Effect 
Since the early '70s it has been known that a good correlation exists between the 
chemical shift of a tertiary phosphine and the change in chemical shift upon 
coordination to a metal. More recently a new parameter has been described, AR, (the 
ring contribution) accounting for the change in chemical shift due to incorporation of 
the phosphine in a chelate ring. ' 6 This parameter is defined as the difference 
between the coordination chemical shift of a cis-disubstituted phosphine complex 
and the observed coordination chemical shift of an equivalent phosphorus atom in a 
chelate complex. Using the series of complexes [Pt{Ph 2P(CH2),1PPh2 }(CH 3) 2] with n 
= 1-4, and the acyclic analogue cis-[Pt(Ph 2PCH3 )2(CH3 )2] a pattern relating chelate 
ring size to chemical shift has been determined. 17  P atoms in four and six-membered 
rings have increased shielding and move slightly upfield, but in five-membered rings 
the P atoms are deshielded and shift downfield. A comparison of these phenomenon 
with the X-ray structures for an analogous Pd series show that this anomalous shift is 
not related to the stain in the chelate ring which is low in the five-membered case. 
To date this effect remains well documented but unaccounted for.' 3,18 
2.2.1.2 NMR of Nucleotide Reactions with Platinum 
'H NMR is possibly the single most powerful technique for studying the interactions 
between platinum and nucleotides. It allows the study of complex formation, the 
assignment of binding sites and also allows structural changes such as ligand rotation 
and metal migration to be followed. 19  
Chemical Shift with Pt Coordination 
Platinum coordination to a heteroatom in a nucleobase generally causes a downfield 
shift in the resonances of the nonexchangeable ring protons. 20 This downfield shift 
originates from the inductive effect - that is the effect of diminishing the electron 
density at these protons and deshielding them. 
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Ligand Rotation 
The number of observed 'H resonances as a function of temperature can often allow 
conclusions to be reached about the number and geometries of isomers. In 
complexes containing more than one nucleobase (such as GG adducts) isomers have 
been attributed to the restricted rotation of the Pt-nucleobase bond producing so-
called head —to-head (HH) isomers (both guanines perpendicular to Pt square-plane 
and orientated in the same direction) and head-to-tail (HT) isomers (both guanines 
perpendicular to Pt square-plane and orientated in opposite directions) as shown in 
Figure 2.2. 21  Conformations of the cisplatin moiety {Pt(NH 3 )2 } 2 , are difficult to 
elucidate by NMR since attachment of the NH 3 to Pt via a single bond allows the 
NH3 ligands to adopt independently numerous orientations in which the NH groups 
form hydrogen bonds to the nucleotide target or avoid steric interactions with the 
target. As a result, multiple similar conformations co-exist and the barriers between 
the conformations are probably shallow making these adducts especially fluxional. 22 
However, for nucleotide binding of Pt(II) moieties with larger amine groups 'H 
NMR can be a useful tool for studying complex conformation. 
sugar 	N 	N 
Pt 	 Pt 
NH 
HH 	 HT 	
NH2 
Figure 2.2 Possible isomers of complexes of the form [PtA 2G2] where A = 
am(m)ine ligand, G = guanine. Arrows represent an N7 bound G as shown on right 
hand side of the figure. 
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Binding Site 
Monitoring the chemical shift of nonexchangeable 'H protons of heterocyclic rings 
as a function of pH permits determination of relevant pKa values of acid-base 
equilibria at the heteroatoms. This is due to the fact that protonation of the 
heteroatom causes a downfield shift by the inductive effect. The method can also be 
applied to platinated nucleobases. Since sites occupied by Pt can no longer be 
protonated as in the free nucleobase, a pH titration of the platinated product will no 
longer show the expected chemical shift for proton signals in the region of the 
heteroatoms PKa values. Also when Pt is bound at one ring N, the pK a values of 
other sites can be significantly changed, again causing a distinctive change in the 
chemical shift profile. For example, Pt binding at N7 of guanine can unambiguously 
be established on the basis of the downfield shift of the H8 resonance. 23  The pKa of 
this site is ca. 2-3, but when platination occurs the chemical shift of the H8 shows no 
change over a wide pH range 0-6. The binding at N7 also acidifies the Ni proton 
(pKa ca. 7.8-8.3) 24  which is reflected by the sensitivity of the H8 signal to pH in the 
range 6-10. 
2.2.2 Capillary Electrophoresis 
Electrophoresis is a separation method based on the differential rate of migration of 
charged species in a buffer solution across which has been applied a dc electric field. 
The classical method of electrophoretic separation is carried out on a slab of porous 
semisolid gel containing an aqueous buffer within its pores and is therefore referred 
to as slab electrophoresis. This technique has many disadvantages including low 
resolution, the requirement of large sample volumes, and the limitation of using a 
low electric field due to the convection currents created by Joule heating in the gel. 
Major efforts have been directed towards the development of new eiectrophoretic 
media to improve the technique. Capillary electrophoresis (CE) was developed only 
in the last 20 years by the groups of Mikkers 25 and Jorgenson .26  CE uses a fused 
silica capillary, coated with a protective polyimide layer, as the separating medium. 
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Typical capillaries have an internal diameter of only 10-100 p.m and are 40-100 cm 
long. CE presents many advantages over slab electrophoresis: 
high resolution separations can be achieved on exceptionally small sample 
volumes (0.1-10 nl in contrast to volumes in the p.1 range required for slab 
electrophoresis), 
the high surface-to-volume ratio allows for very efficient dissipation of Joule 
heat, so high voltages can be used for faster separations, 
the separated species are eluted from the end of the capillary so quantitative 
detectors such as UV spectrometers can be used instead of the staining 
techniques of slab electrophoresis. 
Detailed descriptions of CE theory can be found in many analytical texts and 
reviews, 2730 these are summarised in the following sections. 
Instrumentation for Capillary Electrophoresis 
As shown in Figure 2.3 the instrumentation required for CE is very simple. The 
capillary is filled with the required electrolyte solution and the ends of the capillary 
dipped into reservoirs of electrolyte containing high voltage electrodes. The 
electrodes are made of an inert material such as platinum and apply a voltage of 5-30 
kV across the capillary. This causes an overall movement of solution towards one 
electrode (usually the cathode). A detector is placed at the end of the capillary 
nearest this electrode and the sample for detection is introduced at the other end. The 
ions in the sample move at different rates (as discussed in the next section) along the 
capillary and are therefore separated by the time they reach the detector. A plot of 
the detector response (usually UV absorbance) with time is generated and is termed 
an electropherogram. 
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DETECTOR 	 COMPUTER 
Figure 2.3 A schematic representation of capillary electrophoresis apparatus 
(Adapted from ref. 28) 
Samples can be introduced into the capillary by three methods all of which involve 
immersing the capillary end into the sample solution and exerting a force to inject the 
sample into the capillary. All the methods are quantitative allowing reproducible 
analysis. 
Pressure Differential - The sampling end of the tube is immersed in the solution 
and a pressure difference applied (positive pressure at the sample end or a 
vacuum at the detector end) allowing sample to be pushed or pulled into the 
capillary. The volume of sample will depend on the viscosity of the solution and 
the temperature. 
Gravity Injection - The capillary, while dipping in the sample vial, is 
mechanically raised above the height of the detector electrolyte vial. The volume 
entering the capillary will depend on the height raised, and the density of the 
liquid. 
Elecrokinetic - The sampling end of the capillary and the high-voltage electrode 
are both inserted into the sample solution and a voltage is applied for a set length 
of time allowing sample ions to enter the capillary by electrophoretic migration 
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and electro-osmotic flow (see next section). This can have bias effects as a 
greater number of more mobile ions will enter the tube. 
Numerous detection methods can be employed in CE, the most usual being UV 
absorbance, as for HPLC, although fluorescence is also common. Due to the very 
small sample volumes encountered, detection occurs on-column. A small section of 
the polyimide capillary coating is removed by burning, allowing that section of the 
tube to act as a detection cell. The very small flow rates of under 1 tl/min from 
electrophoresis capillaries make it possible to couple the effluent directly to the 
ionisation source of a mass spectrometer for sample detection. The most common 
interface is electrospray, which is discussed in section 2.2.3. This method of 
detection is particularly useful to biologists for large biomolecules such as proteins 
and DNA fragments. More recently the concept of linking CE to inductively-
coupled plasma-mass spectrometry (ICP-MS) has been developed allowing 
elemental speciation of the eluted products. 31,32  This requires an interface to link the 
low elution rate of the CE to the rate required for aspiration into the ICP which is of 
the order of 1 ml/min. 
Ion Movement through the Capillary 
Ions travel through the capillary by two mechanisms. 
1. Electrophoretic Migration (EM)- This is the movement of sample ions under the 
influence of the applied voltage. The ion will move towards the appropriate 
electrode depending on its charge. The migration rate is governed by the size and 
charge of the ion according the following equations: 
Migration velocity = ,LLE V 
where V is the applied voltage and 111E, the ionic mobility, is given by: 
pE(q/6r) )7 r 
q is the number of charges, i is the solution viscosity and r is the radius of the 
ion. 
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Therefore when separating a mixture of ions in a sample, the smaller more highly 
charged ions will reach the detector first. 
2. Electro-osmotic Flow (EOF)- From the set up in Figure 2.3, it appears that only 
cations will be detected as they pass the detector travelling to the cathode. 
Anions however can also be detected due to a bulk flow of the electrolyte 
solution towards the cathode. The walls of the capillary are coated in weakly 
acidic silanol groups. If the buffer has a sufficiently high pH (above 4), these 
groups are dissociated resulting in a negatively-charged surface. To maintain 
electroneutrality, cations build up near the surface in a double layer (Figure 2.4). 
At the wall, there is a fixed layer of cations followed by a diffuse layer to fully 
balance the charge. When a voltage is applied, the ions in the diffuse layer move 
towards the cathode. Since the cations are solvated they drag the bulk solvent 
with them contributing to the overall rate of migration. Since the EOF is a bulk 
effect, it acts on all molecules in the sample to the same extent, hence all 
positive, neutral and even negative species will eventually reach the cathode and 
the detector. 
The total migration rate of an ion is the sum of its EM and the EOF, with the latter 
generally being the greater. In a typical capillary electrophoretic separation, cations 









Figure 2.4 Formation of a double layer of cations at the capillary wall leading to 
electro-osmotic flow (Adapted from ref. 29) 
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The cations will be separated with the smallest and most highly charged eluting first. 
Secondly all the neutral molecules will elute since these have only an EOF acting on 
them. There will therefore be no separation between different neutral components. 
Finally the anions will be eluted since they have an EM in the opposite direction to 
the EOF reducing their rate of migration. These will be separated with the largest 







Dl __ F-I 
 ~  I 
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time 
Figure 2.5 Elution order of positive, neutral and negative components in an 
electrophoretic separation 
Modes of Capillary Electrophoresis 
The simplest mode of CE, as described above, is called Capillary Zone 
Electrophoresis (CZE). This can be used for a diverse range of separations from 
small organic or inorganic molecules to large biomolecules such as proteins and 
DNA fragments. The resolution of a separation can be maximised by varying several 
parameters such as the applied voltage to shorten analysis times and decrease line- 
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DNA fragments. The resolution of a separation can be maximised by varying several 
parameters such as the applied voltage to shorten analysis times and decrease line-
broadening, capillary temperature to change the buffer viscosity, capillary diameter 
to increase detector sensitivity, capillary length to vary detection time and 
separation, and buffer to determine pH. This basic technique can also be modified 
further for more specific applications. 
Micellar Elect ro kinetic Capillary Chromatography (MECC) was initially 
developed for the resolution of uncharged compounds which all co-elute in 
CZE. 33 The electrolyte solution contains relatively high levels of a surfactant, 
such as sodium dodecyl sulphate, which self-aggregates forming micelles in 
which the hydrophilic head groups form the outer shell and the hydrophobic tails 
form a non-polar core. Sample species can partition into this core in a similar 
fashion to retention on a stationary phase in HPLC. The differential partitioning 
between the buffered aqueous mobile phase and the micellar phase is the basis 
for separation of neutral molecules. 
Capillary Gel Electrophoresis (iT2GE) is used to analyse large biomolecules such 
as DNA which have very similar charge to mass ratios so are difficult to separate 
by CZE. The capillary is filled with a porous gel matrix, the pores of which 
contain the separation buffer. This provides a molecular sieving action, which 
retards the migration of analyte species to various extents depending on the pore 
size of the polymer and the size of the analyte anions. 
Capillary Isoelectric Focusing (ClEF) is used to separate amphiprotic species, 
such as amino acids and proteins containing both acid and base groups. These 
species have a p1 value, a pH at which they form a zwitterion and hence possess 
no net charge, so will have no tendency to migrate. The capillary is filled with a 
pH gradient that remains fixed during the application of the separation voltage. 
The sample is injected at the low pH end and so is positively-charged and moves 
towards the detector. When the solute reaches the point where the pH matches 
its p1 value it will remain in a fixed position. The various components of the 
mixture will therefore be separated according to p1 value. Pressure is then 
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applied across the capillary to force the pH gradient along allowing detection of 
all the separated zones. 
4. Capillary Isotachophoresis (CITP) can sharpen the resolution of analytes with 
similar migration velocities. The sample is injected between two buffers, a 
leading buffer with a high mobility and a terminating buffer with a low mobility. 
The difference in migration rates results in separation of the various analyte 
species into adjacent bands, with the fastest located just after the leading buffer. 
After the bands have formed they all move at the same velocity because the 
potential field becomes smaller for the more mobile bands and greater for the 
slower bands so the current is the same in all parts of the buffer. The boundaries 
formed are very sharp giving high resolution. 
A recent development by Knox and Grant 34  is Capillary Electrochromatography 
where a capillary is filled with a reversed-phase HPLC packing. A polar solvent is 
driven by electro-osmotic flow through the capillary. Separation depends on the 
distribution of the analyte species between the mobile phase and the liquid stationary 
phase held on the packing. This has advantages over both parent techniques; it is 
applicable to uncharged species like HPLC but can provide efficient separations from 
very small sample volumes. It also does not require high-pressure pumps, so 
simplifying the system. The electro-osmotic pump has a flat flow profile as opposed 
to the parabolic flow profile from hydrodynamic pressure, which significantly 
reduces the line-broadening effect seen in HPLC. 
2.2.2.1 	Capillary Electrophoresis of Nucleotides 
Nucleotides have been quantified by HPLC for approximately 30 years, however 
HPLC analyses do have limitations. Due to their negative charge, nucleotides can be 
readily separated by capillary electrophoresis, which has the advantage of using 
smaller quantities of both sample and buffer. 
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As detailed in Section 1 .7, the total charge on a nucleotide is derived from the 
charges on the phosphate, the base and the sugar. At pH values close to neutral, the 
four DNA nucleotides will all have the same charge derived only from the phosphate 
group since their bases are all neutral. They can therefore only be separated 
according to their different sizes in the basic CZE mode. At high pH the guanosine 
N-i and thymidine N-3 will be deprotonated and will be further distinguished from 
the other two bases due to an increased charge and electrophoretic mobility. 
Conversely at low pH adenosine N-i, cytosine N-3 and guanine N-7 can be 
protonated reducing the overall charge and reducing the migration rate. 
The analysis of nucleotides by CE has become widespread in recent years and has 
been recently reviewed .35  The separations have been performed in both CZE and 
MECC modes under a variety of conditions. In the CZE mode, separation has been 
achieved in acidic, neutral and basic conditions. Commonly-used buffers include 
sodium salicylate, acetic acid, ammonium acetate and sodium formate, for acidic 
separations in the range pH 2-6. Neutral separations are generally carried out in 
sodium phosphate buffer. Alkaline buffers provide a good separation medium for a 
mixture of mono- di- and tn- phosphates since ionisation of the additional 
phosphates occurs at around pH 6 giving differently charged species. The most 
common alkaline buffer is sodium borate. Buffer composition becomes more 
complicated when MECC is used. Sodium dodecyl sulphate is usually the surfactant 
added in combination with phosphate and borate salts. 
UV detection is ideal for nucleotides since it is inexpensive and can detect species 
on-column. The detection limit for nucleotide separations by CE is in the picomolar 
range and is restricted only by the very small pathlength since the UV cell is the 
capillary. The usual wavelength used for detection is 254 rim. All the nucleotides 
have a strong absorbance in the region around 260 nm due to 7c7t transitions from 
the aromatic rings in the bases. 
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CE has also been used to study the interaction of platinum complexes with 
nucleotides. Sharma et. al.36 used MECC to separate a dansylated mixture of normal 
nucleotides and platinated cross-link adducts of d(pGpG) and d(pApG). The use of a 
laser-induced fluorescence (LIF) detector gave very high sensitivity allowing 
quantitation of platinated DNA to be determined. The study compared the adducts 
formed by cisplatin and carboplatin on calf thymus DNA. After Pt binding, the DNA 
was enzymatically digested and the resulting nucleotide mixture was analysed. A 
comparison of HPLC and CE as techniques for the separation and identification of 
platination products of oligonucleotides has been published. 37 The conclusion was 
that CE was much more sensitive for the resolution of the very similar Pt-products 
but that adduct identification was much more difficult due to the very small amounts 
of material eluted from the capillary. The binding of cisplatin to individual 
nucleotide monophosphates has also been investigated using CE separations in a 
sodium phosphate buffer using an instrument equipped with a diode array detector. 38 
This technique allowed the selectivity of the complex for each nucleotide to be 
determined as well as the kinetics of binding. 
2.2.3 Electrospray lonisation Mass Spectrometry 
Mass spectrometry (MS) is a versatile technique that can provide information on the 
elemental composition of samples of matter and the structures of inorganic, organic 
and biological molecules. The general principle of mass spectrometry is the 
conversion of an analyte sample into gaseous ions which are attracted through the slit 
of a mass spectrometer and separated according to their mass-to-charge ratios. A 
spectrum is produced which is like a bar chart depicting the relative intensity of mass 
peaks according to this ratio. The components of a mass spectrometer are shown in 
Figure 2.6. 
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Figure 2.6 Components of a mass spectrometer 
lonisation 
The classical methods of ionisation used in MS are based on gas phase encounters of 
the molecule (having already been vaporised) with electrons, photons, other ions, or 
electronically excited atoms. Such encounters can remove a negatively or positively 
charged entity from a neutral molecule transforming it into an ion. These methods 
are not suitable for large biomolecules, which undergo extensive decomposition by 
fragmentation of the analyte molecules. Electrospray ionisation 19-41  (ESI) is a 
desporption ion source where a sample in solution is converted directly into gaseous 
ions. It is a soft ion source in that it does not impart enough energy to the analyte 
molecules to fragment ions during analysis. The technique was first developed over 
30 years ago by Dole and co-workers. 43  ESI takes place under atmospheric pressures 
and temperatures in an apparatus such as that shown in Figure 2.7. A solution of the 
sample is pumped through a stainless steel capillary needle at a rate of a few 
microlitres per minute. The needle is maintained at several kilovolts with respect to 
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a cylindrical electrode that surrounds the needle. The resulting field at the needle tip 
charges the surface of the emerging liquid, dispersing it by Coulomb forces into a 
fine spray of charged droplets. Driven by the electric field, the droplets migrate 
towards the inlet end of the glass capillary at the end wall of the chamber. A drying 
gas at 320 to 350 K, encourages evaporation of solvent from each droplet, decreasing 
its diameter. Consequently, the charge density at its surface increases until the 
Rayleigh limit is reached at which point the Coulomb repulsion becomes of the same 
order as the surface tension. The resulting instability tears the droplet apart, 
producing charged daughter droplets that also evaporate. This sequence of events 
repeats until the radius of curvature of the daughter droplet becomes small enough 
that the field due to the surface charge density is strong enough to desorb ions from 
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Figure 2.7 Apparatus for electrospray ionisation (Adapted from ref. 40) 
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A useful feature of ESI is the formation of multiply charged ions so that even very 
large molecules, such as proteins, have m/z values small enough to be detected with a 
quadrupole instrument with a range of only 4000. In these spectra, adjacent peaks 
are for analyte ions that differ by one charge. The charge state corresponding to each 
peak can be determined from peak distribution, thus making it possible to determine 
the molecular weight of the protein. 
Mass Analyser 
The most commonly used analyser in MS is the quadrupole mass analyser. This 
instrument is based around four cylindrical rods acting as electrodes. Opposite rods 
are connected electrically, one pair to the positive terminal and one to the negative 
terminal of a variable dc source. In addition variable radio-frequency ac potentials 
which are 180° out of phase are applied to each pair of rods. The ions from the ESI 
source are accelerated into the space between the rods and the dc and ac voltages on 
the rods increased simultaneously while maintaining their ratio constant. This varies 
the trajectories of the ions passing between them. At any given moment all ions 
except those having a certain m/z value strike the rods and are converted to neutral 
molecules. Thus only ions with the specific ni/z reach the transducer. As the 
voltages are increased, the m/z range will change. Quadrupole mass analysers can 
cover a m/z range of up to 4000 and can resolve ions that differ in mass by one unit. 
The instrument also has the advantage of high scan rates so that an entire mass 
spectrum can be obtained in less than 100 ms. 
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2.3 Experimental Methods 
2.3.1 Nuclear Magnetic Resonance Spectroscopy 
NMR spectra were recorded on a Bruker DMX 500 spectrometer using 5 mm tubes. 
The frequencies for 'H and 31 P detection were 500 MHz and 202 MHz respectively. 
Typically 'H spectra were acquired with 64-256 transients using a pulse width 45600 
into 16-32 K data points with a relaxation delay of 2-3 s. The water resonance was 
suppressed by presaturation. The 'H chemical shifts were internally referenced to 
dioxane (3.768 ppm relative to TSP at 293 K) . 31 P- {'H} spectra were aquired with 
512-2048 transients using inverse-gated decoupling and a pusle width of 90 0 into 16-
32 K data points with a relaxation delay of 0.2 s. The 31 P chemical shifts were 
externally reference to 85% H3PO4 . 
Coupling constants (J) are given in Hz and NMR signals are described as singlets (s), 
doublets (d), triplets (t), multiplets (m) and broad (br). 
Some NMR spectra for characterisation purposes were also recorded at the NMR 
service, University of Edinburgh. 
2.3.2 Capillary Electrophoresis 
All CE experiments were carried out on an ISCO Model 3850 Capillary 
Electropherograph instrument equipped with an in-line, wavelength detector set to 
254 nm. 
The nucleotide separations were run at 25 kV (90-100 jxA) with a fused silica 
capillary from Composite Metal Services Ltd. of 100 p.m internal diameter. The total 
capillary length was 94 cm (71 cm to detector). 
The capillary was conditioned with 0.1 M NaOH overnight before use, then flushed 
with distilled water and buffer before use. It was then washed with 0.1 M NaOH, 
water and buffer to recondition the capillary after every four runs. 
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The separation buffer was 20 mM Na2HPO 4 at pH 7.75 prepared by dissolving 
Na2HPO4  (1.42 g, 10 mmol,) in 500 ml of water and adjusting the pH with HCI (1 
M). All water for CE was purified using a Millipore Elix 5 system, followed by an 
Elgastat UHQ II deioniser. The buffer solution was then filtered using Varian 0.45 
tm filter paper and degassed by bubbling with nitrogen gas. Samples were injected 
into the capillary by applying a vacuum at the detector end for 5 s. 
2.3.3 Electrospray lonisation Mass Spectrometry 
Negative and positive ion electrospray mass spectrometry was performed on a 
Platform II mass spectrometer (Micromass, Manchester, U.K.). The samples were 
infused at a flow rate of 0.48 ml h' and the ions produced in an atmospheric pressure 
ionisation (API)/ESI ion source. The temperature was 338 K and the drying gas flow 
rate 300 1h'. A potential of 3.0 kV was applied to the probe tip and a cone voltage of 
70 V over 500-2000 Da was used. The quadrupole was scanned at 100 amu s 1 . The 
acquisition and deconvolution of data was performed on Mass Lynx (V. 2.3) 
Windows NT PC data system using the Max Ent Electrospray software algorithm 
and calibrated versus a Nal calibration file. 
2.3.4 X-ray Crystallography 
X-ray crystal structure analyses were performed by Dr. Simon Parsons, Dr. Robert 
Coxhall and Mr. Andrew Parkin of the University of Edinburgh. X-ray data were 
recorded on either a Bruker SMART APEX CCD diffractometer or a Stoe Stadi-4 
diffractometer, equipped with an Oxford cryosystem low-temperature device, using 
graphite-monochromated Mo-Ka radiation. 
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2.3.5 High Performance Liquid Chromatography 
The following equipment was used: a Hewlett-Packard Series 1100 Chemstation, HP 
1100 series quaternary pumps, HP 1100 series vacuum degasser, HP variable 
wavelength D 2 lamp UV/Vis detector, HP enhanced integrator, Rheodyn sample 
injector with 100 tl loop, Hamilton microlitre syringes. All water for HPLC was 
purified using a Millipore Elix 5 system, followed by an Elgastat UHQ II deioniser. 
All solvents were filtered prior to use using Varian 0.45 m filter paper from 
Anachem. The data were analysed using HP chemstation for Windows '95. The 
mode of HPLC employed was reverse-phase and the column used was a Nucleosil 
100 —5 C18 column purchased from Hichrom. 
2.3.6 Microanalyses 
CHIN analyses were performed by the Cl-IN service at the University of Edinburgh, 
Department of Chemistry. 
2.3.7 Mass Spectrometry 
Samples were run by the service at the University of Edinburgh on a Kratos M.S. 
50TC instrument using fast atom bombardment. Xenon gas was used at 7kV and the 
matrix was CH 3 CN/3-NOBA. 
2.3.8 pH Measurements 
These were made using a Corning 145 pH meter equipped with an Aldrich micro 
combination electrode calibrated with standard buffer solutions at pH 4, 7 and 10. 
Readings of the pH meter for D 20 solutions were not corrected for deuterium isotope 
effects and are designated as pH*  values. 
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Values of pK were obtained by plotting the relative concentrations of species (from 
NMR peak integrals) against pH and fitting to the Henderson-Hasselbalch equation 
using the programme KALEIDAGRAPH 44 . 
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This chapter is concerned with the synthesis and crystal structures of some Pt(II) 
aminophosphine complexes using the ligands shown in Figure 3.1, and with their 
potential chelate ring-opening reactions. 
3.1 Experimental 
3.1.1 Synthesis of Aminophosphine Ligands 
3.1.1.1 Ph2P(CH2)3NMe2 (DMDPPA) 
PPh2H (5.5 ml, 5.88 g, 31.6 mmol) was added via syringe to a suspension of Bu tOK 
(9.0 g, 80 mmol) in dry and freshly distilled THF (150 ml). The resulting red 
solution was stirred at ambient temperature for 40 mm. Me 2N(CH2) 3 Cl.HC1 crystals 
(5 g, 31.6 mmol), previously stored in a dessicator over P20 5 , were added and the 
reaction mixture then heated under reflux for 24 hours until the solution had turned 
almost colourless. The solvent was removed in vacuo and the residue taken up in 
10% HC1 solution. The solution was washed with benzene and made alkaline with 
10% NaOH solution. The product was extracted into benzene (3 x 50 ml), washed 
with brine and dried over Na2SO4. After filtration and rotary evaporation, a 
colourless oil was obtained. This was purified by distillation under vacuum: B.p. = 
403 K (0.05 mm Hg). 
Yield = 5.72 g, 21.1 mmol, 66.8%. 
'H NMR (CDC13): ö 1.54-1.63 (2 H, m, -CH 2-), 2.06 (2 H, t, P-CH 2), 2.16 (6 H, s, 2 
CH3), 2.34 (2 H, t, N-CH 2), 7.25-7.45 (10 H, m, 2 Ph) 
31 P NMR (CDC13): 8 -15.18 
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3.1.1.2 Ph2P(CH 2)3NH2 (DPPA) 
This was prepared by an analogous procedure to that described in Section 3.1.1.1 
replacing Me2N(CH2)3C1.HC1 with H 2N(CH2) 3 Cl.HC1. 
Distillation of product: B.p. = 388 K (0.01 mm Hg) 
Yield = 2.41 g, 9.92 mmol, 40.2% 
'H NMR (CDC13): 6 1.10 (2 H, s, H 2N), 1.51-1.65 (2 H, m, -CH 2-), 2.01-2.09 (2 H, 
m, P-CH2), 2.74 (2 H, t, N-CH2), 7.23-7.50 (10 H, m, 2 Ph) 
31 P NMR (CDC1 3): 6 -15.47 
3.1.1.3 Ph2P(CH2)3N(H)Me (MDPPA) 
CHO(H)N(CH2)30H 
3-Amino-1-propanol (50 ml, 0.66 mol) was placed in a flame-dried flask under 
argon. An excess of ethyl formate (150 ml, 1.86 mol) was added dropwise and the 
mixture heated under reflux for 20 h. After cooling, the excess ethyl formate and 
ethanol by-product were removed under vacuum to leave an oily product. 
Yield = 65.37 g, 0.64 mol, 96.6% 
'H NMR (CDC13): 6 1.75 (2 H, m) 3.4 (2 H, m), 3.6 (2 H, m), 6.5 (1 H, br, s), 8.1 (2 
H, s) 
C4H9NO2 (103.14) Caic. %C = 46.60 %H = 8.74 %N = 13.58 
Found %C = 44.92 %H = 8.45 %N = 13.02 
m/z(FAB): 103 
Me(H)N(CH2)30H 
LiAIH4 (18.4 g, 0.49 mol) was placed in a flame dried flask under argon. Dry and 
freshly distilled THF (150 ml) was added slowly and the mixture cooled to 273 K. 
HO(CH2)3N(H)CHO (32.39 g, 0.31 mol) in dry THF (50 ml) was added dropwise 
with mechanical stirring and the reaction heated under reflux for 3 h. Excess LiA1H4 
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was hydrolysed by addition of a 1:1 diethyl ether/water mixture (Ca. 100 ml) and the 
solution was made basic with 20% NaOH. The remaining slurry was filtered to a 
give clear liquid, which was purified by distillation. B.p. = 313 K (0.2 mm Hg). 
Yield = 18.34 g, 0.21 mol, 65.6% 
'H NMR (CDC1 3): ö 1.6 (2 H, q, -CH 2 -) 2.35 (3 H, s, CH 3), 2.7 (2 H, t, C112), 3.2 (1 
H, br, NH), 3.7 (2 H, t, CH 2) 
m/z (FAB): 90 
Me(H)N(CH2)3C1.HCI 
Me(H)N(CH2 )30H (9.24 g, 0.10 mol) was placed in a flame-dried and argon filled 
flask. Dry and freshly distilled chloroform was added slowly and the reaction cooled 
to 0°C. Thionyl chloride (60 ml, 0.82 mol) was added to the solution, dropwise with 
stirring. The reaction vessel was allowed to warm slowly and then heated under 
reflux for 3 h. After cooling, the solvent and excess thionyl chloride were removed 
under vacuum leaving a brown oily residue. After repeated recrystallisation from 
ethanol/diethyl ether, a white solid product was obtained. 
Yield = 10.40 g, 0.07 mol, 69.5% 
'H NMR (CDC1 3): ö 2.3 (2 H, q, -CH 2-) 2.7 (3 H, s, CH 3), 3.1 (2 H, t, CH2), 3.7 (2 H, 
t, CH), 9.6 (1 H, br, NH) 
C4H,0NC12 (144.06) Caic. %C = 33.33 %H = 7.64 %N = 9.72 
Found %C= 32.25 %H=7.32 %N=9.27 
m/z (FAB): 108 {Me(H)N(CH 2)3 C1} 
Ph2P(CH2)3NHMe 
This was prepared by in an analogous procedure to that described in Section 3.1.1.1 
replacing Me 2N(CH2) 3C1.HC1 with Me(H)N(CH2) 3 C1.HC1. 
Distillation of product: B.p. = 403 K (0.01 mm Hg) 
Yield = 2.79 g, 0.01 mol, 39.2% 
'H NMR (CDC13): ö 1.6 (2 H, m, -CH 2-), 2.1 (2 H, m, P-CH 2), 2.4 (3 H, s, C11 3), 2.6 
(2 H, m, N-CH 2), 7.3 (10 H, m, 2 Ph) 
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31 P NMR (CDC1 3 ): 6 -15.45 
C 16H20NP (257.34) Cale. %C = 74.71 %H = 7.78 %N = 5.45 
Found %C = 74.62 %H = 7.62 %N = 5.27 
m/z (FAB): 258 
3.1.1.4 Ph2P(CH2)3N(H) tBu (BDPPA) 
'B U (H)N(CH)OH 
Trimethylene oxide (3.25 ml, 49.97 mmol) was added to freshly distilled acetonitrile 
(50 ml), via a syringe, under argon. Tert-butylamine (10.5 ml, 0.1 mol) was dried by 
refluxing over CaH 2 and also added to the mixture together with lithium 
tetrafluoroborate (10.00 g, 0.11 mol). The reaction mixture was stirred at room 
temperature for 84 h. The solution was diluted with 36% aqueous ammonia (200 ml) 
and a saturated NaCl solution (50 ml). The product was extracted with chloroform (4 
x 60 ml), washed with saturated NaCl solution and dried over Na 2 SO4 . Filtration and 
rotary evaporation yielded a crude product, which was recrystallised from 
ethanol/diethyl ether to give white crystals. 
Yield = 4.39 g, 33.4 mmol, 67.1% 
'H NMR (CDC1 3 ): 6 1.1 (9 H, s, 'Bu), 1.7 (2 H, m, CH 2), 2.8 (2 H, t, CH 2), 3.8 (2 H, 
t, CH) 
C71417N0 (131.25) Cale. %C= 64.12 %H= 12.98 %N= 10.69 
Found %C= 63.78 %H= 13.44 %N= 10.42 
m/z(FAB): 132 
tB u (H)N(CH)CIHCI 
The chloride was prepared by an analogous procedure to that described in Section 
3.1.1.3, replacing Me(H)N(CH 2) 30H with 'Bu(H)N(CH 2)30H. A shiny off-white 
solid was obtained from recrystallisation from ethanol/diethyl ether. 
Yield = 4.05 g, 21.8 mmol, 79.0% 
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'H NMR (CDCI 3): 6 1.5 (9 H, s, 'Bu), 2.5 (2 H, m, CH 2), 3.1 (2 H, m, CH2), 3.7 (2 H, 
t, CH) 9.3 (1 H, br, NH) 
C7H 1 6NC1.HC1 (186.15) 	Caic. %C = 45.16 %H = 9.14 %N = 7.53 
Found %C=45.07 %H=9.31 %N=7.30 
m/z (FAB): 150 { tBu(H)N(CH 2) 3 C1} 
Ph2P(CH2)3N(H) tBu 
This was prepared as described in Section 3.1.1.1 replacing Me 2N(CH2)3 C1.HC1 with 
tBu(H)N(CH2) 3C1.HC1. 
Distillation of product: B.p. = 416 K (0.01 mm Hg) 
Yield = 3.48 g, 11.6 mmol, 55.7% 
'H NMR (CDC13 ): 6 1.1 (9 H, s, 'Bu), 1.6 (2 H, m, -CH 2-), 2.1 (2 H, m, P-CH 2), 2.7 
(2 H, t, N-CH 2), 7.2 (10 H, m, 2 Ph) 
31 P NMR (CDC1 3 ): 6 -15.3 
C 19H26NP (299.43) Caic. %C = 76.25 %H = 8.70 %N = 4.68 
Found %C75.05 %H8.65 %N4.35 
m/z (FAB): 301 
3.1.2 Synthesis of Platinum Complexes 
3.1.2.1 [Pt(1 ,5-cyclooctadiene)C12] 
Potassium tetrachioroplatinate (1.04 g, 2.76 mmol) was dissolved in 16 ml distilled 
water and filtered. Glacial acetic acid (24 ml) was added to the deep red filtrate 
followed by 1,5 cyclooctadiene (1.00 ml, 8.00 mmol), via a syringe, under argon. 
The reaction mixture was then stirred rapidly and heated to 363 K. Over 30 mm, the 
red solution became pale yellow and some fine off-white crystals were deposited. 
Some solvent was removed under vacuum to leave a volume of about 15 ml. The 
product formed as pale yellow needle-like crystals, which were filtered off and 
washed with water, ethanol and diethyl ether. 
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Yield = 0.80 g, 2.13 mmol, 85.4% 
C8H,2C12Pt (374.18) Caic. %C = 25.67 %H = 3.21 
Found %C=25.46 %H= 3.13 
3.1.2.2 [Pt{Me2N(CH2)3PPh2-P}2C12] (24) 
Me2N(CH2) 3PPh2 (0.11 g, 0.30 mmol) and Pt(COD)C1 2 (0.16 g, 0.59 mmol) were 
dissolved in the minimum amount of dichloromethane. The resulting solution was 
stirred at room temperature overnight, then diethyl ether was added to precipitate the 
product. A small amount of product was filtered off and the filtrate left overnight to 
allow more solvent to evaporate. White crystals formed. 
Yield = 0.22 g, 0.28 mmol, 92.8%. 
'H NMR (CDC1 3):8 1.71-1.73 (2 H, m), 2.11 (6 H, s, 2 CH 3), 2.16-2.11 (2 H, m), 
2.26-2.32 (2 H, m), 7.25-7.53 (10 H, m, 2 Ph) 
3 'P NMR (CDC13): 5 8.45 'J(P-Pt) 3643 Hz 
C34H44N2P 2C12Pt (808.72) 	Caic. %C = 50.50 %H = 5.45 %N = 3.47 
Found %C=50.29 %H= 5.44 %N=3.39 
m/z (FAB): 773 (M +-C1) 
The following complexes were prepared by an analogous method to that described 
for complex 24. 
3.1.2.3 [Pt{H2N(CH2)3PPh2-P,N}2]C12 (25) 
DPPA ligand (0.129 g, 0.53 mmol) was used as described in Section 3.1.2.2. The 
reaction solution was refrigerated overnight after addition of diethyl ether and a 
white powdery product was formed which was filtered and washed with diethyl 
ether. Crystals suitable for X-ray structure determination were obtained by slow 
evaporation of a nitromethane solution at room temperature. 
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Yield = 0.177 g, 0.26 mmol, 98.1% 
'H NMR (CDC1 3): 1.84-1.99 (2 H, m), 2.60-2.69 (2 H, m), 3.18-3.20 (2 H, m), 
6.06-6.21 (2 H, br, NH 2) 7.25-7.53 (10 H, m, 2 Ph) 
31 P NMR (CDC1 3 ): 5 -2.47 'J(P-Pt) 3285 Hz 
C30H36N2P2C12Pt (752.60) Caic. %C = 47.87 %H = 4.83 %N = 3.72 
Found %C = 47.26 %H = 5.04 %N = 3.71 
3.1.2.4 [Pt{Me(H)N(CH2)3PPh2}2C1]CI (26) 
MDPPA ligand (0.139 g, 0.54 mmol) was used as described in Section 3.1.2.2. The 
product yielded on addition of diethyl ether was an oily residue. The solvent was 
removed under vacuum and the product washed with more diethyl ether. After 
repeated washing and decanting a white solid remained. The product was 
recrystallised from dichloromethane and diethyl ether, filtered and washed. A single 
crystal suitable for X-ray diffraction was obtained from the CDC1 3 NMR solution. 
Yield = 0.121 g, 0.15 mmol, 55.5% 
31 P NMR (CDC13): ö 3.82 (d) 'J(P-Pt) 3728 Hz, 4.89 (d) 'J(P-Pt) 3166 Hz 
C32H40N2P2Cl2Pt (780.66) 	Calc. %C = 49.23 %H = 5.18 %N = 3.59 
Found %C=48.84 %H=5.63 %N3.18 
3.1 .2.5[Pt{tBu  (H)N(CH2)3PPh2-P}2C12] (27) 
BDPPA ligand (0.165 g, 0.55 mmol) was used as described in Section 3.1.2.2. After 
addition of diethyl ether a white precipitate formed slowly. After 24 h the product 
was filtered and washed with more ether. Crystals suitable for X-ray structure 
determination were obtained by slow diffusion of diethyl ether into a 
dichloromethane solution at 277 K. 
Yield = 0.127 g, 0.15 mmol, 54.6% 
31 P NMR (CDC13): 5 8.85 (s) 'J(P-Pt) 3665 Hz 
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C38H52N2P2C1 2Pt (864.83) 	Caic. %C = 52.78 %H = 6.02 %N = 3.24 
Found %C = 52.93 %H = 6.09 %N = 3.01 
3.1.2.6 [Pt(1 ,5-cyclooctadiene)MeCI] 
A slight excess of SnMe4 (0.2 ml, 1.47 mmol) was added to a suspension of 
Pt(COD)C1 2 (0.50 g, 1.34 mmol) in a 1:1 mixture of dichioromethane and methanol. 
The solution was left to stir for 72 h. The solvent was then removed under vacuum 
at 273 K to give a white powdery product, which was washed three times with 
diethyl ether. The product was recrystallised from dichloromethane and diethyl 
ether. 
Yield = 0.285 g, 0.81 mmol, 60.1%. 
'H NMR (CDCI 3): 6 0.89(3 H, t, CH,) 2J(Pt-H) = 71.2 Hz, 2.1-2.7 (8 H, m, 4 CH2), 
4.50 (2 H, t, 2 CH,) 2J(Pt-H) = 76.5 Hz, 5.59 (2 H, t, 2 CH) 2J(Pt-H) = 35.4 Hz 
C9H 15CIPt (353.77) Caic. %C = 30.55 %H = 4.28 
Found %C=29.98 %H=3.87 
3.1.2.7 [Pt{Ph2P(CH2)3NMe2-N,P}MeCI} (28) 
Pt(COD)MeC1 (0.222 g, 0.63 mmol) was dissolved in dichioromethane. DMDPPA 
ligand (0.167 g, 0.62 mmol) was dissolved in the minimum amount of 
dichloromethane and added dropwise. The mixture was left to stir at room 
temperature overnight. The same volume of diethyl ether was then added yielding a 
cloudy precipitate. The flask was stored at 277 K overnight and a white crystalline 
product was obtained which was filtered and washed with ether. Crystals suitable for 
X-ray diffraction were obtained by slow diffusion of diethyl ether into a 
dichioromethane solution at 277 K. 
Yield =0.211 g,0.41 mmol,65.1% 
'H NMR (CDC13): ö 0.36 (3 H, t, Pt-CH3) 2J(Pt-H) = 70.1 Hz, 2.79 (6 H, t, 2 N-CH 3) 
3J(Pt-H) = 12.1 Hz 
103 
Synthesis and Characterisation of Platinum Aminophosphine Complexes 
C 18H25NPC1Pt (516.94) 	Calc. %C =41.82 %H = 4.84 %N = 2.71 
Found %C=41.l1 %H=4.55 %N=2.39 
3.1.2.8 [Pt{Ph2P(CH2)3NMe2-N,P}C12] (29) 
Pt{Ph2P(CH2)3NMe2-N,P}MeC1 (0.050 g, 0.096 rnmol) was dissolved in THF and a 
3-fold excess of 5 M HCl (0.055 ml, 0.287 mmol) was added dropwise. An 
immediate yellow cloudy precipitate was formed. The reaction mixture was left to 
stir overnight. The yellow product was then filtered off, washed with diethyl ether 
and dried at 373 K. 
Yield = 0.039 g, 0.072 mmol, 74.7% 
C 17H22NPC12Pt (537.35) 	Calc. %C = 37.99 %H = 4.10 %N = 2.61 
C 17H22NPC12Pt.HC1 (573.81) CaIc. %C = 35.57 %H = 3.84 %N = 2.44 
Found %C = 34.94 %H = 3.63 %N=2.21 
3.2 Results and Discussion 
3.2.1 Preparation and Properties of Ligands 
A series of ligands of the form Ph 2P(CH2)3NRR' was prepared, with various R 
groups, the structures of which are shown in Figure 3.1. A number of methods has 
been reported for the preparation of aminophosphine ligands.' 4 In this work the 
favoured starting materials were amino-chlorides which were either commercially 
available (see Section 2.3.1) or prepared as described below. The phosphination of 
the amino-chloride was achieved by reaction with the diphenylphosphine anion 
(formed in situ by the reaction of tert-potassium butoxide and diphenyiphosphine) in 
THF under argon, affording the ligand. (Scheme 3.1) 
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Figure 3.1 Structures of ligands and abbreviations 
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Ph 2PH + RR'N(CH 2 )3 CLHCI 
	
RR'N(CH 2 )3 PPh 2 + 2HCI 
Scheme 3.1 Preparation of ligands from the amino-chloride 
For the preparation of the MDPPA ligand, the 3-aminopropanol was reacted with 
ethyl formate to give N-formyl-3-hydroxypropylamine which was then reduced to 
form N-methyl-3-hydroxypropylamine. 5 This was chlorinated with thionyl chloride 















SOd 2 I CHCI3 	
HO N 
H 	 H 
Scheme 3.2 Preparation of N-methyl-3-chloropropylamine 
For the BDPPA ligand, the amino-alcohol was prepared by using LiBF 4 to promote 
the ring-opening aminolysis of methylene oxide. 6 This was then chlorinated in the 
same manner as for MDPPA above to give the necessary amino-chloride (Scheme 
3.3). 
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LiBF4 I CH 3CN 
El + tB U NH o 	 HO 	 N 
H 
SOCl2 / CH C 1 3 
Cl
N /tB u 
.HCI 
H 
Scheme 3.3 Preparation of N-(tert-butyl)-3 -chioropropylamine 
The ligands were obtained as viscous oils, which were all soluble in organic solvents. 
The oily ligands were easily purified by distillation, with boiling points ranging from 
388-416 K (at 0.01 mm Hg). 
The 'H NMR spectra of the ligands in CDC1 3 showed the expected peaks with the 
backbone -CH 2- giving multiplets and the R groups on the amine giving singlet 
resonances. The 31 P{'H} NMR also showed singlet resonances in the region of ö -15 
ppm. In some cases minor impurities were observed with ö -35 ppm. These were 
attributed to the formation of oxidised phosphine product and were seen to increase 
with time if the ligands were not stored in an inert atmosphere. 
3.2.2 Structures and Properties of Platinum Aminophosphine 
Complexes 
The ligands prepared in Section 3.1 were used to prepare square planar platinum(II) 
complexes by reaction with platinum( 1,5 cyclooctadiene) starting materials. 
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3.2.2.1 Bis-aminophosphine Complexes 
Complexes 24-27 were prepared by reaction of two mole equivalents of the 
appropriate ligand with [Pt(COD)C1 2 ] in dichioromethane solution. (Scheme 3.4) 
The {Pt(COD)C1 2] used in this work was either prepared as described in Section 
3.1.2. 17  or purchased commercially. Since the resulting complexes are more polar 
than either starting material they could be precipitated from the reaction mixture by 
the addition of diethyl ether. 
/01 	
CH2Cl2 
Pt + 2 Ph2 P(CH 2 )3 NRR' 	 Complexes 24 - 27 
Cl 
Scheme 3.4 Preparation of bis-aminophosphine Pt(II) complexes 
Complexes 24-27 were initially characterised by elemental analysis, which 
established a stoichiometry of two ligands per platinum. Further analysis, by 31 P 
NMR, allowed the detection of chelate ring formation. All the 31 P resonances shifted 
downfield upon coordination to Pt from —15 ppm for the free ligands to —2.5 to 8.9 
ppm for the bound ligands. The value of the 'J(P-Pt) coupling constants allowed 
assignment of the atom in the trans position as N or Cl (see Section 2.1.1.1). This 
indicated whether the ligands were chelated or not as detailed below. 
[Pt{Me 2N(CH2) 3PPh2-P} 2C1 2] (24) - The 31 P NMR spectrum showed only a singlet 
resonance and 195Pt satellites with a 'J(P-Pt) of 3643 Hz. The single peak indicated 
that the two ligands are equivalent. This could be achieved by having both ligands 
chelated (bound through P and N) or ring-opened (bound only through P). The large 
coupling constant suggests that the trans ligand is most likely to be Cl due to its 
W. 
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lower trans influence compared to N (Section 2.2.1.1). This suggests that both 
ligands are ring-opened. 
[Pt{H 2N(CH2)3PPh2-P,N} 2JC1 2 (25)— As for complex 24, both ligands are equivalent 
and only a single resonance was observed. The coupling constant in this case is 3285 
1-Iz suggesting N in the trans position (higher trans influence than Cl). The structure 
of 25 is therefore fully chelated. 
[Pt{Me(H)N(CH 2) 3PPh2 } 2C1]Cl (26)— The spectrum of this complex contained two 
resonances, both doublets with 195Pt satellites, indicating two inequivalent P ligands. 
Resonance A at 3.82 ppm had a 'J(P-Pt) of 3768 Hz (31 P trans to Cl) and resonance 
B had a 'J(P-Pt) of 3166 Hz (31 P trans to N). This suggested a species with one 
chelated ligand (A) and one ring-opened ligand (B). The splitting of each peak to 
form a doublet is due to the 2J(P-P) coupling of the two P, confirming the cis 
geometry of the complex. (see Section 2.2.1.1) 
[Pt{'Bu (H)N(CH 2)3PPh2-P} 2Cl2] (27) - As for complex 24, a single resonance was 
observed with a 'J(P-Pt) of 3665 Hz (31 P trans to Cl) indicating a fully ring-opened 
species. 
The structures of bis-aminophosphine complexes 24 - 27 are shown in Figure 3.2. 
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rj 	
H OH3 	 / 
Ph2 P\ Cl/ 	 Ph2 P\ /N_H 
Pt Pt 
\ /\ 	 / 
Ph2 P 	CI Ph 2 P 	Nç—H 
N 
CH 3 
Complex 24 	 Complex 25 
/CH3 
Ph2P\ /N—H 	 Ph2 P\ Cl/  
Pt 	 Pt 
/\ /\ 
Ph2 P 	Cl 	 Ph2P 	CI 
H 	
\f~ 
Complex 26 	 Complex 27 
Figure 3.2 Structures of platinum aminophosphine complexes 24 - 27 
Based on the 31 P NMR assignments the structures of the complexes formed by 
aminophosphine ligands with platinum(II) vary from fully ring-opened (for 
DMDPPA and BDPPA ligands) to fully ring-closed (for DPPA) with an intermediate 
open/closed complex (for MDPPA). This variation reflects the increasing steric bulk 
of the R groups on the amine of the ligand, which hinders the coordination of the N. 
(Figure 3.3) 
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Increasing Steric Bulk 
H H 
H 	 /C_H 
I"\CH 	 H 
/'\\H 
HHH 
I/,,,,,• /H 	 /H 
H H 
BDPPA 	 DMDPPA 	 MDPPA 	 DPPA 
both open 	 both open 	 open/closed 	both closed 
Increasing Chelation 
Figure 3.3 Relationship between steric bulk on amine and chelate formation 
Most of the complexes showed good solubility in organic solvents such as 
dichioromethane, but were also water soluble to varying extents. Complexes 25 and 
26 were the most soluble at concentrations in excess of 20 mM, while complex 24 
could only be dissolved up to 5 mM. Complex 27 was not soluble in water, probably 
due to the presence of the bulky, non-polar tert-butyl groups. Water solubility could 
be achieved for this complex by lowering the pH of the solution to allow protonation 
of the amine groups in the ligands. Solutions of 20 mM were easily be obtained by 
adjusting to pH-4. 
3.2.2.2 Mono-aminophosphine Complexes 
As described in the previous section, reaction of the aminophosphine ligands with 
[Pt(COD)C12] always afforded the bis-aminophosphine complexes. When 
[Pt(COD)C12] was reacted with only one mole equivalent of ligand, the bis product 
was still formed, and some Pt starting material remained. The preparation of a 
mono-aminophosphine complex was therefore undertaken by a different route 
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(Scheme 3.5). [Pt(COD)MeC1] was prepared according to a published procedure  
and characterised according to previous 'H NMR data. 8 The methyl group was 
clearly distinguished as a sharp singlet with a shift of 0.89 ppm. This peak had 
satellites due to 1 95p coupling with 2J(Pt-H) = 71.2 Hz. Two distinct resonances 
were also observed for the olefinic hydrogens. The peak at higher field (4.50 ppm) 
had an associated 2J(Pt-H) value of 76.5 Hz and was assigned to the olefinic group 
trans to chloride. The second peak (5.59 ppm) had a 2J(Pt-H) value of 35.4 Hz and 
was assigned to the olefinic group trans to methyl. This was determined by the 
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/ CH 2 Cl2 
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Scheme 3.5 Synthesis of [Pt {Ph 2P(CH 2) 3NMe2-P,N} Cl2] 
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The DMDPPA ligand was then reacted with the [Pt(COD)MeC1] in a 
dichloromethane solution. Microanalysis confirmed that the mono complex had been 
formed. The 'H NMR spectrum showed a high frequency shift of the N(CH3) 2 
resonance from 2.16 ppm for free DMDPPA to 2.79 ppm, indicating that the ligand 
is N-bound. This was confirmed by the presence of 3J(Pt-H) coupling for the 
N(CH3)2 peak (12.1 Hz). The Pt-CH 3 resonance was at 0.36 ppm and had an 
associated 2J(Pt-H) coupling of 70.1 Hz, similar to the parent complex. This 
resonance was further split by 3 J(P-H) coupling (4.2 Hz) suggesting that the P from 
the ligand was cis to the methyl group on the Pt. The resulting complex 28, is shown 
in Scheme 3.5. 
To allow direct comparison between the mono-aminophosphine and the bis-
compound (complex 24) the methyl ligand was replaced by chloride. This procedure 
was based on a published method for a similar series of Pt(II)-aminophosphine 
complexes (cis-[PtMe 2L2] where L = H2NC6H4PPhR, R = H, Me, Ph). 9 Complex 28 
was reacted with a 3-fold excess of HC1 in THF solution to yield a yellow solid 
product. This product, complex 29 (Scheme 3.5), was confirmed by microanalysis to 
have formed as the hydrochloride salt due to the high excess of HC1 in the reaction. 
The methyl resonance from the 'H NMR had disappeared confirming that the 
reaction was complete. 
Both the mono-aminophosphine complexes 28 and 29 showed very poor solubility in 
water so proved to be unsuitable for biological studies such as nucleotide and DNA 
binding. 
3.2.2.3 X-ray Structure Determination 
The X-ray crystal structures determined for complexes 24, 25 and 27 confirmed the 
structures proposed on the basis of 3 'P NMR data (Figure 3.2). Complex 26 turned 
out to be a mono-aminophosphine complex with a chelated ligand and two chloride 
ligands trans to P and N (Figure 3.4). 
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Complex 26A 	 Complex 26B 
Figure 3.4 Bis- and mono-Pt(II) complexes formed by MDPPA ligand 
It likely that the mono-complex 26B was present as a minor species in the NMR 
solution and that this species crystallised in preference to the bis-complex 26A 
despite this species being in a high excess as observed from the 31 P NMR spectrum. 
This seems probable since further preparations of complex 26 have always produced 
a mixture of complexes 26A and 26B and the bis-complex has proved difficult to 
isolate (see Section 3.2.2.1). 
All data collection and refinement details for the bis-aminophosphine complexes are 
given in Table 3.1, and for the mono-aminophosphine complexes in Table 3.2 The 
X-ray structures were solved by Dr Simon Parsons, Dr Robert Coxall and Mr 
Andrew Parkin of the University of Edinburgh. 
Full atomic coordinates for all the structure determined are given in the Appendix to 
this thesis. 
114 
Synthesis and Characterisation of Platinum Aminophosphine Complexes 












Reflections for cell 
z 
Density/g cm 3 




































































































Table 3.1 Details of X-ray data collection and refinements for 
bis-aminophosphine complexes 
liEu 
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Complex 26B 28 
Empirical Formula C1 9H23 C1 1 NPPt C 18H25C1NPPt 
M 881.39 516.90 
Temperature/K 220(2) 150(2) 
Space Group P-i P21/n 
Crystal System Triclinic Monoclinic 
Wavelength VA 0.71073 0.71073 
a/A 11.089(4) 9.027(2) 
b/A 11.223(4) 18.889(4) 
C/A 15.198(5) 10.928(2) 
of 91.440(17) 90 
Or 109.712(16) 94.772(18) 
YP 117.034(14) 90 
Volume/A3 1549.7(9) 1857.0(7) 
Reflections for cell 53 78 
z 2 4 
Density/g cm 3 1.889 1849 
Absorption coefficient .i/mm' 5.539 7.783 
F(000) 848 1000 
Crystal Description Colourless block Colourless block 
Crystal Size/mm 0.31 x 0.31 x 0.31 0.23 x 0.21 x 0.18 
Orange!° 2.79-30.03 2.51-25.00 
Index Ranges (h,k,l) -15-14, -15-15, 0-21 -10-10, 0-22, 0-12 
Reflections collected 9034 3680 
Independent reflections 9031 3260 
Scan Type (0-0 
Data/restraints/parameters 9031/12/302 3260/0/203 
Goodness of fit on F 2 1.013 1.008 
Conventional/weighted R 0.0527/0.1171 0.0270/0.0570 
Maximum th 0.002 0.002 
Table 3.2 Details of X-ray data collection and refinements for 
mono-aminophosphine complexes 
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Selected bond angles and lengths from the X-ray structures are listed in Table 3.3 








24 25 27 26B 28 
2.247(2) 2.2565(11) 2.2570(11) 2.2064(17) 2.1849(14) 
2.251(2) 2.2543(11) 2.2534(12) 
2.354(3) 2.35 10(11) 2.3747(17) 2.3815(14) 
2.361(2) 2.3588(12) 2.2978(17) 

























































Table 3.3 Selected bond lengths/A and angles/ ° for complexes 24, 25, 26B, 27, and 
28 with estimated standard deviations in parentheses 
ifl'; 
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C12 
II 
Figure 33 X-ray crystal structure of [Pt{Me 2N(CH2)3PPh2-P}2C12 (24) 
plotted using Cerius2' °, H atoms omitted 
[Pt{Me2 N(CH2)3PPh2-P}2C12]. CH2Cl2 (24) 
The structure of complex 24 is shown in Figure 3.5. It is square-planar with a small 
degree of distortion. The structure was also shown to contain a molecule of 
dichloromethane from the recrystallisation solvent. The PI-Pt-P2 angle, 99.760, is 
rather larger than expected for a square-planar complex. This is caused by the steric 
crowding around the phosphorus atoms due to the presence of the phenyl rings. The 
opening up of this angle has resulted in the reduction of the other three angles in the 
118 
Synthesis and Characterisation of Platinum Aminophosphine Complexes 
square plane to less than 90°. The trans angles, P1-Pt-Cl I and P2-Pt-C12, of 169.84 ° 
and 173.61 0, respectively, also show deviations from the ideal value of 180 °. The 
distortion around the platinum can be considered by looking at the displacement of 
the two chloride ions from a plane defined by the Pt and two P atoms. This would be 
zero for an ideal square-planar arrangement, a larger displacement indicating more 
distortion in the complex. The least-squares plane through Pt!, P1 and P2 was 
calculated using SHELXTL 1 ' and the deviations of Cli and C12 were shown to be 
0.2029 A and -0.2170 A respectively. Both the Pt-P bond lengths of -2.25 A are 
consistent with average lengths reported from a compilation of data from the 
Cambridge Structural Database. 12  The Pt-Cl bond lengths of 2.354(3) and 2.361(2) 
A are longer than average (2.32 A' 2) due to the high trans influence of the P ligands. 
The orientation of the DMDPPA ligands appears to be fixed by the presence of 
intramolecular it-it interactions between the phenyl rings of each of the ligands in the 
structure (Figure 3.6). 
z- 
Figure 3.6 View of complex 24 showing it-stacking between ligands (plotted using 
SI-IELXTL") 
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As can be seen from Figure 3.6 the two aromatic rings are not directly aligned in a 
face-to-face geometry but are offset from one another. This parallel displacement 
can be described by the positioning of a vector from the central point of one ring to 
the central point of the other. (Figure 3.7) 
ring 
normal 	 - 
r2 
= centre-centre distance 
c 	 r 	= angle between normal to ring plane and 
1 
/ 	 centre vector 
= parallel displacement between rings 
i'l= interplane angle between ring 1 and ring 2 
Figure 3.7 Definitions of angles and distances relating two it-stacked phenyl rings 
The centre-centre distance (c-c) is 3.57 A which is typical for it-interactions.' 3 The 
two rings are offset by an angle of 22.5 ° from the normal to the lower plane (n-c-c) 
which gives a parallel displacement (n-c) of 1.37 A between the two rings. The 
upper ring is not completely co-planar with the lower ring but is tilted at a slight 
angle (rl-r2) of 7.3 ° 
The two planes are sufficiently separated that there is a favourable van der Waals 
interaction between the atoms in the two rings. However the geometry of the overlap 
is predominantly due to electrostatic interactions. This interaction has been 
described by Hunter and Sanders 14  based on a simple model of charge distribution in 
a it-system which is summarised in Figure 3.8. The phenyl ring is considered to be 
made up of a positively charged a framework sandwiched between two negatively 
charged it electron clouds. The dominant interaction between two stacked phenyl 
rings will be the repulsion of the closest approaching it-clouds (Figure 3.8(a)). If the 
two rings are then offset from one another favourable interactions can occur by 
attraction between the CT-framework of one ring and the it-electron cloud from the 
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other. (Figure 3.8 (b)). This attraction is further optimised in the case of the phenyl 
rings by the polarisation of the C-H bond giving a + charge over the electron cloud. 
The repulsion between the it-clouds is also reduced due to the electron withdrawing 
nature of the P atom attached to the ring reducing the electron density in the it-cloud. 








Figure 3.8 Schematic illustration of the attractive electrostatic interaction between 
the cy framework and the it electron density in an offset it-stacked geometry (adapted 
from reference 13) 
The offset of 1.37 A and interplane angle of 7.3 ° are within the limiting geometries 
required for attractive interactions between the rings, as determined in reference 14 
from studies on porphyrin it-it interactions in solution and solid state. 
[Pt{H2N(CH2)3PPh2-P,N}2]C12.2CH3NO2.H20 (25) 
The structure of complex 25 is shown in Figure 3.9 and confirms the presence of two 
six-membered chelate rings in the complex. The resulting species is a dianion and 
hence two chloride counter ions are present. The structure also contains two 
molecules of nitromethane and a molecule of water. Despite the chelation of the 
aminophosphine ligands, the structure shows many features similar to complex 24. 
The P1-Pt-P2 angle is opened up to 98.16 ° and the other cis angles reduced below 
90° accordingly. The trans angles are distorted from square-planar at 171.67(10) ° 
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and 171.43(l0)° for P1-Pt-N2 and P2-Pt-NI, respectively. A least-squares plane was 
calculated through Pt 1, P1 and P2 and the two N atoms are displaced from this plane 
by —0.2519 A and 0.1347 A. This shows the complex to be distorted from square-





Figure 3.9 X-ray crystal structure of [Pt {H 2N(CH 2 )3PPh2-P,K}2]Cl2 (25) 
plotted using Cerius2 10, H atoms omitted 
The six-membered rings show some steric strain as indicated by the bond angles in 
the alkyl chain which show deviations from ideality. In ring 1, these angles are 
115.6(3)', 113.3(4) 0 and 112.190, and in ring 2 they are 113.6(3), 113.5(4)' and 
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112.7(3). Both rings are in chair conformations as shown in Figure 3. 10. one 
orientated above the Pt plane and one below. The Pt-P bond lengths are again close 
to the mean reported values, as for complex 24 despite the change of ligand in the 
trans position from Cl to N. The N bond lengths are longer than the reported mean 
value for primary amines coordinated to platinum (2.04 A' 2), at 2.116(3) and 
2.129(3) A. This is again due to the high trans influence of the P ligands. The 
structure showed no it-stacking. This is because the Pt-P bond is constrained in a 




Figure 3.10 Ring conformations of chelate rings in complex 25 
(red = Pt, pink = P. blue = N, white = C) 
[Pt{tBu  (H)N(CH2)3PPh2-P}2C12] (27) 
The structure of complex 27 is shown in Figure 3.11 and shows the same ring-
opened structure as complex 24. Again distortion from the ideal square-planar 
geometry can be observed with an increased P1-Ptl-P2 bond angle of 102.03(4) °. 
The trans angles P1-Pt-Cu and P2-Pt-Cl2 are 173.71 (4) 0 and 170.99(4)0 , 
respectively. Calculation of a least-squares plane through Ptl, P1, P2 shows the 
displacement of CI  to be 0.0756 A and C12 to be 0.0650 A from the plane. This 
shows the distortion to be much less than for the analogous complex 24. The Pt-P 
bond lengths are as expected at 2.2570(11) A and 2.2534(12) A and the Pt-Cl bond 
lengths are again longer than mean values due to the P trans influence. In contrast to 
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24, no it-stacking between the two ligands is observed and this could be the reason 
for the reduced distortion around the platinum. Ligand 2 lies almost in the platinum 
square-plane, while ligand 1 lies almost perpendicular above the plane. This is also 
different from structure 24 in which the molecule is close to C2 symmetric with both 




Figure 3.11 X-ray crystal structure of [Pt( tBu (H)N(CH 2 )3 PPh2-P}2C12] (27) 
plotted using Cerius2 t0, H atoms omitted 
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[Pt{Ph 2P(CH2 )3NMe(H)-P,N}Cl21.3CHC13 (26B) 
The structure determined for complex 26B showed a ,nono-aminophosphine complex 
with one MDPPA ligand chelated, forming a six-membered ring, and two cis 
chloride ligands (Figure 3.12). The structure contained three molecules of CDC13 
from the NMR solvent in which the crystal was formed. The geometry is still 
distorted from square-planar since the P1-Pt-NI angle is increased to 93.75(16)° to 
minimise strain in the ring. The trans angles are 178.95(6) 0 for P1-Pt-Gil and 
174.18(17) °  for Nl-Pt-C12. These values are closer to the ideal values than for the 
bis-structures. The Cii and C12 ligands are displaced from the P1-Pt-NI least-
squares plane by 0.0199 A and 0.1272 A, respectively. This distortion is less than 
observed for the bis-chelated complex 25. The six-membered chelate ring is again 
strained as shown by the angles in the alkyl chain: 1 13.8(5)', 114.6(6)' and 
114.4(6)'. Again the chelate ring adopts a chair conformation as shown in Figure 
3.13. The Pt-P bond length is significantly shorter than the mean reported value 
12 
and the values determined for the previous bis-aminophosphine complexes, at 
2.2064(17) A. This is unexpected because it cannot be attributed to the inclusion of 
the P in a six-membered ring, since this does not affect the bond length in complex 
25. Also it cannot be attributed to the Cl ligand in the trans position which did not 
affect the bond length in complexes 24 and 27. The Pt-N bond length is the same as 
the mean reported value for a secondary amine (2.06 Al 2 ) at 2.060(5) A. This is 
shorter than in complex 25 since the trans ligand is Cl which has a much smaller 
trans influence than P. 
125 




Figure 3.12 X-ray crystal structure of [Pt {Ph 2P(CH2)3NMe(H)-P,N}C12] (26B) 
plotted using Cerius2 10 , H atoms omitted 




Figure 3.13 Ring conformations of chelate rings in mono-aminophosphine 
complexes (red = Pt, pink = P. blue = N, white = C) 
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[Pt{Ph 2 P(C H2) 3NMe2-P, N}MeC] (28) 
Complex 28 (Figure 3.14) has a structure analogous to complex 26B. The DMDPPA 
ligand is chelate ring-closed with a methyl ligand present cis to the P and a Cl ligand 
cis to the N. The P1-Pt-NI bond angle is increased to 95.58(12) ° as for complex 26B 
and the trans angles are 170.28(5)' for P1-Pt-Cl 1 and 176.02(18) 0 for NI-Pt-Cl. The 
least-squares plane for Pt 1, P1 and N I was calculated and the Cli and C  atoms are 
displaced from this by —0.3405 A and —0.0189 A, respectively. This structure is 
therefore more distorted from an ideal square-plane than complex 26B. The angles 
for the alkyl chain in the six-membered ring are 113.6(4) 0. 113.4(5) ° and 117.7(4)0 , 
the ring is again a strained chair conformation (Figure 3.13). The unexpectedly short 
Pt-P bond is again a feature and the long Pt-N bond length of 2.20(4) A indicates the 
high trans-influence of the methyl ligand. This is greater even than that seen for P in 
the trans position in complex 25. The reported mean length for a tertiary amine to 
platinum is only 2.108 A' 2 . The Pt-C(methyl) bond length, 2.055(5) A is shorter 
than average (2.107 A' 2). 
CII 
Figure 3.14 X-ray crystal structure of [Ptf Ph 2P(CH2)3NMe2-P,N) MeCl] (28) 
plotted using Cerius2 10 , H atoms omitted 
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3.3 Ch&aton of Amnophosphine Ugands 
3.3.1 pH Titrations 
In order to determine the effect of pH on the chelation of the ligands in complexes 
24-27, pH titrations were undertaken. Only the results for complexes 25 and 26A are 
reported here since the titrations were not successful for complexes 24 and 27. 
Complex 24 underwent unusual hydrolysis reactions in aqueous solution and these 
are detailed further in the next section, while complex 27 was soluble only in water 
under conditions of low pH. It can be assumed that under these conditions the free 
amine arms of the ligand are protonated resulting in a charged species with increased 
water solubility compared to the parent complex. When the pH was increased above 
4, the complex precipitated out of solution making NMR detection impossible. 
For the pH titrations, a 20 mM solution of each complex in D 20 was prepared and 
the pH adjusted with 0.1 M DN0 3 and 0.1 M NaOD. Details of pH measurement 
and NMR parameters are given in Section 2.2. 31 P spectra were recorded at several 
different pH values and the results are discussed in the following sections. 
[Pt{H2N(CH2)3PPh2-P,N}2]C1 2 (25) 
The 31 P spectra at various pH values are shown in Figure 3.15. At high pH only one 
single peak (A) can be seen at ca. -1.89 ppm. This corresponds to the fully ring-
closed species, as observed in the CDC1 3 spectrum. The 'J(Pt-P) coupling constant 
of 3199 Hz confirmed the presence of N in the trans position. As the pH was 
lowered two doublets emerged at 4.25 (C) and 0.56 (B) ppm. These correspond to 
the species formed by the opening of one of the chelate rings. The two P are thus 
inequivalent and have 2J coupling giving two doublets. The 'J(Pt-P) coupling 
constants are 3272 Hz and 3625 Hz, confirming N and Cl, respectively, in the trans 
positions. The relative amount of each species was determined from the peak 
integrals and plotted against pH (Figure 3.16). The pK value for the ring-closing 
reaction was determined to be 2.93 ± 0.05 using Kaleidagraph' 5 . This means that 
the pH must be lowered to less than 3 before half of the complex present is ring- 
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opened. This is in contrast to the analogous [Pt(H2N(CH2)2PPh 2)2 ]C!2 which 
contains two five-membered and shows no ring-opening even below pH 2.16  This 
reflects the lower stability of the six-membered chelate ring in contrast to the five-
membered ring. 
pH 	
I 	 (C) 
I 	 (B) 
1.2 
1.7 
I 	 (A) 	 I 
I 	 I 	 I I 	 I 
15 10 5 	0 -5 	-10 ppm 
Figure 3.15 31 P NMR spectra showing pH titration of complex 25 
(A = fully ring-closed species, B/C = ring-closed/open species) 
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pH 
Figure 3.16 Graphs showing formation of fully ring-closed species with increasing 
pH' for compex 25 (A) and complex 26A (B) 
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[Pt{Me(H)N(CH 2 )3PPh2}2C1}CI (26A) 
The 31 P NMR spectra of this complex at various pH values are shown in Figure 3.17. 
The pH titration for this complex showed a similar profile to that for complex 25. At 
high pH the fully ring-closed species was observed with a single peak (A) ( 1 J(Pt-P) = 
3178 Hz, trans to N) and at lower pH the ring-opened species formed with two 
doublets ('J(Pt-P) = 3166 Hz, trans to N (B) and 3728 Hz, trans to Cl (C)). The peak 
integrals were again used to determine the amount of each species and these were 
plotted against pH (Figure 3.16). The pK for the closing of this species was 
determined to be 6.14 ± 0.06. This value is much higher than for complex 25 
indicating that the chelate ring can be opened much more easily. Almost half the 
complex present will be ring-opened when the pH is lowered to 6. This increase in 
pK reflects the increase in stenc bulk on the amine which destabilises the chelate 
ring formation. 
A scheme depicting the pH dependent ring-opening reaction is shown in Scheme 3.6. 
Ph2P\ /NR2 
/ Pt \ 





Ph 2 P 	C 
NR2 
Scheme 3.6 pH-dependent equilibrium between ring-opened and closed forms of the 
bis-aminophosphine complexes 
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pH 
	
I 	 (C) 




I 	 (A) 	 I 
I 	 I 	 I 	 I 	 I 
10 5 0 -5 -10 	ppm 
Figure 3.17 31 P NMR spectra showing pH titration of complex 26A 
(A = fully ring-closed species, B/C = ring-closed/open species) 
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3.3.2 Hydrolysis of [Pt{Me2N(CH2)3PPh2.P}2Cl 2] (24) 
Whilst following aqueous reactions of complex 24 with nucleotides (see chapter 4), it 
was observed that the molecular ion peak for the complex [Pt{Me 2N(CH2 )3PPh2 -
P} 2Cl2] was not present but appeared to be replaced by a number of peaks at lower 
mass. The aqueous behaviour of this complex was therefore investigated further. 
3.3.2.1 Electrospray lonisation Mass Spectrometry 
An aqueous solution of complex 24 was prepared at a concentration of 50 tM. The 
solution was kept at room temperature (298 K) and electrospray ionisation mass 
spectra recorded at various time intervals over a two day period. Experimental 
parameters for ESI-MS are detailed in Section 2.3.3. 
In the initial spectrum, recorded after the complex had been in solution for only 15 
mm, the molecular ion peak (808) was already not present. Three main peaks were 
observed at 737 (A), 754 (B), and 773 (C) (Figure 3.18). As further spectra were 
recorded these three peaks were all seen to decrease with time, whilst another peak 
gradually appeared at mlz = 709 (D). No further change was observed after about 40 
hours and peak (D) then remained constant and was still observed when the solution 
was analysed over a week later. 
In order to aid identification of the species present in the solution several isotope 
models for possible complexes were calculated using Mass Lynx software. These 
models are shown in Figure 3.19 along with the recorded spectrum from the solution 
at 15 mm. The initial species were thus identified as [Pt{Me 2N(CH2 )3PPh2 } 2 ] - A, 
[Pt{Me2N(CH2) 3PPh2 } 20H] - B, and [Pt1Me 2N(CH2)3PPh2 } 2Cfl - C. Similarly the 
end product D was identified as [Pt{Me(H)N(CH 2)3PPh2 1 2 1. This seems to indicate 
that a hydrolysis takes place which results in the eventual formation of the fully ring-
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 Figure 3.19 (I) - (V) = Calculated mass spectra for possible species formed from 
complex 24 in aqueous solution (VI) = observed mass spectrum after 0.25 hours 
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Scheme 3.7 Possible hydrolysis scheme for [Pt {Me 2N(CH2 )3PPh2 -P} 2 C1 2 ] (24) as 
shown by ESI-MS 
Since neither of the fully ring-opened species can be observed in the ESI-MS after 15 
minutes, it can be assumed that the rates of the first substitution and ring closure 
steps in the scheme are very fast and the closure of the first ligand has already 
occurred prior to analysis. Both the chioro- and hydroxy species C and B 
respectively are then observed and also the fully closed species A. The equilibria of 
the second chloride removal and second ring closure steps must be such that these 
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three species are all observed concurrently. These species do however eventually 
disappear to produce a new species D. 
Product 0 has a mass lower than that of the fully closed species by 28 mass units. 
This could be accounted for by the loss of two methyl groups from the ligands to 
leave secondary rather than tertiary amines. This was confirmed by the calculated 
isotope model for [Pt{Me(H)N(CH 2)3PPh2 } 2 1 which matched the observed peak 
(Figure 3.19). This reaction is not expected and has not been observed for any of the 
other Pt-aminophosphine complexes studied. The N-C bond cleavage is likely to 
have been mediated by a nucleophilic OH ligand from the Pt with the formation of 
MeOH as a driving force. This is not unprecedented and can be likened to Pd-
activated OH reactions used in catalysis, such as the Wacker Process. It seems likely 
therefore that it is species B that is converted to species 0 as in Scheme 3.8. 
me 
Ph2P\ /N_Me 	H 
Pt 




Ph2 P 	N—H 
Pt 	 + MeOH 
/\ 
Ph2 P 	NMe 2 
Scheme 3.8 Possible conversion of tertiary to secondary amine via hydroxy- species 
Further work would be needed to understand more fully this unusual dealkylation 
mechanism. 
3.3.2.2 NMR Spectrospcopy 
In order to obtain more information about the aqueous reactions of 
[Pt{Me2N(CH2)3PPh2-P}2C12] (24), 31 P NMR spectra were recorded of a 5 mM 
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solution in D20. Experimental parameters for 31 P are detailed in Section 2.3.1. An 
external reference of free ligand {Ph 2P(CH2)3NIvle2 }, 35 mM/CDC13 in a sealed glass 
capillary was used. 
As described in section 3.2.2.1, a 31 P NMR spectrum of complex 24 in CDC1 3 
showed the presence of only a filly ring-opened species (singlet), the same species 
as was observed in the solid state by X-ray crystallography. When a spectrum was 
recorded immediately after dissolution of the complex in D 20, four doublets were 
observed (Figure 3.20). These disappeared with time and two new doublets and a 
singlet emerged suggesting the changes in species observed by ESI-MS. 
Measurement of the integrals of the initial peaks showed that they comprised two 
pairs of doublets. The coupling in each doublet was 19 Hz corresponding to 2J(P-P) 
for two P atom cis to each other. Each pair of doublets can therefore be attributed to 
a species with two inequivalent P in a cis orientation. Species W has doublets at 
4.15 and -1.74 showing 'J(Pt-P) couplings of 3403 Hz and 3357 Hz, respectively. 
These values suggest P atoms with nitrogen atoms in the trans position in the 
complex. These peaks could therefore correspond to the fully closed species A seen 
in the mass spectra. It would, however, be expected that a species in which both 
ligands are ring-closed would result in both P being equivalent and would hence be 
observed as a singlet in 31 P NMR. Another anomaly between the NMR and ESI-MS 
results is the presence of only two species as opposed to the previously observed 
three species. The second NMR species X, had doublet peaks at 8.68 and 4.65 ppm. 
The platinum satellites for these peaks were too weak to observe. It is therefore 
impossible to correlate this to any specific complex from the mass spectra. 
Further 3 P NMR spectra were recorded over the next 3 days and the changes in 
species present were monitored. Figure 3.20 shows spectra from various points 
during the time course experiment. Species X appeared to be stable and the integrals 
of the peaks only reduced slightly over the time. The peaks for species W were seen 
to decrease gradually with the emergence of a singlet at 0.53 ppm and two new 
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doublets at 0.53 and —3.25 ppm, for species Y and Z respectively. Again the two 
doublets represent a species with two inequivalent P atoms in a cis arrangement 
(2J(P-P) = 19 Hz). The 'J(Pt-P) couplings for these peaks were 3417 Hz and 3446 
Hz respectively, indicating that both P atoms are again trans to nitrogen. The 
platinum satellites for the singlet peak Y are at the same shift as for the upfield 
doublet from Z, suggesting nitrogen to be the trans ligand in this species too. 
Species Y is therefore likely to be a fully ring-closed species with two equivalent P 
atoms. 
The observed behaviour of complex [Pt{Me2N(CH2)3PPh2-P}2C12] (24) under NMR 
conditions is clearly not the same as under electrospray ionisation mass spectrometry 
conditions. This could be due to the large difference in the concentrations of the 
solutions used in each experiment, 5 mM for NIMR and 50 jiM for ESI-MS. Since 
the reactions of the complex are likely to involve hydrolysis it would be expected 
that concentration would be an important factor. It is clear that while 31  NMR is an 
extremely useful tool, it is still relatively insensitive in the study of Pt-P containing 
complexes due to the high concentrations/long acquisition times needed to observe 
the 1 J(Pt-P) coupling constants. 
139 
Synthesis and Characterisation of Platinum Aminophosphine Complexes 
time 
10 	 5 	 0 	 ppm 	- 
Ph2P(CH2 )3NMe2 reference 
Figure 3.20 31 P spectra of [Pt{Me2N(CH 2)3PPh2-P} 2 C12] (24) recorded at various 
times after dissolution in D 20 at ambient temperature 
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34 Conclusions 
A series of aminophosphine ligands {Ph2P(CH2)3RR'} has been prepared from 
amino-chloride and diphenyiphosphine starting materials, with varying levels levels 
of substitution on the amine group. The preparations used were successful but did 
not yield particularly large quantities of products due to their ease of oxidation 
during the reaction. Distillation was therefore required to purify the aminophosphine 
products. 
The aminophosphines were then complexed to platinum via a Pt(COD)Cl 2 starting 
material. This lead predominantly to the formation of complexes with two ligands 
bound per Pt, with binding through the phosphorus atom in the ligand occuring 
preferentially over nitrogen atom binding. Analysis of the complexes by 31 P NMR 
showed that binding of the nitrogen was influenced by the steric bulk of the groups 
on the amine(R, R'). The complexes therefore ranged from fully ring-closed (both 
ligands bound through both P and N) for low steric bulk to fully ring-opened (both 
ligands bound through P only) for high steric bulk. One anomaly in the preparation 
of these complexes was for the ligand Ph 2P(CH2)3NMeH which formed a mixture of 
the bis-aminophosphine complex and a mono-aminophosphine complex with the 
ligand ring-closed. In general the preparation of mono-aminophosphine complexes 
was achieved by the use of Pt(COD)MeC1 starting material. The mono-
aminophosphine complexes had very poor water-solubility and were not suitable 
candidates as Pt anticancer agents. 
The X-ray crystal structures of the complexes prepared have been solved and show 
that the structure in the solid state is the same as that in solution as determined by 
NMR. The bis-aminophosphine structures all show Pt to exist in a distorted square-
planar geometry with an increased bond angle between the two ligand phosphines 
due to the presence of the bulky phenyl groups. The structure of complex 24 
[Pt{Ph2P(CH2)3NMe2-P} 2C12 ] also showed it-stacking between the phenyl rings of 
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the two ligands. The ring-closed structures contained six-membered rings in a chair 
conformation. 
Further studies on the bis-aminophosphine complexes showed that their solution 
structures are pH-dependent. Low pH values cause protonation of the amine groups 
of the ligands and force them into a ring-opened conformation. High pH values 
promoted deprotonation of the ligand and allowed ring-closing to occur, dependent 
on the steric bulk on the amines. 
The most interesting complex studied was complex 24 [Pt {Ph 2P(CH 2 ) 3NMe2 -. 
P} 202], which underwent unusual reactions in aqueous solution leading to 
hydrolysis and ring-closure of the complex and eventually to de-methylation of the 
tertiary amine ligands. This could open a number of new possibilities for these 
complexes as potential catalysts. 
142 
Synthesis and Characterisation of Platinum Am inophosphine Complexes 
3.5 References 
1 G. K. Anderson, R. Kumar, Inorg. Chem. 1984, 23, 4064 
2 G. P. C. M. Dekker, A. Buijs, C. J. Elsecier, K. Vrieze, P. W. N. M. van Leeuwan, 
W. J. J. Smeets, A. L. Spek, Y. F. Wang, C. H. Stam, Organometallics, 1992, 11, 
1937 
3 M. Basset, D. L. Davies, J. Neild, L. J. S. Prouse, D. R. Russell, Polyhedron, 1991, 
10,501 
4 S. Naili, J.-F. Carpenter, F. Agbossou, A. Mortreux, G. Nowogrocki, J.-P. 
Wignacourt, Organometallics, 1995, 14, 1, 401 
5 S. Koepke, R. Kupper and C. Michejda, I Org. Chem. 1979, 44, 2718 
6 M. Chini, P. Crotti, L. Favero and F.Macchia, Tetrahedron Letters, 1994, 35, 761 
7 J. McDermott, J. White, G. Whitesides, I Am. Chem. Soc. 1976, 98, 6525 
8 H. C. Clark, L. E. Manzer, .1. Organomet. Chem. 1973, 59, 411 
9 S. Chatterjee, D. C. R. Hockles, G. Salem, P. Waring, I Chem. Soc., Dalton 
Trans., 1997, 3889 
10 CERIUS2 , Molecular Simulations Incorporated, San Diego, California, 1997 
11 G.M Sheldrick, SHELXTL, Bruker Analaytical X-Ray, Madison, Wisconsin, 
1995 
12 A. G. Orpen, L. Brammer, F. H. Allen, 0. Kennard, D. G. Watson, R. Taylor, .1 
Chem. Soc., Dalton Trans., 1989, Si 
13 C. Janiak, I Chem. Soc., Dalton Trans., 2000, 3885 
14 C. A. Hunter, J. K. M. Sanders, I. Am. Chem. Soc., 1990, 112, 5525 
15 Kaleidagraph 3.09, Synergy Software, 1997 
16 A. Habtemariam, B. Watchman, B. S. Potter, R. Palmer, S. Parsons, A. Parkin, P. 
J. Sadler, I Chem. Soc. Dalton Trans., 2001, 1306 
143 
Interactions of Platinum Aminophosphine Complexes with Nucleotides 
Chapter Four 
III1[11N [S]iIIS) 1FT1i III 	 Ti1 liii]'] iI.1i] fl i 
"lii 1 rTrrr r 
In this Chapter the reactions of the platinum aminophosphine complexes, prepared 
and characterised in Chapter 3, with nucleotides are investigated. As discussed in 
Section 1.7, nucleotides are the building blocks of DNA and as such are ideal for 
simplifying and studying the potential reactions of platinum drugs with DNA, their 
major biological target.' In this work the selectivity and rate of binding of 














Figure 4.1 Structures of platinum aminophosphine complexes 24, 25 and 27 
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4.1 Experimental  
4.1.1 NMR Spectroscopy - Reactions with Nucleotides 
Acquisition details for NMR spectroscopy are given in Section 2.3.1. Samples 
containing the relevant complex at a concentration of 5 mM and the relevant 
nucleotide at either 5 mI\4 or 10 mM, depending on the reaction ratio, were prepared 
in D20. The pH*  values of the samples were measured as described in Section 2.3.7 
and adjusted using 0.1 M DN03 orNaOD. Dioxane solution (2 tl, 5%) was added to 
each sample to act as a reference. The samples were all placed in a water bath at 310 
K overnight to ensure complete reaction. 
4.1.2 High Performance Liquid Chromatography - Competition 
Reactions 
The HPLC set-up is detailed in Section 2.3.5. A mixture of all four nucleotides was 
separated on a reverse phase C18 column, by a method based on that described by 
Meynial2 An isocratic solvent mixture was used incorporating 95% solvent I (50 
mM K2HPO4 , 2.5 mM tetrabutyl ammonium hydrogen sulphate - TBAHS, pH 7) and 
5% solvent 11 (100 mM K2HPO4 , 2.5 mlvi TBAHS, diluted with 50% acetonitrile, pH 
7). The pH of both solvents was adjusted using 85% orthophosphoric acid. The 
nucleotides were detected by UV absorbance at 254 nm. 
Calibration solutions were prepared containing equimolar amounts of all four 
nucleotides at concentrations ranging from 0.1 - 1 mM in water. Each sample was 
separated and analysed by HPLC and a calibration graph of peak area versus 
concentration for each nucleotide was plotted. Samples were then prepared 
containing the appropriate complex and all four nucleotides at 1 mM concentration. 
These samples were then analysed and the peak area of each nucleotide was used to 
determine the amount of free nucleotide remaining. 
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4.1.3 Capillary Electrophoresis - Competition Reactions 
The CE equipment and operation parameters used are detailed in Section 2.3.2. The 
method used is based on a previously reported method. 3 The separation buffer used 
was 20 mM NaHPO4 at pH 7.75. Calibration samples were prepared containing all 
four nucleotides in equimolar amounts at concentrations ranging from 10 —100[LM in 
water. The four peaks were identified by using spiked samples containing an excess 
of one of the nucleotides. A calibration graph was plotted of peak area versus 
concentration for each nucleotide. 
Samples were prepared containing the appropriate complex and the four nucleotides 
all at 100 tM concentration in water. The pH was adjusted to close to physiological 
pH and the samples were incubated at 310 K in a water bath overnight, prior to 
analysis, to ensure complete reaction. The amount of each nucleotide bound was 
determined as in the HPLC method by determining the concentration corresponding 
to the decrease in peak area for the free nucleotide. It should be noted that the 
equipment used did not hold a precise voltage, so the elution times of the nucleotides 
varies slightly between runs, although the order of elution remains constant. 
4.1.4 Electrospray lonisation Mass Spectrometry - Detection of 
Nucleotide Adducts 
The ESI-MS equipment and experimental parameters are described in Section 2.3.3. 
Samples were prepared containing the appropriate complex at 1 mlvi concentration 
and two mole equivalents of the nucleotide in water. The pH of each sample was 
adjusted to close to physiological pH (7.4) and the samples incubated overnight at 
310 K to ensure complete reaction. Prior to analysis, the samples were diluted to 50 
tM with water. 
146 
Interactions of Platinum Aminophosphine Complexes with Nucleotides 
WI*tft.ii .1 
4.2.1 NMR Spectroscopy 
4.2.1.1 Guanosine 5'-Monophosphate 
1:1 (Nucleotide: Complex) Reaction 
In the recorded 111  NMR spectrum the resonances for all the protons in free 5'-GMP 
have completely disappeared, showing all the nucleotide has been bound in the 
reaction. 
Shifts for resonances offree nucleotide: 
H8: 8.21 ppm, s 	Hi': 5.94 ppm, t 	dH3': 4.50 ppm, dd H4': 4.32 ppm, q 
2H5': 3.99 ppm,t 
New peaks appeared with an upfield shift from the free GMP signals. 
2:1 (Nucleotide:Complex) Reaction 
Some free GMP peaks were observed, with new peaks for Pt-bound products with 
upfield shifts. The 'H spectrum of the 2:1 reaction is shown in Figure 4.2. The 
clearest signal to observe was that of the Hi' proton (d, 5.9 ppm) in an area of the 
spectrum with a flat baseline allowing integration of individual peaks. As shown in 
the expansion in Figure 4.2, eight new Pt-GMP resonances are produced in the 
reaction, with Hi' doublets in the region 5.32 - 5.76 ppm. All the doublets have a 
coupling of 6 Hz, the same as that in free GMP. Measurement of the integrals of the 
free and bound GMP Hi' peaks showed that 71% (1.42 mole equivalents) of the 
GMP present was bound to Pt in the reaction. 
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free 	 dioxane 
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Figure 4.2 'H spectrum of [Pt{Me 2N(CH2)3PPh 2-P} 2 C12] (24) with two mole 
equivalents of 5'-GMP (expansion shows Hi' resonances for free and bound 5'-GMP) 
As described in Section 2.1.1.2 it is usual for the protons on the heterocycle of a 
nucleotide to shift downfield upon platination of the nucleotide. 4 In the reaction 
between complex 24 and 5'-GMP however these new product peaks are shifted 
upfield of the free GMP peaks. The H8 signals for the platinated products, which are 
often useful in following Pt-binding 5 , are shifted into the phenyl region of the 
spectrum (ca. 8.0 ppm) making them difficult to observe and separate. For this 
reason, the Hi' doublet (ca. 5.9 ppm) is used to follow the platination of the 
nucleotide since it appears in a clear region of the spectrum. Whilst not directly 
bound to the base, this proton is close enough to experience a change in electron 
density on platination and is also seen to undergo a chemical shift change. The 
upfield shift observed for proton resonances of the nucleobase is very unusual but 
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could be due the presence of phenyl groups in the ligand. The ring current of the it-
system on the ring could be positioned over the protons in question. 
As described above, virtually all the GMP was bound in the 1:1 reaction indicating 
that the complex is capable of forming a monofunctional GMP adduct (i.e. one GMP 
per platinum). The reaction was then repeated with two mole equivalents of 5'-GMP 
and the 'H NMR spectrum is shown in Figure 4.2. By studying the HI' region, it was 
determined that 29% of the GMP was still free (5.93 ppm) and peaks for eight bound 
products (71% of the GMP present) were also seen in the region 5.32-5.75 ppm. 
Some bifunctional adducts (i.e. two GMP bound per platinum) must therefore have 
been formed. It is difficult to see if all the complex present has bound GMP since 
the 'H NMR spectrum of [Pt{Me 2N(CH2)3PPh2-P} 2C12 ] in D20 is already 
complicated by the presence of a number of new species in solution (see section 
3.3.2). It is impossible to separate the signals for nucleotide-bound species (up to 8 
different forms) and non-bound species (up to 4 different forms). 
If it is assumed that all the Pt binds to the nucleotide, then the 71% (1.4 mole 
equivalents) of GMP that is bound in a 2:1 reaction mixture suggests that 40% of the 
complex forms bifunctional adducts and 60% of the complex forms monofunctional 
adducts. However, this may not be the case, as it is possible that any fully ring-
closed species present in solution would be incapable of ring-opening and therefore 
would not have a free binding site for the GMP. The presence of both 
monofunctional and bifunctional adducts would help to explain why there are so 
many distinct bound Hi' signals observed in the spectrum. The number of distinct 
species produced can be accounted for by a combination of two factors: (i) 
monfunctional adducts can have different groups at the vacant site (C17OH7NMe 2 ), 
(ii) both monofunctional and bifunctional adducts can exist as different isomers with 
the GMP adopting either a head or tail conformation  relative to the platinum square-
plane (section 2.2.1.2). 
As discussed in Section 3.3.2, complex 24 is likely to undergo chelate ring-closing in 
aqueous solution. If this is the case then the pH is likely to have an effect on 
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nucleotide binding since low pH can indice ring-opening of the ligand by protonation 
of the amine and leave a vacant site. To investigate this possibility, a pH titration 
was carried out on a 1:2, complex:GMIP sample and the percentage of bound 
nucleotide determined at each pH using the integrals of the Hi' signals. The change 
in binding with pH is shown as a graph in Figure 4.3. The amount of GMP bound 
does not vary greatly with pH suggesting that the complex does not readily ring-close 
in the presence of GMP. The nucleotide binding reaction must be more favourable 
than the ring-closing mechanism in aqueous solution. The GMP present is never all 
bound at any pH suggesting that at least one of the Pt-species present is not capable 
of binding a second GMP to form a bifunctional adduct. There is a small decrease in 
the amount of GMP bound at ca. pH 8 followed by an increase at higher pH values. 
This could indicate a switch from N7 to Ni binding of the Pt as has previously been 
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Figure 4.3 Graph showing the percentage of 5'-GMP and 5'-dTMP bound to 
[Pt {Me2N(CH2)3PPh2-P} 2C12] (24) in separate reactions, with 2:1 ratio, at various pH 
values 
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4.2.1.2 Adenosine 5'-Monophosphate 
1:1 (Nucleotide:Complex) Reaction 
As for 5'-GJvlIp the reaction between [Pt{Me2N(CH2)31PPh 2-P} 2C1 2] (24) and 5-AMP 
was initially carried out with one mole equivalent of the nucleotide. Strong 
resonances for free 5'-AMP remained after completion of the reaction (Figure 4.4). 
Shifts for resonances offree nucleotide: 
H2: 8.52 ppm, s 	H8: 8.27 ppm, s 	HI': 6.15 ppm, d 
H3': 4.51 ppm, dd 	H4': 4.39 ppm, in 	2H5': 4.11 ppm, in 
Two small sets of peaks for new Pt-bound AMP had appeared, one shifted upfield 
and one downfield of free AMP. The clearest signal to observe and measure was 
again the Hi' signal. As shown in the expansion in Figure 4.4, the Hi?  for free AMP 
was observed at 6.13 ppm and the Hi' for bound AMP were at 6.57 and 5.86 ppm (a) 
and (b), respectively. Measurement of the integrals for these peaks showed that 25% 
of the AMP was bound during the reaction. The same pattern can also be seen for 
the H2 and H8 resonances (8.59 and 8.25 ppm) with two bound peaks for bound 
products (a) and (b) appearing either side of the free AMP peak. 
The very low level of binding observed is not expected since N7 of adenine is 
usually a common binding site on DNA  and is favoured by Pt-amine anticancer 
complexes. 9 The very simple spectrum observed suggests that only one of the Pt 
species in solution can bind AIvIIP and this forms two isomers in a ratio 56% (a) to 
44% (b). 
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Figure 4.4 'Fl spectrum of [Pt{Me2N(CH2)3PPh2-P} 2C12] (24) with one mole 
equivalent of 5'-AMP (expansion shows Hi' resonances for free and bound 5'-AMP) 
4.2.1.3 Cytidine 6-Monophosphate 
The reaction was carried out as described for 5'-GMP, between 5'-CMP and 
[Pt{Me2N(CH2)3PPh2-P}2C12] (24) in a 1:1 ratio. The signals for free 5' CMP were 
observed with no new product peaks. 
Shifts for resonances offree nucleotide: 
H6: 8.14 ppm, d 	Hi': 6.15 ppm, d 	H5: 6.02 ppm, q 
H3': 4.36 ppm, q 	H4': 4.25 ppm, br 	2H5': 4.02 ppm, mm 
This suggests that no binding occurs between the complex and 5'-CUT 
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4.2.1.4 Deoxythymidine 5'-Monophosphate 
1:1 (Nucleotide:Complex) Reaction 
In the 'H NMR spectrum for [Pt{Me 2N(CH2)3PPh2-P} 2C12] (24) and 5'-dTIVIP the 
resonances for all the protons of free 5'-dTMP completely disappeared, showing that 
all the nucleotide had reacted. 
Sh/ts for resonances offree nucleotide: 
1-16: 7.83 ppm, s 	Hi': 6.36 ppm, t 	H3': 4.59 ppm, m 	H4': 4.15 ppm, q 
21-15': 3.97 ppm, t 	H2': 2.38 ppm, mm Me: 1.94 ppm, s 
New peaks appeared shifted upfield of free TMP signals. 
2:1 (Nucleotide:Complex) Reaction) 
In the reaction with two mole equivalents of 5'-dTMP some free dTMP peaks were 
observed, with new peaks for Pt-bound products shifted upfield. The 'H spectrum of 
the 2:1 reaction is shown in Figure 4.5. As for GMP, the clearest signal was that of 
the Hi' proton (t, 6.35 ppm) where the flat baseline allowed integration of individual 
peaks. As shown in the expansion in Figure 4.5, only two major new Pt-TMP 
resonances are produced with Hi' triplets in the region 6.04 - 6.27 ppm. Products a 
and b are present in the ratio 1:1.4. All the product triplets have couplings of 7 Hz, 
the same as the coupling in free TMP. The same ratios of products can be observed 
for the methyl signal of TMP (s, 1.94 ppm) with a and b at 1.72 and 1.70 ppm with 
relative intensities 1:1.4. Measurement of the integrals of the free and bound TMP 
Hi' peaks showed that 58% (1.2 mole equivalents) of the TMP present was bound to 
Pt in the reaction. 
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Figure 4.5 'H spectrum of [Pt{Me2N(CH2)3PPh2-P}2C12] (24) with two mole 
equivalents of 5'-dTMP (expansion shows Hi' resonances for 
free and bound 5'-dTMP) 
As seen from the results above, virtually all the TMP was bound in the 1:1 reaction 
suggesting that complex (24) is capable of forming monofunctional adducts with 5'-
dTMP as was seen for 5'-GMP. In contrast when the reaction ratio was increased to 
2:1 nearly half of the 5'-dTMP remained free in solution suggesting that very few 
bifunctional adducts were formed. 
Binding of a platinum complex to thymine is much less common than to G or A.' ° 
This is largely a consequence of the kinetic preference of platinum for other sites 
such as N7 on G and A which are unprotonated at physiological pH and the 
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inaccessibility of the main T binding site, N3, in a DNA duplex structure. Binding of 
Pt complexes to thymine has however been obseved with poly(dT) and thymine 
nucleotides and nucleobases in isolation. 10 
It has been shown that with the Ni site blocked, by the ribose-linkage, the major 
binding site on thymine is N3." Since binding to 5'-dTMP appears to require the 
deprotonation of the N3 site, the effect of pH on the binding to complex (24) was 
therefore investigated by means of a pH titration. 'H spectra of the sample above 
were recorded at various pH values and the Hi' signal used to determine the 
percentage of the nucleotide bound. The results are plotted as a graph in Figure 4.3. 
The graph shows that at all pH values, the binding to 5'-dTMP occurs only in a 
monofunctional manner, since the percentage of nucleotide bound is limited to Ca. 
50%. The graph also shows that the TMP remains bound even as low as pH 4, well 
below the pKa value of the N3 site. Below pH 4 the amount of thyrnine binding 
decreases but significant amounts of bound species are detected even as low as pH 2. 
As well as establishing the change in amount of 5'-dTMP bound, the pH titration also 
identified a change in the nature of the bound species, Figure 4.6. 
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Figure 4.6 1 H NMR spectra showing H1'signals for free and Pt-bound 5'-dTMP on 
reaction with [Pt {Me2N(CH2)3PPh2-P}2C12] (24) at various pH values 
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At high pH two platinum bound species are present. Measurement of the HI' signals 
for these species showed their relative intensities were 1:1.4. The peaks for both 
signals shift with pH but with very different profiles. The larger peak, b, at 6.19 ppm 
shifts upfield as the pH decreases. This shift pattern is similar to that for free 5'-
dTMP. The smaller peak, a, at 5.98 ppm, shows a much more prominent shift 
downfield with decreasing pH. This is opposite to the shift exhibited by free TMP. 
Between p11 8 to 5 more HI' peaks are seen suggesting a mixture of products is 
present in this range. At low pH there are again only 2 bound species which have the 
same relative intensities as the species at high pH (1:1.4). These two species a and b 
can be followed through the range of pH values and their chemical shift is shown at 
each pH in the graph in Figure 4.7. 
TMP 
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pH 
Figure 4.7 Graph showing chemical shift of HI' protons of 

















Interactions of Platinum Aminophosphine Complexes with Nucleotides 
At high pH the usual binding site for Pt on TMP, N3, is deprotonated (pKa = 10 . 47) 12 
so it is likely that the species formed are N3-bound monofunctional adducts. At low 
pH the N3 site would be expected to be protonated so the mode of binding could be 
quite different. In order to further identify the nature of the bound species 31  NMR 
spectra were recorded at both low and high pH. (Figure 4.8) 
At high pH two pairs of small doublets and two pairs of overlapping large doublets 
can be seen, with relative intensities 1:1.4, corresponding to species a and b observed 
in the 'H NIvIIR spectra. Each doublet has 2J(P-P) = 17 Hz suggesting that each pair 
corresponds to a species with two inequivalent P in a cis orientation. Both species a 
and b have a downfield doublet at Ca. —2.2 ppm with 'J(Pt-P) = 3310 Hz and an 
upfield doublet at ca. —8.5 ppm with 'J(Pt-P) = 3295 Hz. These values indicate that 
both species contain nitrogen atoms in the positions trans to both phosphorus 
atoms. ' 3" 4 This is consistent with N3 binding of TMP. Since only a monofunctiona 
adduct is formed, the adduct is likely to contain one DMDPPA ligand chelated and 
one 5'-dTMP molecule bound through N. (Figure 4.9). Chelation of the 
aminophosphine would be favoured at high pH as discussed in section 3.3. Since the 
two distinct species a and b exhibit very similar shifts in the 31 P N1v[R spectrum it is 
likely that these are two isomers of the same product. This could be caused by the 
restriction of rotation of the Pt-N3 bond due to the presence of the bulky 
aminophosphine ligands. This would lead to two head and tail isomers differing by 
orientation of the plane through the rings in the nucleotide relative to the platinum 
square-plane' 5 (Figure 4.10). The isomers could be fixed in position by hydrogen 
bonding between either 04 or 02 on the TMP with a proton on the amine in the 
dangling ligand. Similar intermolecular H-bonds have been observed between Nil-I 
and 02 in the 1-methyl thymine structure, [Pt(NH3)2(1-MeT)](NO 3 ) 2 . 16  It is possible 
that the added flexibility of the propyl amine ligand could allow intramolecular H-
bonds to form. 
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Figure 4.8 3 1  P NMR spectra of complex 24 with 2 mole equivalents of 5 '-dTMP at 
low and high pH values (P = phosphate) 
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Figure 4.9 N3-bound monofunctional adduct of 5 '-dTMP and complex 24 at high 















Figure 4.10 Possible head and tail isomers of N3-bound Pt-TMP species 
At low pH two pairs of doublets are again observed (Figure 4.8). Again these 
correspond to two species, probably isomers containing inequivalent P atoms in a cis 
orientation (2J(P-P) = 17 Hz). Each species has a downfield doublet (4.5 ppm) with 
'J(Pt-P) = 3899 Hz and an upfield doublet (0.8 ppm) with 1 J(Pt-P) = 3128 Hz, which 
overlaps the phosphate signal. This suggests that in each species one phosphorus 
atom has chloride in the trans position and the other phosphorus has nitrogen in the 
trans position. This is indicative of a product which is fully ring-opened and 
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contains TMP again bound through N3 (Figure 4.11). Ring-opening of the 




Figure 4.11 N3-bound monofunctional adduct of 5 '-dTMP and complex 24 
at low pH (coloured P atoms correspond to 31 P peaks in Figure 4.8) 
The fact that TMP can bind to [Pt{Me2N(CH2)3PPh2-P}2C12] through the N3 site 
over such a wide pH range is very unusual since it would be expected that the site 
would be protonated above pH 10.47. It is possible that the amine groups on the 
ligands in the complex are influential in abstracting a proton from the TMP allowing 
binding to occur. 
In the low pH spectrum (Figure 4.8) a singlet peak at 8.5 ppm is also seen. This is 
likely to belong to unbound complex since at pH 3.2 only about 35% of the TMP is 
bound (from graph in Figure 4.3). The two P atoms are equivalent and the 'J(Pt-P) 
coupling of 3732 Hz indicates Cl in the trans position as would be expected for a 
fully opened species at this pH. 
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4.2.2 High Performance Liquid Chromatography 
The competitive binding of [Pt{Me 2N(CH2)3PPh2 -P} 2 C12] (24) to the four 
nucleotides GMP, TMP, AMP and CMY was also studied by HPLC. The reverse-
phase separation of the four nucleotides by the method described in Section 4.1.2 is 
shown in Figure 4.12 below. 
Absorbance 
at 254 nm 
Time / mm 
Figure 4.12 HPLC separation of nucleotides in a 1 mM sample with isocratic solvent 
mixture 95% 1(50 mM K2HPO4, 2.5 mM TBAHS, pH 7), 5% 11 (100 mM K2HPO4 , 
2.5 mlvi TBAHS, diluted with 50% acetonitrile, pH 7) as described in Section 4.1.2 
As described in section 4.1.2, platinum binding can be detected as a reduction in the 
peak area of the free nucleotide. The reaction sample was analysed at various time 
intervals to give an indication of the rate of reaction. A graph showing the 
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Time / minutes 
Figure 4.13 Graph showing percentage of each nucleotide bound in a competition 
reaction between [Pt{Me 2N(CH2)3PPh2-P}2C12] (24) and equimolar amounts of all 
four nucleotides 
It can immediately be seen from the graph that complex 24 binds neither AMP nor 
CMP in the presence of the other nucleotides. This is consistent with the NMR 
results where there were very low levels of binding observed even with the isolated 
nucleotides. There are two rather unexpected results from the competition reaction. 
Firstly that the complex appears to bind as strongly to thymine as it does to guanine 
both of which are bound up to about 50%. This is very unusual for platinum which 
tends to have a very strong preference for binding guanine residues 9 as discussed 
previously. Thymine binding although possible is not generally favoured in the 
presence of purine bases. ° Secondly, the rate of reaction between the complex and 
the nucleotides is fast. There is no change in the amount of nucleotide bound after 
163 
Interactions of Platinum Aminophosphine Complexes with Nucleotides 
about 25 min for TMP and after about 100 min for GIVIP. Again this is unusual if 
compared to cisplatin which undergoes relatively slow binding to nucleotides and 
DNA. 17  As discussed in Section 1.3.2.1 the rate determining step for cisplatin 
binding is hydrolysis of the complex since the dichioro form in relatively unreactive. 
In this complex the chloride ligands may be more labile due to the high trans 
influence of the P ligands' 8, this was indicated by long Pt-Cl bond lengths in the 
crystal structure. 19 If the chloro complex can react directly with the nucleotides this 
may explain the increased rate of binding. 
The method employed above for the separation of nucleotides and competitive 
binding studies proved not to be suitable for long term use since there was 
precipitation of the sample in the column which resulted in a build up of pressure. 
Capillary electrophoresis was therefore investigated as an alternative method of 
nucleotide separation. 
4.2.3 Capillary Electrophoresis 
The separation of the four nucleotides by the method described in Section 4.1.3 is 
shown in Figure 4.14 for a 100 tM sample. A reaction sample containing 
[Pt{Me2N(CH2)3PPh2-P} 2C12 1 (24) incubated with equimolar quantities of the 
nucleotides was analysed and the amount of each nucleotide bound to the complex 
determined by measurement of the peak area for the free nucleotide remaining. The 
electropherogram showing the analysis of binding to complex 24 is also shown in 
Figure 4.14. 
The figure shows clearly that there has been no change in the peaks for AMP and 
CMP upon reaction with the complex. This is the same as determined in the HPLC 
experiment. The peaks for both GMT and dTMP have decreased in intensity 
showing that these nucleotides are bound to platinum. Measurement of the peak 
areas show that 60% of the GMP and 59% of the dTMP was bound. This is 
consistent with the HPLC results confirming that the complex shows high selectivity 
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for thymine binding, even to the same extent as the more typical guanine binding. In 
the electropherogram for the platinated sample a new peak appeared which eluted 
before the free nucleotides (10.2 mm). This is likely to correspond to the platinum 
bound species since the incorporation of a Pt 2+  will increase the charge on the 
nucleotide and hence increase its electrophoretic mobility. Thus platinated species 
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Figure 4.14 Electropherograms showing: (A) four nucleotides at 100 M 
concentration, (B) four nucleotides with [Pt {Me 2N(CH2) 3PPh2-P} 2 C12 } (24), 
all at 100 1.tM concentration, pH 7. 1, after incubation at 310 K for 12 hours. 
4.2.4 Electrospray lonisation Mass Spectrometry 
4.2.4.1 Guanosine 5'-Monophosphate 
A mass spectrum showing the products of the reaction between 
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monofunctional adduct containing Pt with two DMDPPA ligands and one GMP is 
clearly seen at 1099 mlz (calculated mlz for PtC 44H56N708P3 = 1099). The 
assignment of this species was confirmed by the calculation of an isotope model for 
the corresponding compound using the Mass Lynx (V 2.3) program. This major 
peak is accompanied by a smaller peak at 1121 corresponding to the same species 
with an attached Na atom. This is because the nucleotides were all used as sodium 
salts, as purchased. If the resolution of the spectrum is reduced a very small set of 
peaks can be seen corresponding to the bifunctional adduct (two GMP bound) with a 
mass of 1461 (calculated mlz for PtC 54H68N 120 16P4 = 1461). Again additional peaks 
can be seen in a series at 1484, 1506 and 1528 corresponding to the species with 
increasing numbers of sodium ions attached. This confirms the H NMR results 
which suggested that complex 24 was capable of forming bifunctional adducts. The 
number of bifunctional molecules detected is very small in comparison to the number 
of monofunctional. It must be noted however that ESI-MS is not a quantitative 
technique since the number of molecules detected depends on the ability of the 
compound to ionise. 
m/z 
Figure 4.15 ESI-MS spectrum of [Pt{Me2N(CH2) 3PPh2-P} 2Cl2] (24) after reaction 
with two equivalents of 5'-GMP at pH 7.3 (expansion shows isotope pattern for 
monofunctional and bifunctional adducts more clearly, using lower resolution) 
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4.2.4.2 Adenosine 5'-Monophosphate and Cytidine 5'-Monophosphate 
The analysis of the reactions between complex 24 and both 5'-AMP and 5'-CMP 
yielded no observable platinated species. This correlates with the lack of binding 
observed by 'H NIMR. 
4.2.4.3 Deoxythymidine 5'-Monophosphate 
A mass spectrum showing products of the reaction between complex 24 and 5'-
dTMP is shown in Figure 4.16. Again a monofunctional adduct, with one bound 
TMP and two DMDPPA ligands, can clearly be seen at mlz 1057 (calculated mlz for 
PtC44H56N4O8P3 = 1057). An additional peak for the species with one Na bound 
was also observed at 1080 and also a peak at 1096 corresponding to a 
monofunctional species with one coordinated chloride remaining. No bifunctional 
adducts, (calculated m/z for PtC 54H68N6016P4 = 1376), can be observed even at low 
resolution. This corresponds to the, 'H NMR results which suggested that complex 
24 formed only monofunctional complexes with 5'-dTMP. 
4.2.4.4 Competition Reactions 
As in the HPLC and CE reactions, complex 24 was incubated with all four 
nucleotides in equimolar amounts and the mixture analysed by ESI-MS. From the 
region where monofunctional adducts should be observed, the only peaks seen were 
those corresponding to the GMP and TMP adducts already described. This confirms 
that GMP and TMP binding are preferred over AMP and CMP. 
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Figure 4.16 ESI-MS spectrum of [Pt {Me2N(CH2)3PPh2-P} 2C12 ] (24) after reaction 
with two equivalents of 5'-dTMP at pH 7.2 (expansion shows isotope pattern for 
monofunctional adducts) 
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4.3 Reactions of [Pt{tB u (H)N(CH 2 ) 3 PPh 2 P 2 C1 21 (27) 
4.3.1 NMR Spectroscopy 
4.3.1.1 Guanosine 5'-Monophosphate 
1:1 (Nucleotide: Complex) Reaction 
As for the previous complex, [Pt{ tBu(H)N(CH2)3PPh2-P}2C12] (27) and GMP were 
initially reacted in a 1:1 ratio. 
In the 'H NMR spectrum, the resonances for all the protons of free 5'-GMP had 
completely disappeared, showing all the nucleotide had bound to Pt. Again new 
peaks appeared with upfield shifts from the free GMP signals. 
2:1 (Nucleotide:Complex) Reaction 
Some free GMP peaks were observed with new peaks for Pt-bound products shifted 
upfield. The 'H spectrum of the 2:1 reaction is shown in Figure 4.17. As for 
complex 24, the Hi' signal (d, 5.9 ppm) was used to determine the amount of GMP 
bound to platinum in the reaction. 
As shown in the expansion in Figure 4.17, the resulting spectrum from the reaction 
of [Pt{ tBu(H)N(CH2)3PPh2-P} 2C12] (27) and GMP is less complicated than the 
spectrum from the analogous reaction of complex 24. Only two major adducts are 
formed with Hi' doublets overlapping at 5.74 ppm (a) and 5.72 ppm (b). All the 
doublets have a coupling of 6 Hz, the same coupling as in free GMP. Measurement 
of the integrals of the free and bound GMP Hl' peaks showed that 85.5% (1.7 mole 
equivalents) of the GMP present was bound to Pt in the reaction. 
As was the case for complex 24, [Pt{ tBu(H)N(CH2)3PPh2-P}2C12] (27) must form 
some bifunctional adducts in the reaction with GMP since more than one mole 
equivalent of the nucleotide is bound. If it is assumed that all of the complex binds 
nucleotide (since it exists in the ring-opened form with labile chloride ligands) then 
69 
Interactions of Platinum Aminophosph me Complexes with Nucleotides 
70% of the complex must have formed bifunctional adducts and 30% must have 
formed monofunctional adducts. This would suggest that the two predominant Pt-
bound species identified from their Hi' shifts in Figure 4.17 are bifunctional adducts. 
Again, these could correspond to the head-head and head-tail isomers 15  of the 
bifunctional adduct as discussed in Section 2.2.1.2. 
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Figure 4.17 1 H spectrum of [Pt{ tBu(H)N(CH2) 3PPh2-P} 2C12] (27) with two mole 
equivalents of 5'-GMIP (expansion shows Hi' resonances for free and bound 5'-GMP) 
Again the pH dependence of GMP binding to [Pt{ tBu(H)N(CH2)3PPh2-P} 2 C12 ] (27) 
was investigated by recording spectra at various pH values and determining the 
amount of nucleotide bound from the integrals of free and bound Hi' peaks. The 
results are shown in Figure 4.18. As was shown for complex 24, there is little 
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change in the amount of binding with pH. The profile is very similar for the two 
complexes and again the two equivalents of GMP are never completely bound 
suggesting that there is a Pt species present in solution that is not capable of binding 
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Figure 4.18 Graph showing the percentage of 5'-GMP and 5'-dTMP bound to 
[Pt { tBu(H)N(CH2)3PPh2-P} 2C12 1 (27) in separate reactions, with 2:1 ratio, at various 
pH values 
4.3.1.2 Adenosine 5'-Monophosphate 
As for 5'-GMP, the reaction between [Pt{ tBu(H)N(CH2)3PPh2-P} 2C12 ] (27) and 5'-
AMP was initally carried out with one mole equivalent of the nucleotide. Strong 
resonances for free 5'-AMP remained after completion of the reaction (Figure 4.19). 
Six bound species can be identified from the Hi' signals as shown in the expansion 
in Figure 4.19 (6.07-5.61 ppm). Integration of these peaks showed that 33% of the 
AMP was bound during the reaction. This is higher than the amount of binding to 
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complex 24 (Section 4.2.1.2) but is still lower than would be expected due to the 
high electron density of the N7 binding site, usually favourable to Pt binding. 
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Figure 4.19 'H spectrum of [Pt{ tBu(H)N(CH 2)3PPh2-P} 2 C12] (27) with two mole 
equivalents of 5'-AMP (expansion shows Hi' resonances for free and bound 5'-AMP 
4.3.1.3 Cytidine 5'-Mono phosphate 
The reaction was carried out as described for 5'-GMP, between 5'-CMP and 
[Pt{'Bu(H)N(CH 2)3PPh2-P} 2 C12 1 (27) in a 1:1 ratio. Contrary to the spectrum 
obtained for complex 24 and CMP, the resulting spectrum showed new resonances 
for Pt-bound species with upfield shifts. The spectrum is shown in Figure 4.20. 
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Two distinct species can be observed by studying the Hi' doublet and H5 multiplet. 
Species a and b are present in the ratio 1:0.9. Integration of these signals for the 
free and bound species shows that 56% of the CMP was bound in the reaction. This 
suggests that [Pt { tBu(R)N(CH2)3PPh2-P} 2 C12] (27) can form monofunctional 
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Figure 4.20 'H spectrum of [Pt{ tBu(H)N(CH 2)3PPh2-P} 2 C12 ] (27) with two mole 
equivalents of 5'-CMP (expansion shows Hi' and H5 resonances for free and bound 
5 '-CMP) 
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4.3.1.4 Deoxythymidine 5'-Monophosphate 
1:1 (Nucleotide:Complex) Reaction 
In the 'H NMR spectrum of [Pt{ tBu(H)N(CH2)3PPh 2-P} 2 C1 2] (27) with 1 mole 
equivalent of 5'-dTMP present the resonances for all the protons in free 5'-dTMP 
have completely disappeared, showing that all the nucleotide is bound. 
2:1 (Nucleotide:Complex) Reaction 
In the reaction with two mole equivalents of 5'-dTMP, some free dTMP peaks are 
observed with new peaks for Pt-bound species shifted upfield. The 'H spectrum of 
the 2:1 reaction is shown in Figure 4.21. Integration of the Hi' peak for free dTMP 
(6.34 ppm) and the overlapping Hi' peaks for the two bound species (a: 6.16 ppm, b: 
6.15 ppm) showed that 57% of the TMP is bound to Pt. Due to the overlap of the 
Hi' signals the ratio of the two species cannot be determined, however the same 
pattern can also be observed for the methyl signal (1.93 ppm) with two bound species 
(1.70 and 1.67 ppm). Here the ratio of a:b can be measured as 0.9:1. 
As seen from the results above, virtually all the TMP was bound in the 1:1 reaction 
suggesting that complex 27 is capable of forming monofunctional adducts with 5-
dTMP as was seen for 5'-GMP. In contrast, when the reaction ratio was increased to 
2:1 nearly half of the 5'-dTMP remained free in solution suggesting that very few 
bifunctional adducts were formed. 
The effect of pH on the binding of [Pt{ tBu(H)N(CH2)3PPh2-P}2C12] (27) to thymine 
was also investigated by means of a pH titration. The percentage of TMP bound at 
each pH value was determined by measuring the free and bound Hi' integrals. The 
results are show in Figure 4.18. The graph of pH dependence of nucleotide binding 
to complex 27 looks very similar to that for complex 24. Binding of 5'-dTMP seems 
to be restricted to the formation of monofunctional adducts in comparison to that of 
5'-GMP which allows formation of a proportion of bifunctional adducts. Again the 
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binding to thymine occurs over an unusually wide pH range with no reduction in 
binding occurring in the range 4-12. Below pH 4 the binding begins to decrease, but 
even as low as pH 2, 10% of the TMP remains bound. 
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Figure 4.21 'H spectrum of [Pt{ tBu(H)N(CH 2)3PPh2-P} 2 Cl2 ] (27) with two mole 
equivalents of 5'-dTMP (expansion shows Hi' resonances for free and bound 5'- 
dTMP) 
The pH titration is shown in Figure 4.22 and shows a mixture of bound species in the 
region pH 6-9 but, as for complex 24, at low and high pH values the spectra are 
simpler with only two peaks for bound species a and b, again probably isomers. 
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Figure 4.22 'H spectra showing Hi' signals for free and Pt-bound 5'-dTMP on 
reaction with [Pt{ tBu(H)N(CH2)3PPh2-P}2C12] (27) at various pH values 
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The chemical shift of Hi' in the two bound species shows the same pattern as those 
for complex 24. Species b shifts upfield with decreasing pH, following the shift of 
the free TMP. Species a, however, shifts downfield opposite to free TMP. 
In order to further identify the nature of the bound species, 31 P NMR spectra were 
recorded at both low and high pH (Figure 4.23). 
At high pH two pairs of overlapping doublets with ' 95Pt satellites were observed at 
2.0 ppm and -0.8 ppm. As described for complex 24, these doublets can be attributed 
to the two bound species a and b observed in the 1 H NMR spectrum. Each species 
contains two inequivalent P atoms, leading to two doublets with 2J(P-P) = 17 Hz, one 
at each chemical shift. For both species the 'J(Pt-P) coupling of the downfield 
doublet, at 2.0 ppm, is 3474 Hz and the coupling of the upfield doublet, at - 0.8 ppm, 
is 3452 Hz. This indicates that in both species the two P atoms have N atoms in the 
trans position. Again this would be consistent with N3 binding of TMP at one site 
on Pt with one chelate ring-closed ligand, as shown in Figure 4.24. The two distinct 
species a and b would then be attributed to two head and tail isomers formed by 
restriction of rotation of the Pt-N3 bond. Hydrogen bonding between 0 on the TMP 
and the ring-opened ligand could be responsible for fixing the conformations of these 
isomers. 16 
At low pH, two pairs of 31 P doublets were observed at 4.3 ppm and 0.2 ppm. Again 
these correspond to two species, probably isomers containing inequivalent P atoms in 
a cis orientation (2J(P-P) = 17 Hz). In each species the downfield doublet (4.3 ppm) 
has a 'J(Pt-P) coupling of 3911 Hz indicating chloride as the trans ligand whilst the 
upfield doublet (0.2 ppm) has a coupling of 3235 Hz indicating N in the trans 
position.. This is consistent with a species in which TMP is N3 bound and both 
aminophosphine ligands are ring-opened with chloride bound at the vacant site 
(Figure 4.23). The remaining singlet peak at 8.4 ppm is likely to be due to some 
unbound, fully-ring-opened complex remaining (Figure 4.24). As seen in Figure 
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4.18 only about 40% of the TMP is bound at this pH. The 'J(Pt-P) for this species is 
3733 Hz showing Cl in the trans position. 
pH = 11.1 
pH = 3.1 ------- 
1 ------ - ----- 
18 16 14 12 10 8 6 4 2 0 -2 -4 -6 -8 -10-12-14-16-18 
Figure 4.23 31 P spectra of IIPt{'Bu(H)N(CH2)3PPh2-P}2C121 (27) with two mole 
equivalents of 5'-dTMP at low and high pH (P = phosphate) 
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Figure 4.24 (a) N3- bound monofunctional adduct of 5'-dTMP and complex 27 at 
high p1-I, (b) N3- bound monofunctional adduct of 5'-dTMP and complex 27 and 
unbound frilly ring-opened species at low pH (coloured P atoms correspond to 
 31  P 
NMR peaks in Figure 4.23) 
This again demonstrates the unusual N3 binding of Pt to TMP at very low pH values 
well below the pKa value for the N3 site on the nucleotide. 
4.3.2 Capillary Electrophoresis 
The method was used as described for complex 24 (section 4.2.3) with equimolar 
amounts of [Pt1 tBu(H)N(CH2)3PPh2-P}2C121 (27) and all four nucleotides incubated 
at physiological pH for 12 hours. The sample was then analysed and the amount of 
each nucleotide bound was determined from the decrease in peak area of the free 
nucleotides. The analysis of the reaction and a control separation with no complex 
present are shown in Figure 4.25. 
The analysis showed that 85% of the GMP was bound, 46% of the dTMP, 20% of 
the AMP and 18% of the CMP. It is clear that complex 27 is much less selective in 
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same extent as GMIP and the more usual platinum target guanine shows the most 
binding. The binding of AMP is to be expected due to its favourable N7 site but the 
extent of this binding is low and is of the same order as CMP which showed no 
binding to complex 24. 
Time I mm 
Figure 4.25 Electropherograms showing: (A) four nucleotides at 100 tM 
concentration, (B) four nucleotides with [Pt {tBu(H)N(CH 2 ) 3PPh2-P} 2 C1 2 1 (27), all at 
100 .tM concentration, pH 7. 1, after incubation at 310 K for 12 hours. 
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4.3.3 Electrospray Oonisation Mass Spectrometry 
4.3.3.1 Guanosine 5'-Monophosphate 
The electrospray ionisation mass spectrum of the reaction between 
[Pt{ tBu(H)N(CH 2 )3PPh2 -P} 2 C12] (27) and 5'-GMP was recorded as described in 
Section 4.1.4 and is shown in Figure 4.26. 
A monofunctional adduct containing Pt with two BDPPA ligands and one GMP is 
seen at 1154 m/z (calculated mlz for PtC 48HN708P3 = 1155). This is accompanied 
by peaks at 1177 and 1193 corresponding to the monofunctional adduct with Na and 
Cl bound, respectively. When the spectrum was recorded at a lower resolution, a 
smaller peak for the bifunctional adduct was observed at 1516, (calculated mlz for 
PtC58H76N12016P4 = 1516), along with a series of peaks for the same species with 1, 
2 and 3 sodium ions. These assignments were confirmed by comparing the isotope 
models for the predicted structures using the Mass Lynx program. The detection of 
bifunctional species confirms the 1 fl NMR results suggesting more than one GMP 
was bound per platinum. 
It can also be seen in the ESI mass spectra in Figure 4.26 for complex 27 that the 
predominant peak for the unbound complex occurs at 792 and not 864 (calculated 
mlz for PtC 38H52N2P2C12 = 864) as expected. From this it can be deduced that either 
this complex also undergoes chelate ring-closing in aqueous solution or the chloride 
ligands are lost under the ionisation conditions. This peak is also observed in all the 
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Figure 4.26 ESI-MS spectrum oflPt{ tBu(H)N(CH2)3PPh2-P}2C12] (27) after reaction 
with two equivalents of 5'-GMP at pH 7.3 (expansion shows isotope pattern for 
monofunctional and bifunctional adducts) 
4.3.3.2 Adenosine 5'-Monophosphate 
The analysis of the ESI-MS spectra for the reaction between 
[Pt{ tBu(H)N(CH2)3PPh2-P}2C12] (27) and 5'-AMP showed the formation of 
monofunctional adducts which were not observed for complex 24 (Figure 4.27). The 
adduct is seen at mlz 1139 with additional peaks for adducts with Na and chloride 
bound (calculated mlz for PtC48HN707P3 = 1139). No bifunctional adducts, 
(calculated m/z for PtC58H76N12014P4 = 1484), were observed which again 
corresponds to the binding pattern observed by 'H NMR. 
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Figure 4.27 ESI-MS spectrum of [Pt { tBu(H)N(CH2)3PPh2-P}2C12] (27) after reaction 
with two equivalents of 5-AMP at.pH 7.5 (expansion shows isotope pattern for 
monofunctional adducts) 
4.3.3.3 Cytidine &-Monophosphate 
Monofunctional binding was also observed for the reaction between complex 27 and 
5'-CMP. The species at 1115 corresponds to Pt with 2 BDPPA ligands and one CMP 
(calculated mlz for PtC47HN508P3 = 1115). Again the Na bound species can also 
be seen. As for AMP, no bifunctional binding is observed, (calculated mlz for 
PtC56H68N80 1 6P4 = 1436). The spectrum is shown in Figure 4.28. 
183 








Figure 4.28 ESI-MS spectrum of[Pt{ tBu(H)N(CH2)3PPh2-P}2Cl2] (27) after reaction 
with two equivalents of 5'-CMP at pH 7.3 (expansion shows isotope pattern for 
monofunctional adducts) 
4.3.3.4 Deoxythymidine 5'-Monophosphate 
The mass spectrum showing products of the reaction between complex 27 and 5'-
dTMP is shown in Figure 4.29. A monofunctional adduct, with one TMP and two 
BDPPA ligands, can be assigned to the peak at 1113 mlz (calculated m/z for 
PtC48H64N408P3 = 1113). An additional peak for the sodium adduct was observed at 
1136 and a species containing one remaining bound chloride remaining at mlz 1152. 
Again, even at low resolution, no bifunctional adducts were detected (calculated mlz 
for PtC58H76N6016P4 = 1432). This suggests that [Pt{ tBu(H)N(CH2)3PPh 2 -P}2C121 
(27), as complex 24, can form only bifunctional adducts with GMP and not the other 
nucleotides. 
184 





500 	 1000 	 1500 
mlz 
Figure 4.29 ESI-MS spectrum of [Pt{ tBu(H)N(CH2) 3PPh2-P} 2 C12] (27) after reaction 
with two equivalents of 5'-dTMP at pH 7.4 (expansion shows isotope pattern for 
monofunctional adducts) 
4.3.3.5 Competition Reaction 
The mass spectrum of products from the reaction of [Pt { tBu(H)N(CH 2) 3PPh2 -P} 2 C1 2 ] 
(27) with all four nucleotides, showed that the only Pt bound species observed were 
the monofunctional adducts of GIV[P and TMP described previously. The CMP 
adduct is very close in mass to the TMP adduct (I 115 and 1113). However, based on 
the CE results, it seems likely that the TMP adducts will be more abundant than 
those of CMP. 
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4.4 Reactions of [Pt{H 2 N(CH2)3 PPh2 P,N 21C 2 (25) 
4.4.1 NMR Spectroscopy 
4.4.1.1 Guanosine 5'-Monophosphate 
1:1 (Nucleotide:Complex) Reaction 
In the recorded 'H NMR spectrum of an equimolar mixture of complex 25 and 5'-
GMP, the resonances for the protons in the free nucleotide could still be clearly 
observed. Very small peaks for Pt-bound species were observed, shifted upfield 
from the free nucleotide resonances. The spectrum is shown in Figure 4.30. These 
new peaks were too small to allow integration, so the percentage of nucleotide 
binding could not be determined. 
The level of binding to GMP for this complex is obviously much lower than for the 
two complexes previously discussed. It is not surprising that this complex does not 
show significant binding to GMP since the pH of the sample was close to 
physiological and, from the pH titration in section 3.3.1, it can be seen that at this pH 
the complex exists in a totally ring-closed form. This means that there are no labile 
chloride ligands present to allow complexation of the nucleotide. For this reason the 
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Figure 4.30 1 11 spectrum of [Pt {H2N(CH2) 3PPh2-P,N} 2 ]Cl2 (25) with one mole 
equivalent of 5'-GIvIP (expansion shows Hi' resonances for free and bound 5'-GMP) 
As can be seen in Figure 4.31, as the pH of the 1:1 reaction mixture of complex 25 
and GMP is lowered the amount of nucleotide bound increases up to almost 90% at 
pH 1.7. The percentage of GMP bound at each pH is shown in Figure 4.32. This 
increase in binding reflects the fact that the complex ring-opens at low pH due to 
protonation of the amine groups of the ligands. (Section 3.3.1) This leaves a vacant 
site for binding of the nucleotide as shown in Scheme 4.1. 
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Figure 4.31 'H NMR spectra showing Hi' signals for free and Pt-bound 5'-GMP 
after reaction with [Pt{H2N(CH2)3PPh2-P,N}2]C12 (25) at various pH values 
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Figure 4.32 Graph showing the percentage of 5'-GMP and 5t-dTMP bound to 
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Scheme 4.1 Binding of 5'-GMP to [Pt{H 2N(CH2)3PPh2-P,JV) 2]C12 (25) at low pH 
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4.4.1.2 Adenosine 5'-Monophosphate and Cytidine 5'-Monophosphate 
[Pt {H2N(CH2)3PPh2-P,N}2]C12 (25) was also reacted separately with 5'-AMP and 5'-
CMP, each in a 1:1 reaction. As for the 'H spectrum of the GMP reaction, all the 
resonances for the protons in the free nucleotide were observed in both cases and no 
new peaks were observed for Pt-bound species. 
4.4.1.3 Thymidine 5'-Monophosphate 
1:1 (Nucleotide:Complex) Reaction 
In the 'H NMR spectrum of the reaction of complex 25 with 5'-dTMP, some Pt-
bound species were observed with protons exhibiting an upfield shift from those of 
free TMP. The spectrum is shown in Figure 4.33. The expansion shows the Hi' 
signals for both the free and bound TMP species and integration of these signals 
determined that 13% of the TMP is bound in this reaction at physiological pH (7.4). 
This is in contrast to the reaction with GMP where binding occurred only at lower 
pH values when the complex was ring-opened. 
The binding of [Pt{H 2N(CH2)3PPh2-P,N}2]C12 (25) to TMIP has also been 
investigated at various pH values and the spectra are shown in Figure 4.34. The 
percentage of nucleotide bound at each pH is shown in Figure 4.32. 
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rrs ,s 
ppm 
Figure 4.33 'H NIMR spectrum of[Pt{H2N(CH 2)3PPh2-P,N} 2 ]C12 (25) with one 
mole equivalent of 5'-dTMP (expansion shows Hi' resonances for free and bound 5'- 
dTMP) 
Complex 25 does not appear to bind the nucleotide TMP to as great an extent as it 
does GMP. This is in keeping with traditional nucleotide binding of platinum 
complexes which target the more electron donating N7-site on guanine. It is not, 
however, in keeping with the other platinum aminophosphine complexes in this 
series, (24) and (27), previously discussed. 
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Figure 4.34 'H spectra showing Hi' signals for free and Pt-bound 5'-dTMP after 
reaction with [Pt {H2N(CH2)3PPh 2-P,N} 2]C12 (25) at various pH values 
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The pH dependence of the TMP binding also shows a very different profile to the 
GMP binding (Figure 4.32), which increased with decreasing pH as the complex was 
forced to ring-open. TMP binding starts to increase as the pH is lowered from 8.5 to 
6.5 but then begins to decrease below this value, until no TMP is bound at pH 1.5. 
This demonstrates the fact that although low pH favours ring-opening of the complex 
and therefore TMP binding, it also favours protonation of the N3-site on the TMP 
preventing binding to the Pt. These two effects are in opposition to give the resulting 
binding profile. 
This supports the theory that TMP still binds to aminophosphine complexes through 
N3, even at pH values well below the usual pK a value for the site, as has been 
proposed in the previous sections 4.2.1.4 and 4.3.1.4 for complexes 24 and 27. 
4.4.2 Capillary Electrophoresis 
As for the previous complexes, [Pt{H2N(CH 2)3PPh2-P,N} 2 ]C12 (25) was incubated 
with all four nucleotides at close to physiological pH for 12 hours prior to analysis. 
The sample was analysed and the amount of each nucleotide bound to the complex 
was determined from the decrease in peak area for the free nucleotide. The resulting 
electropherogram is shown in Figure 4.35 with a control sample (no complex 
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Figure 4.35 Electropherograms showing: (A) four nucleotides at 100 .jM 
concentration, (B) four nucleotides with [Pt {H 2N(CH2 ) 3PPh2 -P,N} 2 1C1 2 (25) all at 
100 tM concentration, pH 7. 0, after incubation at 310 K for 12 hours 
The analysis showed that neither CMP nor AMP reacted with complex 25 as would 
be predicted from the NMR results. 21% and 20% of the GMP and TMP respectively 
were bound to the complex. This correlates to the NMR data which shows that at pH 
7 similar amounts of binding to each nucleotide occur (Figure 4.32). 
4.4.3 Electrospray lonisation Mass Spectrometry 
Mass spectra were recorded for [Pt{H 2N(CH2)3PPh2-P,N} 2 ]C12 (25) after reaction 
with each of the nucleotides in a 1:2 ratio. None of the resulting spectra revealed any 
nucleotide-bound products at all. An example of the spectrum from the reaction with 
GMP is shown in Figure 4.36. The major peak at 680 is for the fully ring-closed 
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species, (calculated mlz for PtC30H3 6N2P2 = 681), as would be expected at this pH 
(7.3). The absence of any bound products reflects the much lower reactivity of this 




Figure 4.36 ESI-MS spectrum of [Pt {H 2N(CH2)3PPh2 -P,iV} 2 ]C1 2 (25) after reaction 
with two equivalents of 5'-GMP at pH 7.3 
4.5 Conclusions 
The results discussed in this chapter highlight an interesting variety of nucleotide 
binding for the series of aminophosphine complexes studied. As would be expected 
the binding is most extensive for the complexes in the chelate ring-opened form with 
labile chloride ligands. 
Initial studies by 1 11 NIMR, following reactions of the complexes with each 
nucleotide individually, showed varying binding patterns for each complex. The 
reactions were all carried out at 5 mlVI concentration and the reaction mixtures were 
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incubated at 310 K overnight to ensure completion of reaction prior to analysis. The 
results are summarised in Figure 4.37. The pH values of the samples were not 
adjusted after preparation and were all in the region 6.5 - 8.5 depending on the 
complex and nucleotide used. 
Complex 24 preferentially binds GMP and TMP with a small amount of AMP 
binding as well. With GMP some bifunctional adducts were formed as determined 
by the proportion of GMP bound and confirmed by detection of these adducts in ESI-
MS. Binding to TMP however appears to be limited to monofunctional adducts. 
Complex 27 is able to bind to all four nucleotides and shows much less selectivity in 
nucleotide binding than complex 24, but again bifunctional adducts are only formed 
with GMP. Complex 25 shows the least amount of binding and products are only 
seen in the reaction with TMP in this pH range. 
CE allowed the selectivity of the complexes to be determined when reacted with all 
four nucleotides in competition. These results are also summarised in Figure 4.37. 
The reactions were carried out at pH 7.1 for complexes 24 and 27 and pH 7.0 for 
complex 25. 
Unexpectedly the binding to TMP is still abundant even in the presence of the purine 
bases which are usually the kinetically preferred sites for platinum binding. The 
binding profile is distinctly different to the usual platinum amine complexes such as 
cisplatin which show high selectivity for guanine closely followed by adenine. 20 
Complex 27 shows the highest amount of overall binding with the least selectivity 
whilst complex 25 shows the least binding due to the high proportion of the ring-
closed species present. 
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5'-GMP 	5-dTMP 	5'-AMP 	5'-CMP 
Figure 4.37 Bar charts showing binding of complexes 24, 27, and 25 
(A) to four nucleotides in isolation as determined by 'H NMR spectroscopy 
(B) to all four nucleotides in competition as determined by capillary electrophoresis 
197 
Interactions of Platinum Aminophosphine Complexes with Nucleotides 
The binding to 5'-dTMP was further investigated by means of pH titrations followed 
by 'H NMR. For both complexes 24 and 27, TMP was seen to bind fully between 
pH 4 and pH 12 with binding decreasing below pH 4. A significant amount of the 
bound species could still be observed even as low as pH 2. The bound species was 
shown, by 31 P NIMR, to still contain TIVIIP bound via N3. This is unusual since the 
PKa of N3 is 10.47, thus the nitrogen must be binding Pt preferentially instead of a 
proton. The N3 site seems the most likely binding site since the Ni site is blocked, 
however, other binding modes have previously been identified for thymine to 
platinum. Binding of Pt to the N3 site results in an increase of basicity at the 04 
site 21,22  which promotes Pt-binding at this site. This can lead to the formation of 
dimers with thymine bound via both N3 and 04.162325  The NMR results did not 
indicate an 0-bound species to be present ('J(Pt-P), trans to 0 is > 4000 Hz) and the 
ESI-MS results did not show the presence of any dimers, so it can be assumed that 
the bound products are monofunctional, N3-bound species. 
The unusual preference for TMP binding exhibited by this series of complexes could 
be explained by the "dangling" amine group on the unchelated aminophosphine 
ligands. This group could be capable of abstracting a proton from the N3 site to 
allow Pt-binding. The amine could also play a role in hydrogen bonding to the 
nucleotide stabilising the Pt-nucleotide adduct formed. Hydrogen bonding could also 
play a role in the formation of the head and tail isomers of Pt-TMP adducts by 
restricting rotation around the Pt-N3 bond. 
Since the binding profile of these complexes is so different to current cisplatin-type 
platinum anticancer drugs, these complexes could be useful in the quest to find a new 
generation of drugs which can overcome cisplatin resistance in cells. 
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Chapter Five 
Interactions of [Pt{Me 2N(CH2)3PPh2}2C12] with Natural 
and Synthetic Nucleic Acids 
51 Background 
In collaboration with the group of Professor V. Brabec at the Academy of Sciences 
of the Czech Republic, the interactions of [Pt{Me 2N(CH2)3PPh2 } 2C12] (24) with 
natural and synthetic DNAs in cell-free media were studied using various biomedical 
and biophysical techniques.' 
Complex 24 (Figure 5.1) was chosen as a representative of the aminophosphine 
series of complexes since it is bifunctional with two leaving chloride ligands in cis 
positions, making it ideal for comparison to cisplatin binding. 
OH3 
flN  \ CH 3 





Ph P CI 	 H3 N 	CI 
L_t' N 
CH 3 
(24) 	 Cisplatin 
Figure 5.1 Structures of [Pt{Me2N(CH2)3PPh2}2C12] (24) and cisplatin 
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5.1.1 Rate and Selectivity of Binding to Nucleic Acids 
Double helical calf thymus (CT) DNA was incubated with complex 24 at a molar 
ratio of 0.08 (Pt:nucleotide phosphates), in 10 mM NaC10 4 (pH 7), at 310 K. At 
various time intervals the amount of Pt bound to the DNA was determined by 
differential pulse polarography (DPP). The results are shown in Figure 5.2. 
The amount of Pt bound increased with time until after 48 h approximately 100% of 
the complex was bound to the DNA. The time taken to bind 50% of the available Pt 
under these conditions (T 50) was ca. 3 h. This compares to a T 50 value of Ca. 4 h for 
cisplatin2 (structure shown in Figure 5.1) suggesting that the presence of the 
aminophosphine groups increases the rate of coordination of Pt (II) complexes to 
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Figure 5.2 Formation of DNA adducts by [Pt{Me 2N(CH2)3PPh2 } 2 C12] (24) as a 
function of incubation time, determined by differential pulse polarography 
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The binding of [Pt{Me2N(CH2)3PPh2}2C12] (24) to several synthetic single-stranded 
homopolydeoxyribonucleotides and double-stranded synthetic alternating 
polydeoxynbonucleotides, was also investigated under the same conditions as for the 
CT DNA above. The percentage of Pt bound in each case was determined DPP. The 
results are shown in Table 5.1. 
Complex 24 was shown to bind readily to single-stranded poly (dG), poly (dA) and 
poly (dC), with approximately the same rate, but not to poly (dT). The complex 
bound to double-stranded poly (dA-dT) and poly (dG-dC) with markedly higher rates 
than to the single-stranded polynucleotides. 
Nucleic Acid T50 / h Binding after 48 h / % 
dsCTDNA 3.0 99 
poly (dA) 2.2 89 
poly (dC) 1.9 79 
poly(dG) 2.0 83 
poly (dT) - 0 
poly (dA-dT) 0.3 90 
poly (dG-dC) 0.7 96 
Table 5.1 The binding of [Pt {Me2N(CH2) 3PPh2 } 2 C12 1 (24) to CT DNA and synthetic 
polydeoxyribonucleotides determined by DPP 
These results suggest that complex 24 has different base sequence preference to 
cisplatin which binds predominantly to guanine residues and to a lesser extent 
adenine residues. 3,4,5 
203 
Interactions of fPt1Me2N(GH2)3PPh2)2G121 with Natural and Synthetic Nucleic Acids 
5.1.2 Characterisation of DNA adducts 
In order to further characterise the coordination mode of complex 24, a 40 base-pair 
(bp) deoxyribonucleic duplex modified by reaction with the complex (in 0.1 M 
NaCI04) was enzymatically digested to mononucleotides and analysed by HPLC. 
By comparison to an enzymatically digested control sample (no Pt) the reduction in 
peaks for the free mononucleotides allowed determination of the proportion of each 
nucleotide that was bound to the complex in the reaction. The results are shown in 
Table 5.2 along with comparative results for cisplatin. 4 ' 5 
% reduction Number of Number of 
Mononucleotide in peak after residues in 40 residues 
Peak reaction with bp duplex platinated 
24 
GMP 28 17 5 
Complex 24 
AMP 21 23 5 
GMP 70 17 12 
Cisplatin 
AIVIIP 5 23 1 
Table 5.2 Nucleotide specificity of binding complex 24 and cisplatin to a 40 bp 
DNA duplex, as determined by enzymatic digestion and HPLC analysis 
As shown in Table 5.2, the 40 bp sequence contained 5 platinated guanine residues 
and 5 platinated adenine residues after reaction with [Pt{Me 2N(CH2)3PPh2 } 2C] 2 ] 
(24). Since the ratio of bound Pt to nucleotide (rb) in the reaction was 0.09, this 
suggests that there were only 7.2 Pt-adducts on average per DNA strand. The 
formation of 10 platinated nucleotides must therefore be due to the presence of 3 
bifunctional adducts per DNA strand. 
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When the same analysis was carried out with cisplatin, 12 guanine residues and 1 
adenine residue were platinated on the 40 bp strand (Table 5.2) suggesting that 80% 
of all adducts were bifunctional. This is in good agreement with previous analyses 
on the nature of cisplatin-DNA adducts. 4 '5 
These results again suggest that complex 24 has less nucleotide specificity than 
cisplatin, forming more adenine adducts. The complex also forms less bifunctional 
lesions than cisplatin. 
5.1.3 Effect of Binding on Global DNA Conformation 
The effect of binding complex 24 to DNA was also investigated by circular 
dichroism (CD) spectroscopy. This reflects changes in the global DNA 
conformation. Previous studies 6,7  have shown that the intensity of the positive CD 
band yielded by B-DNA at ca. 280 rim is increased as a consequence of DNA 
modification by complexes containing the cis-[PtC12(amine) 2 ] unit, up to an rb value 
of ca. 0.05. With higher levels of platinum modification the band then decreases 
again. This trend is shown in Figures 5.3 and 5.4 for cisplatin. On the other hand, 
modification of the DNA by the clinically inactive transpiatin only slightly decreased 
this positive band . 6 '7 It has been suggested that the enhancement of the CD band at 
280 rim by cisplatin and active analogues reflects distortions in DNA of a non-
denaturational nature. At higher Pt concentrations the decrease in the band is 
consistent with the occurrence of short segments containing unpaired bases. 
When complex 24 was bound to DNA, the effect on the CD spectrum was great, but 
distinctly different to that of cisplatin binding (Figure 5.3). There was a marked loss 
in the intensity of the positive CD band as a linear function of rb (ratio of bound Pt to 
DNA nucleotides). This was accompanied by a reduction in the intensity of the 
negative band at 245 rim. The changes in intensity are shown in the Figure 5.4. The 
changes observed are reminiscent of the DNA transformations seen in the presence 
of high concentrations of electrolyte or by the reaction with a variety of amines. 8,9 
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For instance at the level of DNA binding corresponding to rb = 0.13, the reduction in 
rotational strength of the positive band in the CD spectrum in 10 MM NaC104 , was 
similar to that obtained for underivatised DNA in Ca. 6 M LiC1 or at ca. 0.1 mol of n-
butylamine covalently fixed per mol of nucleotide. This transformation has been 
demonstrated to be roughly correlated with the reduction of the electrostatic 
repulsive interactions in the DNA molecule. It is possible therefore that the two 
positively-charged amine groups in the dangling ligands of complex 24 could 
position close to the DNA negatively charged phosphate groups, reducing the 
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Figure 5.3 CD Spectroscopy of calf thymus DNA modified by (A) 
[Pt{Me2N(CH2)3PPh2 } 2Cl2] (24) and (B) cisplatin at various 
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Figure 5.4 Graph showing changes in intensity of positive CD band for DNA (280 
nm) with modification by complex 24 and cisplatin at increasing rb values 
5.1.4 Aims of Collaborative Visit to Czech Republic 
The collaborative work discussed above, whilst providing a useful insight into the 
formation of DNA adducts by [Pt{Me 2N(CH2)3PPh2 } 2C12] (24) also highlights some 
different trends to those observed when binding the complex to individual 
nucleotides, as discussed in Chapter 4. 
The most notable differences are: 
the lack of binding to poly (dT) shown by DPP, although binding to dTMP is 
highly favoured for complex 24 even when in the presence of the purine 
nucleotides, the more common Pt binding targets 
the rate of binding to nucleotides is very fast as shown by HPLC (Section 4.2.2) 
with T50 < 1 h. whilst the rate of binding to DNA is much longer with T 50 > 3 h, 
shown by DPP. 
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In order to try to account for these discrepancies between the Czech work and the 
results already discussed in this thesis, a working visit to the Institute of Biophysics, 
The Academy of Sciences of the Czech Republic in Brno was undertaken for further 
collaboration work with Prof. Brabec's group. This visit was part of the Cost D8 
programme - Chemistry of Metals in Medicine (working group D8/0009 - Platinum 
Binding to Nucleic Acids), and took place in March 1998. 
The aims of this visit were: 
to study the effect of pH on the binding of [Pt{Me 2N(CH2)3PPh2 } 2 C12 ] (24) to 
poly (dT), to see if this accounts for the differences in binding between the DPP 
experiment and the reported dTMP experiments, 
to study the effect of concentration on binding to 5'-dTMP (since the NMR 
experiments were carried out at 10 mM, whilst the DPP experiments were carried 
out at 10 tM) to see if this accounts for the differences in binding to thymine, 
to study the kinetics of binding of complex 24 to CT DNA by following the 
changes in the CD spectrum, and 
to study the effect of pH on the changes induced in the CD spectrum by binding 
complex 24, in order to prove the postulate that the changes are caused by 
interaction of protonated amine groups from the ligands on the Pt. 
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5.2 Experimental  
All samples contained 10 jiM complex and 100 jiM nucleic acids in 10 mM NaC10 4 
unless otherwise stated. 
5.2.1 Differential Pulse Polarography 
All experiments were carried out on a EG and G Princeton Applied Research model 
384B Polarographic analyser. A three electrode system was used comprising a EG 
and G PARC model 303A static mercury drop electrode and a Ag/AgC1 (saturated 
KC1) reference electrode. All potentials were quoted vs. this electrode. 
Parameters for the DPP operation were: is drop time, 5 mV/s voltage scan rate, -50 
mV modulation amplitude, negative scanning direction, -0.6 V initial potential, -1.05 
V final potential. 
The electrolyte used was 0.08% formaldehyde, 0.008% hydrazine, and water, in a 
ratio 1:1:2. This caused the DNA to precipitate out along with any bound Pt 
complex. Hence only unbound Pt was detected by polarography. 1° 
Reaction between [Pt{Me 2N(CH2)3PPh2}2C12] (24) and poly (dT) at pH 8 
A 1 ml sample was prepared using NaCI04 with the pH kept at 8 by addition of tris 
buffer. The samples were incubated in the dark at 310 K. Aliquots (40 pA) were taken 
at regular intervals, placed in 4 ml of electrolyte and a polarogram recorded. 
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5.2.2 High Performance Liquid Chromatography 
These experiments were performed using a Hitachi series 4 liquid chromatograph 
with LCI-100 computing integrator and a Waters jiBondapack C18 column. The 
products were separated by reverse phase HPLC (isocratic elution with 0.1 M 
ammonium acetate, pH 5.0 in 4% acetonitnie at 1 ml/min flow rate). 
[Pt{Me 2 N(CH2)3PPh2}2Cl2] (24) and 5thymidine monophosphate 
Samples containing complex 24 with dTMP, both at a concentration of 10 tM, were 
incubated at 310 K and chromatograms recorded at regular intervals up to about 24 
hours. 
5.2.3 Circular Dichroism Spectroscopy 
CD Spectra were recorded at 310 K on a JASCO spectrapolarimeter, model J720. 
Parameters were band width 2 run, sensitivity 10 mdeg, response 0.25 sec, 
wavelength range 350.0 - 200.0 nm, step resolution 0.1 nm, scan speed 50 nm/mm. 
Kinetics of [Pt{Me2N(CH2)3PPh2}2Cl2] (24) binding to calf thymus DNA 
A 2.5 ml sample of complex 24 and CT DNA was prepared in NaC10 4 and incubated 
in the spectrapolanmeter at 310 K. Spectra were recorded at regular intervals up to 
48 hours. 
Effect of high pH on binding of [Pt{Me 2N(CH 2)3PPh2}2C12] (24) to calf thymus 
DNA 
Two samples of [Pt{Me2N(CH 2)3PPh2 } 2Cl2] (24) and CT DNA were incubated for 
48 hours to allow binding to occur. One sample was left unaltered as a control and 
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the other was adjusted to pH 9 using 0.1 M NaOH. The samples were left and 
spectra recorded after 1 and 6 hours for comparison. 
5.3 Thymine Binding 
5.3.1 Effect of pH 
As previously discussed, [Pt{Me 2N(CH2)3PPh2 } 2 Cl2] (24) was seen to bind strongly 
and rapidly to dTMP in 'H NIVIR experiments (Section 4.2.1.4). This was confirmed 
by HPLC (Section 4.2.2) and CE (Section 4.2.3) experiments which showed that 
binding to TMP occurred even in the presence of the more usual Pt targets GMP and 
AMP. However, DPP experiments on the reaction between 
[Pt{Me2N(CH2)3PPh2}2C12] (24) and synthetic poly (dT) showed no binding to occur 
at all (Section 5.1.1). 
In order to determine if this was due to pH differences between the two experimental 
methods, DPP experiments were performed at pH 8 (original measurements were at 
pH 7) as described in Section 5.2.1. Higher pH should favour thymine binding due 
to deprotonation of the N3 binding site. It was difficult to increase the pH much 
beyond this value due to the instability of the poly (dT). 
Polarograms of the sample were recorded after various time intervals and the height 
of the peak for the unbound Pt (at Ca. —0.72 V) was measured. By comparison of the 
height of the peak at each time, (I,,), to that of the sample immediately after mixing, 
(Ia), the concentration of the complex remaining unbound, (c), at each time was 
calculated using the following equation; 
C = I /I x C0 
(c0 = initial concentration of Pt = 10 tM) 
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It was assumed that in the initial poiarogram no binding had occurred and hence the 
peak height was taken to correspond to all Pt being free. 
The amount of Pt bound at each time is shown in the graph in Figure 5.5. The 
maximum level of binding was 20% and this was only achieved after 9 hours. This 
is significantly less than the binding observed to dTMIP and a much slower rate of 
binding, despite the thymine being in a 10 fold excess in the reaction (Pt = 10 .tM, T 
= 100 jiM). In the 'H NMR experiment at pH 8 Ca. 50% of the TMP was bound to Pt 
in a 2:1 reaction, forming monofunctional adducts (Figure 4.2, Section 4.2.1). Also, 
it appears from the binding curve in Figure 5.5 that there is some prereaction taking 
place before binding, since there is an induction period of about 8 hours before any 
reaction takes place. This was not observed for the NMR or HPLC experiments with 
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Figure 5.5 Binding of [Pt {Me2N(CH2)3PPh2}2C12] (24) to synthetic poly (dT) as 
determined by DPP 
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It seems from these results that pH, whilst it does affect the level of binding, does not 
account for the differences between the experimental data from the binding of 
[Pt1Me2N(CH2)3PPh2 } 2C12 1 (24) to poly (dT) and dTMP, by DPP and NMR 
respectively. 
5.3.2 Effect of Concentration 
The binding of [Pt{Me2N(CH2)3PPh2}2Cl2] (24) to dTMP was carried out at 5 mM 
concentration, 	for observation by NIMIR, whilst 	the binding of 
{Pt{Me2N(CH2 )3PPh2 } 2Cl2] (24) to poly (dT) was carried out at 10 tM 
concentration, for observation by DPP. The difference between these two 
concentrations is very large (500x) and could have an effect on the amount of 
binding. For this reason the effect of concentration was investigated further. 
Since it was impossible to effectively carry out NMR on these samples at 10 riM, or 
DPP at 5 mM, another technique had to be employed. [Pt{Me 2N(CH2 ) 3PPh2 } 2 C1 2 ] 
(24) and dTMIP were reacted in a 1:1 ratio at 10 jiM and the amount of Pt bound was 
determined by HIPLC as described in Section 5.2.2. This replicates the NMR 
experiments but at the concentration used in the DPP experiments. 
The free dTM.P peak eluted at 2.3 min and as the reaction proceeded the decrease in 
height of this peak corresponded to the amount of dTMP bound to Pt. The results are 
shown in Figure 5.6. 
213 












0 	 50 	 100 	 150 
Time (mm) 
Figure 5.6 Graph showing amount of dTMP bound to [Pt{Me 2N(CH2 ) 3PPh2}2C!2] 
(24) at 10 tM concentration, as determined by HPLC 
In the corresponding 1:1 reaction at 5 mM, analysed by 'H NMR (Section 4.2.1.4) all 
the TMP was bound to Pt. This result shows much lower binding with only 20% of 
the nucleotide being bound in total. The previous results from the HPLC 
competition reactions with all four nucleotides and the complex present at 1 mM also 
showed that 50% of the TMP was bound despite being in competition with GMP, 
AMP, and CMP. These results therefore suggest that the concentration of the 
reaction mixture has a big effect on the amount of TMP binding that occurs to 
complex 24. 
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5.3.3 Ageing of Complex Solution 
Another factor which has been identifed as influential in the thymine binding 
reactions of [Pt{Me 2N(CH2)3PPh2 } 2C12] (24) is the length of time the complex has 
been in aqueous solution. As discussed in Section 3.3.2, complex 24, changes into 
new species over a 3 day period in solution at ambient temperature. 
The DPP and HPLC reactions described in this chapter were carried out using a stock 
solution of complex which was prepared and stored at room temperature in a flask, 
protected from sunlight. The solution was aged more than 2 weeks when used in the 
reactions. In order to determine the effect of time in solution on the binding of 
complex 24 to dTMP, the CE competition reaction as described in Section 4.2.3 was 
repeated using complex that had been aged in solution for 2 weeks. The results are 
shown in Figure 5.7. 
By measuring the area of the peaks for the free nucleotides it was determined that 
when a fresh solution of complex 24 was used in the reaction 60% of the GMP and 
59% of TMP were bound to Pt. However when the aged solution of complex 24 was 
used only 35% of the GMP and 22% of the TMP was bound to Pt. This shows that 
the new species formed change the selectivity of nucleotide binding. The overall 
amount of binding was reduced from 1.19 mole equivalents of nucleotide (i.e. all Pt 
is nucleotide bound with at least 19% bifunctional adducts formed) to 0.57 mole 
equivalents (i.e. only just over half the Pt has formed a nucleotide adduct at all). 
Also the preference for thyinine binding has been reduced compared to guanine. 
This could be due to the demethylation of the ligands in [Pt {Me 2N(CH2 ) 3PPh2 
 } 
2 C12 ] 
(24) as proposed in Section 3.3.2. The amine groups could play an important role in 
thymine binding by abstracting the N3 proton to allow Pt to bind at this site. 
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Time / Mm 
Figure 5.7 Electropherograrns showing four nucleotides at 100 p.M concentration 
with: (A) no Pt added, (B) complex 24 from fresh solution added, (C) complex 24 
from aged solution added, at pH 7.1 after incubation at 310 K for 12 hours 
The same trend was observed when the HPLC competition reaction as described in 
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A - Fresh Solution 
	
B - Aged Solution 
Figure 5.8 Graph showing percentage of TMP and GMP bound in a competition 
reaction between complex 24 and equimolar amounts of all four nucleotides: (A) 
using fresh complex solution, (B) using solution aged 2 weeks 
With fresh solution the complex bound a maximum of 50% TMP and 48% GMP. 
After ageing the complex in solution for 2 weeks only 14% TMP and 30% GMP 
were bound. This highlights the reduction in overall binding and the loss of 
selectivity for thymine as the species in solution have changed. 
5.4 Rate of Binding to DNA 
The HPLC reactions described in Section 4.2.2 showed that binding of 
[Pt{Me2N(CH2) 3PPh2 } 2C12] (24) to nucleotides took place rapidly (T 50 for dTMP = 
25 mm) in a 1:1 reaction with all nucleotides (GMP, AMP, CMP, dTMP) present 
(Figure 4.12). DPP reactions with calf thymus DNA showed T 50 = 3 h, a much lower 
rate of binding despite the 10 fold excess of nucleotide residues present. 
Due to the inconsistencies of these results the rate of binding complex 24 to calf 
thymus DNA was determined by following the changes in the CD spectra with Pt 
binding. As discussed in Section 5.1.3, Pt binding induces a reduction of the positive 
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band in the spectrum (280 nm) and a corresponding reduction of the negative band 
(245 nm). The reaction was carried out as described in Section 5.2.3 and the results 
are shown in Figure 5.9. 
250 	 300 	 350 
wavelength nm 
Figure 5.9 CD Spectroscopy of CT DNA modified by [Pt{Me 2N(CH2)3PPh2}2C12] 
(24) at various time intervals after reaction 
The reaction was seen to be complete after 24 hours as no further change was 
observed in the spectrum from 24 to 48 hours. The height of the band at 280 nm in 
the 24 hour spectrum was taken to correspond to all the Pt being bound to the DNA. 
In the same way the band height at 280 nm for the control spectrum was taken to 
correspond to no Pt binding. By plotting the peak height versus time for all the 
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Figure 5.10 Graph showing amount of Pt bound to calf thymus DNA as determined 
by following changes in the CD spectrum of the DNA 
This rate of binding is much lower than that observed in the DPP experiments with 
calf thymus DNA, with a T50 value similar to that seen in HPLC experiments with 
mononucleotides. It was therefore postulated that there are two forms of interaction 
between complex 24 and DNA. One is covalent binding to N-sites on the bases on 
DNA, which occurs relatively slowly and is observed by DPP. The other is a purely 
electrostatic interaction between the protonated amine arm of the ligand in the 
complex and the negative phosphate groups in DNA. This occurs prior to covalent 
binding and leads to conformational changes in the DNA leading to the observed 
changes in the CD spectrum as discussed in Section 5.1.3. This electrostatic 
interaction is not strong enough to allow the Pt to be precipitated out with the DNA 
in the electrolyte solution in the DPP experiment, hence Pt is seen as unbound for 
longer until covalent binding takes place. The electrostatic interaction may aid 
covalent binding by positioning the Pt in close proximity to the DNA bases. This 
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would account for the increased rate of covalent binding of complex 24 to CT DNA 
compared to cisplatin as described in Section 5.1.1. 
5.4.1 Effect of pH on changes to CD Spectrum 
In order to support the postulate above, that [Pt{Me 2N(CH2) 3PPh2 } 2 Cl2 ] (24) forms 
electrostatic interactions with DNA, the effect of increasing pH on the changes in the 
CD spectrum was investigated. Higher pH should reduce the number of protonated 
amines on the ligand and hence reduce the amount of electrostatic attraction to the 
DNA phosphates. The results of increasing the pH to 9, as described in Section 
5.2.3, are shown in Figure 5.11. 
A blank sample was recorded at high pH to confirm that the pH was not having any 
effect on the DNA conformation. The platinated sample was recorded after 2 hours 
when DNA binding was seen to have occurred by the reduction in the positive band 
at 280 run. The pH of the sample was then increased to 9 and the recorded spectra 
after 1 hour and 6 hours at this pH showed the band at 280 nm to have increased 
again. This indicated that the Pt binding had reduced allowing the conformation of 
the DNA to move back to that of unmodified DNA. This supports the postulate that 
the binding is of an electrostatic nature and is reduced by increasing pH and 
deprotonating the amine groups on the ligands of the complex. 
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Figure 5.11 CD Spectroscopy to show effect of increased pH on changes induced in 
DNA by modification with [Pt {Me 2N(CH2)3PPh2}2C12] (24) 
5.5 Conclusions 
The binding of {Pt{Me2N(CH2)3PPh2}2C12] (24) to natural and synthetic DNAs has 
been investigated by a variety of methods including differential pulse polarography, 
cicular dichroism spectroscopy and high performance liquid chromatography. The 
most notable result was the lack of binding to poly (dT), despite the previous 
evidence of strong, rapid binding to the mononucleotide dTMP. This was shown to 
be due to a combination of factors. Firstly the concentration plays a role - this was 
proved by HPLC studies reaction complex 24 with dTMP in a 1:1 ratio at a 
concentration of 10 j.tM. Only 20% of the nucleotide was bound in the reaction in 
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comparison to the same reaction at 5 mM followed by 'H NMR in which all the 
dTMP was bound to Pt. Secondly the age of the complex solution used was shown 
to play a role. Since [Pt{Me 2N(CH2)3PPh2 } 2C12] (24) changes species in aqueous 
solution with time, the CE and HPLC competition reactions described in Section 4.2 
were repeated using complex aged in solution for 2 weeks as opposed to freshly 
made. The results showed that the new species formed had a much reduced level of 
nucleotide binding and the preference for thymine binding was greatly reduced too. 
The rate of the reaction between [Pt{Me 2N(CH2)3PPh2 } 2C12] (24) and calf thymus 
DNA was also investigated. By following the change in the CD spectrum of the 
DNA during the reaction, the kinetics were very fast (T 50 = 20 mm), this is due to a 
fast electrostatic interaction between the protonated amines in the ligands of the 
complex and the negative phosphates on the DNA. This was proved by a reversal of 
the effect induced by using a higher pH to deprotonate the amines and reduce the 
electrostatic attraction. By following the amount of Pt binding to CT DNA by DPP, 
the rate of the reaction was shown to be much slower (T 50 = 3 h). This is due to the 
fact that the electrostatic interaction is too weak to cause precipitation of the Pt in the 
electrolyte with the DNA. The experiment therefore highlights the rate of covalent 
binding of the complex to DNA. This is much slower than the electrostatic 
interaction but still faster than that observed for cisplatin, perhaps because the initial 
electrostatic attraction places the Pt in close proximity to the binding sites on the 
DNA. 
Overall [Pt{Me2N(CH2) 3PPh2 } 2C12] (24) shows a comparable level of DNA binding 
to cisplatin but with different site selectivity. This could provide potential for the 
development of the next generation of Pt anticancer agents with reduced resistance 
compared to cisplatin. 
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As discussed in the previous two chapters, the series of platinum aminophosphine 
complexes synthesised in this thesis have an unusual affinity for binding to thymine 
residues. This is in contrast to traditional platinum anticancer drugs which have been 
shown to bind predominantly to guanine and adenine residues on DNA.' For this 
reason it was hypothesised that these complexes would be good targets for binding 
the anti-viral drug 3'-azido, 3'-deoxy tymidine, AZT. This is a thymine analogue 
used as a drug in the treatment of HIV 2 (Section 1.6.1.2). The structure of AZT is 
shown in Figure 6.1. 
A platinum—AZT adduct could have potential as a multifunctional drug with 
synergistic interactions between the Pt agent and the antiviral nucleoside acting via 
different mechanisms of action to produce a more effective drug. This idea has 
already been employed, and the therapeutic potential of a Pt-Acyclovir complex has 
been investigated. [PtCl(NIH 3 )2(acyclovir)]NO3 has been shown to have similar 
antiviral activity to that of the acyclovir parent drug whilst also exhibiting in vivo 






Figure 6.1 Structure and numbering scheme of the anti-HIV agent AZT 
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6.1 1 NMR Spectroscopy 
Acquisition details for NIvIR spectroscopy are given in Section 2.3.1. Samples were 
prepared containing the relevant complex and AZT both at a concentration of 5 mM 
in D20. The pH*  values of the samples were measured as described in Section 2.3.7 
and adjusted as required using 0.1 M DN0 3 or NaOD. Dioxane solution (2 11, 5%) 
was added to each sample to act as a reference. The samples were placed in a water 
bath at 310 K overnight to ensure complete reaction. 
6.1.2 Electros pray lonisation Mass Spectrometry 
The ESI-MS equipment and experimental parameters are described in Section 2.3.3 
Samples were prepared containing the appropriate complex at 1 MM concentration 
and AZT at 2 mM concentration in water. The pH of each sample was adjusted to 
close to physiological pH (7.4) and the samples were incubated overnight at 310 K in 
a water bath to ensure complete reaction. Prior to analysis the samples were diluted 
to 50 iM with water. 
The reaction of complexes 24, 25, 26, and 27 (Figure 6.2) with AZT was carried out 
as described above, and studied by 1 H and 31 P NMR. Previous studies on reactions 
with the nucleotide dTMP (Chapter 4) showed that binding of these complexes 
increased with increasing pH due to deprotonation of the N3 binding site. For this 
reason the reactions were carried out at Ca. pH 9 in order to achieve maximum 
binding. All the reactions were carried out at a 1:1 Pt:AZT ratio. 
225 
Platinum—AZT Complexes as Potential Anti—HIV Agents 





Ph2P\ /Cl 	 Ph2 P\ /NH 
Pt Pt 





Complex 24 	 Complex 25 
N 
/CH H 
Ph2P\ /NH 	 Ph2 P\ /Cl 
Pt 	 Pt 
/\ /\ 
Ph2P 	Cl 	 Ph2 P 	Cl 
CH3 	 H 
N\H 	
N\ 
Complex 26 	 Complex 27 
Figure 6.2 Structures of platinum aminophosphine complexes 24 - 27 
In the 'H spectra for each of the four reactions, Pt bound species could be identified 
with resonances upfield from free AZT. 
Shifts for resonances in free AZT: 
	
H6: 7.67 ppm, 	Hi': 6.23 ppm 
H3': 4.36 ppm 	H4': 4.03 ppm 
	
H2': 3.83 ppm 2H5': 2.54 ppm 
Me: 1.90 ppm 
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As in the dTMP reactions, the amount of AZT bound to the complex in the reaction 
was determined by measurement of the integrals of the Hi' signals (occurring in a 
clear region of the spectrum with a flat baseline) for free and bound species. The 
results for the four complexes are shown in Table 6.1. 
Complex % AZT Bound 
[Pt {H2N(CH2)3PPh2-P,N} 2]C12 7.0 
[Pt {Me(H)N(CH2)3PPh2 } 2 C1]Cl 37.0 
24: [Pt {Me2N(CH2)3PPh2-P} 2 C12] 86.5 
[Pt { tBu(H)N(CH2)3PPh2-P} 2 C12 ] 95.5 
Table 6.1 Amount of bound AZT determined by 'H NMR, for complexes 24-27 in a 
1:1 reaction at pH 9 
These results show a clear correlation between the amount of AZT binding and the 
tendency for the complexes to exist in a ring-opened form. Complex 27 has shown 
no evidence of ring-closing, probably due to the steric bulk of the tertiary butyl 
groups, and binds virtually all the AZT present. This would be expected due to the 
presence of labile chloride leaving groups. Complex 24, whilst prepared only as the 
ring-opened species, does undergo hydrolysis reactions in aqueous solution to form 
some ring-closed species (Section 3.3.2). The ring-closed species does not promote 
AZT binding since there are no labile ligands and so only 86.5% of the AZT is 
bound. Complex 26 undergoes ring-closing dependent on pH, as shown in Section 
3.3.1, with a pK = 6.1. At high pH a large proportion of the complex is fully ring-
closed preventing AZT binding, hence only 37% of the AZT is bound during this 
reaction. Complex 25 also undergoes ring-closing at high pH but the pK for this 
complex is much lower at 2.9. Hence at high pH this complex is nearly all ring-
closed and virtually no AZT binding is observed, only 7%. The amount of AZT 
binding is therefore dependent on the amount of ring-opened species present which is 
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related to the steric bulk of the alkyl groups on the amine in the ligand as discussed 
in Section 3.3.2. 
The amount of binding for all complexes is less than 100% suggesting that binding is 
occuring in a monofunctional manner only. The 31 P NMR of the four AZT reactions 
were also recorded to obtain further information about the binding mode. 
The spectrum of the 1:1 reaction between [Pt{Me 2N(CH2 )3PPh2-P} 2Cl21 (24) and 
AZT is shown in Figure 6.3. There are three pairs of doublets, identified by their 
coupling constants, all in the range 19-21 Hz, suggesting 3 species (a, b and c) with 
non-equivalent P atoms in a cis orientation. Species c corresponds to unbound 
complex (only 86.5% of the AZT was bound in the reaction leaving 13.5% unbound 
Pt). This species has two doublets at 0.6 and —3.2 ppm and corresponds to the final 
species produced in the hydrolysis reactions of[Pt{Me 2N(CH2)3PPh2 -P} 2 Cl2] (24) as 
described in Section 3.3.2. Species a and b are both new products with AZT bound, 
and both contain one P atom with a downfield doublet at Ca. —2.5 ppm and another P 
atom with an upfield doublet at ca. —8.5 ppm. The 'J(Pt-P) coupling constants for 
both species are 3293 Hz for the downfield peak and 3252 Hz for the upfield peak, 
indicating N to be present in the positions trans to both P.4 '5 The very similar shifts 
and coupling for these two species a and b suggest that they are likely to be isomers 
of the same product, this will be discussed further in Section 6.2.3. The bound 
species is likely to contain AZT bound via N3 and one ring-closed ligand (Figure 
6.4), thus accounting for the coupling constants observed. 
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Figure 6.3 3 1  P NMR spectrum of [Pt {Me 2N(CH2)3PPh2-P}2C12] (24) with 1 mole 
equivalent of AZT present, pH 9 
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Figure 6.4 N3-bound monofunctional adduct of AZT and complex 24 (coloured 
atoms correspond to resonances in 31 P NIMR spectrum in Figure 6.3) 
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The 31 P NMR spectrum for the reaction between [Pt{H 2N(CH2) 3PPh2-P,N}2]C12 (25) 
and AZT produced only one singlet at —1.95 ppm with platinum satellites. The 
singlet is due to the unbound complex, which is fully ring-closed therefore 
containing two equivalent P atoms. The 'J(Pt-P) = 3205 Hz consistent with N in the 
trans position. 4'5 This correlates to the 'H NAM results which showed that only a 
very small amount of the complex was bound to AZT in the reaction. 
The reaction between [Pt{Me(H)N(CH 2)3PPh2 } 2C1]Cl (26) and AZT produced the 
spectrum shown in Figure 6.5. Some unbound complex can be seen as a singlet at - 
4.7 ppm. This is in the fully ring-closed form as would be expected at pH 9 with two 
equivalent P atoms. In addition to this peak, there are 4 bound species, each with 2 
inequivalent cis P atoms producing 4 pairs of doublets (a-d). Each product has a 
downfield doublet at Ca. —1.5 ppm and an upfield doublet at Ca. —11.0 ppm. These 
four species are again likely to be isomers of an N3-bound adduct. This is discussed 
further in Section 6.2.3. 
The spectrum from the reaction between [Pt{ tBu(H)N(CH 2)3PPh2-P} 2 C1 2 ] (27) and 
AZT is shown in Figure 6.6. Here, no free complex can be observed as would be 
expected from the 'H NIMR results. As for the reaction of complex 26, there are four 
bound products, a-d, each containing two inequivalent P atoms and producing two 
doublets each in the spectrum. Products a and b have a downfield doublet at ca. 4.6 
ppm and an upfield doublet at ca. 0.0 ppm. Products c and d have an downfield 
doublet at ca. 1.5 ppm and an upfield doublet at Ca. —1.0 ppm. In all four species the 
downfield doublet has a 1 J(Pt-P) coupling much greater than 3600 Hz suggesting that 
the ligand in the trans position is chloride, whilst the upfield doublet has a 1 J(Pt-P) 
coupling much less than 3600 Hz suggesting that the ligand in the trans position is 
nitrogen. 4'5 The bound species is therefore thought to contain AZT bound via N3 and 
both aminophosphine ligands ring-opened with a chloride in the fourth site. This 
structure is shown in Figure 6.7. The four distinct species are likely to be isomers of 
this compound, as discussed in Section 6.2.3. 
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ppm 
Figure 6.5 31P NMR spectrum of [Pt{Me(H)N(CH2)3PPh2}2C1]C1 (26) with 1 mole 
equivalent of AZT present, pH 9 
ppm 
Figure 6.6 31P NMR spectrum of [Pt{ tBu(H)N(CH2)3PPh2-P}2C12] (27) with 1 mole 
equivalent of AZT present, pH 9 
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Figure 6.7 N3-bound monofunctional adduct of AZT and complex 27 (coloured 
atoms correspond to resonances in 31 P NMR spectrum in Figure 6.6) 
6.2.1 Effect of pH on AZT Binding 
As was seen for the reactions of the complexes with the nucleotide dTMP in Section 
4.2 1, the reactions with AZT are likely to be affected by the pH of the reaction since 
the Pt binding site is N3 which is usually protonated up to pH values of about 10. 
Titrations of pH were therefore carried out on the reaction mixtures of complexes 24 
and 27. 'H NMR spectra were recorded at various pH values as described in Section 
6. 1.1 and the amount of AZT bound was determined by integration of the signal 
for the bound and free AZT. The results are shown in Figure 6.8 and 6.9 for 
complexes 24 and 27 respectively. pK values were obtained by fitting to the 
Henderson-Hasselbach equation using the program KALEIDAGRAPH. 6 
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Figure 6.8 Graph showing effect of pH on amount of AZT binding to 
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Figure 6.9 Graph showing effect of pH on amount of AZT binding to 
[Pt {tBu(H)N(CH2) 3PPh2-P} 2C12] (27) in a 1:1 reaction 
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Both graphs clearly show an increase in the amount of AZT bound with increasing 
pH as predicted. Binding occurs over a large pH range starting as low as 2 and 
continuing up to 12. For complex 27, a precipitate appeared in the solution above pH 
9 causing a reduction in the intensities of the signals in the NMR. For complex 24, 
the pK value for binding AZT was determined to be 3.29 ± 0.17 and for complex 27 
the pK value was 2.80 ± 0.05. These values are remarkably low since the pKa value 
for the AZT N3 site is in the region of 10. This again indicates the influence of the 
amine groups, in the ligands of the complex, in abstracting a proton to allow Pt 
binding. 
6.2.2 Characterisation of AZT Adducts 
As for the nucleotide adducts of complexes 24, 25, and 27, electrospray ionisation 
mass spectrometry was used to determine the nature of the AZT adducts. The ES!-
MS spectrum of the reaction between [Pt {Me2N(CH2)3PPh2-P} 2 C12] (24) and AZT 
was recorded as described in Section 6.1.2 and is shown in Figure 6.10. 
100 
% 
0 500 	 1000 	 1500 
mhz 
Figure 6.10 ESI-MS spectrum of [Pt {Me 2N(CH2)3PPh2-P}2C121 (24) and AZT 
(expansion shows isotope pattern for monofunctional adducts) 
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A monfunctional adduct containing Pt with two DMDPPA ligands and one AZT is 
clearly seen at 1004 mlz. (Calculated mlz for PtC 44H56N704P2 = 1004) The 
assignment of this species was confirmed by the calculation of an isotope model for 
the corresponding compound in the Mass Lynx (V 2.3) program. No bifunctional 
adducts were observed. (Calculated mlz for PtC 54H68N 1208P2 = 1270) This 
confirms the assumption from the ratio of AZT bound in the 'H NIMR experiment, 
that complex 24 only forms monofunctional adducts with AZT. 
The ESI-MS spectrum of the reaction between [Pt{H 2N(CH2 ) 3PPh2-P,N} 2 ]C1 2 (25) 






Figure 6.11 ESI-MS spectrum of [Pt {H 2N(CH2)3PPh2-P,N} 2]C12 (25) and AZT 
(expansion shows isotope pattern for monofunctional adducts) 
Again this confirmed the 'H NMIR results, where very little binding was observed, 
since no Pt bound AZT adducts were detected. The major peak observed was at 680 
m/z and corresponds to Pt with two DPPA ligands. (Calculated mlz for PtC 30H36N2P 2 
= 680) 
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The ESI-MS spectrum of the reaction between [Pt{tBu(H)N(CH2)3PPh2P}2C121  (27) 
and AZT was recorded as described in Section 6.1.2 and is shown in Figure 6.12. 
% 
m/z 
Figure 6.12 ESI-MS spectrum of [Pt { tBu(H)N(CH 2) 3PPh2-P} 2 C1 2] (27) and AZT 
(expansion shows isotope pattern for monofunctional adducts) 
In this spectrum quite intense signals were detected for the monofunctional adduct of 
complex 27 and AZT at 1096 mlz. (Calculated mlz for PtC 48H64N704P2C1 = 1095.5) 
This assignment was again confirmed by the use of an isotope model. This main 
peak is accompanied by peaks at 1060 (adduct with loss of chloride) and 1118, 1134, 
1159 m/z (addition of sodium ions). Complex 27 also seems to be limited to the 
formation of monfunctional adducts as was the case for complex 24. (Calculated mlz 
for PtC58H68N 1208P2 = 1328) 
6.2.3 Diastereomers of AZT Adducts 
It is apparent from the NMR results already discussed for the AZT reactions that 
AZT binding gives rise to a number of different species. The similarity in the NMR 
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parameters for the species produced in each reaction suggest that the adducts are very 
similar, probably isomers. 
Whilst the complexes themselves are not chiral, an unsymmetrical incoming ligand 
like AZT will produce enantiomers when added, as a consequence of having 
head/tail directionality. Such chirality is termed planar chirality and is defined as 
the stereoisomerism resulting from the arrangement of out-of-plane groups with 
respect to the chirality plane. 7 This is caused by the a monodentate planar ring with 
only C symmetry orthogonally bound to a metal centre with two other different 
ligands cis-coordinated with respect to the ring. 8 In these complexes the AZT is the 
monodentate planar ring and can coordinate in either a "head" or "tail" position, 
determined by the direction the methyl group points, above or below the ring 
respectively creating two possible isomers. 
In the cases of complexes 24 and 26 where one aminophosphine ligand in the 
complex is fixed in a ring-closed comformation, these two isomers can be defined as: 
the methyl group on the AZT and the pendant aminophosphine ligand are on the 
same side of the Pt coordination plane 
the methyl group on the AZT and the pendant aminophosphine ligand are on 
opposite sides of the Pt coordination plane 
It has been shown that in analogous Pt-nucleotide complexes, that the presence of 
bulky ligands on the Pt can slow down rotation of the Pt-nuc bonds and create 
species which are distinct in their NIVIR observation. 9-12 
Since the AZT molecule is itself chiral, as is also the case for the nucleotide GMP, 
diastereomers are generated. Four energetically distinct species are possible since 
there are two diastereomeric forms of each rotational isomer. These species are 
shown in Scheme 6.1. 
Previous work on a similar complex to those used in this thesis, cis- 
[Pt{Me2N(CH2)2PPh2}2C1]Cl, showed that the same possible isomers could be 
237 
Platinum—AZT Complexes as Potential Anti—HIV Agents 
formed with GMP.' 3 Molecular modelling allowed the barriers to rotation between 
the isomers to be calculated. The rotation of the Pt-P bond appeared to be a 
relatively facile process which could occur at a significant rate but rotation of the Pt-
N7(guanine) bond was impeded by interactions between the guanine and the 
coordination plane and would occur only at elevated temperatures. This could 
account for the fact that for [Pt {Me 2N(CH2)3PPh2-P} 2C12] (24) only two bound 
species were identified in the 31 P NIMIR spectrum after AZT binding. If the 
interconversion between A and B is very fast then these two species would not be 
distinct in the NMR spectrum. In the case of [Pt{Me(H)N(CH 2)3PPh2 } 2C1]Cl (26) 
however, 4 distinct species were observed in the 31 P NMR spectrum, this could be 
due to the presence of hydrogen bonding between the secondary amine on the 
dangling ligand and the exocyclic 0 groups on the AZT ring. This would increase 
the barrier to rotation around Pt-P and prevent interconversion between isomers, 
leading to the detection of all diastereomers. Such H-bonds have been observed in 
Pt(NH3)2 complexes of thymine between N-H from the amine and an exocylic 
oxygen from the thymin& 4 but only intermolecular bonds. The aminophosphine 
ligand in this complex has the added flexibility of a propyl chain before the amine 
group which could allow the amine to be positioned correctly for intramolecular H-
bonds to occur. 
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Scheme 6.1 Possible diastereomers formed with AZT and a ring-closed complex 
The diastereomers produced when AZT is bound to {Pt{ tBu(H)N(CH2)3PPh2-P} 2 C1 2 ] 
(27) are further complicated by the fact that the complex contains two ring-opened 
ligands. This increases the number of possible diastereomers to 8 since each species 
in Scheme 6.1 can exist as two further rotational isomers with the second dangling 
ligands either above or below the Pt coordination plane. These are represented 
schematically in Figure 6.13. 
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Figure 6.13 Eight possible diastereomers of the AZT adduct of complex 27, 
determined by orientation of ligands relative to the Pt coordination plane 
Of the eight possible diastereomers, the most favourable are likely to be ii, iii, vi and 
vii since in these conformations the two aminophosphine ligands are on opposite 
sides of the coordination plane. This will be favoured due to the steric bulk of the 
tertiary butyl groups in the ligands hindering the conformations with the ligands on 
the same side of the plane. This would account for the observation of only four 
distinct species in the 31 P NMR of the reaction between complex 27 and AZT. 
In all the AZT adducts there is also the possibility for electrostatic interactions 
between the azide group in the AZT and the protonated amine group in the ligand. 
This would stabilise diastereomers with the azide and dangling arm ligand on the 
same side of the coordination plane. It would also be possible for hydrogen-bonding 
to occur between one of the exocyclic oxygens on the AZT and the NH on the ligand. 
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1i.1ii.4IIT[,]j]i 
The binding of the complexes studied to AZT was shown by NMR experiments. The 
extent of binding was determined by the amount of ring-opened complex present, 
which is related to the steric bulk on the aminophosphine ligands. The binding was 
also controlled by pH, with high pH leading to increased binding due to 
deprotonation of the N3 binding site on the AZT. The adducts formed with AZT 
were all monofunctional, as determined by both NIVIR and ESI-MS experiments. In 
the binding reactions a number of different diastereomers of the bound adducts were 
observed. These are due to the variation of the orientation of the ligands and AZT 
relative to the Pt coordination plane. Different diastereomers are preferred for each 
complex. These may be due to the presence of hydrogen-bonding stabilising some 
comformations or the destabilising effects of steric hindrance. 
The binding to AZT could prove to be very useful in the development of new 
antiviral drugs against HIV. Potentially the AZT could be used to terminate virus 
replication whilst the Pt could be employed to kill the damaged host cell and prevent 
transfer of HIV to other healthy cells. The therapeutic benefits of these Pt-AZT 
complexes need to be investigated further to assess their potential as multifunctional 
drugs. 
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Figure A.! X-ray crystal structure of complex 24 plotted in SHELEX showing the 
atom labeling scheme 
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Table A.1 Atomic coordinates ( x 10 114), equivalent isotropic displacement 
parameters (AA2 x 10^3) and site occupancies for complex 24. (U(eq) is defined as 
one third of the trace of the orthogonalized Uij tensor.) 
x y z U(eq) 0cc 
PT! 7040(1) 9485(1) 2706(1) 23 1.00 
CL! 8389(3) 8569(1) 3271(1) 39 1.00 
CL2 7669(3) 9096(1) 1702(1) 37 1.00 
P1 6028(2) 10371(1) 2052(1) 23 1.00 
Cli 7232(9) 10806(6) 1605(5) 32 1.00 
C21 8642(9) 10921(6) 2034(4) 37 1.00 
C31 9510(10) 11359(5) 1634(5) 49 1.00 
N41 9602(7) 11061(5) 1001(3) 48 1.00 
C51 10290(10) 10374(8) 1091(6) 68 1.00 
C61 10320(10) 11518(8) 621(6) 77 1.00 
Clii 5282(8) 11131(3) 2398(4) 16 1.00 
C211 3959(8) 11333(4) 2172(4) 33 1.00 
C311 3471(7) 11962(5) 2382(5) 35 1.00 
C411 4320(10) 12400(4) 2829(5) 39 1.00 
C511 5651(9) 12210(5) 3076(5) 37 1.00 
C611 6114(7) 11576(5) 2864(4) 32 1.00 
C121 4715(8) 10037(4) 1368(3) 25 1.00 
C221 4150(10) 9371(5) 1437(4) 36 1.00 
C321 3210(10) 9085(4) 917(4) 39 1.00 
C421 2840(8) 9468(6) 333(4) 38 1.00 
C521 3370(10) 10126(5) 265(3) 35 1.00 
C621 4317(9) 10416(4) 788(4) 30 1.00 
P2 6339(3) 9736(1) 3670(1) 26 1.00 
C12 6200(10) 8945(4) 4171(4) 29 1.00 
C22 5358(9) 8328(5) 3824(4) 32 1.00 
C32 5700(10) 7646(4) 4239(4) 40 1.00 
N42 5440(10) 7691(4) 4913(4) 46 1.00 
C52 4000(20) 7646(9) 4902(6) 82 1.00 
C62 6090(20) 7139(7) 5337(6) 69 1.00 
C112 4660(6) 10125(4) 3560(4) 27 1.00 
C212 3610(8) 9786(4) 3134(4) 27 1.00 
C312 2321(8) 10037(5) 3048(5) 38 1.00 
C412 2060(7) 10668(5) 3373(5) 39 1.00 
C512 3086(9) 11021(4) 3807(5) 35 1.00 
C612 4365(7) 10755(4) 3893(4) 26 1.00 
C122 7501(8) 10282(5) 4251(3) 25 1.00 
C222 8651(9) 10541(6) 4058(3) 33 1.00 
Appendix 
x 	 y 	 z 	 U(eq) 	0cc 
C322 9618(9) 10912(7) 4517(5) 49 1.00 
C422 9390(10) 11036(6) 5157(5) 46 1.00 
C522 8260(10) 10782(6) 5355(4) 41 1.00 
C622 7305(8) 10397(5) 4905(4) 33 1.00 
C20 9550(20) 3080(10) 2870(10) 104 1.00 
CL21 9568(6) 2499(4) 3553(3) 124 1.00 
CL22 8070(5) 3072(3) 2306(3) 92 1.00 
Hill 6858 11280 1442 22 1.00 
H112 7322 10503 1209 22 1.00 
H211 8565 11181 2455 53 1.00 
H212 9079 10449 2153 53 1.00 
H311 9099 11844 1554 41 1.00 
H312 10433 11401 1911 41 1.00 
H511 10345 10172 640 77 1.00 
H512 11213 10439 1364 77 1.00 
H513 9771 10041 1330 77 1.00 
H611 10369 11288 180 91 1.00 
H612 9845 11984 538 91 1.00 
H613 11255 11598 882 91 1.00 
H2111 3347 11018 1852 17 1.00 
H3111 2513 12101 2214 40 1.00 
H4111 3968 12858 2974 39 1.00 
H51 11 6257 12524 3399 40 1.00 
H61 11 7063 11427 3046 17 1.00 
H2211 4420 9099 1867 27 1.00 
H3211 2805 8607 965 36 1.00 
H4211 2172 9263 -49 40 1.00 
H5211 3085 10399 -163 31 1.00 
H621 4700 10900 740 35 1.00 
H121 5791 9094 4562 26 1.00 
H122 7127 8762 4340 26 1.00 
H221 4381 8439 3785 41 1.00 
H222 5559 8258 3364 41 1.00 
H321 6678 7541 4270 32 1.00 
H322 5153 7248 3999 32 1.00 
H521 3836 7678 5372 90 1.00 
H522 3530 8046 4627 90 1.00 
H523 3648 7183 4698 90 1.00 
H621 5887 7189 5798 70 1.00 
H622 7087 7174 5364 70 1.00 
H623 5768 6667 5144 70 1.00 
H2121 3800 9350 2886 29 1.00 
H3121 1570 9772 2756 41 1.00 
Appendix 
x 	 y 	 z 	 U(eq) 	0cc 
H4121 1127 10866 3290 38 1.00 
H5121 2893 11460 4051 41 1.00 
H612 5111 11009 4198 29 1.00 
H221 8787 10463 3587 50 1.00 
H3221 10461 11084 4383 34 1.00 
H4221 10061 11315 5483 50 1.00 
H5221 8122 10873 5823 33 1.00 
H6221 6487 10205 5050 41 1.00 
H21 9721 3571 3042 127 1.00 
H22 10277 2931 2626 127 1.00 
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Figure A.2 X-ray crystal structure of complex 25 plotted in SHELEX showing the 
atom labeling scheme 
V 
Appendix 
Table A.2 Atomic coordinates ( x 104) and equivalent isotropic displacement 
parameters (A"2 x 1 0A3)  for complex 25. (U(eq) is defined as one third of the trace 
of the orthogonalized Uij tensor.) 
x y z U(eq) 
Pt(1) 3167(1) 3594(1) 3034(1) 17(1) 
N(1A) 2618(4) 3092(3) 4108(2) 22(1) 
C(2A) 1396(5) 3366(4) 4460(2) 23(1) 
C(3A) -158(5) 2597(4) 4024(2) 25(1) 
C(4A) -459(5) 2935(4) 3223(2) 22(1) 
P(5A) 700(1) 2595(1) 2557(1) 18(1) 
C(6A) -125(5) 3072(4) 1717(2) 20(1) 
C(7A) -1188(5) 2232(4) 1140(2) 26(1) 
C(8A) -1851(6) 2663(5) 541(3) 31(1) 
C(9A) -1452(6) 3945(5) 518(3) 33(1) 
C(1OA) -416(5) 4780(4) 1100(3) 29(1) 
C(11A) 240(5) 4353(4) 1704(3) 24(1) 
C(1 2A) 203(5) 906(4) 2411(2) 18(1) 
C(1 3A) -1274(5) 104(4) 2366(2) 22(1) 
C(14A) -1588(5) -1190(4) 2295(2) 26(1) 
C(1 5A) -443(5) -1667(4) 2256(2) 27(1) 
C(1 6A) 1022(5) -886(4) 2292(3) 29(1) 
C(1 7A) 1361(5) 415(4) 2379(2) 23(1) 
N(113) 5371(4) 4599(3) 3634(2) 20(1) 
C(2B) 6756(5) 444 1(4) 3400(2) 26(1) 
C(313) 7019(5) 4836(4) 2632(2) 24(1) 
C(413) 5905(5) 3946(4) 1968(2) 23(1) 
P(5B) 4005(1) 3991(1) 1922(1) 18(1) 
C(6B) 3001(5) 2893(4) 1052(2) 20(1) 
C(7B) 2132(5) 3202(4) 482(2) 25(1) 
C(8B) 1389(5) 2341(4) -165(3) 29(1) 
C(9B) 1501(5) 1164(4) -242(3) 30(1) 
C(1OB) 2370(6) 849(4) 327(3) 32(1) 
C(11B) 3135(5) 1709(4) 976(2) 26(1) 
C(1 2B) 4226(5) 5548(4) 1686(2) 21(1) 
C(1 3B) 4738(5) 5880(4) 1012(2) 25(1) 
C(1413) 4954(5) 7082(4) 839(3) 30(1) 
C(1 5B) 4660(5) 7950(4) 1340(3) 32(1) 
C(1 6B) 4177(5) 7634(4) 2015(3) 27(1) 
C(1 7B) 3949(5) 6431(4) 2190(2) 22(1) 
C1(1) 5802(1) 3598(1) 5262(1) 29(1) 
C1(2) 5393(1) 952(1) 2569(1) 29(1) 
VI 
Appendix 
x y z U(eq) 
C(1N) 3776(6) 919(5) 6016(3) 41(1) 
N(1N) 2574(5) 1466(4) 5884(2) 36(1) 
0(1N1) 1473(5) 882(4) 5415(3) 77(2) 
0(1N2) 2726(4) 2478(3) 6245(2) 43(1) 
C(2N) 8183(6) 1732(4) 5774(3) 39(1) 
N(2N) 8821(5) 3022(4) 6201(2) 34(1) 
0(2N1) 8494(5) 3221(4) 6823(2) 58(1) 
0(2N2) 9645(4) 3830(3) 5899(2) 50(1) 
0(1W) 5920(5) 8936(4) 5892(3) 45(1) 
H(1A1) 2403 2239 4069 26 
H(1A2) 3491 3457 4458 26 
H(2A1) 1541 4269 4476 28 
H(2A2) 1466 3186 4992 28 
H(3A1) -929 2723 4319 29 
H(3A2) -270 1696 3976 29 
H(4A1) -306 3843 3274 26 
H(4A2) -1533 2475 3003 26 
H(7A) -1466 1355 1155 31 
H(8A) -2579 2082 145 37 
H(9A) -1891 4242 103 40 
H(1OA) -149 5657 1089 35 
H(11A) 938 4937 2110 29 
H(13A) -2070 436 2383 26 
H(14A) -2594 -1740 2275 31 
H(1 5A) -664 -2550 2203 32 
H(1 6A) 1804 -1230 2258 35 
H(17A) 2375 959 2416 27 
H(1B1) 5498 5437 3651 24 
H(1B2) 5371 4436 4129 24 
H(2B1) 6671 3549 3381 31 
H(2B2) 7640 4946 3790 31 
H(3B1) 8056 4893 2559 29 
H(3B2) 6949 5684 2627 29 
H(4B1) 5876 3079 2012 27 
H(4B2) 6268 4159 1484 27 
H(7B) 2041 4012 532 30 
H(8B) 800 2565 -559 35 
H(9B) 981 571 -684 35 
H(1OB) 2447 35 275 38 
H(11B) 3743 1491 1363 32 
H(13B) 4940 5284 670 30 
H(14B) 5302 7307 378 36 
H(15B) 4792 8769 1218 38 
VII 
Appendix 
x y z U(eq) 
H(1 6B) 4000 8241 2361 33 
H(1 7B) 3605 6212 2653 26 
H(1N1) 4599 1483 6407 61 
H(1N2) 4164 804 5539 61 
H(1N3) 3364 104 6189 61 
H(2N1) 8550 1715 5284 58 
H(2N2) 7078 1468 5683 58 
H(2N3) 8501 1159 6073 58 
H(1W1) 5610(70) 8990(50) 6300(30) 49(19) 
H(1 W2) 5270(80) 8320(60) 5610(40) 80(30) 
VIII 
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A.1.3 [Pt{Me(H)P(CH 2 ) 3NMe2}C1 2] (26B) 
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Figure A.3 X-ray crystal structure of complex 26B plotted in SHELEX showing the 
atom labeling scheme 
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Table A.3 Atomic coordinates ( x 10"4) and equivalent isotropic displacement 
parameters (AA2 x lO"3) for complex 26B. (U(eq) is defined as one third of the trace 
of the orthogonalized Uij tensor.) 
X y z U(eq) 0cc 
Pt(1) 1175(1) 587(1) 2281(1) 33(1) 1 
C1(1A) -366(2) 926(2) 909(1) 49(1) 1 
C1(2A) 1232(2) 2259(2) 3225(1) 46(1) 1 
C(1 A) -380(10) -2297(8) 1275(6) 61(2) 1 
N(2A) 909(7) -960(6) 1348(4) 47(2) 1 
C(3A) 2195(9) -1119(8) 1416(5) 53(2) 1 
C(4A) 2907(9) -1452(8) 2354(5) 51(2) 1 
C(5A) 3759(8) -268(7) 3219(5) 44(2) 1 
P(6A) 2621(2) 257(2) 3538(1) 34(1) 1 
C(7A) 3939(7) 1759(6) 4502(5) 39(2) 1 
C(8A) 3970(8) 1789(7) 5418(5) 48(2) 1 
C(9A) 5006(9) 2961(8) 6141(6) 57(2) 1 
C(1 OA) 5974(9) 4088(8) 5930(7) 64(2) 1 
C(11A) 5950(9) 4068(8) 5023(7) 64(2) 1 
C(1 2A) 4916(5) 2937(4) 4356(3) 56(2) 1 
C(1 3A) 1564(5) -1120(4) 4026(3) 36(1) 1 
C(14A) 438(5) -1055(4) 4184(3) 49(2) 1 
C(1 5A) -388(9) -2053(8) 4604(5) 58(2) 1 
C(1 6A) 60(9) -2964(8) 4966(5) 57(2) 1 
C(1 7A) 1316(9) -2878(7) 4921(5) 49(2) 1 
C(1 8A) 2095(8) -1942(7) 4490(5) 42(2) 1 
C(1 X) 7032(10) 9808(9) 1915(6) 65(2) 1 
CI(1X) 7074(4) 8321(4) 2233(3) 102(1) 0.80 
CI(2X) 5425(6) 9329(8) 941(3) 107(2) 0.80 
CI(3X) 7219(4) 10788(4) 2894(3) 96(1) 0.80 
CI(1W) 6770(20) 11300(20) 2295(16) 138(7) 0.20 
C1(2W) 7120(30) 9200(30) 2833(19) 163(9) 0.20 
CI(3W) 5590(50) 8960(50) 870(30) 210(20) 0.20 
C(1 Y) 4027(17) 3769(16) 1527(11) 131(5) 1 
CI(1Y) 3867(6) 4994(5) 776(5) 206(3) 1 
CI(2Y) 5963(6) 4753(5) 24 18(3) 172(2) 1 
CI(3Y) 3834(6) 2468(4) 813(4) 162(2) 1 
C(1 Z) -420(9) -6102(9) 1735(6) 61(2) 1 
C1(1Z) -2075(5) -6603(6) 810(3) 113(2) 0.80 
C1(2Z) 1034(5) -5175(4) 1342(3) 83(1) 0.80 
C1(3Z) -193(10) -5129(10) 2750(5) 79(2) 0.80 
CI(IV) -2358(16) -6850(30) 1144(15) 119(10) 0.20 
CI(2V) 401(18) -5239(18) 1003(11) 86(5) 0.20 
KII 
Appendix 
X y z U(eq) 	0cc 
C1(3V) 90(30) -4980(30) 2782(18) 46(4) 	0.20 
H(1A1) -1184 -2151 1259 92 
H(1 A2) -100 -2678 1824 92 
H(1 A3) -691 -2928 694 92 
H(2A) 618 	- 752 758 56 
H(3A1) 2938 -269 1337 64 
H(3A2) 1879 -1851 886 64 
H(4A1) 2136 -2221 2480 61 
H(4A2) 3578 -1750 2278 61 
H(5A1) 4505 516 3085 53 
H(5A2) 4274 -538 3768 53 
H(8A) 3292 1018 5557 58 
H(9A) 5036 2973 6766 69 
H(1 OA) 6661 4882 6412 77 
H(11A) 6636 4821 4876 77 
H(1 2A) 4858 2958 3726 67 
H(14A) 171 -399 3967 59 
H(1 5A) -1238 -2095 4636 69 
H(16A) -487 -3637 5240 68 
H(1 7A) 1644 -3474 5192 59 
H(1 8A) 2988 -1854 4506 51 
D(1 X) 7874 10341 1734 78 
D(1 Y) 3304 3458 1831 157 
D(1Z) -385 -6935 1904 73 
xl 
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A.1.4 [Pt{tBu (H)N(CH2)3PPh2} 2C1 2] (27) 
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Figure A.4 X-ray crystal structure of complex 27 plotted in SHELEX showing the 
atom labeling scheme 
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Table A.4 Atomic coordinates ( x 10''4) and equivalent isotropic displacement 
parameters (A"2 x 10"3) for complex 27. (U(eq) is defined as one third of the trace 
of the orthogonalized Uij tensor.) 
X y z U(eq) 0cc 
Pt(1) 3513(1) 9576(1) 3784(1) 30(1) 1 
C1(1) 3280(1) 10990(1) 4214(1) 41(1) 1 
C1(2) 3904(1) 10649(1) 3315(1) 40(1) 1 
P(1 A) 3132(1) 8689(1) 4304(1) 30(1) 1 
C(1A) 2874(2) 7483(4) 393 1(2) 35(1) 1 
C(2A) 2954(2) 6641(3) 4347(3) 38(1) 1 
C(3A) 2733(2) 5767(4) 4030(3) 47(1) 1 
C(4A) 2425(2) 5703(4) 3287(3) 45(1) 1 
C(5A) 2338(2) 6535(4) 2861(3) 44(1) 1 
C(6A) 2563(2) 7420(4) 3 183(2) 36(1) 1 
C(7A) 3549(2) 8528(3) 5267(2) 31(1) 1 
C(8A) 3365(2) 8272(3) 5747(2) 37(1) 1 
C(9A) 3688(2) 8246(4) 6486(3) 45(1) 1 
C(1OA 4195(2) 8458(4) 6752(3) 50(1) 1 
C(1 1A) 43 80(2) 8704(4) 6294(3) 57(2) 1 
C(1 2A) 4063(2) 8745(4) 5548(3) 45(1) 1 
C(1 3A) 2574(2) 9283(4) 4279(3) 37(1) 1 
C(14A) 2171(2) 9584(4) 3519(3) 42(1) 1 
C(1 5A) 1757(2) 10212(4) 3529(3) 46(1) 1 
N(1 6A) 1480(2) 9682(4) 3828(3) 70(1) 1 
C(1 7A) 1060(2) 10211(5) 3848(4) 75(1) 1 
C(1 8A) 687(2) 10640(5) 3131(4) 83(1) 1 
C(19A) 1266(2) 11027(5) 4408(4) 82(1) 1 
C(20A) 781(3) 9467(5) 4061(4) 86(1) 1 
P(1B) 3812(1) 8387(1) 3336(1) 35(1) 1 
C(1 B) 4485(2) 8538(3) 3636(3) 38(1) 1 
C(213) 4799(2) 8907(3) 4318(3) 43(1) 1 
C(313) 5319(2) 8904(3) 4600(3) 47(1) 1 
C(413) 5532(2) 8541(4) 4199(3) 58(2) 1 
C(513) 5231(2) 8180(6) 3525(3) 77(2) 1 
C(613) 4705(2) 8155(5) 3238(3) 65(2) 1 
C(713) 3491(2) 8400(3) 2346(3) 34(1) 1 
C(813) 3640(2) 9027(3) 1955(3) 37(1) 1 
C(913) 3379(2) 9056(3) 1213(3) 42(1) 1 
C(1OB) 2959(2) 8472(4) 838(3) 48(1) 1 
C(1 1B) 2795(2) 7866(4) 1212(3) 57(2) 1 
C(1 2B) 3063(2) 7820(3) 1961(3) 47(1) 1 
C(1 3B) 3798(2) 7094(4) 3565(4) 83(3) 1 
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x 	 y 	 z 	 U(eq) 	0cc 
C(14B) 41 14(3) 6446(5) 3523(5) 30(2) 
C(1 5B) 4034(4) 5396(6) 3729(6) 41(2) 
N(1 6B) 4282(5) 4701(6) 3515(6) 59(1) 
 4137(4) 6625(6) 4164(6) 52(1) 
 4099(5) 5502(6) 4232(6) 54(1) 
N(16) 4192(5) 4912(6) 3712(6) 58(1) 
C(1 7B) 4202(2) 3786(4) 3722(3) 61(1) 
C(1 8B) 4583(2) 3515(4) 4488(3) 68(1) 
C(1 9B) 4509(5) 3030(9) 3415(6) 63(1) 
C(19) 4201(5) 3477(8) 3079(6) 62(1) 
C(20B) 3679(2) 3474(4) 3589(3) 74(1) 
H(2AA) 3163 6672 4856 45 
H(3AA) 2791 5197 4322 57 
H(4AA) 2275 5092 3071 54 
H(5AA) 2126 6499 2352 53 
H(6AA) 2506 7991 2891 43 
H(8AA) 3016 8114 5566 45 
H(9AA) 3559 8083 6810 54 
H(1 OA) 4417 8432 7258 60 
H(11A) 4730 8849 6483 69 
H(1 2A) 4197 8920 5233 54 
H(13A) 2418 8826 4487 44 
H(13B) 2685 9878 4590 44 
H(14A) 2336 9955 3280 51 
H(14B) 2018 8983 3230 51 
H(1 5A) 1909 10811 3822 55 
H(15B) 1520 10423 3029 55 
H(16A) 1705 9496 4293 84 
H(16B) 1354 9115 3562 84 
H(1 8A) 858 11133 2979 125 
H(18B) 408 10953 3177 125 
H(18C) 552 10114 2768 125 
H(1 9A) 1437 11520 4256 123 
H(19B) 1509 10750 4877 123 
H(19C) 987 11339 4452 123 
H(20A) 665 8925 3710 129 
H(20B) 488 9782 4067 129 
H(20C) 1009 9208 4544 129 
H(2BA) 4653 9169 4599 52 
H(3BA) 5528 9155 5072 57 
H(4BA) 5890 8541 4390 70 
H(5BA) 5381 7940 3244 93 













x 	 y 	 z 	 U(eq) 
H(8BA) 3927 9441 2206 44 
H(9BA) 3490 9482 955 50 
H(1OB) 2782 8489 324 57 
H(11B) 2498 7478 957 68 
H(12B) 2953 7386 2215 56 
H(1 3B) 3850 7074 4068 99 
H(13C) 3450 6850 3250 99 
H(13D) 3466 6996 3552 99 
H(13E) 3784 6713 3153 99 
H(14C) 4467. 6655 3849 36 
H(14D) 4067 6440 3022 36 
H(15C) 4166 5357 4260 50 
H(1 5D) 3667 5246 3494 50 
H(16C) 4157 4722 3021 71 
H(16D) 4624 4836 3731 71 
H(14E) 4123 6932 4583 62 
H(14F) 4478 6765 4216 62 
H(15E) 4347 5301 4730 64 
H(15F) 3756 5344 4165 64 
H(16E) 4498 5117 3756 69 
H(16F) 3949 5096 3257 69 
H(18D) 4922 3729 4583 101 
H(18E) 4582 2800 4550 101 
H(18F) 4492 3842 4829 101 
H(1 9D) 4295 2909 2897 95 
H(19E) 4584 2403 3678 95 
H(19F) 4827 3340 3493 95 
H(1 9G) 3911 3770 2662 93 
H(1 9H) 4176 2757 3044 93 
H(191) 4516 3690 3083 93 
H(20D) 3424 3732 3120 111 
H(20E) 3614 3735 3975 111 
H(20F) 3659 2753 3585 111 
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Figure A.5 X-ray crystal structure of complex 28 plotted in SHELEX showing the 





Table A.5 Atomic coordinates (x 10' 14) and equivalent isotropic displacement 
parameters (AA2 x 10'3) for complex 28. (U(eq) is defined as one third of the trace 
of the orthogonalized Uij tensor.) 
x y z U(eq) 
Pt(1) 2567(1) 1558(1) 1493(1) 17(1) 
Cl(1) 1361(1) 2202(1) -179(1) 7(1) 
C(1) 543(6) 1552(3) 2225(5) 29(1) 
P(1) 3388(1) 831(1) 2949(1) 18(1) 
 2795(5) 961(3) 4495(5) 20(1) 
 3309(6) 1565(3) 5133(5) 27(1) 
 2901(6) 1687(3) 6305(5) 33(2) 
 1942(6) 1234(4) 6843(5) 34(2) 
 1406(6) 644(3) 6202(5) 33(2) 
 1849(6) 510(3) 5041(5) 27(1) 
 2850(5) -75(3) 2565(5) 21(1) 
 1775(5) -206(3) 1594(5) 24(1) 
 1296(6) -893(3) 1328(5) 26(1) 
 1862(6) -1454(3) 2030(5) 29(1) 
 2947(7) -1329(3) 2975(5) 34(2) 
 3423(6) -652(3) 3242(5) 29(1) 
C(2) 5395(5) 803(3) 3269(5) 24(1) 
C(3) 6243(6) 809(3) 2115(5) 29(1) 
C(4) 6088(6) 1493(3) 1410(5) 29(1) 
N(5) 4680(5) 1608(3) 592(4) 26(1) 
 4869(7) 2304(4) -5(7) 49(2) 
 4560(6) 1061(4) -365(5) 39(2) 
H(1A) 431 1109 2677 44 
H(1 B) -254 1588 1562 44 
H(1 C) 486 1954 2786 44 
H(12) 3937 1891 4762 33 
H(13) 3285 2088 6749 39 
H(14) 1654 1327 7644 40 
H(15) 738 331 6556 39 
H(16) 1493 98 4612 32 
H(22) 1370 177 1112 28 
H(23) 575 -977 660 31 
H(24) 1509 -1921 1866 35 
H(26) 4158 -575 3902 35 
H(2A) 5711 1216 3784 29 
H(213) 5665 371 3747 29 
H(3A) 7310 722 2354 35 
H(3B) 5876 416 1571 35 
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x 	 y 	 z 	 U(eq) 
H(4A) 6937 1529 894 34 
H(4B) 6184 1887 2009 34 
H(51A) 5787 2301 -425 74 
H(51B) 4926 2677 619 74 
H(51C) 4020 2393 -603 74 
H(52A) 3691 1157 -939 59 
H(52B) 4451 596 14 59 
H(52C) 5459 1065 -810 59 
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A2 Conferences Attended 
Conference Title Dates 
Cost D8 - Chemistry of Metals in Medicine 11th - 14 th December 1997, 
Workshop - Chelators and Metal Macromolecule Windsor, UK 
Interactions in Medicine 
Cost D8 - Chemistry of Metals in Medicine 5th - 81h December 1998, 
Workshop - The Industrial Perspective Ivrea, Italy 
Universities of Scotland Inorganic Club Conference 15th - 16th September 1998, 
University of Strathclyde, UK 
8th International Symposium on Platinum and other 28th - 31st March 1999, 
Metal Coordination Compounds in Cancer Therapy Oxford, UK 
Royal Society of Chemistry, Scottish Dalton Meeting 8th April 1999, 
Macrocycles, Mechanisms and Medicine University of St. Andrews, UK 
Annual Highlights of Chemistry Research and R & D 3rd May 1999, 
by Younger Research Chemists London, UK 
Universities of Scotland Inorganic Club Conference 20th - 21 S September 1999, 
Heriot Watt University, UK 
The Royal Society of Chemistry - 14t11 International 27th June 	2nd  July 1999, 
Meeting on NMR Spectroscopy University of Edinburgh, UK 
The Royal Society of Chemistry - 341h International 9th 	14th July 2000, 
Conference on Coordination Chemistry University of Edinburgh, UK 
5th European Biological Inorganic Chemistry 17t1 - 20th July 2000, 
Conference Toulouse, France 
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A3 Lecture Courses Attended 
Title Dates Duration / Hours 
Medicinal Inorganic Chemistry - Prof. P. J. 10th November - 10 hours 
Sadler 1  01h December 
1997 
Introduction to UNIX - Edinburgh University 14th  November 6 hours 
Computing Services 1997 
Hazards in the Laboratory - Merck 6th January 1998 6 hours 
Modern NMR Spectroscopy - Various 15th January - 10 hours 
Lecturers 19th March 1998 
Techniques for Ligand Synthesis - Various 22nd April 1998 6 hours 
Lecturers 
AMES Symposium - Biomolecular Structure 81h June 1998 4 hours 
and Mechanism 
Computers in NMR - Dr. J. A. Parkinson 17th June 1998 3 hours 
Crystallography and the Cambridge Structural 0 July 1998 3 hours 
Database Workshop - Dr. S. Parsons 
Special Topics in Inorganic Synthesis - 17" February 4 hours 
Various lecturers 1999 
Collection of Lectures by Prof. A. Sargeson, 3 rd - 	7th March 5 hours 
Australian National University 1999 
Chemistry and the Discovery of New 22' March 1999 3 hours 
Medicines Symposium 
Fourier Transform Mass Spectrometry for the 19th November 5 hours 
Life Sciences - The Royal Society of 1999 
Edinburgh 
AMES Symposium - Lighting the Way: 25th November 3 hours 
Recent Developments in Applied 1999 
Luminesence 
An Introduction to Patents - Avecia 13th April 2000 3 hours 
Edinburgh Magnetic Resonance Forum 291h March 2000 5 hours 
xx 
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Departmental requirements, also attended: 
Meeting Description Duration 
PJS Group Meetings Presentations on current 1 hour per week 
research by postgraduate 
and postdoctoral group 
members 
Inorganic Section Meetings Presentations on current 1 hour per week 
research by postgraduates 
and postdoctoral workers in 
the inorganic section 
Inorganic Colloquia Presentations by visiting 1 hour per month 
Lectures lecturers from other 
universities 
Firbush Meetings Final presentations for Annual 2/3 day meeting 
inorganic PhD. students and 
poster presentations 
A.4 Published Papers 
1 K. Neplechová, J. Kapárková, 0. Vrána, 0. Nováková, A Habtemariam, B. 
Watchman, P. J. Sadler, V. Brabec, Mol. Pharm. 1999, 56, 20 
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ABSTRACT 
Mechanistic studies are presented of a novel class of amin-
ophosphine platinum(II) complexes as potential anticancer 
agents. These new agents, which have demonstrated activity 
against murine and human tumor cells including those resistant 
to cisplatin are cis-[PtCl 2(Me2N(CH 2)3PPh2 -P)21 (Comi) and 
cis-[PtCl(C 0 H 11 NH(CH 2 ) 2 PPh2-N,P)(C 6H 11 NH(CH 2 ) 2 PPh 2-P)] 
(Com2). We studied modifications of natural and synthetic 
DNA5 in cell-free media by Comi and Com2 by various bio-
medical and biophysical methods and compared the results 
with those obtained when DNA was modified by cisplatin. The 
results indicated that Comi and Com2 coordinated to DNA 
faster than cisplatin. Bifunctional Comi formed DNA adducts 
coordinating to single adenine or guanine residues or by form-
ing cross-links between these residues. In comparison with 
cisplatin, Comi formed the adducts more frequently at adenine 
residues and also formed fewer bidentate lesions. The mono-
functional Com2 only formed DNA monodentate adducts at 
guanine residues. In addition, Comi terminated DNA synthesis 
in vitro more efficiently than cisplatin whereas Com2 blocked 
DNA synthesis only slightly. DNA unwinding studies, measure-
ments of circular dichroism spectra, immunochemical analysis, 
and studies of the B-Z transition in DNA revealed conforma-
tional alterations induced by the adducts of Comi, which were 
distinctly different from those induced by cisplatin. Com2 had 
little influence on DNA conformation, It is suggested that the 
activity profile of aminophosphine platinum(II) complexes, 
which is different from that of cisplatin and related analogs, 
might be associated with the specific DNA binding properties of 
this new class of platinum(II) compounds. 
Current platinum-based drugs are limited in their use by 
their severe side effects, narrow spectrum of anticancer ac-
tivity, and problems due to drug resistance. We are investi-
gating the design of novel platinum(II) aminophosphine com-
plexes as potential anticancer agents. 
The aminophosphine complexes of platinum(II), cis-lPtCl 2 -
(Me2N(CH2 )3PPh2-P)21 (Comi) and cis-lPtCl(C 0H 11NH-
(CH 2)2PPh2-N,P)(C6H 1 1NH(CH2 )2PPh2-P)l (Com2; Fig. 1) 
contain the possibility of cis amine ligands, which are a 
feature found in many active platinum anticancer agents 
This work was supported by Grants 305/99/0695, 301/98/P231, 307/97IPO2s, 
and 204/9711`028 from the Grant Agency of the Czech Republic, Grants 
A5004702 and A7004805 from the Grant Agency of the Academy of Sciences of 
the Czech Republic, the Biotechnology and Biological Sciences Research Coun-
cil, and the Engineering and Physical Sciences Research Council. V.B. in the 
recipient of an International Research Scholar's award from the Howard 
Hughes Medical Institute. This research is part of the European Cooperation 
in the Field of Scientific and Technical Research program (Projects DS/0009/97 
and 08/0012/97).  
(Reedijk, 1996), together with cis phosphine ligands. Certain 
diphosphines have also been shown to exhibit anticancer 
activity, especially 1,2-diphenylphosphine (dppe) complexes 
of Cu(I), Ag(I), and Au(I) (Berners-Price and Sadler, 1988). 
Furthermore, lipophilic cations such as lAu(dppe)l can dis-
rupt the mitochondrial membrane potentials (Berners-Price 
et al. 1997), and thereby act via a different mode of action to 
platinum am(m)ine antitumor complexes for which DNA is 
the target (Johnson et al., 1989). 
Metal aminophosphine complexes have been shown to be 
cytotoxic toward cancer cells with a potency approaching that 
of cis-diamminedichloroplatinum(II) (C'S-lPtCl 2(NH3 )21 I (cis-
platin) and, moreover, are active against some cisplatin-re-
sistant cell lines (Habtemariam and Sadler, 1996; Papatha-
nasiou et al., 1997). These complexes can exist in chelate 
ring-opened and ring-closed forms in aqueous solution (Fig. 
2). The equilibrium can be controlled under conditions of 
ABBREVIATIONS: Coml, cis-1PtCl 2(Me2N(CH03PPh2-P)2]; Com2, cis-lPtCl(C 6H, 1 NH(CH2)2PPh2-N,P)(C6H, 1 NH(CH)2 PPh2-P)l; Ab50 , polyclonal anti-
bodies that bind selectively to adducts formed on linear double-helical DNA by cisplatin at r b  = 0.08; bp, base pair(s); CD, circular dichroism; cisplatin, 
cis-diamminedichtoroplatinum(ll) (cis-lPtCl 2(NH 3)21); lPtCl(dien)]Cl, chlorodiethylenetrismineplatinum(ll) chloride ([PtCl(H 2NCH2CH2NHCH2CH2 NH2)}Cl); 
DPP, differential pulse polarography; EtBr, ethidium bromide; FAAS, flameloss atomic absorption spectrophotometry; RP, reversed phase; ICL 
inlerstrand cross-link; r 5 the number of the molecules of the platinum complex fixed per nucleotide residue; r,, the molar ratio of free platinum complex 
to nucleotide-phosphates at the onset of incubation with DNA; CT, calf thymus. 
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biological relevance by variation of pH and chloride concen-
tration (Habtemariam and Sadler, 1996). The ring-closed 
form (Fig. 2A), being a lipophilic cation, could thus act as an 
antimitochondrial agent and the ring-opened forms (Fig. 2, B 
and C), which contain labile chloride ligands, offer potential 
binding sites to DNA. 
Recently we have shown that chelate ring-opening plati-
num(II) aminophosphine complexes can bind rapidly and 
reversibly to the DNA bases guanine (Habtemariam and 
Sadler, 1996) and thymine as well as to the RNA base uracil 
(Margiotta et al., 1997), under physiologically relevant con-
ditions, in contrast to platinum am(m)ine anticancer com-
plexes (Reedijk, 1996). The binding was observed to the bases 
contained in monomeric nucleotides or in a short oligonucle-
otide duplex [8 base pairs (bp)]. In this work the modification 
of natural DNA and synthetic single- or double-stranded 
polydeoxyribonucleotides in cell-free media was studied by 
using various biomedical and biophysical methods. Coral 
was chosen for these studies as a representative of the bi-
functional aminophosphine complexes with leaving chloride 
ligands in cis position to compare its effects on double-helical 
DNA with those of cisplatin, whereas Com2, which has one 
chloride-leaving group, was used as a model. 
Experimental Procedures 
Materials. Cisplatin and chlerodiethylenetriamineplatinum(lI) 
chloride {lPtCl(H 2NCH2CH 2 NHCH 2CH 2NH2 )lCll (lPtCl(dien)ICI) 
were synthesized and characterized in Lachema (Brno, Czech Re-
public). Coral and Cem2 (Fig. 1) were prepared and characterized as 
reported elsewhere (A.H., R. Palmer, P. Potter, and P.J.S., submit-
ted). Calf thymus (CT) DNA (42% guanine + cytosine, mean molec-
ular mass ca. 2 x 10) was prepared and characterized as described 
previously (Brabec and Pale8ek, 1970). Denatured CT DNA was 
prepared by heating at 100°C for 10 min and subsequent rapid 
cooling on an ice bath. Plasmids pSP73 (2464 bp) or pSP73KB (2455 
we + 	 1 
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Fig. 1. Structures of bis(aminophosphmne) platinum(II) complexes: 1, 
cis-lPtCl 5(Me5N(CH2 )3PPh2-P)21, 2, cis- lPtCl(C 5H ,NH(CH2 )5PPh-N, 
P)(C6H I 1 NH(CH2 ) 2 PPh2-P)), 3, cis-(PtCl(Me 2N(CH2 )2PPh5-N, P)(MeN-
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Fig. 2. Schematic representation of chelate ring opening in bis(amin- 
ophosphine) platinum(II) complexes. 
bp) were isolated according to standard procedures and banded twice 
in CsCllethidium bromide (EtBr) equilibrium density gradients. Syn-
thetic single-stranded hornopolydeoxyribonucleotides poly(dA), 
poly(dC), poly(dG), poly(dT), and double-helical alternating 
polydeoxyribonucleotides poly(dA-dT) and poly(dG-dC) were pur-
chased from Boehringer-Mannheim Biochemica (Mannheim, Ger-
many) loll references in the text to poly(dA-dT) and poly(dG-dC) refer 
to duplex molecules] (the concentrations of synthetic polynucleotides 
are related to their phosphorus content). The oligodeoxyribonuclo-
otide duplex containing 40 bp, 5'-CCCGGA'Vl'ATACGGC'J°I'AAA-
CCAAATTGCTTAAATTGGCC)/5 '-GGCCAA'rrFAAGCAATTTGG-
'ITFAAGCCGTATAATCCGGG was obtained from East Port (Pra-
gue, Czech Republic); the single-stranded oligonucleotides constitut-
ing this duplex were purified by strong onion exchange chromatog-
raphy (Pharmacia MsnoQ column) on a Pharmacia fast protein 
liquid chromatography system with 10 m NaOH, 0.2 to 0.8 M NaCl 
gradient. The duplex was formed by heating the mixture of the 
complementary single-stranded oligonucleotides at equal concentra-
tions (related to the mononucleotide content) at 90°C for 5 mm 
followed by incubation at 25°C for 4 h. Restriction endonucleases and 
Thermal Cycle Dideoxy DNA Sequencing Kit with Vent 15(exo) or 
Vent15(exo') DNA polymerases were purchased from New England 
Biolabs (Beverly, MAY A primer 5'-d(GA'ITTAGGTGACACTATAG) 
was obtained from BioVendor (Brno, Czech Republic). T4 polynucle-
otide kinase and Klenow fragment of DNA polymerase I were also 
obtained from Boehringer-Mannheim Biochemica (Mannheim, Ger-
many). DNase I from bovine pancreas, nuclease P1 from Peisicilliunz 
cilrinanz, and alkaline phosphatase from calf intestine were pur-
chased from Sigma-Aldrich (Prague, Czech Republic). EtBr, acryl-
amide, (bis)acrylamide, urea, and agarose were obtained from Merck 
KgaA (Darmstadt, Germany). The radioactive products were pur-
chased from Amersham (Arlington Heights, IL). 
Platination Reactions. DNAs were modified by platinum com-
plexes in 10 m NaCIO.m (pH 7.0) at 37°C in the dark for 48 h unless 
stated otherwise. In these samples, the number of the molecules of 
the platinum complex fixed per nucleotide residue (rb)  was deter-
mined by flamelesa atomic absorption spectrophotometry (FAAS) or 
by differential pulse polarography (DPP; Kim et al., 1990). 
HPLC Analyses. These analyses were performed using a Hitachi 
Series 4 liquid chromatograph equipped with a LCJ-100 computing 
integrator and a Waters tLBondapack C18 column. If not stated 
otherwise, the products were separated by reversed phase (RP)-
HPLC (isocratic elution with 0.1 M ammonium acetate, pH 5.0 in 4% 
CH 3CN at 1 ml/min flow rate). The following enzymatic digestion 
protocol was used to characterize the platinated deoxyribooligonucle-
otides. The samples (50 Ag of the oligonucleotide) were incubated 
with 72 U DNsse I at 37°C. After 4 h nuclease P1 (40 fig) was added, 
and the reaction was allowed to continue at 37°C for 18 h. Finally, 
alkaline phosphatase (39 U) was added and the incubation continued 
for additional 4 h at 37°C. The digested samples containing constit-
uent nucleosides were then heated for 2 min at 80°C, centrifuged, 
and the supernatant was analyzed by RP-HPLC. Each analysis was 
performed four times and the data varied on average ± 1% from their 
mean. 
Sequence Specificity of DNA Adducts. The (HpaI/NdeI) re-
striction fragment of pSP73KB DNA (212 bp) was obtained as de-
scribed previously (Brabec and Leng, 1993). Ten micrograms of 
pSP73KB were treated with NdeI to obtain linear plasmid followed 
by treatment with alkaline phosphatase. The linear fragment was 
then 5°-end labeled by treatment with T4 polynucleotide kinase in 
the presence of 132Ply-ATP.  The 212-bp fragment was obtained by 
subsequent treatment with HpaI and isolated by electrophoresis 
through a preparative 1% agarose gel. The modification of this frag-
ment by cisplatmn, Coral, or Com2 was carried out in 10 mM NaClO 4 
(pH 7) for 48 h at 37°C to obtain rb = 0.01. CircumVent Thermal 
Cycle Dideoxy DNA Sequencing Kit with Vent 15(exo) or (exo') DNA 
polymerases was used with the protocol for thermal cycle DNA 
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sequencing with 5' end-labeled primer recommended by the manu- otide-phosphates 
facturer with small modifications (Novdkovd et al., 1995). 	 values of 0.08 in 
ELBr Fluorescence. These measurements were performed with time intervals an 
the aid of a Shimadzu RF 40 spectrofluorophotometer using a 1-cm 
quartz cell. Fluorescence measurements of DNA modified by plati-
num in the presence of EtBr were performed using the excitation 
wavelength of 546 nm and the emitted fluorescence was measured at 
590 nm. The fluorescence was measured at 25°C in 0.4 M NaCIto 
avoid the second fixation site of EtBr to DNA (Butour and Macquet, 
1977). The concentrations were 0.01 mg/ml for DNA and 0.04 mg/mI 
for Etfir, which corresponded to the saturation of all intercalation 
sites of EtBr in DNA (liutour and Macquet, 1977). 
Unwinding of Negatively Supercoiled DNA. Unwinding of 
closed circular supercoiled pSP73 plasmid DNA was assayed by an 
agarose gel mobility shift assay (Keck and Lippard, 1992). The un-
winding angle 'I', induced per platinum-DNA adduct was calculated 
upon the determination of the rb value at which the complete trans-
formation of the supercsiled to relaxed form of the plasmid was 
attained. Samples of pSP73 plasmid were incubated with Coml or 
Com2 in 10 mM NaCIO 4 , pH 7.0 at 37°C in the dark for 48 h. All 
samples were precipitated by ethanol and redissolved in TAE or the 
TBE buffer (0.04 M Tris-acetate + 1 mM EDTA, pH 7.0 or 0.09 M 
Tris-borate + 1 mM EDTA, pH 9.0, respectively). An aliquot of the 
precipitated sample was subjected to electrophoresis on 1% agarose 
gels running at 25°C in the dark with TAE or TBE buffer with 
voltage set at 30 V. The gels were then stained with EtBr, followed 
by photography on Polaroid 667 film with transilluminator. The 
other aliquot was used for the determination of rb  values by FA.AS. 
Interstrand Cross-Link (ICL) Assay. If not stated otherwise, 
Com 1 or Com2 at varying concentrations were incubated with 2 jig of 
pSP73 DNA linearized by EcoRl. The platinated samples were pre-
cipitated by ethanol and analyzed for DNA ICLs in the same way as 
described in several recent papers (Farrell et al., 1990; Brabec and 
Leng, 1993). The linear duplexes were first 3-end labeled by means 
of Klenow fragment of DNA polymerase I and la- 32PIdATP. The 
samples were deproteinized by phenol, precipitated by ethanol, and 
the pellet was dissolved in 18 1.sl of a solution containing 30 mM 
NaOH, 1 mM EDTA, 6.6% sucrose, and 0.04% bromophenol blue. The 
number of ICLs was analyzed by electrophoresis under denaturing 
conditions on alkaline agarose gel (1%). After the electrophoresis was 
completed, the intensities of the bands corresponding to single 
strands of DNA and ICL duplex were quantified by means of a 
Molecular Dynamics Phosphorinsager (Storm 860 System with Im-
ageQuant software; Sunnyvale, CA). As shown below, some plati-
nated DNA samples were also analyzed for the ICLs using milder 
conditions, when the DNA samples were treated with fornsamide or 
dinsethyl sulfoxide at 40 or 55°C and then analyzed in native agarose 
gel. The details of these milder assays can be found in the papers 
previously published (Konopa, 1983; Cullinane and Phillips, 1994). 
Circular Dichroism (CD). If not stated otherwise, CD spectra of 
DNA modified by the platinum complexes were recorded at 25°C in 
10 m NaCl04 (pH 7.0) on a JASCO spectropolarimeter, Model J720 
(Tokyo, Japan). 
Immunochemical Analysis. Polyclonal antibodies that bind se-
lectively to adducts formed on linear double-helical DNA by cisplatin 
at r5 = 0.08 (Ab 1 ) were elicited against double-helical calf-thymus 
DNA modified by cisplatin at r 5 = 0.08 in 10 mM NaCI0 5 for 48 h at 
37°C. They were purified and characterized as described in previ-
ously published papers (Sundquist et al.. 1987; Vrdna et al., 1992). 
The procedures for their immunoenzymatic analysis and enzyme-
linked immunosorbont assay have been also described (Sundquist et 
al., 1987; Vrána et al., 1992). 
Results and Discussion 
DNA Binding. Solutions of double-helical CT DNA at a 
concentration of 32 )sg/ml were incubated with Comi or 
Com2 at the molar ratio of free platinum complex to nude- 
at the onset of incubation with DNA (r) 
10 mM NaCl04 (pH 7.0) at 37°C. At various 
1 aliquot of the reaction mixture was with-
drawn and assayed by DPP for the amount of platinum 
bound to DNA (rb) (Kim et al., 1990). Figure 3 shows a plot of 
rb against the time of DNA incubation with Coml or Com2. 
The amount of platinum coordinated to DNA increased with 
time. After 48 h, approximately 100% or 80% of the complex 
Comi or Com2, respectively, present in the reaction mixtures 
was coordinated to DNA [exhaustive dialysis of the samples 
of DNA treated with Comi or Com2 against platinum-free 
background solution (10 mM NaCI0 4 ) did not affect the 
amount of the platinum bound to DNA]. In these binding 
reactions, the time at which the binding reached 50% (Tsov ) 
was Ca. 3 h for both Corn  and Com2. The value of Tsov. for 
the reaction of cisplatin or monofunctional [PtCI(dien)[Cl 
with DNA under conditions identical with those specified in 
Fig. 3 were -4 h, respectively (Bancroft et al., 1990). This 
comparison indicates that the presence of the aminophos-
phine groups as nonleaving ligands enhances the rate of the 
coordination of monofunctional chloro or bifunctional di-
chioro platinum(II) complexes to natural double-helical DNA. 
When the same binding experiment was carried out with 
thermally denatured CT DNA, the binding of Com2 remained 
unchanged whereas the binding of Comi was somewhat 
faster (T50% was -2 h; Table 1). 
We also studied the binding of Comi and Com2 to several 
synthetic single-stranded homopolydeoxyribonucleotides and 
double-helical synthetic alternating polydeoxyribonucleotide 
complexes (Table 1). The polynucleotides at a concentration 
of 1 X 10-4 M (the concentration is the mononucleotide con-
tent) were incubated with Comi or Com2 at r, = 0.08 in 10 
mM NaC104 (pH 7.0) at 37°C. The binding of the platinum 
compounds was quantified in the same way as described 
above for the reaction ofComl and Com2 with CT DNA. Both 
complexes bound readily to single-stranded poly(dA), 
poly(dC), and poly(dG) (the values of T50, were about 2 h for 
Comi and 6-7 h for Com2; Table 1). Importantly, at pH 7 
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Fig. 3. Formation of DNA adducts by bis(aminophasphine) platinum(II) 
complexes as a function of incubation time. CT DNA at the concentration 
of 32 jog/mI was mixed with Comi (C) or Com2 (•) at r = 0.08 in 10 m 
NaClO and at 37°C in the dark. At various time intervals the aliquots 
were withdrawn and platinum coordinated to DNA was estimated by 
DPP assay. Data points measured in triplicate varied on average ± 2% 
from their mean. 
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was bound to poly(dT), but considerably more slowly than to 
other single-stranded polynucleotides (Table 1). Also impor-
tantly, both platinum complexes bound to double-stranded 
poly(dA-dT) or poly(dG-dC) with markedly higher rates than 
to single-stranded polynucleotides (Table 1). The binding of 
Corni and Com2 to double-helical CT DNA and poly(dT) was 
also quantified in the following way. Aliquots of the reaction 
withdrawn at various time intervals were quickly cooled on 
an ice bath and then exhaustively dialyzed against 10 mM 
NaCI0 4 at 4°C to remove free (unbound) platinum com-
pound. The content of platinum in these samples was deter-
mined by FAAS. Results identical with those obtained using 
the DPP assay were obtained. Taken together, the results of 
these binding studies suggest that at pH 7 Comi binds to 
adenine, cytosine, and guanine residues in synthetic 
polynucleotides with approximately the same rate, and it 
does not bind to thymine residues. On the other hand, the 
monofunctional complex Com2 seems to bind to all base 
residues in synthetic polynucleotides including thymine res-
idues. The binding to the latter residues is, however, notice-
ably slower than to other DNA base residues, and in general 
the DNA binding of Com2 is slower than that of Coml. Thus, 
these results suggest that Coral and Com2 bind to different 
base residues in DNA and have different base sequence pref-
erences than their simpler analogs cisplatin or [Pt-
Cl(dien)]CI, which both bind preferentially to guanine resi-
dues, and cisplatin to a less extent to adenine residues 
(Johnson et al., 1982, Fichtinger-Schepman et al., 1985; 
Eastman, 1987). 
It has been shown by NMR studies that under physiologi-
cal conditions the monofunctional complex 3 (Fig. 1) binds to 
the mononucleotide dTMP or thymine residues at the ends of 
a short (8-bp) oligodeoxyribonucleotide duplex (Margiotta et 
al., 1997). It was found that these reactions were fast (com-
pleted within several minutes) and that the amount of bind-
ing increased with increasing pH. Similar results have been 
obtained for Comi, with binding to dTMP observed over a 
large pH range (4-12). For this reason we repeated studies on 
the binding of Comi and Com2 to poly(dT) at pH 8 (the pH 
was adjusted by adding a small amount of 2 M NaOH or 1 
TABLE 1 
The binding of the Coin 1 and Cons2 to CT DNA and synthetic 







1 	 2 
Ii 
do CT DNA 3.0 3.3 99 78 
Denatured CT DNA" 1.7 3.3 99 85 
Poly(dA) 2.2 5.7 89 89 
Poly(dC) 1.9 7.6 79 75 
Poly(dG) 2.0 6.2 83 79 
Poly(dT), pH 7.0 18.2 0 68 
Pely(dT), pH 8.0' 17.6 30 70 
Poly(dA-dT) 0.3 4.0 90 80 
Poly(dG-dC) 0.7 1.5 96 91 
CT DNA (double-stranded or denatured) at the concentration of 32 pg/mI or 
synthetic single- or double-stranded polynucleotides at the concentration of 1 5 10-4 
M were mixed with the platinum complexes at r, = 0.08 in 10 m NaCI05 (pH 7) and 
at 37 0C in the dark. Data measured In triplicate varied on overage 2% from their 
mean. 
The time of the reaction at which the binding reached 50'S. )r,, = 0.041. 
Doable-helical DNA. 
a DNA was thermally denatured before the platinum complex was added. 
'pH was adjusted by NaOH. 
mM Tris/HCI buffer, pH 8, to 10 m NaCIO 4 ). The binding of 
Com2 was affected only negligibly whereas 30% of Coin l was 
now bound after 48 h (Table 1). However, when the binding of 
Comi and Com2 to CT DNA was also investigated at pH 9 
(the pH was again adjusted by adding either a small amount 
of 2 M NaOH or 1 mM TrisIHCl buffer, pH 9, to 10 mM 
NaClO4) no binding of either complex was observed. 
The amount of binding of the complexes to poly(dT) is lower 
than might have been expected from the NMR work on the 
monomeric nucleotides. The reason for this is unclear but it 
may imply that N3 atoms in poly(dT) under these conditions 
are not accessible to platinum. 
In addition, it was previously shown by NMR studies 
(Habtemariam and Sadler, 1996) that the addition of 0.5 M 
KCI led to the displacement of coordinated 5 dGMP from 
cis- [PtCl(Me 2 N(CH 2 ) 2 PPh2-N,P) (Me 2N(CH 2 ) 2PPh 2-P1(5-
dGMP-N7)1 3 . Therefore, we prepared a sample of CT DNA 
modified by Cornl or Com2 at rb = 0.08 (at 37°C in 10 mM 
NaCI04 for 48 h). The concentration of KCI in these samples 
was adjusted by 5 M KCI to give a final concentration of 0.5 
M. The samples were incubated at 37°C for an additional 
48 h, and the content of unbound platinum was determined by 
DPP. No free platinum compound was found, indicating that 
the presence of chloride ions did not result in the displacement 
of Coin  or Com2 from high molecular mass DNA. Therefore, it 
appears that the duplex structure of DNA increases the kinetic 
stability of platinum aminophosphine adducts perhaps by 
shielding platinum from attack by chloride ions. Such a shield-
ing is thought to increase the stability of 5'-G monofunctional 
adducts with cisplatin (Reeder et al., 1997). 
Characterization of DNA Adducts by HPLC Analysis 
of Enzymatically Digested DNA. To further characterize 
the coordination mode of the two aminophosphine plati-
num(II) complexes, a 40-bp deoxyribooligonucleotide duplex 
(with a random nucleotide sequence, see Experimental Pro-
cedures) modified by Comi or Com2 (in 0.1 M NaClO 4 , pH 7) 
was enzymatically digested to mononucleosides and analyzed 
by RP-HPLC. RP-HPLC analysis of enzymatic digests of 
Comi- or Com2-modified oligonucleotide duplex was per-
formed by recording optical density at 260 nm. The profile in 
Fig. 4 (curve 1) shows well resolved mononucleoside peaks 
that reflect the proper proportions of the single mononucleo-
sides in unplatinated duplex when integrated and normal-
ized by their extinction coefficients. Digestion of the plati-
nated samples (Fig. 4, curves 2 and 3) resulted in the 
decrease of the integrated area of the deoxyriboguanosine 
peak and, in the case of the digestion of the duplex modified 
by Corn 1, also in the decrease of deoxyriboadenosine peak. 
The peaks of deoxyribocytidine and thymidine were not af-
fected. It was verified by FAAS that no product containing 
platinum coeluted with the peaks corresponding to unplati-
nated deoxyribonucleosi des. The platinated products were 
not retained by the column under the conditions used, so they 
could not be identified and quantified. 
The integrated area of the deoxyriboguanosine peak de-
creased by -24% as a consequence of the platination of the 
duplex by the monofunctional compound Com2 at r,, = 0.05 
(Fig. 4, curve 3). The 40-bp duplex used in these analyses 
contained 17 guanine residues. Thus, this decrease corre-
sponds to the loss of four guanine residues due to the modi-
fication by Com2. The peaks corresponding to other nucleo-
sides were unchanged, which implies that only guanine 
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residues were platinated by Com2 in a monofunctional man-
ner. Thus, the DNA binding mode of Com2 appears to be 
similar to that of the other monofunctional platinum(II) com-
plex, [PtCl(dien)]Cl, which also binds preferentially to gua-
nine residues in DNA (Johnson et al., 1982). In other words, 
the presence of aminophosphine groups in the coordination 
sphere of platinum in monofunctional triamineplatinum(II) 
complexes has no effect on the preference of these complexes 
to bind to guanine residues in double-helical DNA. 
The modification of the duplex by bifunctional Comi at rb 
= 0.09 resulted in the decrease of the integrated area of the 
deoxyriboguanosine and deoxyriboadenosine peaks by —28% 
and --21%, respectively (Fig. 4, curve 2; the duplex contained 
17 guanine and 23 adenine residues). This decrease corre-
sponds to the loss of five guanine and five adenine residues. 
The duplex was, however, modified at rb = 0.09, which im-
plies that each duplex only contained 7.2 adducts on the 
average. The loss often unmodified bases due to the platina-
tion by Comi suggests that ca. three adducts, i.e., Ca. 40% of 
all platinum adducts, were bifunctional cross-links. The re-
sults of RP-HPLC analyses are consistent with the idea that 
cisplatin analog Comi preferentially forms DNA adducts by 
coordinating to both a single purine or to two purine residues. 
For comparative purposes, the modification of the 40-bp 
duplex used in the present study by cisplatin at r b = 0.09 was 
also investigated. This modification also resulted in the de-
crease of the integrated areas of the deoxyriboguanosine and 
deoxyriboadenosine peaks (not shown). However, in contrast 
to the modification by Comi, the areas of these peaks de-
creased by 70% and 5%, respectively. These decreases corre-
spond to the loss of --12 guanine and —1 adenine residues, 
which suggests that ca. 80% of all cisplatin adducts were 





Fig. 4. RP C18 HPLC separation of the products of enzymatic digest of 
the 40-bp oligonucleotide duplex nonmodified (curve 1) or modified by 
Comi at rb = 0.09 (curve 2) or by Com2 at r b = 0.05 (curve 3). For other 
details, see the text. 
bifunctional cross-links. This is in good agreement with the 
previous analyses (Fichtinger-Schepman et a)., 1985; East-
man, 1987) indicating that cisplatin forms mainly bifunc-
tional adducts (intrastrand cross-links and ICLs) and that 
the preferential sites involved in the adducts of cisplatin are 
guanine residues and, in a considerably smaller extent, also 
adenine residues. Thus, the results of the present work based 
on RP-HPLC analysis of enzymatically digested platinated 
DNA strongly support the view that in comparison with 
cisplatin, Coml forms DNA adducts more frequently at ade-
nine residues and also forms fewer bifunctional lesions. 
Mapping of DNA Adducts. Recent work has shown that 
the in vitro DNA synthesis by DNA polymerases on DNA 
templates containing several types of bidentate adducts of 
platinum complexes can be prematurely terminated at the 
level or in the proximity of adducts (Comess et a)., 1992; 
Murray et al., 1992; Vrflna et al., 1996). Importantly, the 
efficiency of monofunctional DNA adducts of several plati-
num(II) complexes to terminate DNA synthesis is consider-
ably smaller (Comess et al., 1992). 
DNA synthesis by Vent 1 DNA polymerase using HpaI/ 
NdeI fragment of pSP73KB modified by Comi at r 1, = 0.01 in 
10 mM NaCI04 (pH 7) yielded fragments corresponding to 
the DNA synthesis that was prematurely terminated at the 
level of the platinum adducts (Fig. 5A, lane 1). Thus, the 
adducts formed by Comi formed on the DNA template were 
capable of terminating DNA synthesis in vitro. Several ter-
mination sites were identical with those yielded by the ad-
ducts of cisplatin, but several termination sites were differ-
ent. Comi terminated DNA synthesis preferentially at 
guanine and adenine residues whereas cisplatin terminated 
DNA synthesis preferentially at guanine residues in d(GG) 
and 5'-d(AG)-3' sites (Comess et al., 1992; Murray et al., 
1992; Vrána et al., 1996), the termination sites produced by 
Coml were mainly at guanine and adenine residues flanked 
by various base residues [CGA, GOT, TGA, GGG, TAA, TAT, 
AAC, CAG (bold and italic letters represent the termination 
site)] (Fig. SB). These results are consistent with the results 
of RP-HPLC analysis of enzymatically digested DNA modi-
fied by Comi (Fig. 4), which suggest that the preferential 
sites in DNA at which Comi is coordinated are guanine and 
adenine residues. In addition, the results of the present rep-
lication mapping studies indicate that Comi binds to DNA 
with a less regular sequence preference, i.e., with a consid-
erably different nucleotide sequence specificity than cispla-
tin. 
The monofunctional compound Com2 terminated DNA 
synthesis only slightly. Very faint bands were observed if the 
DNA template was modified at rb values as high as 0.05 (Fig. 
5A, lane 2). This result indicates that the efficiency of DNA 
adducts of Com2 to inhibit DNA synthesis in vitro is low, 
and similar to that of DNA adducts of the monofunc-
tional platinum(I1) complexes such as [PtCl(dien)]Cl and 
[PtCl(NH 3 )3]Cl. 
Characterization of DNA Adducts by EtBr Fluores-
cence. EtBr as a fluorescent probe can be used to distinguish 
between perturbations induced in DNA by monofunctional 
and bifunctional adducts of platinum(II) compounds (Butour 
and Macquet, 1977; Zaludová et al., 1997b). Binding of EtBr 
to DNA by intercalation is blocked in a stoichiometric man-
ner by formation of the bifunctional adducts of a series of 
platinum complexes including cisplatin and transpiatin, 
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which results in a loss of fluorescence intensity (Butour and 
Macquet, 1977; 2ikovski et al., 1998). On the other hand, 
modification of DNA by monodentate platinum(II) complexes 
(having only one leaving ligand) results in only a slight 
decrease of EtBr fluorescence intensity as compared with 
nonplatinated DNA-EtBr complex. 
Double-helical DNA was modified by Comi or Com2 and 
for comparative purposes also by cisplatin or lPtCl(dien)]Cl 
for 48 h. The levels of the modification corresponded to the 
values of rb in the range between 0 and 0.15. Modification of 
DNA by all platinum complexes resulted in a decrease of 
EtBr fluorescence (Fig. 6). In accordance with the results 
published earlier (Butour and Macquet, 1977; Zaludovsi et 
al., 1997b; 26kovskd et al., 1998), cisplatin considerably de-
creased the fluorescence. The binding of Comi to DNA also 
considerably decreased EtBr fluorescence although less than 
DNA adducts of cisplatin. On the other hand, the decrease of 
the fluorescence intensity by the adducts of Com2 was only 
very small and similar to that induced by the adducts of 
EPtCl(dien)JCl. This result suggests that Com2 forms the 
DNA adducts, which resemble, from the viewpoint of their 
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Fig. 5. A, autoradiogram of 6% polyacrylamidel8 M urea sequencing gel 
showing inhibition of DNA synthesis by Vent 1 DNA polymerase on the 
HpaliNdel restriction fragment of pSP73KB plasmid DNA modified by 
platinum complexes. The gel contained the linear amplification products 
of DNA treated with Comi, Com2, and cisplatin. Lanes: control, unmod-
ified template; cioDDP, DNA modified by ciaplatin at r 5 = 0.01; 1, DNA 
modified by Comi at rb = 0.01; 2, DNA modified by Com2 at rb = 005; C, 
G, T, A, chain-terminated marker DNAs (note that these dideoxy-se-
quencing lanes give the sequence complementary to the template strand). 
The numbers correspond to the nucleotide sequence numbering of 5B. B, 
schematic diagram showing a portion of the sequence used to monitor 
inhibition of DNA synthesis on the template containing adducts of the 
platinum complexes. * indicates the 5-end labeling of the primer. The 
dashed arrow indicates the start site of the DNA polymerase and the 
direction of the synthesis. I , step signals from A, lane 1. Nucleotides 1 
and 18 correspond to 2539 and I on the pSP73KB nucleotide sequence 
map. 
capability to inhibit EtBr fluorescence, those formed by 
monofunctional platinum complexes. Taken together, the flu-
orescence analysis is consistent with the idea and supports 
the postulation that the major DNA adducts of Com2 are 
monofunctional lesions even after long incubations of DNA 
with this platinum complex (48 h). On the other hand, under 
comparable conditions Comi forms monofunctional adducts 
and also bifunctional cross-links on DNA that are capable of 
inhibiting EtBr fluorescence. The amount of the cross-links 
is, however, smaller in comparison with DNA modification by 
cisplatin. 
CD. CD spectroscopy has already been used to obtain in-
formation about the global changes in DNA conformation 
induced by platinum complexes. It has been shown (Vrána et 
al., 1986; Braboc et al., 1990) that the intensity of the positive 
CD band yielded by B-DNA at —275 nm is increased as a 
consequence of DNA modification by the complexes contain-
ing the cis-lPtCl 2(amine)21 unit (Fig. 7, B and C); at higher 
levels of the modification (rb > —0.5) the intensity of this CD 
band begins to decrease (Fig. 7, B and C). On the other hand, 
the modification of DNA by clinically ineffective transplatin 
or dienPt only slightly decreases this positive band (Vrána et 
al., 1986; Brabec et al., 1990). It has been suggested (Vrána 
et al., 1986; Brabec et al., 1990) that the enhancement of the 
CD band at —275 nm due to the modification by the com-
plexes containing cis-[PtCl 2(amine)2] unit reflects distortions 
in DNA of a nondenaturational nature. The slight reduction 
of this CD band induced by the binding of platinum com-
plexes is consistent with the occurrence of short segments 
containing unpaired bases (denatured regions). 
The modification of CT DNA by Com2 had only a negligible 
effect on the CD spectrum (not shown). In this respect, the 
monofunctional Com2 resembled other platinum(II) com-
plexes that bind to DNA monodentately e.g., IPtC1(dien)lCl 
or lPtCl(NH 3 )lCl). In contrast, the bifunctional compound 
Coral (having leaving ligands in cis positions) radically af-
fected the CD spectrum of DNA at pH 7 (Fig. 7A), but in a 
distinctly different way than the binding of cisplatin (Fig. 
7B). As a linear function of r b , there was a marked loss in the 
intensity of the positive band at around 280 nm already at 
low rb values (<0.05; Fig. 7, A and C) accompanied by a loss 
in the intensity of the negative band at around 245 am. The 
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Fig. 6. Dependences of the Etfir fluorescence on r 5 for DNA modified by 
various platinum complexes in 10 mM NaClO, at 37CC for 48 h. (+), 
cisplatin; (5), (PtCl(dien)lCl; (D), Coml; and (s), Com2. Data points 
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Fig. 7. CD spectroscopy of CT DNA modified by Cornl and cisplatin. The 
spectra were recorded for DNA in 10 mM NaClO, pH 7.0. A, CD spectra 
of DNA modified by Con!. Curves: 1, control (nonmodified) DNA; 2, rb = 
0.04; 3, rb = 0.065; 4, rA = 0.09; 5, rA = 0.13; 6, rb = 0.18. B, CD spectra 
of DNA modified by cisplatin. Curves: 1, control (nonmodified) DNA; 2, 
r5 = 0.02; 3, iA = 0.04; 4, iA = 0.065; 5, ra = 0.09; 6, rA = 0.13; 7, rA = 0.18. 
C, dependence of the maximum ellipticity of the positive CD band at 
around 280 nm on rA. (X), cisplatin; (0), Corn!. Data points measured in 
duplicate varied on average ± 1% from their mean. 
DNA transformations seen in the presence of high concen-
trations of electrolyte or by the reaction with a variety of 
amines. For instance, at the level of DNA binding corre-
sponding to rb = 0.13, the reduction of the rotational strength 
of the positive band above 260 nm in the CD spectrum of 
DNA in 10 mM NaClO 4 , pH 7.0 (Fig. 7A) was similar to that 
obtained for underivatized DNA in Ca. 6 M LiCI or at Ca. 0.1 
mol of n-butylamine covalently fixed (via CH 2O)/rnol of nu-
cleotide (Chen et al., 1981; Gray, 1996). This transformation 
has been demonstrated to be roughly correlated with the 
reduction of the electrostatic repulsive interactions in the 
DNA molecule. These interactions are reduced by high con-
centrations of electrolytes in the solution or by simple amines 
(retaining their positive charge) covalently attached to DNA. 
At pH 7, binding of Coral to DNA could position two posi-
tively charged amino groups in the dangling arms of this 
complex close to DNA phosphate groups. Such salt bridges 
could result in an additional stabilization for DNA adducts of 
Coin 1 compared to those of Com2 (which contains only one 
dangling arm with amino group) or cisplatin. This interpre-
tation is also corroborated by the observation that the 
marked loss in the intensity of the positive band at around 
280 nm due to the binding of Comi became considerably less 
pronounced if the sample of DNA modified by Comi at pH 7 
for 48 h was transferred into the medium of pH 9 (not shown). 
The increase of pH could decrease the number of positively 
charged amino groups of dangling arms due to their depro-
tonization. It was verified by DPP that due to the increase of 
pH to 9, no platinum compound dissociated from the DNA 
modified by Comi at pH 7. 
The changes induced in double-helical DNA by Comi do 
not have the character of extensive denaturational distor-
tions. The cooperative character of the melting profile and 
the hyperchromic increase upon melting are the same as for 
the unpiatinated control, which contains intact Watson-Crick 
hydrogen bonds (not shown). It has been shown (Chen et al., 
1981; Gray, 1996; Johnson, 1996) that the conformation of 
DNA in concentrated electrolyte solutions or when modified 
by some amines, which gives rise to a CD spectrum with a 
markedly decreased rotational strength above 260 nm, is a 
variant of the B structure. This variant has a higher winding 
angle than that present in the nonmodified DNA in more 
modest concentrations of electrolyte. Thus, we suggest that 
double-helical DNA modified by Comi adopts some features 
of the conformation of DNA in concentrated electrolyte solu-
tions or DNA to which positively charged amines are co-
valently bound. Also importantly, this conformational alter-
ation is apparently unique for bifunctional DNA binding of 
bifunctional bis(aminophosphine) compounds (no change 
such as that seen for Coral was observed for monofunctional 
Com2). 
Unwinding Induced in DNA by Platinum Coordina-
tion. The results described above suggest that Comi forms 
bifunctional adducts on DNA although to a smaller extent 
than its bifunctional analog, cisplatin. It has been shown that 
DNA adducts of cisplatin (and its direct analogs) unwind 
DNA (e.g., Bellon et al., 1991; Keck and Lippard, 1992; 
Huang et al. 1995; Gelasco and Lippard, 1998). CD spectra of 
DNA modified by Comi (Fig. 7A) suggest that this modifica-
tion also results in an overall overwinding of the DNA mol-
ecule as a whole if the platinated DNA is dissolved in neutral 
media, whereas no changes in CD spectra indicating over- 
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winding occur if DNA is modified under identical conditions 
by cisplatin or if the pH of the sample of DNA modified by 
Comi is adjusted to 9. 
The unwinding induced by a random modification of DNA 
by various platinum(II) complexes including cisplatin can be 
determined by electrophoresis in native agarose gels by mon-
itoring the degree of supercoiling in plasmid DNA (Keck and 
Lippard, 1992). A compound that unwinds the DNA duplex 
reduces the number of supercoils in closed circular, nega-
tively supercoiled DNA. This decrease upon binding of un-
winding agents causes a decrease in the rate of migration 
through agarose gels, which makes it possible that the un-
winding can be observed and quantified. We used this assay 
to determine the unwinding induced in pSP73 plasmid by 
Coin  (Fig. 8). Figure 8A shows an electrophoresis gel run at 
pH 9 of samples in which an increasing amount of Comi was 
bound to a mixture of nicked and supercoiled pSP73 DNA. 
The unwinding angle is given by 1 = 18 u/rb(c)  where a is the 
superhelical density and rb(c) is the value of r 1, at which the 
supercoiled and nicked forms comigrate (Keck and Lippard, 
1992). Under the present experimental conditions, a was 
calculated to be —0.063 on the basis of the data for cisplatin 
for which the r t,(c) was determined in this study and (1) = 13° 
was assumed (Keck and Lippard, 1992). The rb(c) for Coml 
was determined to be 0.08 (Fig. 8A; this value represents the 
mean from three measurements and varied on average ±3% 
from this mean) so that the unwinding angle for Comi at pH 
9 is 14 ± 1°. This value for the average unwinding angle 
caused by DNA adducts of Coml is very similar to that found 
for DNA adducts of cisplatin and its direct analogs using the 
same experimental approach (13°; Keck and Lippard, 1992). 
Thus, unwinding of DNA modified by Coin  and transferred 
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Fig. 8. Unwinding of supercoiled pSP73 plasmid DNA by Coral. DNA 
was modified in 10 m NaClO., pH 7, precipitated by ethanol, dissolved 
in TBE buffer, pH 9.0 (A) or TAB buffer, pH 7.0 (B), and analyzed by gel 
electrophoresis using the same buffer in which DNA was dissolved. The 
top bands correspond to the form of nicked plasmid and the bottom bands 
to the closed, negatively supercoiled plasmid. A, lanes: 1 and 10, r, = 0; 
r = 0.008; 3, r,, = 0.01; 4, r1, = 0.02; 5, r,, = 0.04; 6, r, = 0.06; 7, r, 
0.08; 8, r,. = 0.09; 9, rb = 0.11. B, lanes: 1 and 14, rh = 0; 2, rb = 0.0008; 
r,, = 0.002; 4, r, = 0.004:5, r,, = 0.0064; 6, r,, = 0.008; 7, r,, = 0.02; 8, 
r,, = 0.04; 9, r,, = 0.064; lO,r 5 = 0.08; 11, r,, = 0.2; 12, r,, = 0.4; 13, r,, = 
0.64.  
into the medium of pH 9 is similar to that of DNA modified by 
cisplatin and its direct, simple analogs. 
CD spectra of DNA modified by Comi and dissolved in 
neutral media (Fig. 7A) made it possible to suggest that at 
pH 7 DNA unwinding induced by the binding ofComl is more 
complicated than at pH 9. It is reasonable to suggest that 
DNA adducts of Comi unwind DNA similar to cisplatin or 
Coin  at pH 9 [i.e., that they increase the number of bp per 
turn of B-DNA by Ca. 0.38 or 0.41 (these values Correspond to 
the unwinding angle of 13° found for cisplatin or 14° found for 
Comil. In addition, CD spectra of DNA modified by Comi 
and dissolved in neutral media (Fig. 7A) suggest that Comi, 
upon binding to DNA and at pH 7, is also capable of over-
winding DNA (i.e., to decrease the number of bp per turn of 
DNA). It has been shown (Gray, 1996; Johnson, 1996) that 
the dramatic reduction of the intensity of DNA-positive CD 
band at around 280 nm (Fig. 7, A and C) corresponds to a 
decrease in the number of bp per turn in B-DNA by approx-
imately 0.2, which corresponds to the winding angle of —7°. 
Thus, the resulting DNA unwinding by Comi at pH 7 could 
be the sum of the two antagonistic effects. The rb(c) value for 
the sample of plasmid pSP73 determined by means of gel 
electrophoresis at pH 7 was 0.2 (Fig. 813) so that the total 
unwinding angle for Comi at pH 7 was only 6 ± 1 1 . A 
plausible explanation of this observation is that in neutral 
media DNA unwinding caused by the adducts ofComl (-14°) 
is partially compensated by overall overwinding of DNA mol-
ecules (-7°) induced by the binding of Coral and deduced 
from CD spectra (Fig. 7, A and Q. 
No comigration of the relaxed and supercoiled forms of 
pSP73 DNA at pH 7 or 9 was reached even at a value of r b as 
high as 0.2 if the sample of the plasmid was modified by 
monofunctional Com2 (not shown). This result indicates that 
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Fig. 9. The formation of lCLs by Coin  in the pSP73 plasmid linearized 
by EcoRl. A, autoradiogram of a denaturing 1% agarose gel of DNA which 
was 3-end labeled. The interatrand cross-linked DNA appears as the top 
bands migrating on the gel more slowly than the single-stranded DNA 
(contained in the bottom bands). DNA was incubated with Comi for 48 h 
at 37°C. rbvslues.  lane 1,0; lane 2,0.0007; lane 3,0.0016; lane 4,0.0032. 
B, dependence on rh  of the number of lCLs per adduct (%ICIJPt). The 
ratio of ICLs to total platinum bound was calculated as described previ-
ously (Farrell et a)., 1990; Brabec and Lang, 1993); %ICIJPt was then 
calculated by multiplying this ratio by 100. Data paints measured in 
triplicate varied on average 3% from their mean. 
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Com2 induces a very small DNA unwinding (<< 6), which is 
consistent with a low DNA unwinding efficiency of monofunc-
tional adducts of several platinum(II) compounds observed 
earlier (Keck and Lippard, 1992; Zaludová et al., 1997b; 
Balcarovd et al., 1998). 
Interstrand Cross-Linking. The amounts of ICLs 
formed by Comi or Com2 in linear DNA were measured in 
pSP73 plasmid (2464 bp) that was first linearized by EcoRl 
(EcoRI cuts only once within pSP73 plasmid) and subse-
quently modified by Comi or Com2 at various rb. The sam-
ples were analyzed for the ICLs by agarose gel electrophore-
sis under denaturing conditions. 
An electrophoretic method for precise and quantitative 
determination of interstrand cross-linking by platinum com-
plexes in DNA was described previously (Farrell et al., 1990; 
Brabec and Leng, 1993). Upon electrophoresis under dena-
turing conditions, 3-end labeled strands of linearized pSP73 
plasmid containing no lCLs migrated as a 2464-base single 
strand, whereas the interstrand cross-linked strands mi-
grated more slowly as a higher molecular mass species. The 
bands corresponding to more slowly migrating interstrand-
cross-linked fragments were observed if Comi was used to 
modify linearized DNA at rb as low as 7 X 10 ° (shown in Fig. 
9A, lane 2). The intensity of the more slowly migrating band 
increased with the growing level of the modification. The 
radioactivity associated with the individual bands in each 
lane was measured to obtain estimates of the fraction of 
noncross-linked or cross-linked DNA under each condition. 
The frequency of ICLs (the amount of ICLs per one molecule 
of the platinum complex bound to DNA) was calculated using 
the Poisson distribution from the fraction of noncross-linked 
DNA in combination with the rb values and the fragment size 
(Farrell et al., 1990). Com2 showed no interstrand cross-
linking efficiency even at a high r 1, such as 0.1 (not shown). 
On the other hand, Comi formed in DNA ICLs with a similar 
efficiency as cisplatin (frequency of ICLs formed in DNA was 
small, 4-6%; Fig. 913). 
It has been demonstrated that the ICLs formed in DNA by 
some nonmetal-based anticancer drugs are destroyed at al-
kaline pH and/or elevated temperatures. It is, therefore, pos-
sible that the lability of the ICLs ofComl or Com2 in alkaline 
medium used in gel electrophoresis under denaturing condi-
tions (Fig. 9) could account for the negligible frequency of 
DNA ICLs of Com2 or could result in underestimation of the 
frequency of ICLs formed in DNA by Corn 1. Therefore, we 
have also used a milder procedure that has allowed determi-
nation of alkali-unstable DNA ICLs formed by several an-
thracyclines (Konopa, 1983; Cullinane and Phillips, 1994). 
These techniques are based on the denaturation of modified 
DNAs at significantly lower temperatures, in the presence of 
either formamide or dimethyl sulfoxide and subsequent anal-
ysis in native agarose gel. The milder DNA interstrand cross-
linking assays gave, however, frequencies of the ICLs of 
Comi or Com2 that are similar to those determined by means 
of the agarose gel electrophoresis in an alkaline medium. 
Thus, it appears unlikely that Comi or Com2 form alkali-
unstable ICLs in DNA. 
Immunochemical Analysis. We prepared Ab 1 , which 
recognizes two neighboring purine residues of the same 
strand of DNA cis coordinated to the platinum atom of cia-
[Pt(amine) 2 1 2 (Sundquist et al., 1987; Vrana et al., 1992). 
They do not recognize monofunctional platinum adducts and 
the adducts of transpiatin and its analogs. 
Using competitive enzyme-linked immunosorbent assay, 
the inhibition of the binding of Ab, to their immunogens 
(double-stranded CT DNA modified by cisplatin at r i, = 0.08 
for 48 h) by double-stranded DNA modified by Comi or Com2 
at various rb values in the range of 0.005 to 0.1 was mea- 
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Fig. 10. CD spectroscopy of poly(dG-dC) nonmodified (A) or treated with Coral (B) or Com2 (C) at rb = 0.1. The polymer was modified when it was 
in B-form (in 10 mM NaCIO 4) and was subsequently transferred into the media containing 10 m NaCIO4 with 1 mM phosphate buffer, pH 7.5, plus 
10 m EDTA and various concentrations of NaCl. A, control, nonmodified polymer; curves: 1, 0.19 M NaCl; 2, 1.53 M NaCl; 3, 2.17 M NaCl; 4, 2.29 
M NaCl; 5, 4.18 M NaCl. B, polymer modified by Coral; curves: 1, no NaCI added; 2, 1.01 M NaCl; 3, 1.51 M NaCl; 4, 2.00 M NaCl; 5, 3.14 M NaCl. 
C, polymer modified by Com2; curves: 1, no MCI added; 2, 0.97 M NaCl; 3, 1.44 M NaCl; 4,1.89 M NaCl; 5, 2.82 NaCl. D, plot of the molar ellipticity 
at 290 am (5o ,,,,,) 000 function of Na Concentration for poly(dG-dC) nonmodified (x) or treated with Coral (0), ComZ (•), and cisplatin at rb 
0.1 (5). Data points measured in duplicate varied on overage ±1% from their mean. Other details are described in the text. 
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sured. It was found (not shown) that double-stranded DNA 
modified by Coral or Com2 did not inhibit the binding of the 
Ab 1 , 
exhibits an equally good specificity for DNA modified 
by several analogs of cisplatin having varied nonleaving 
amine groups (Sundquist et al., 1987; Vrána et al., 1992). The 
observation that Ab. i . did not recognize DNA modified by 
bifunctional Comi is very likely related to distinct conforma-
tional alterations induced in DNA by Coral in comparison 
with cisplatin. 
B-aZ Transition. The effect of various platinum com-
pounds on the salt-induced B-aZ transition in poly(dG-dC) 
has already been described in several papers (for instance, 
Ushay et al., 1982; Perez-Martin et al., 1993; 2aludovd et al., 
1997a). In the present work, DNA modifications by Coral or 
Com2 are compared with those by cisplatin or lPtCl(dien)lCl, 
respectively. Cisplatin was found to facilitate the B-oZ tran-
sition, but the resulting Z form was distorted and the tran-
sition cooperativity was considerably reduced. [PtCl(dien)]Cl 
has been shown to stabilize the Z-form of DNA; for [Pt-
Cl(dien)lCl-treated poly(dG-dC), the Z conformation is ob-
served at a considerably lower salt concentration than for the 
nontreated polymer, and the transition cooperativity is con-
siderably reduced. 
The effect of Comi and Com2 binding on the B-oZ transi-
tion in DNA was investigated in poly(dG-dC) during salt-
induced transition from the right- to left-handed double he-
lix. The transition was monitored by CD spectroscopy at a 
series of NaC1 concentrations between 0 and 4 M added to the 
medium containing 10 mM NaCI0 41  1 mM phosphate buffer, 
pH 7.5 and 0.1 mM EDTA. All of our experiments were done 
at rb of 0 or 0.1. The rb value of 0.1 was chosen as a compro-
mise between a low value, which would have some relevance 
to the therapeutic effects of the platinum compounds, and a 
larger value, which would cause more pronounced changes in 
the spectra. 
The CD spectra of nonplatinated poly(dG-dC) at various 
concentrations of NaCl are shown in Fig. 10A. The figure 
shows the characteristic inversion in the CD spectrum on 
going from the right-handed B form to the left-handed Z form 
after addition of at least 2.0 M NaCl, and is used as the 
standard with which to compare the platinum-treated du-
plexes. The CD spectra at different NaCl concentrations of 
poly(dG-dC) pretreated with either Comi or Com2 in 10 mM 
sodium perchlorate (i.e., the polymer was treated when it was 
in the B conformation) are shown in Fig. 10, B and C, respec-
tively. 
A plot of the molar ellipticity at 290 nm as a function of the 
concentration of NaCl added to 10 mM NaCI0 4 with 0.1 mM 
EDTA plus 1 mM phosphate buffer, pH 7.5 (Fig. 10D) can be 
used to monitor the B-vZ transition in poly(dG-dC) (aludová 
et al., 1997a). From an examination of these plots presented 
in Fig. 10D it is evident that the maximum variation in the 
ellipticity at 290 nm for the nonmodified (control) polymer 
and the polymers treated with Comi or Com2 occurs over a 
more or less narrow range in salt concentration. Thus, the 
transitions appear to be cooperative. The efficiency of plati-
num complexes to inhibit or facilitate the B-aZ transition in 
DNA can be evaluated by means of the comparison of the 
midpoints in salt-induced transitions of control and modified 
polymers. The transition midpoint for control poly(dG-dC) 
occurs at 2.3 M whereas the transition midpoints of poly(dG- 
dC) modified by Comi or Com2 were at -1.6 M NaCl (Fig. 
1OD). 
The results of the present work indicate that Comi and 
Com2 facilitate the B-sZ transition in DNA, but the resulting 
Z forms are distorted. Comi distorts the Z-DNA more exten-
sively than Com2. Comi and Com2 affect B--aZ transition 
differently, which implicates a different mode of their bind-
ing to DNA. In addition, the different effects of Comi or 
Com2 on the B-aZ transition in comparison with the effects 
of cisplatin (Fig. 10D) and [PtCI(dien)]Cl are consistent with 
unique DNA binding modes of the new aminophosphine 
platinum(II) complexes, as potent drugs with antitumor effi-
cacy different from that of cisplatin. 
Conclusions. In broad terms, we have demonstrated that 
the DNA binding mode, and very likely also the mechanism 
of antitumor activity of the new class of platinum(ll) amin-
ophosphine complexes, is different from that of cisplatin. 
This difference reflects the distinct nature of nonleaving Ii-
gands. The replacement of amine ligands in cis-dichloroplati-
num(II) complexes by phosphine groups has been shown to 
influence considerably the selectivity for the adducts contain-
ing adenine and guanine residues and for monodentate and 
bidentate lesions. In addition, conformational alterations in-
duced in DNA by Comi are different from those induced by 
cisplatin. The different conformational changes and the in-
creased bulk of the lesions are consistent with a role of these 
factors in the processing of DNA platinated by Coral. In 
particular, Coral is more efficient than cisplatin in blocking 
DNA synthesis. A specific role of aminophosphine ligands in 
the modification of DNA by Coml is also evident from the 
observation that DNA platinated by Comi is not recognized 
by the antibodies elicited against DNA modified by cisplatin 
despite an equally good specificity of these antibodies for 
DNA modified by several analogs of cisplatin having varied 
nonleaving amine groups. A further processing of platinu-
m(II) adducts by cellular components has been suggested to 
play an important role in the mechanism underlying antitu-
mor activity of platinum compounds. The different cellular 
processing of DNA modified by cis -dichloroplatinum(II) com-
plexes containing on the one hand nonleaving amine groups 
and aminophosphine ligands on the other might be relevant 
to the different biological activity of these two classes of 
platinum compounds. Structural studies of site-specific DNA 
adducts with aminophosphine platinum(II) complexes should 
provide a basis for analyzing and re-evaluating the structure-
pharmacological activity relationships of platinum com-
pounds. Studies toward this end are in progress, from which 
may ultimately arise a rational basis for design of a novel 
class of platinum antitumor drugs. 
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We show that bis(aminophosphine) complexes of the type [M(R'R 2 N(CH2)PPh2)2]2 , M = Pt(n) or Pd(ii), can exist in 
chelate ring-closed and ring-opened forms both in the solid state and in aqueous solution. The equilibrium between 
them in solution can be controlled by the nature of the groups R' and R 2 (H, Mc, Bz, cyclohexyl), by the bridge 
length n, and by the pH and Cl concentration. X-Ray crystal structures are reported for the ring-closed complexes 
cis-[Pt(H 2 N(CI-I2)2 PPh2-P,A' 2]Cl2, cis-[Pt(H 2N(CH2) 3 PPh2 -P,IV) 2)C12 , and cis-tPt(Me(H)N(CH 2)2 PPh2-P,IV)21[HCI21 2 , 
the mono-ring-opened complex cis-[Pd(Me 2N(CH 2)2 PPh2-N,P)Cl(Me 1 NH(CH2) 2PPh2-P)J(NO 3 )21  the di-ring-opened 
complex cis-[Pt(Me 2 N(CH 2) 3 PPh2-P)2C121, and, for comparison, the monochelate cis-[Pd(Me 2 N(CH2)3 PPh2-N,P)C1 2]. 
These square-planar complexes exhibit varying degrees of distortion and variable M—N bond lengths dependent not 
only on the trans influence of P but also on steric effects within the complex. pH-induced chelate ring-opening of 
cis-[Pt(Me 2 N(CH 2)2 PPh2-P,Ai)2]Cl 2  had an associated pK value of 6.9. In contrast, complexes with R' and R 2 = I-I, 
it = 2 or 3 or R'= H and R'= Me, it = 2, are more difficult to ring-open. Thus the complexes cis-[Pt(Me(H)N(CH 2)r 
PPh2-P,1V)2]Cl2 and cis-[Pt(H 2N(CH 2)3 PPh2-P,IV)2]C12 , had associated pK values of 2.1 and 2.9, respectively. These 
aminophosphine complexes may exhibit anticancer activity by two mechanisms: by disrupting mitochondrial 
membrane potentials as bis-chelated (ring-closed) lipophilic cations, or by direct binding to DNA bases as 
ring-opened complexes. 
Introduction 
Aminophosphine complexes contain mixed donor ligands: one 
soft phosphorus donor and one relatively hard nitrogen donor, 
and can act as bridging ligands or as chelating agents thereby 
conferring enhanced stability to the complex. In Pt(n) com-
plexes, the nitrogen atom binds more weakly than phosphorus, 
especially when N is trans to P, which exerts a high trans 
influence.' Furthermore, the strength of M—N bonds is affected 
much more by sterie factors than for the corresponding M—P 
bonds.' Thus with the appropriate choice of nucleophiles, and 
under a given set of conditions such as pH, and chloride 
concentration, equilibria involving the dissociation of the 
amino group can be established resulting in ring-opened 
complexes with a potential binding site on the metal centre. 
Consequently, P,N chelated P1(u) complexes are known to 
display a considerably higher reactivity than the bis(phoaphine) 
complexes.' Depending on the sterie demands of the aubstit-
uents on N and the length of the N—P linker in the amino-
phoaphine ligand, bis-chelate, mono-chelate ring-opened, or 
non-ehelate complexes can be formed (Scheme I). 
Ph ('=\ R' 	Ph (\ 
_R 1 
Ph- PA .NR2 Ph'5 N.R2 
Ph,,, 	t 	I 'Pt 




Scheme I Ring-closed (I), mono-ring-opened (II) and di-ring-opened 
(III) aminophosphine complexes. X = Cl, 01-1 3 . 
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There are many previous reports relating to the potential use 
of aminophoaphine Pt(ii) complexes in catalysis. 7 However, 
very few' of these studies have explored the potential biological 
activities of these complexes, even though they contain cis 
amine ligands, a feature found in many active platinum anti-
cancer agents,' together with cis phosphine ligands. Certain 
diphosphines have also previously been shown to exhibit 
anticancer activity, especially 1,2-diphoaphinoethane (dppe) 
complexes of Cu(i), Ag(i) and Au(i).' ° In addition a range 
of monophosphine complexes of Au(i) exhibit antiarthritic 
activity and one of these, the PEt 3 complex auranofin, is now in 
clinical use as an antiarthitic drug.' ° In addition, they offer 
potential as anticancer agents via disruption of mitochondrial 
function due to their lipophilie cationic character." 
Recently we have established that the ehelate ring-opening 
reactions of Pt(n) aminophosphine complexes can be con-
trolled under conditions of biological relevance, and that they 
bind reversibly to the DNA base guanine .' 2" We have also 
shown that chelate ring-opened Pt(ii) aminophosphine com-
plexes can bind rapidly and strongly to the DNA base thymine 
an well as to the RNA base uracil under physiological con-
ditions, in contrast to platinum(ii) am(m)ine anticancer com-
plexes.' 4 Some aminophosphine complexes are cytotoxic to 
cancer cells including cisplatin-resistant cells, but the potency 
depends on the cell type. Different complexes may act via differ-
ent mechanisms in different kinds of cells." The biological 
activity may arise from a combination of antimitoehondrial 
activity due to the ring-closed forms and attack on DNA by the 
ehelate ring-opened complexes. 
In the present work, we have prepared and characterised both 
chelate ring-closed and ring-opened aminophosphine com-
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chloride on chelate ring-opening in aqueous solution. Our aim 
is to develop a rational approach towards the design and 
synthesis of new Pt and Pd drugs with improved therapeutic 
properties, in particular overcoming factors which limit the use 
of current Pt anticancer drugs: resistance, toxicity, and narrow 
spectrum of treatable cancers. 
Experimental 
Reagents 
H2 N(CH 2)2C1•HCI, H 2 N(CH 2) 3Cl•HCI, Me2 N(CH 2)2C1-HCI, 
Bz2N(CH 2) 2Cl-HCI, BzN(H)Me, 5%Pd/C and ethylene oxide 
were purchased from Aldrich, C 6 H II (H)N(CH 2)20H and 
Bz(H)N(CH 2)2OH from Lancaster Synthesis. (COD)PtCl 2 
(COD = cyeloocta-1,5-diene) and (COD)PdCl 2 were purchased 
from Aldrich or prepared by literature methods . 15"6 Solvents 
were generally dried and purified by standard methods, and 
freshly distilled before use. 
NMR spectroscopy 
Spectra were recorded on JEOL GSX270 (67.80 MHz for ' 3C 
109.25 MHz for 31 P and at 57.94 MHz for "'Pt) and DMX 500 
spectrometers (202 MHz for 3 P). Chemical shifts (5) are 
reported in ppm relative to internal TMS (CDCI,) or TSP 
(D,O) for 'H and "C, and to external 85% H 3 PO4 for "P. and 
I M Na,PtCI 6 for `Pt. Coupling constants (J) are given in Hz 
and NMR signals are described as singlets (s), doublets (d), 
triplets (t), multiplets (m) and quintets (q). 
Microanalyses and mass spectrometry 
Microanalyses were obtained from the Department of 
Chemistry, University College, London, and the University of 
Edinburgh. Fast atom bombardment (FAB) mass spectra were 
obtained at the School of Pharmacy, University of London on 
a VG Analytical ZAB-SE instrument. 
pH Measurements 
These were made using a Corning 145 pH meter equipped with 
an Aldrich micro combination electrode calibrated with 
standard buffer solutions at pH 4 and 7. Readings of the pH 
meter for D 20 solutions were not corrected for deuterium 
isotope effects and are designated as pH* values. 
pK Determinations 
The relative concentrations of species were determined from 
"P peak integrals and fitted to the Henderson-Hasselbalch 
equation using the program KALEIDAGRAPH." 
Crystallography 
Table I summarises the crystal data, data collection, Structure 
solutions and refinement parameters for complexes 1, 2, 8, 9, 
14b and 18. The X-ray data for complexes 1, 14b and 18 were 
collected on a Nonius CAD4 diffractometer. The structures 
were solved by heavy atom methods using SHELXS-97 8  and 
SHELXL-93.' 9 Subsequent refinements were made by the 
full-matrix least-squares technique on P[.  Anisotropic dis-
placement parameters were used for non-H-atoms, isotropic for 
H-atoms in geometrically fixed, riding mode. 
X-Ray data for 8 were collected on a Bruker SMART APEX 
CCD diffractometer. The structure was solved by the Patterson 
method and refined against F2 (SHELXTL).'° Hydrogen atoms 
attached to 01W were placed using the difference map and 
refined freely. Other H-atoms were placed in calculated 
positions and treated using a riding model. 
X-Ray data for 2 and 9 were collected on a Stoe Stadi-4 
diffractometer. The structures were solved by the Patterson 
method; structure 2 was refined against F' (SHELXTL),'° and  
structure 9 was refined against F(CRYSTALS)." In Structure 2, 
one of the two phenyl rings exhibited 50/50 rotational disorder 
about a common pivot atom (Cl 1). The disorder components 
were restrained to be similar and have a C, axis of symmetry 
running through the ordered atoms. Partial weight C-atoms 
were refined with common isotopic thermal parameters 
for C2IIC2I', C31/01' etc. The assignment of the anion as 
[Cl-H-Cl] was made on the basis of the Cl' Cl distance and 
the suggestion of a hydrogen position in a AF map, this H-atom 
being subsequently refined freely. Other H-atoms were placed in 
calculated positions and treated using a riding model. H-atoms 
on partially occupied H 2O molecules were placed to form 
favourable H-bonds. In 9 the ligands were restrained to be 
geometrically similar. 
CCDC reference numbers 152973-152978. 
See http://www.rsc.org/suppdata/dtib0/b009117k!  for crystal-
lographic data in CIF or other electronic format. 
Preparation of ligands 
H,NCH,CH,PPh,. The preparation was based on a literature 
method. 22 To a suspension of 13u'OK (8.5 g, 76 mmol) in dry 
and freshly distilled THF (100 ml), PPh 2 H (5 ml, 5.35 g, 28.76 
mmol) was added under Ar, and stirred at ambient temperature 
for 40 mm. Then crystalline H 2 NCH 2CH 2Cl'HCI (3.24 g, 28.2 
mmol) was added and the reaction mixture was heated under 
reflux for 20 h. During that time the deep-red solution became 
almost colourless. The solvent was then removed in vacua and 
10% HCl solution was added. The solution was then washed 
with benzene and made alkaline with 10% NaOH solution. The 
product was then extracted into benzene (3 x  50 ml), washed 
with brine, and dried over Na 2SO4 . After filtration and rotary 
evaporation, a colourless viscous liquid was obtained, which 
was dissolved in ether and purified by passage through a short 
alumina column. Yield 46%,'H NMR (CDCI,): (5 1.51(2 H, br, 
s, H,N), 2.26(2 H, rn P-CH,), 2.86 (2 H, m, N-CH,), 7.1-7.4 
(10 H, m, Ph); "P-('H) NMR (CDCI,):ô -21.5. The following 
compounds were prepared by analogous methods. 
I-J 2 NCH 2CH2CI-1 2PPh2, Yield 40%,'H NMR (CDCI,): (5 1.32 
(2 H, br, a, H 2N), 1.43-1.49 (2 H, q, CH,), 1.91-1.97 (2 H, t, 
CH 2), 2.62-2.67(2 H, t, CH,) 7.17-7.33 (10 H, m, Ph); "P-{'H} 
NMR (CDCI,): (5-21.5. 
Me,NCH,CH,PPh,. Yield 40%, 'H NMR (CDCI,): 6 2.24 
(6 H, s, N-CH 2), 2.26-2.28(2 H, rn, P-CH,), 2.38-2.44(2 H, m, 
N-CH 2), 7.31-7.34 (10 H, m, Ph); °P-{'H) NMR (CDCI,): 
(5-19.07. 
(c-C6H 11 )HNCH,CH2 PPh2 . To a cooled solution (0 °C) of 
(c-C6 H 11 )HNCH,CH,OH (14.32g. 0.1 mol) in CHCI, (200 ml) 
thionyl chloride (90.44 g, 60 ml, 0.76 mol) was added dropwise 
under Ar. The reaction mixture was then heated under reflux 
for 3 h. The solvent and excess thionyl chloride were removed 
in vacua to leave a dark-brown oily solid. This was washed 
with ether and dried over P,O The product was recrystallised 
from ethanol-ether to give a shiny whitish crystalline solid of 
(c-C6H,,)HNCH 2CH 2Cl'HCI. Yield 70%, (Found: C, 48.76; 
H, 8.64; N, 6.99. CaIc. for C 8 H, 6C1 2N: C, 48.48; H, 8.58; N, 
7.07%). 
The above compound was then used to prepare (e-C 6H,,)-
HNCI-I 2CH 2 PPh 2  in a similar way to that described for 
the above ligsnd. Yield 50%, 'H NMR (CDCI,): (51.18-1.26, 
1.69-1.86 (Il H, br), 2.26-2.29(4 H, m), 7.36-7.48 (10 H, m, 
Ph); "P-{ HI  NMR (CDCI,): (5 -19.92. 
(Me)HNCH,CH,PPh,. In the first instance (Me)BzNCH,-
CH,OH was prepared as described below. TH F (200 ml) was 
added to ethylene oxide (100 ml, 2.38 mol), obtained by con-
densation of the gas from a lecture bottle into a 500 ml 3-neck 
round-bottom flask fitted with a dry ice-acetone condenser, 




Table I Details of X-ray data collection and refinements for compounds 1,2,8,9, I4b, and 18 
Compound 1 2 8 9 14b 18 
Empirical formula CH,Cl 2N 2O 2 P2 Pt C30H 0C14N20P2Pt C32HCl 2 N4O5P2 Pt C 35HCI,P2N2Pt C32 H4 5CIN4O8PIPd C,,!-I 22Cl 2 NPPd 
M 778.49 843.47 892.64 893.61 817.54 448.48 
Temperature/K 291(2) 220(2) 150(2) 220(2) 291(2) 293(2) 
Space group P2,1n P2,1n P1 P2,1c P2,1n P2,1n 
Crystal system Monoclinic Monoclinic Triclinic Monoclinic Monoclinic Monoclinic 
;JA 1.54180 0.71073 0.71073 0.71073 1.54180 1.54180 
a/A 9.1827(4) 8.938(4) 9.4849(8) 10.141(1) 12.120(2) 10.128(4) 
b/A 25.826(5) 12.149(4) 11.3914(9) 18.817(2) 12.4800(10) 11.527(4) 
c/A 13.384(3) 15.7788(5) 17.8243(15) 20.230(2) 24.400(2) 15.795(6) 
uS" 95.7700(10) 
/5/" 92.25(l) 99.35(3) 96.9850(10) 101.25(1) 91.838(9) 102.42 
109.0030(10) 
u/A' 3171.6(9) 1691.6(11) 1787.1(3) 3786.31 3688.8(7) 1800.8(12) 
Z 4 2 2 4 4 4 
D,/gcm 5 1.618 1.656 1.659 1.57 1.380 1.485 
p/mm' 11.027 (Cu-Ku) 4.584 (Mo-Ku) 4.209 (Mo-Ku) 4.14 (Mo-Ku) 5.904(Cs-Ku) 12.593(Cu-Ku) 
F(000) 1520 836 892 1777.39 1576 796 
Scan mode w-20 u,-O , and w scans w.-O ru-20 w-20 
Crystal size/mm 0.42 X  0.25 x  0.18 0.27 x  0.16 x  0.12 0.38 a  0.10 x 0.05 0.16 x 0.16 X  0.04 0.2 x 0.3 x  0.4 0.3 X  0.3 x  0.4 
Colour, habit White, needles Colourless, block Colourless, lath Colourless, tablet White, needles Colourless, needles 
Orange/" 3.42-71.82 2.61-25.01 1.91-26.38 2.50-25.00 3.62-73.91 4.76-73.89 
/z,k,lranges -11-0,0-31-16-16 -10-10,0-14,0-18 -1I-11,-14-14,-22-22 -12-11,0-22,0-24 -15-t5,0-15,0-30 0-12-14-0-19-19 
Reflections collected 6631 3783 12153 11044 7648 3873 
Independent reflections (R,,) 6239 (0.0564) 2980 (0.0445) 7160 (0.0261) 6096 (0.05) 7473 (0.0633) 3663 (0.0312) 
Data/restraints/parameters 6236/0/308 2970/32/180 7160/0/423 454310/398 7424/0/468 3663/0/225 
Goodness of lit on F' 1.089 1.087 0.940 1.0742 0.921 1.010 
Final R indices RI, ,vR2 0.0535, 0.1546 0.0528, 0.1475 0.0296, 0.0669 0.0530, 0.0547 0.0751, 0.2114 0.0443, 0.1208 
Maximum 4/a 0.0 0.1 0.001 0.078326 0.001(1) 0.001(1) 
and the reaction mixture was kept at 0 °C. To this cold mixture, 
PhCH,NH(Me) (15 ml, 0.12 mol) was added dropwise. The 
reaction was then initiated by the addition of ZnBr 2 (I g) and 
was left stirring overnight at ambient temperature. The solvent 
was removed in vacua and the residual oil distilled (100-107 °C, 
2 mm Hg) to give (Me)BzNCH 2CH 20H. Yield 55%, 'H NMR 
(CDCI 3): (52.18, (3 H, S. CH,). 3.43 (2 H, t, O-CH 2), 3.58 (2 H, 
t, N-CM2) 7.18-7.25 (5 H, m, Ph); "C-{'H} NMR (CDCI,): 
o 41.57 (CH,), 58.49 (N-CH 2), 62.29 (0-CH 1), 127.13 (para), 
128.6 (ortl,o), 128.93 (nleta), 138.54. 
A solution of(Me)BzNCI-I 2CH2OH (10 g, 0.06 mol) in 98% 
ethanol (20 ml) was placed in a bomb at ambient temperature 
and 2-3 atm in a standard hydrogenation set-up, in the presence 
of 2 g of 5% palladium on carbon. The hydrogenolysis 
was complete in about 2 h. The catalyst was then removed by 
filtration and the solvent removed on a rotary evaporator to 
leave a slightly yellowish oil. This was distilled (30-32 °C, 1 mm 
Hg) to give (Me)HNCH 1 CH2OH as a colourless oil. Yield 67%, 
'H NMR (CDCI 3): (52.48, (3 H, s, N-CR,), 2.69 (2 H, t, CH,), 
3.42 (br, NH) 3.61 (2 H, t, CH,); "C-{'H} NMR (CDCI,): 
0 35.97, 53.95, 60.44. I'mJcm  3641, 1060 (OH), 3294, 1688, 
1656 (NH). 
It was then chlorinated in the usual manner to give 
(Me)HNCH 2CH 2CIHCI in 95% yield. (Found: C, 27.56; H, 
7.01; N, 10.57. CaIc. for C 3 H9Cl 2N: C, 27.69; H, 6.92; N, 
10.77%). The above salt was then used to prepare (Me)-
HNCH,CH,PPh 2 using a similar procedure to that described 
earlier. Yield 30%,'H NMR (CDCI,): (52.34(2 H, m, CH,) 2.81 
(6 H, s, N-CH,), 3.12(2 H, m, CH 2) 3.6(2 H, t, CH,), 7.36-7.48 
(10 H, m, Ph); "P-{'H) NMR (CDCI 3 ):0 -19.97. 
(Bz)HNCH 2CH,PPh2 . The hydrochloride salt (Bz)HNCH 2-
CH2CIHCI was prepared from (Bz)HNCH 2CH10H in the 
usual manner. Yield 81%, mp 197 C (dec.) (Found: C, 52.53; H, 
6.40; N, 6.79. Calc. for C9H,,Cl2N: C, 52.42; H, 6.31; N, 6.79%). 
'H NMR (CDCI,): (53.46 (2 H, m) 3.84 (2 H, m), 4.25 (2 H, s) 
7.46 (6 H, s). 
The preparation of (Bz)HNCH 2CH2PPh2 was carried out in 
the usual fashion, but the work-up was modified as follows. 
After the THF was removed in vacuo, addition of 20% HCI 
solution gave rise to a whitish solid that was filteredoff, 
redissolved in CHCI, and filtered to remove the insoluble 
impurities. The solvent was removed on a rotary evaporator 
to leave a whitish powder, which was recrystallised from 
methanol-ether to give shiny white crystals. Yield 84%, (Found: 
C, 70.41; H, 6.44; N, 4.14. CaIc. for C 2 ,H 23 CINP: C 70.88; H, 
6.46; N, 3.93%). 'H NMR (CDCI,): 0 2.59 (m) 2.82 (s, br) 3.8 
(s, br) 7.4-7.62 (Ph) 10.09 (NH); "P-H) NMR (CDC',): 
0-20.33. 
The following were also prepared analogously. 
(Bz)MeNCH 2CH,PPh2. (Bz)MeNCH 2CH3OH was chlorin-
ated to give (Bz)MeNCH 1 CH 2 CIHCI as a whitish solid in 95% 
yield. mp 144 C. (Found: C, 54.85; H, 7.04; N, 5.97. CaIc. for 
C,,H,,Cl,N: C, 54.54; H, 6.81; N, 6.36 1/6). This was then used to 
prepare (Bz)MeNCH 2CH 2PPh 2 with a yield of 45%. 'H NMR 
(CDCI 3): (52.5 (s, br) 3.2-3.50 (m, br) 3.9-4.4 (m, br) 7.1-7.92 
(Ph); "P-{'H) NMR (CDCI,): 0 -19.00. 
(Bz)2NCH 2CH 2PPh2. This was prepared as above in 66% 
yield. mp 105 °C. (Found: C, 72.25; H, 6.84; N, 3.34. CaIc. for 
C23 H28NP3H 20: C, 72.41; I-I, 7.32; N, 3.03%). 'H NMR 
(CDCI 3): 0 2.59 (m) 2.87 (m) 4.06, 4.27 (m) 7.19-7.77 (Ph); 
"P-('H) NMR (CDCI,): 0 -19.59. 
Me2NCH 2CH 2CH,PPh,. To a mixture of 37% HCOH (37 g, 
0.46 mol) and 98% HCOOH (27 g, 22 ml, 0.57 mol), H 2 -
NCH 2CH 2CH,CIHCI (10 g, 0.076 mol) was added and the 
reaction mixture heated under reflux for 30 h. The light brown 
solution was made alkaline with 10 1/6 NaOH, extracted with 
CH,CI, (3 x  50 ml) and dried over Na,SO 4 . The solvent was 
then removed in vacua to leave a brownish liquid, to which 
ethanolic hydrogen chloride (20 ml) was added. The solvent was 
then removed in vacua to leave a brownish oil which was 
dissolved in hot propan-2-ol. The precipitate obtained after 
addition of ether was filtered, and washed with ether to gives 
whitish highly hygroscopic solid (Me 2 NCH,CH,CH,Cl•HCI). 
Yield 30%,'H NMR (CDCI,): (52.81(6 H, s, N-CH,) 3.6(2 H, 
t, CH,), 2.34(2 H, m, CH,) 3.12(2 H, m, CH,). 
Me2 NCH 2CH 2CH 2CIHCI was then used to prepare the 
above ligand as described earlier. Yield 38%,'H NMR (CDCI,): 
0 1.44-1.53 (2 H, m) 1.93-1.99 (2 H, m, CH,), 2.05 (6 H, N-
CH,) 2.21-2.26 (2 H, t, CH 2) 7.17-7.21, 7.24-7.35 (10 I-I, m, 
Ph); "P-{'H} NMR (CDCI,): 0 -19.33. 
Preparation of platinum complexes 
(Pt(H 2NCH,Cl-l 2 PPh2),]Cl2 3H20 I. A solution of l-I,NCH 2-
CH,PPh, (0.2 g, 0.26 mmol) in CH,CI, (2 ml) was added 
dropwise to a clear solution of (COD)PtCl, (0.093 g, 0.26 
mmol) in CH 2 Cl 2  (25 ml) and the reaction mixture was stirred at 
ambient temperature for I h. The volume was then reduced to 
Ca. 7 ml and diethyl ether was added to precipitate a whitish 
powder which was then filtered off and washed with diethyl 
ether and recrystallised from acetone-dichloromethane. 
Yield 86%, mp 235 °C (dec.) (Found: C, 43.33; H, 4.80; N, 
3.44; Cl, 9.62. CaIc. for C 2,H 32C12N2 P2 Pt3H2O: C, 43.18; H, 
4.88; N, 3.59; Cl, 9.12%). n,/z (FAB MS): 652 (l00%, 
M - 20). llI  NMR (CDCI,) 0 2.71-2.77 (2 H, m, N-CH,), 
3.02-3.07 (2 H, m, P-Cl-I 2), 7.25 (H IN, br, a, 'J(PtH) 42 Hz), 
7.25-7.53 (10 H, Ph); "P-{'H} NMR (CDCI,): 0 33.70 'J(PtP) 
3300 Hz; "Pt-{'H} NMR (CDCI,): 0 -4589 'J(PtP) 3344Hz. 
The following complexes were also prepared in a similar 
manner. 
[Pt(H(Me)NCH 2 CH 2 PPh 2),][Cl-H-Cl] 2 •H20 2. Yield 71% 
(Found: C, 43.80; H, 4.82; N, 3.30. CaIc. for C 35 H,5CI6 N2 P2 Pt 
H 2O: C, 42.70; H, 4.74; N, 3.32%).'H NMR (CDC',) 0 2.78 
(2H, br), 3.05 (N-Me), 3.35 (2H, br), 6.5 (NH) 7.3-7.6 (10 H, 
Ph); "P-{'H} NMR (D,O, PH* 3.85): (5 28.9 'J(PtP) 3300 Hz, 
'°'Pt-{'H} NMR (CDCI,): 0 -4575 'J(PtP) 3330 Hz. Crystals 
suitable for X-ray structure determination were obtained by 
recrystallisation from H 2O-EtOH (I : I). 
[PtC((c-C 6H,,)HNCH,CH2PPh2),]Cl.4H2O 3. Yield 81% 
(Found: C, 49.56; H, 6.15; N, 2.87. CaIc. for C 40H,2Cl2 N2P2 Pt 
4H 20: C, 49.94; I-I, 6.25; N, 2.91%). "P-{'H} NMR (CDC],): 
0 36.45, 'J(PtP) 3294; "Pt-('H} NMR (CDCI,): (5 -4538 (1) 
'J(PtP) 3233 Hz. A CHCI 3 solution of the crude product of the 
above compound was left at 4 °C for about 10 h after which 
time crystals formed. These were filtered off and dried to give 
the monochelate complex [Pt((c-C 6H,,)HNCH,CH,PPh 2)Cl2 ] 
as a minor product (ca. 5%). (Found: C, 41.10; H, 4.49; N, 2.22. 
CaIc. for C,,H,,Cl 2NPPt: C, 41.59; H, 4.50; N, 2.42%). "P-{'H} 
NMR (CDCI,): (524.81 'J(PIP) 4064Hz. 
[Pt(H(Bz)NCH2CH 2PPh 2),]Cl 2  4. Yield 46% (Found: C, 
51.74; H, 5.08; N, 2.81. Calc. for C 42H44C1,N,P2Pt: C, 51.60; H, 
4.74; N, 2.87%).'H NMR (CDCI 3)0 2.55,2.88,3.1,3.9,3.5,7.0-
7.60, (15 H, Ph); 10.09 (NH) "P-{'H) NMR (CDC',): 0 30.3 
'J(PsP) 3420 Hz, 40.0 'J(PtP) 3800 Hz, 5.0 'J(PtP) 3348 Hz. 
[PtCI(Me2NCH 5CH2PPh,),]CIHCI 5b. Yield 90%, mp 194 
°C (dec.) (Found: C, 47.63; H, 4.99; N, 3.26; Cl, 12.75; P, 8.!. 
CaIc. for C,2H40C12 N2P,PtHCI: C, 47.03; H, 5.02; N, 3.42; Cl, 
13.04; P, 7.59%). nile (FAB MS): 745 (100%, M - Cl). 'H 
NMR (CDCI,) 0 2.15 (s), 2.17-2.20 (s, br), 2.70-2.79 (s, br), 
3.01-3.15 (s, br), 7.16-7.49 (10 H, Ph); "P-{'H} NMR 
(CDCI,): 0 36.52 'J(PtP) 3691 Hz, -0.46 'J(PtP) 3187 Hz; 
"Pt-{'H} NMR (CDCI,): 0 -4505 (dd). 
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[Pt(Me(Bz)NCH 2CH 2 PPh]C12 6. Yield 83% (Found: C, 
56.98; 1-1, 5.13; N, 2.91. CaIc. for C 44 H48Cl 2 N2 P1 Pt: C, 56.65; H, 
5.15; N, 3.00%). 'H NMR (CDCI,) 6 1.8 (s, br), 2.16 (m, br), 
2.46 (s, br), 3.44 (s, br) 7.1-7.9 (15 H, Ph); 3 'P-{'H} NMR 
(CDCI,): 6 30.69 'J(PtP) 3754 Hz, -0.06 'J(PtP) 3184 Hz, 
2J(PBPC) 17 Hz. 
[Pt((Bz) 2NCH 2CH2PPh),JCI 2 7. Yield 81% (Found: C, 61.54; 
H, 5.15; N, 2.40. Calc. for C 56H56C12N2 P2 P1: C, 61.99; H, 5.16; 
N, 2.58%). 'H NMR (CDCI3) (51.18 (s, br), 2.16 (s, br), 2.46 
(s, br), 3.44 (s, br) 7.1-7.9 (20 H, Ph); 3 'P-{'H} NMR (CDCI,): 
(54.5 'J(PtP) 3635 Hz. 
[Pt(H 2NCH 2CH 2CH2PPh2)2JC12  8. Yield 509/6, mp 235 °C 
(dec.) (Found: C, 43.24; H, 5.52; N, 2.93. CaIc. for C, 0 H 36-
Cl 2N2 P2 Pt4H 20: C, 43.68; H, 5.33; N, 3.39%). ,n/z (FAB MS): 
680(100%, M - 2Cl). 'H NMR (CDCI,)d 1.84-1.99(2 H, m), 
2.60-2.69 (2 H, m), 3.18-3.20 (2H, m), 6.06-6.21 (br, H 2 N, 
2J(PtH) 44.7 Hz), 7.20-7.53 (10 H, Ph); 31 P-{'H} NMR 
(CDCI,): 6  -3.77 'J(PtP) 3287 Hz. `Pt-{'F1) NMR (CDCI 3 ): 
(5 -4455 (t). Crystals suitable for X-ray structure determination 
were obtained by recrystallisation from CH 3 NO2 solution as 
8H202CH 3 NO2 . 
[PtCl2(Me2NCH2CH2CH2 PPh2-P)2] 9. Yield 55%, mp 235 °C 
(dec.) (Found: C, 49.59; H, 5.27; N, 3.37. CaIc. for C 34 H44-
Cl2 N 2 P2Pt: C, 49.39; H, 5.56; N, 3.38%). mlz (FAB MS): 773 
(100%, M - Cl). 'H NMR (CDCI,)o 1.71-1.73(2 H, m), 2.11 
(6 H, s), 2.16-2.11(2 H, m) 2.26-2.32(2 H, m), 7.25-7.53(10 H, 
Ph); 3 '1`-{'H} NMR (CDC],): 6 8.18 'J(PtP) 3640 Hz. "'Pt-
('H) NMR (CDCI,): 6 -4408 (t) 'J(PtP) 3642 Hz. Crystals 
suitable for X-ray structure determination were obtained by 
recrystallisation from a CH 2Cl 2-Et20 mixture as 9CH 2Cl 2 . 
[PtC](Me2NCH2 CH2 CH2PPh,) 2]CI 9b. To a solution of 
(PtCl2(Me 2NCH 2CH2CH 2 PPh2)21 (0.1 g, 0.12 mmol) in CHCI 3 
(20 ml) AgBF4 (0.024g. 0.12 mmol) was added and the reaction 
mixture stirred at room temperature for 10 minutes in the dark. 
The milky suspension was then filtered. To this solution Et 20 
was added to initiate recrystallisation. Storage of the solution 
at 4 C resulted in the formation of yellowish crystals of 
[PtCI(Me2NCH 2CH2CH 2 PPh2)2]BF4 in 95% yield. 3 'P-{'H} 
NMR (CDCI,): (57.95 'J(PtP) 3761 Hz, 4.85 'J(PtP) 3199 Hz. 
The preparation of palladium complexes 
The palladium complexes were prepared in an analogous way 
to the platinum complexes. 
[Pd(H,NCH ZCH 2PPh2)2]C12 10. Yield 95%. Recrystallised 
from acetone-dichioromethane (Found: C, 49.05; H, 5.22; N, 
4.07. CaIc. for C 28H,2Cl 2N2 P2Pd3H20: C, 48.76; H, 5.51; N, 
4.06%). miz (FAB MS): 599 (20% M' - 2Cl), 563 (100% 
M - Cl). 'H NMR (CDCI,) 6  "P-{'H} NMR (CDC[,). 
(555.80. 
[Pd(H(Me)NCH 2CH 2PPh2),]C12 .6H20 11. Yield 71 1/,.. 
(Found: C, 46.80; H, 5.20; N, 4.00. CaIc. for C 30H 36Cl2N2P2 Pd• 
6H 20: C, 46.69; H, 5.96; N, 3.63%). "P-{'H} NMR (CDCI,): 
(552.55. 
[Pd((c-C6H,,)HNCH 2CH2PPh2)2)C1 2 .H 20 12. Yield 78%. 
Recrystallised from ether-dichloromethane (Found: C, 57.65; 
H, 6.68; N, 3.35. CaIc. For CH 52Cl2N 2P2PdH20: C, 57.48; H, 
6.46; N, 3.359/6). "P-('H) NMR (CDCI,): (5 54.4 (br). 
[Pd(H(Bz)NCH 2CH2PPh,),]ClHCl-2H 20 13. Yield 46% 
(Found: C, 56.91; H, 5.62; N, 2.87. CaIc. for C 42 HCl2N2 P2 Pd• 
HCl2H2O: C, 56.78; H, 5.52; N, 3.15%). "P.{'H} NMR 
(CDCI,): (560.5,22.5, 2J(PP) 13 Hz. 
[Pd(Me2NCH,CH,PPh,) 2]Cl2  14a. Yield 909/6. Recrystallised 
from acetone-dichloromethane (Found: C, 53.76; H, 5.60; N, 
4.04. CaIc. For C 32 H40C13 N2 P2PdH 2O: C, 54.16; H, 5.92; N, 
3.94%). 'H NMR (CDCI,) (5 1.71-1.73(2 H, m), 2.11(6 H, s), 
2.16-2.11 (2 H, m) 2.26-2.32 (2 H, m), 7.25-7.53 (10 H, Ph); 
3 'P-('H) NMR (CDCI,): (550.0 (broad, Av, 186 Hz). 
[PdCI(Me2NCH2CH 2PPh2)2]CI 14b. To a solution of [Pd-
(Me2NCH2CH 2 PPh2)21C12 (30 mmol), was added HNO, to 
lower the pH to co. 2. After a few hours at ambient temper-
ature, crystals of cis-[Pd(Me 2 N(CH2)2PPh2-N,P)Cl(Me2NH-
(CH 2) 2 PPh2-P](NO 3)2 2H 20 formed which were suitable for 
X-ray structure determination. "P-{'H} NMR (13 20, pH*  4.5): 
(558.90,23.55. 
[Pd(Me(Bz)NCH 2CH2PPh,) 2]Cl,.2HCI 15. Yield 83%. 
(Found: C, 53.07; H, 5.41; N, 3.00. CaIc. for C 44 H 48Cl 2 N2 P2Pd 
2HCI: C, 53.47; H, 5.06; N, 2.83%). 31 P-{'H} NMR (D20-
EtOD-d6): 6 14.60. 
[Pd((Bz) 2NCH,CH 2 PPh2),]C12 •21-ICI 16. Yield 81% (Found: 
C, 62.02; H, 5.44; N, 2.44. CaIc. for C 56U56Cl2 N 2 P2 Pd2HCl: C, 
62.80; H, 5.42; N, 2.61%). "P-{'H} NMR (CDCI 3):6 13.5. 
[Pd(H 2NCH2CH2 CH 2 PPh2)2JC1, 17. Yield 70%. Recrystal-
lised from acetone-dichloromethane (Found: C, 50.32; H, 5.77; 
N, 3.82. CaIc. for C 35H 36Cl2 N2 P2Pd3H 20: C, 50.20; H, 5.85; N, 
3.90%). ,nlz (FAB MS): 628 (28% M - Cl), 591 (62% 
M - 20). 'H NMR (CDCI 3 )6 1.7-1.8(2 H, br, m), 2.5-2.66 
(2 H, br, m) 3.14-3.16 (m, br), 5.62 (NH,, br), 7.20-7.57 (10 H, 
m, Ph); "P-{'H} NMR (CDCI,): (520.0. 
[PdCl2(Me2NCH2CH2CH 2 PPh2)] 18. Yield 88%. Recrystal. 
lised from acetone-dichloromethane (Found: C, 45.62; H, 4.94; 
N, 3.02. CaIc. For C, 7 H 22Cl2NPPd: C, 45.63; H, 4.91; N, 
3.13%). ,n/z (FAB MS): 450 (10% M), 414(21% M 2 - Cl) 376 
(30% M - 2C1). 'H NMR (CD2Cl2-DMF-d7) 6 2.08 (2 H, m), 
2.53 (2 H, m) 2.98 (2H, s), 3.43 (6 H, s), 7.52-7.63 (10 H, m, 
Ph); "P-{'H} NMR (CD 2Cl 2-DMF-d7): (5 16.76. 
Results and discussion 
Preparation and properties of ligands 
A number of methods have been reported for the preparation 
of aminophosphine ligands. 7'22 In the present work, the most 
convenient starting materials were aminoalcohols, a large num-
ber of which are either available commercially or can be pre-
pared by the reduction of amino acids. 22-18 The aminoalcohol, 
H(Me)NCH 2CH 20H was prepared as shown in Scheme 2a. 
Chlorination of the aminoalcohol followed by reaction with the 
diphenylphosphine anion afforded the required ligand (Scheme 
2b). The ligands were obtained as viscous oils except for 
Bz(R)NCH2CH 2 PPh2 (R = H, Me or Ba), which were obtained 
as the hydrochloride salts. The oily ligands were readily purified 
by passing solutions in ether through a short alumina column 
and the salts were recrystallised from methanol-ether. The 'H 
NMR spectra of the ligands in CDCI, showed the expected 
peaks with the backbone CH 2 appearing as triplets and the 
NH2 as broad peaks in the region of 1-2 ppm. The "P NMR 
spectra showed single resonances in the region of -19 to -21 
ppm. 
Synthesis and characterisation of P1(11) and Pd(n) complexes 
The Pt(n) and Pd(n) complexes were characterised by FAB 
mass spectrometry, 'H, 3 'P, "'Pt, "C NMR and IR spectros-
copies, and elemental analysis. X-Ray crystal structures were 
obtained for complexes 1, 2, 8, 9, 14b and 18 (see Table 2 for 
definitions of complexes). The "P NMR spectra showed co-
ordination shifts ranging from 65 ppm to 18 ppm downfield for 
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Scheme 2 Preparation of(a) H(Me)NCH 2CH,OH and (b) aminophosphines and complexes. 
Table 2 Complexes prepared in this work. All have a 2:1 ligand-to-
metal ratio except 18 (I: I). See Scheme I for different coordination 
modes adopted by the complexes 
Ph 





number 	 Substituents 
M=Pt 	M=Pd 	R 	R' 	Linker it 
I" 10 H H 
2" 11 H Me 
3 12 I-I c-CH,, 
4 13 H Bz 
5a 5 14a 
Me Me 5b 14b"' 
6 15 Me Bz 
7 16 Be Bz 
8" 17 H H 
9" 
9b5 18" Me Me 
"X-Ray structure determined. Prepared by reacting 5b with AgNO, or 
9 with AgBF4 and subsequent removal of AgCl. Prepared by lowering 
the pH to <4. 
"P in 5- and 6-membered chelate rings, respectively. Such low-
field shifts upon chelation are common for complexes of Pt(u) 
and Pd(u) phosphines. 29 In the FAB MS spectra, the base peaks 
were usually [molecular ion - Cl] which has also been found 
to be the case for similar complexes.'° The expected isotopic 
patterns for platinum were also found. The "C NMR spectra 
were generally very broad and peaks in the aromatic region 
were difficult to assign. Remarkably, most of the complexes 
were generally soluble in water as well as in common organic 
solvents. 
Complex 1, cis-[Pt(H 2N(CH 2)2 PPh2-P,N) 2]Cl21  is a water-
soluble white solid which decomposes upon heating at about 
250 2C. The FAB MS spectrum had a base peak of 652 
(M 2 - 20) with the expected isotopic pattern for platinum. 
The 'H NMR spectrum in CDCI, indicated that the resonances 
of the CH 2 groups were broad multiplets and the NH 2 peak was 
at 6 7.25 with a 2J(PtH) of 42 Hz. This is a large downfield shift 
from the free ligand at  1.51 indicative of N coordination and 
the formation of 5-membered chelate rings. The "P NMR spec-
trum (Table 3) showed a single peak at 6 33.7 (P A , for atom 
labelling see Scheme 3) with a co-ordination shift of 55 ppm, 
consistent with the formation of a bis-chelated complex. 29 The 
coupling constant 'J(PtPA), of 3300 Hz is typical of ° P trans to 
nitrogen."" The "'Pt NMR spectrum also showed a triplet at 
o -4589 confirming the bis-chelated nature of the complex. The 
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Scheme 3 The effect of pH and chloride as chelate ring-opening and 
closure in 5. 
'H and 3 'P NMR spectra in D,O were similar to those from 
CDCI 5 solutions. The Pd analogue, 10, cis-[Pd(H 2 NCH 2CH2-
PPh2-P,N) 2]C12 , was also shown by "P NMR to exist in a 
ring-closed form in both CDCI, and D 20, and, as for the Pt 
analogue, it remained ring-closed even under highly acidic 
conditions (pH <2). 
The FAB MS spectrum of 5b had a base peak at 745 
(M" - Cl). The elemental analysis showed that the complex 
was isolated as the hydrochloride salt suggesting that one 
of the amino groups is protonated and thus the complex exists 
in a ring-opened form (cis-[Pt(Me,N(CH 2)2 PPh2-N,P)Cl(Me 2-
NH(CH 2)2PPh2-P)]Cl 2) in the solid state. The "P NMR 
spectrum in CDCI, (Table 3) showed two resonances: a peak at 
(536.5 assignable to P in a P,N chelate ring (P 5) and at 0 -0.46 
assignable to P in a P-bound ring-opened ligand (Pa)  (for atom 
labelling see Scheme I). The respective 'J(PtP) couplings were 
3691 and 3187 Hz, which are values typical of  trans to Cl and 
N, respectively ." 5' The corresponding co-ordination shifts 
were 55 ppm for P 3 and 19 ppm for P,. The peaks were 
relatively broad and did not show any doublet splitting due to 
'(5) The "P NMR data thus show that the ring-opened 
species is also the preferred form of the complex in solution 
(CDCI,). The inequivalence of the two phosphorus atoms was 
also confirmed from the "'Pt NMR spectrum, which showed 
a doublet of doublets centred at 6 -4505. The 'H NMR spec-
trum in CDCI, showed the expected peaks, albeit very broad 
ones. The broadening may arise from an exchange process 
involving chelate ring-closing and opening. This was even more 
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Table 3 up NMR data for complexes 1-18 and pK values for ring-opening determined from pH (itrations 
Chemical shifts (V(PtP)/Hz) 
Complex 	o(P) 	 5(P0) 	 ô(P) 	 15 (P5) 	 pH 	pK 
V 33.7(3300) - - 	 - - <I 
28.9(3300) - - - 3.85 2.1 
- 41.1(3770) 1.9(3300) 	- <2 
- 38.89(3783) 0.5(3239) - 4 6.3 
3 36.45(3294) - - 	 - - - 
4 30.3(3420) 40.0(3880) 5.0(3348) 	- - - 
Sb - 36.5(3691) -0.46(3187) - - - 
5bU 25.25(3294) 36. 5(3792) -0.06(3128) 	- 8.6 6.9 
- 36.5(3792) -0.06(3128) - 5.0 
5a U 25.5(3225) - - 	 - 8.6 Ca. 2 
- 25.3(4008) - 1.96(3298) 	- 2.0 
6 - 30.7(3754) -0.06(3184) - - - 
7 - - - 	 4.50(3635) - - 
8' - 1.88(3199) - - - 6.5 2,9 
- 0.55(3625) 4.24(3272) 	- 
8 -3.77(3287) - - 	 - - - 
9 - - - 8.18(3640) - - 
91) - 7.95(3761) 4.85(3199) 	- - - 
10 55.50 - - 	 - - - 
II 52.55 - - - - - 
12 54.44 - - 	 - - - 
13 - 60.5 22.5 - - - 
14a 50.0 - - 	 - - - 
14b' 50.48 - - - 8.6 6.0 
- 58.9 23.55 	 - 4.5 
- - - 	 14.6 - - 
16 - - - 13.5 - - 
17 20.0 - - 	 - - 
18' 16.76 - - - - - 
"See Scheme I for atom labelling. (P, = Pin his chelate, trawl to N; P. = Pin P.N chelate-ring, trans to Cl; Pc = Pin P-bound, ring-opened ligand, 
trans to N; P0 = P in P-bound ring-opened ligand, trans to Cl). Solvent CDC], unless otherwise stated .5 trans  to OH,. "0 20. "D 20-EtOD-d5 . 
'CD2Cl 2-DMF-d,. 
evident in the ' 3C NMR spectrum, in which the ethylene 
carbons were so broad that they were difficult to observe. 
The 3 P NMR spectrum of 6 in CDCI 3 showed that it exists 
exclusively as a mono-ring-opened species, cis-[Pt(Bz(Me)N-
(CH 1)2 PPh2-N,P)Cl(Bz(Me)N(CH 2) 2 PPh2-P)}Cl. In contrast to 
5b, the peaks were sharp doublets: doublets at 6 30.7 (P 5) and 
-0.06 (Pa)  with the corresponding 'J(PtP) values of 3754 and 
3184 Hz, respectively. The doublet splitting can be assigned 
to a 2J(PBPc)  coupling of 17 Hz. The sharpening of the peaks 
suggest the absence of an exchange process involving chelate 
ring-closing and -opening under these conditions. 
Complex 5b dissolves readily in water. The 32 P NMR spec-
trum of the solution in D 20 (Fig. Ia, pH 8.56), in contrast to 
the spectrum recorded in CDCI 3 , showed two sets of peaks. 
There was a broad singlet at 525.25 (PA)  with a J(PIPA ) value 
of 3294 Hz, assignable to a bis-chelated (ring-closed) form of 
the complex, and singlets at 6 36.5 (P a) and -0.06 (Pa) with 
J(PtP) couplings of 3792 and 3128 Hz, respectively, assignable 
to the ring-opened form. The ratio of ring-closed to ring-
opened species was 2:1. The "Pt NMR spectrum showed a 
doublet of doublets centred at 6 -4505 for the ring-opened 
species, with splitting due to two inequivalent P atoms, and a 
triplet centred at 6 -4653 corresponding to the bis-chelated 
species. Thus in aqueous solution the two forms of the complex 
exist in equilibrium. The position of the equilibrium was found 
to be dependent upon pH and chloride concentration, and is 
further discussed in the next section. 
The 32 P NMR spectrum of the palladium analogue, 14a, cis-
[Pd(Me2 N(CH 2)2Ph2-P,N)2JCl2, in COd 3 showed a single peak 
at 6 50.0 (PA) with a co-ordination shift of 70 ppm. The peak 
was broad with a width at half height (Av5) of 186 Hz. The 
spectrum of I4a recorded in D 20 (pH, 8.6), showed a very 
broad single peak at 6 50.5 (Av5 1656 Hz). The broadening 
suggested that exchange between the ring-opened and ring-
closed species was occurring. It was, however, possible to isolate 
(b) pH= 5.0 
PC 
____A__ • 
50 	40 	30 20 10 	0 -10 
6(31 P) 
Fig. I 32 P-{H} N M R spectra of Sb in D 2O (a) pH 5 8.6, (b) pH 5.0. 
Assignments: P. = P is bis-chelate; P a = P in P,N chelate-ring, Pc P in 
P-bound, ring-opened ligand (see Scheme 3). • = "Pt satellites. 
the ring-opened form of the complex (14b) at low pH (ca. 4). 
The X-ray crystal structure of the ring-opened species and the 
pH dependence of the chelate ring-opening and -closing 
processes are discussed further below. 
Complex 2 was prepared as shown in Scheme I and was 
isolated as the hydrogen dichloride salt: cis-[Pt(Me(H)N-
(CH 2) 2 PPh 2-P,N) 2]'[HCl2]2. The 32 P NMR spectrum in D 20 
(pH* 3.85) showed a peak at 6 28.9 (P A) with lJ(PtpA) coup- 
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lings of 3300 Hz. Complex 2 exists as a ring-closed, bis-chelated 
complex above pH 3. The "P NMR spectrum of 3, [PtCI-
((c-C6 H, 1 )HN(CH 2)2 PPh2)2]Cl, in CDCI, showed a broad single 
peak at 6 36.45 (PA) with the 'J(PtPA) value of 3294 Hz. The 
"Pt NMR spectrum showed a triplet centred at 6 -4538. There 
was also a minor product (ca. 51/o) which was isolated by 
fractional recrystallization from chloroform and shown to be 
the mono-chelate complex, cis-(Pt(c-C 6H,,)HN(CH 2)2 PPh,-
N,P)C121, by elemental analysis. The "P NMR spectrum 
showed a peak at  24.8 with a 'J(PtP) value of 4064 Hz, con-
sistent with the formation of a monochelate. The "P NMR 
spectrum of the palladium analogue, [Pd(c-C 6 H 1 
PPh2)2Cl,], 12, was recorded in different solvents. In D20 - 
ethanol the singlet peak was sharp at 6 52.7 (P A) accompanied 
by two minor broad peaks at (563.0 (P,) and 22.0 (Pa),  whereas 
in CDCI, the peak at 6 54.4 (P A) was very broad, and, in 
addition, there were two minor peaks at 6 57.6 (P B) and 
33.7(P). In both cases the ring-closed form is the major species 
and the minor peaks correspond to the ring-opened form. 
Similarly, in CD,CI,, the broad peak at (557.9 (P A) was accom-
panied by two broad minor peaks centred at 6 63.5 (P,) and 
22.8 () possibly as a result of traces of HCI in the solvent. 
The "P NMR spectrum of 4 in CDC], showed that there 
were two sets of peaks assignable to the chelate ring-opened 
complex cis-[Pt(BzHN(CH,) 2 PPh 2-N,P)Cl(BzHN(CH 2)2-
PPh2-P)]CI and ring closed complex cis-[Pt(BzHN(CH,) 2-
PPh2-N,P)2]C12 . In contrast, the "P NMR spectrum of 7, 
cis-(Pt(Bz2N(CH 2)2 PPh 2)2-P)2C1 21, showed a single peak at 
6 4.5 (P0) with 1J(PtP0) value of 3635 Hz, suggesting that 
it exists as a di-ring-opcncd complex co-ordinated through 
phosphorus only 
The 'H NMR spectrum of cis-[Pt(H 2N(CH 2),PPh2-P,N)2]-
C1 2 , 8, in CDCI, showed that the NH 2 peaks had shifted from 
6 1.38 for the free ligand to 6 6.14 (2J(PtH) = 44.7 Hz), a 
shift of 4.72 ppm downfield upon coordination. The "P NMR 
spectrum also showed a single peak at (5 -3.77 (P A), with a 
'J(PtPA) value of 3287 Hz, showing that 8 was isolated as a his-
chelated complex. However the "P NMR spectrum of a solu-
tion in D 20-ethanol showed the expected peaks at 6 -3.8 (P A ) 
with 'J(PtPA) value of 3336 Hz, which corresponds to the ring-
closed form. The "Pt NMR spectrum of the same sample 
showed a triplet centred at 6 -4455 (PA)  with 'J(PtPA) value of 
3330 Hz. The FAB MS spectrum for cis-[Pt(Me2N(CH2),PPh2-
P)2C11 11 9, showed a base peak at 773 for [molecular ion - Cl]. 
The "P NMR spectrum in CDCI, showed a single peak at 
6 8.18 (P0) with 'J(PtP) value of 3640 Hz. Thus the above 
data show that 9 exists as a di-ring-opened complex. When the 
complex was reacted with two molar equivalents of AgBF 4 , it 
was possible to isolate the mono-chelated (ring-opened) species 
(9b). The "P NMR spectrum in CDCI, showed a singlet at 
6 7.95 (PB) with a 'J(PtPB) value of 3761 Hz and a singlet at 
(54.85 (Pa), with a 'J(PtP) value of 3199 Hz. 
When two molar equivalents of Me,N(CH,) 3 PPh 2 were 
reacted with one molar equivalent of (COD)PdCl, in the usual 
manner, the only product which could be isolated was 
the mono-chelated dichloro complex [Pd(Me,N(CH,),PPh,-
P,ACl,], 18, even when a large excess of the ligand was used. 
The structure of the product was confirmed by X-ray analysis 
and the FAB MS spectrum showed a base peak at ,nlz 450 
which corresponds to the molecular ion. 
This series of complexes clearly demonstrates how the steric 
nature of the substituents on nitrogen as well as the length of 
the methylene backbone (P-N linker) can determine whether 
the complex exists in ring-opened or closed forms. Complexes 1 
and 10, which contain only hydrogen substituents on N, exist as 
ring-closed forms in both CDCI, and D,O. As the hydrogen is 
replaced progressively by more sterically demanding substit-
uents for example in 5b, in which H is replaced by CH,, the 
mono-chelate ring-opened species is favoured in chloroform 
and an equilibrium exists between the ring-closed and -opened 
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Fig. 2 Plots of the relative amounts of ring-opened complex 
determined from "P NMR peak areas versus pH. (a) Complex 5b. (b) 
Complex 2. The curves correspond to computer best Its and pK values 
of 6.9 and 2. 1, respectively. 
forms in aqueous solution (Fig. 2). In complex 2, where the 
substituent on N has a steric bulk between that of I and 5b, 
it was possible to open the chelate ring only under acidic con-
ditions. In complex 7, where N has two benzyl substituents, the 
ligand was co-ordinated via the phosphorus atoms only. When 
the number of methylene carbon atoms in the backbone of the 
ligand is increased from two to three, together with an increase 
in the steric bulk on nitrogen, as in 9, the di-ring-opened species 
is formed preferentially, chelation being achieved only in the 
absence of chloride. This illustrates the relatively weak nature 
of the platinum-nitrogen interaction within the 6-membered 
chelate rings. 
Chelate ring-opening and -closing of complexes in aqueous 
solution 
The equilibrium between the chelate ring-opened and closed 
forms in aqueous solution as a function of pH and chloride 
concentration was studied by "P NMR spectroscopy. The 
complexes were titrated over a wide pH' range (ca. 3-I1). For 
complexes 2, 3, 5b, 8 and I4a, the pK values were determined 
from computer best fits of plots of the relative amounts of 
the ring-opened and ring-closed species, as determined by the 
integration of "P NMR peaks, versus pH (see Fig. 2). Chelate 
ring-opening is induced by protonation of amino groups. 
The "P NMR data for complex 5b in aqueous solution 
suggest that an equilibrium exists between the ring-opened, 5b, 
and ring-closed, 5a, complexes which is dependent upon pH' 
and chloride concentrations (Scheme 3). A solution of Sb (20 
mM) in D,O was titrated over the pH' range 2-I1. Under acidic 
conditions, the amount of ring-opened species, 5b, increased 
such that by Ca. pH' 5.5 it was the only product present. The "P 
NM  spectrum at pH' 5 (Fig. Ib) thus shows only one set of 
doublets, and the peaks were considerably sharper than at 
higher PHA  due to the absence of exchange. The doublet 
splitting can be assigned to 'J(P APC) coupling of 18 Hz. The 
reaction was reversible. When the pH was reversed, a "P 
NMR spectrum identical to the original one was obtained. A 
plot of the relative amounts of the ring-opened and ring-closed 
species versus pH', is shown in Fig. 2a, and was fitted to a pK 
value of 6.9. Therefore at neutral pH', the two species exist in 
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Fig. 3 Dependence of the amount of ring-opened complex 5c on the 
concentration of NaCl added to complex Sn, cis-(Pt(Me 2N(CH,),PPh 2 -
P,N),](NO 3) 2 (40 mM, pl-1  8.6), as determined from 31 P NMR peak 
areas. 
almost equal amounts. There was no evidence for the opening 
of the second chelate ring even at very low pH (I). 
When Sb was reacted with AgNO 3 , the isolated product was 
the ring-closed bis-chelate complex, 5a. In this case, in the 
absence of chloride, when the pH was lowered by the addition 
of DN03 , it was possible to observe chelate-ring-opening only 
below pH' 2. The 31 P NMR spectrum at pH' 2 showed a singlet 
at (525.5 (PA) with a 'J(PtP A) coupling of 3225 Hz, correspond-
ing to the ring-closed species 5a and a set of peaks assign-
able to the ring-opened species cis-IPt(Me 2N(CH 2)2 PPh2-N,P)-
(0H2)(Me2N(CH 2)1 PPh2-P)]0NO2 (singlet (5 25.3 (P8) and at 
o -1.96 (Pa), for atom labelling see Scheme 3). The V(PtP) 
couplings were 4008 and 3298 Hz which are within the range for 
phosphorus trans to 0 and N, respectively. 31-31 
A titration of Sa with chloride ions (added as NaCI) was 
studied at pH' 8.6 (Fig. 3) in order to determine the chloride 
association constant K, by measuring the relative intensities of 
peaks for the ring-opened and ring-closed species in the 31 P 
NMR spectra. A pH much higher than the pK value was 
chosen so that protonation of the amino group did not influ-
ence the position of the equilibrium. The amount of Sc 
increased steadily with chloride addition (Fig. 3) and at about 
150 mM chloride about 40% of Sc was present. In a separate 
experiment, 320 mM chloride was added to a sample contain-
ing 20 m of 5a which resulted in the formation of a precipi-
tate. The solid and supernatant were separated by centrifuga-
tion. The 3 P NMR of the supernatant showed that ring-opened 
and ring-closed species were present in about equal amounts. 
The 3 P NMR spectrum of the precipitate redissolved in D 20 
was identical to that of 5a, (see above) with 80% of the amount 
present corresponding to the ring-closed form. From the data 
obtained from a titration of 40 mM 5a with up to 180 mM 
chloride an association constant of 4.95 M' was obtained for 
chloride binding to 5a, at pH 8.6 (K, = [5c]I([5a][Clj); 
[CI - ]f = free chloride.). Thus chelate ring-opening and -closing 
can be controlled as a function of both pH' and chloride 
concentration. 
When the pH' of 14a was measured immediately after dis-
solving the complex in D 20, it was found to be alkaline (pH' 
8.6). When the pH' was lowered to 5 one of the chelate rings 
opened to give cis-[Pd(Me2N(CH 2)2 PPh2-N,P)Cl(Me2 NH-
(CH3)2 PPh2-P)] 2 , 14b, as seen by the appearance of two sharp 
peaks at 6 58.9 (PB) and 23.55 (Pt).  A solution of 14a in D 20 
was titrated over the pH' range of 2-9 and afforded a pK value 
of 6.0. 
The 31 P NMR spectrum of complex 2 at pH' 1.2 showed 
doublets at (541.1 (P A) and 6 1.9 () with 'J(PtP) couplings of 
Ht2B 
H125 
Fig. 4 Crystal structure of the ring-closed complex cis-
lPt(H,N(CHPPh,-P,\),]", I, and numbering scheme. 
assigned to 2J(Ac)  coupling of 18 Hz. A pH' titration of the 
complex (20 mM) showed that the chelate ring is opened below 
pH' 3 and afforded a pKvalue of 2.1 (Fig. 2b). 
Complex 3 was sparingly soluble in water, however the P 
NMR spectrum in D,O-ethanol showed the presence of both 
the ring-opened and closed forms and a pH*  titration of a 20 
mM solution of 3 afforded a pK value of 6.3 uncorrected for 
the presence of EtOH. As for complex 14, the switch from ring-
opened to ring-closed forms occurred within a narrow pH* 
range (ca. I), suggesting that protonation of the amino group 
and chloride binding are co-operative. 
When the pH*  of the aqueous solution of 12, [Pd((c.C6H 1 )-
HN(CH2)2 PPh2-N,P) 21Cl2 was lowered, one of the chelate 
rings opened as seen by the appearance of two P  NMR 
doublets at 6 62.9 (P B) and 29.9 (Pa).  These peaks were rela-
tively sharp with a 2J(PBPC)  coupling of 12 Hz. A pH*  titration 
of the complex (20 mM) afforded a pKvalue of 6.0. Above pH' 
7 only the ring-closed form was observed, whereas below pH' 5 
only the ring-opened form was present. 
A gradual opening of the chelate ring was observed when the 
pH' of a solution of 8, [Pt(H 2 N(CH 2) 3 PPh2-N,P)21C12 in D,O 
was lowered, in contrast to the 5-membered ring analogue, 1, 
which remained ring-closed. The P  NMR resonance for 8 
(0 1.88) began to disappear below pH' 6, and was replaced by 
doublets with 0 0.55 (PB) and 4.24 (Ps)  and corresponding 
1J(PtP) couplings of 3625 and 3272 Hz, respectively, and 
2J(PBPc) of 17 Hz. A pH*  titration of the complex (20 mM) 
afforded a pK value of 2.9. 
The above data show that it was not possible to achieve che-
late ring-opening for the 5-membered ring complexes 1 and 10 
even at very low pH conditions. On the other hand it was pos-
sible to ring-open the 6-membered, chelate ring analogue, 8, at 
very low pH. The replacement of one of Me substituents on N 
in 5b by H as in 2 resulted in a dramatic drop in the pK value: 
from 6.9 for Sb to 2.12 for 2 (Fig. 2). This highlights the highly 
acidic conditions required to ring-open complexes with low 
steric requirements for the substituents on N in these amino-
phosphine complexes and the greater stability of 5-membered 
as opposed to a 6-membered chelate rings. 
Crystallography 
The X-ray crystal structures of 1, 2, 8, 9, 1415 and 18 were 
determined and are shown as SHELXTL 2° plots in Figs. 4-9. 
Data collection and refinement parameters, bond distances and 
angles are listed in Tables I and 4, respectively. The complexes 
have square-planar co-ordination geometry with varying 
degrees of distortion. In complexes 1,2,8,9 and 14b, the two 
3770 and 3300 Hz, respectively. The doublet spitting can be phosphino groups have a cis arrangement. 







Fig. 5 (a) Crystal structure of the ring-closed complex cia-
[Pt(Me(H)N(CFI 2)2 PPh2-P 1 N)2] 2 °, 2, with the numbering scheme. (b) In 
the unit cell one [Cl-.l1-Cl] is associated with each complex ion. The 
Cl-H and I-I-Cl distances are 1.631 and 1.610 A, respectively. The two 
anions are connected via a water molecule with a Cl' H distance of 
2.359 A. One of the ortho H atoms of the phenyl rings is also H-bonded 
(CI ... H=2.359A). 
Fig. 7 Crystal structure of the ring-closed complex, cia-
lPt(H 2 N(CH 2) 3PPh 2-N,P) 2 1 ° ', 8, with the numbering scheme. 
(b) 
Fig. 8 Crystal structure of the di-ring-opened complex, cis-
[Pt(Me,N(CH 2) 3 PPh 2-P) 2Cl 2 ) 1  9, with the numbering scheme. 
Fig. 6 Crystal structure of the ring-opened complex cia-
[Pd(Me2N(CH2)5PPh,-N,P)Cl(Me,NH(CH 2)sPPhrp)]', 14b, with the 
numbering scheme. 
In I, cis-(Pt(H 2 N(CH 2) 1 PPh 2-N,P)2]C1 2 , the square-plane 
formed by N(l), N(2), P(l) and P(2), shown a slight deviation 
from planarity (Fig. 4). If we consider N( I )-Pt-P(2) be in one 
plane, then P(l) is out of plane by +0.052 A and N(2) by 
-0.054 A in the opposite direction. The P(l)-Pt-P(2) angle 
102.98° is rather large for a square-planar complex. The steric 
crowding around the phosphorus atoms due to the presence of 
the phenyl rings, appears to cause the opening up of the angle, 
which presumably also results in the reduction of the other 
angles to below 90°, but within the range for five-membered 
Cl 
Fig. 9 Crystal structure of the monochelate complex, 
lPd(Me2N(CH 2)3 PPh,-P.N)C1 2 1, 18, with the numbering scheme. The 
bond angles of the alkyl chain deviate from ideality: (N(4)-C(3)-
C(2) = 116.6(4), C(2)-C( l).-P( I) = 114.4(3) and C(3)-C(2)- 
C(l) = 1l7.2(4)°. 
chelate rings. 14  The trans angles N(l)-Pt-P(l) and N(2)-Pt-
P(2) of 173.1(2) and 172.1(2)*, respectively, also show slight 
distortions from the ideal value. The Pt-N distances are 
relatively long (2.090 A) compared with the literature values, 34 
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Table 4 Summary of selected bond lengths Aj and angles [") for complexes I, 2, 8, 9, 14b and 18 with estimated standard deviations (e.s.d.$) in 
parentheses 
I 	 2 	 8 	 9 	 l4b 	 18 
M=Pt 	M=Pt 	M=Pt 	M=Pt 	M=Pd 	M=Pd 
Bond lengths 
M-P 2.235(2) 2.34(2) 2.2543(11) 2.247(2) 2.2800(13)" 2.224(11) 
2.239(2) 2.34(2) 2.2565(11) 2.251(2) 2.2438(12)° 
M-N 2.090(6) 2.148(8) 2.116(3) 2.172(4) 2.1299(3) 
2.111(5) 2.148(8) 2.129(3) 
M-CI 2.354(3) 2.3721(13) 2.3817(14)' 
2.361(2) 2.292(I2) 
Irons angles 
P-M-N 173.1(2) 173.9(2) 171.67(10) 
172.1(2) 173.9(2) 171.43(10) 176.49(5) 




P-M-P 02.98(6) 99.33(13) 98.16(4) 99.76(9) 98.57(11) 
P-M-N 83,8(2) 84.0(2) 89.60(10) 84.63(12) 92.42(10) 
84.8(2) 84.0(2) 86.69(10) 
N-M-N 88.4(2) 93.2(4) 86.04(13) 
P-M-CI 83.84(9) 87.68(5) 
89.12(9) 85.37(5) 
Cl-M-CI 87.78(9) 90.66(5) 
N-M-CI 91.32(12) 91.26(10) 
traits to Cl. 	trans to N. 	trans to P. 
Table 5 Comparison of [Cl-H-Cl] - parameters 
Species 	 Cl '- Cl/A 	Cl-H-Cl/° 	Method 	Ref. 
[Cl-H-Cu] - 3.100 180 Calcd. 	36 
[Cl-H-C[] - 3.147 180 Exptl. 37 
cis.[Pt(Me(H)N(CH,),PPh,),] 3.2051 152.4 X-ray 
[CI-H--Cl[ 2 '0.5H 2O (2, Fig. 5) 
[K(18-crown.6)][Cl-H-Cll 3.117(1) X-ray 	38 
[Mg( I 8-crown-6)][Cl-H-Cl[, 3.286(l) 161 X-ray 38 
3.331(1) 173 
[(4-Me0C6 H,)(Me)PCI,[[CI-H-Cl[ 3.210(3) 172 X-ray 	39 
[NMe,[[Cl-H-Cl] 3.22 180 40 
[H 2O(l8-crown-6)]lCl-H-Cl] 3.11(1) 168 X-ray 	41 
'This work. 
but not unprecedented.' These distances provide evidence for 
weakening of the Pt-N bond, due to the strong trans influence 
of the tertiary phosphine. The P-Pt bond distances of 2.235 
and 2.239 A are within the expected range.' 4 
The X-ray analysis of 2, showed that the complex has 
crystallographic Ca symmetry and one of the phenyl rings is 
disordered (Fig. 5a). It was formulated as cis-[Pt(Me(H)N. 
(CH,)2PPh,),][Cl-H-Cl],0.5H 2O. One [Cl-H-01 anion is 
associated with each molecule in the unit cell. The Cl-H and 
H-Cl distances are 1.630 and 1.610 A, respectively, with 
Cl-H-Cl of 152.4°. The [Cl-H-d] - anion appears to be 
involved in a network of H-bonding with each molecule in 
the unit cell, and in turn the two anions are connected via a 
water molecule, for which the Cl... H distance is 2.359 A. The 
[Cl-H-Cl] - anion is also H-bonded to one of the ortho H atoms 
of one of the phenyl rings. (C1 H = 2.359 A) (Fig. 5b). The 
anion [Cl-H-Cl] - was first observed in 1909 in the reaction 
HNR,CI + HCI, which resulted in the formation of [HNR,]-
[Cl-H-Cll." The structure of [Cl-H-Cl] - has been deter-
mined using semi-empirical and ab initio methods" as well as 
experimentally,' 7 and its X-ray structure has been determined in 
several salts.'' The parameters for [Cl-H-Cl] - are compared 
with literature values in Table 5. The platinum atom has a 
slightly distorted square-planar co-ordination. If we consider  
the N(4A)-Pt-P(la) to be in one plane, N(4) is out of plane by 
+0.202 A and P(l) by -0.197 A in the opposite direction. The 
Pt-N bond distances of 2.148(8) A are also longer than that 
observed for I which can be attributed to an increase in sleric 
hindrance at N in 2 compared to 1. The Pt-P distances, both 
2.34 A, are again longer than for the other complexes in 
this series. The P( I )-Pt-P(2) angles of 99.3 3° are larger and 
comparable to 1. The P-Pt-N angles of 84.0° are also low, 
presumably related to the large angle of P(l)-Pt-P(2). The trans 
angles N(l)-Pt-P(l) and N(2)-Pt-P(2), both 173.9(2)", also 
show distortions from the ideal value. 
The X-ray crystal structure for complex 8, cis-[Pt(H 2N(CH 2)3 -
PPh2-N,P)2]Cl2 H 2O2CH,NOa (Fig. 7) shows many similarities 
to that of complex 1 (Fig. 4). Again the square-planar geometry 
shows slight deviations from ideal planarity. The P(5A)-Pt-
P(513) angle is increased to 98.16°, due to the steric bulk of the 
phenyl groups, with corresponding reduction of the other 
angles around the platinum. The trans angles P(5A)-Pt-N(lB) 
and P(5B)-Pt-N(lA) are 171.43° and 171.67°, respectively, 
showing slight distortion. The Pt-N bond lengths are further 
increased to 2.12 and 2.13 A due to the trans influence of the 
tertiary phosphines. Again the Pt-P bond lengths, 2.25 and 2.26 
A, are within the expected range. The ligands form 6-membered 
chelate rings and both adopt the chair conformation, although 
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one ring is oriented above the platinum square-plane and the 
other below the plane. 
Complex 9, cis-[Pt(Me 2 N(CH 2)3 PPh2-P)2C12J, crystallised in a 
fully ring-opened form as a CH 2Cl 2 solvate (Fig. 8). The Pt-P 
bond lengths, 2.25 A, show little change from the ring-closed 
structure despite the presence of chloride and not amine ligands 
in the trans position. The Pt-Cl bond lengths, 2.35 A are longer 
than expected due to the high trans influence of the phosphine 
ligands. Despite the removal of strain in the complex due to the 
lack of chelation, the structure shows a similar distortion from 
square-planar geometry. The P(l)-Pt-P(2) angle is increased to 
99.76° and the trans angles, P(1)-Pt-Cl(l) and P(2)-Pt-Cl(2), 
are reduced to 169.84° and 173.610,  respectively. 
Crystals suitable for X-ray analysis of the ring-opened form 
of the Pd(u) complex 14b were grown under acidic conditions 
(pH* ca. 4) in D20 (Fig. 6). Even though the opening of one of 
the chelate rings must have relieved the severe steric Strain along 
the N-Pd bond, the complex still shows distortion from square-
planar geometry, and greater than that observed for 1 and 2. If 
N(1)-Pd-CI atoms are used to define the plane, P(l) is out of 
plane by 0.072 A and P(2) by 0.195 A. The P-Pd-P angle is 
relatively high at 98.57° due to the steric constraint caused by 
the presence of the phenyl rings. However the trans angles, 
N(l)-Pd-P(2) and P(2)-Pd Cl(l) of 176.49 and 173.68°, 
respectively, suggest only minor distortions. The Pd-N bond 
distance of 2.172 A is relatively long, and is the longest M-N 
bond observed in this work, indicative of the weakening of the 
Pd-N bond. The Pd-Cl distance at 2.37 A is as expected for Cl 
trans to phosphorus.42 The two Pd-P distances are relatively 
short 34 comparable with that trans to Cl, 2.28 A, and somewhat 
longer than that trans to N, 2.243 A, due to the relatively larger 
trans influence of Cl compared to N. 
The X-ray analysis of [Pd(Me 2N(CH 2)3PPh2-P,N)Cl 2], 18 
(Fig. 9), shows that the 6-membered ring is highly sterically 
strained. This is indicated by the bond angles of the alkyl chain, 
which show deviations from ideality (116.6(4), 114.4(3) and 
117.2(4)'). This type of ring strain has also been observed for 
the dppp (I ,3-bis(diphenylphosphino)propane) ligand which 
appears to form a significantly strained complex with palladium 
as opposed to the dppe (1,2-bis(diphenylphosphino)ethane) 
ligarsd which has an ideal square-planar geometry with 
maximum interaction between the phosphorus and palladium 
atom. 43 In addition the geometry at palladium in 18 is highly 
distorted from square-planar. The displacement of the P and N 
from the PdCl 2 plane is +0.465 A and -0.357 A for P and N, 
respectively. Similar geometric features have also been observed 
in [Pd(dppp)(bipy)]PF6], where the two phosphorus atoms were 
displaced by -0.33 and +0.50 A.44 For (Pd(dppm)Cl 2] the 
displacements are -0.136 and +0.242 A 41 and for [Pd(dppp)-
Cl2], are -0.053 and +0.312 A. In contrast, the displacements 
observed for 5-membered chelated complexes are relatively 
small: -0.072 and + 0.195 A for 141,, -0.052 and +0.054 A for 
I, and -0.072 and +0.087 A for [Pd(dppe)C] 2) 41 , confirming the 
highly sterically strained nature of the 6-membered chelated 
complex. The two Pd-Cl bond lengths for 18 are different, with 
that trans to P (2.33 A) being somewhat longer than that trans 
to N (2.22 A) due to the larger trans influence of a tertiary 
phosphine relative to that of the amine. The Pd-P bond dis-
tance is relatively short, at 2.22 A and the Pd-N bond distance 
is rather long, at 2.12 A, a common feature for this type 
of complex (Table 4). The P-Pd-P angle at 92.42° shows only 
a minor distortion although, the trans angles N(4)-Pd-Cl(l) 
and P(l)-Pd-Cl(2) of 170.15 and 167.8°, respectively, show a 
deviation from ideality which can be associated with the steric 
strain of the 6-membered chelated complex. 
The X-ray crystallographic studies show that the metal-
nitrogen bond distances for these complexes are relatively long 
and suggest a weakening of the Pt-N bonds, attributable to the 
strong trans influence of the tertiary phosphine. In addition 
changing the substituents at nitrogen from hydrogen to the  
more sterically demanding methyl group, results in the length-
ening of the metal nitrogen bond. 
Conclusions 
The steric bulk of the substituents on nitrogen as well as the 
length of the (CH 2). P-N linker in aminophosphine complexes 
can determine whether the complexes exist in ring-opened or 
closed forms. The aminophosphine complex, cis-[Pt(Me 2 N-
(CH 2)2PPh2-N,P)Cl(Me 2NH(CH2)2PPh 2-P)]Cl, 5b, has been 
shown by 1 H and 31 P solution studies to undergo reversible 
chelate ring-opening reactions in aqueous solution. These 
processes are dependent upon pH and chloride ion concen-
tration. The equilibrium constant for Cl binding to cis-[Pt-
(MC2N(CH 2)2 PPh2-P,N) 21(NO3)2 at pH* 8.6 was determined 
to be 4.95 M, and pH-induced chelate ring-opening of 
cis-[Pt(Me 2 N(CH 2)2 PPh2-P,IV)2]C12 had an associated pK of 
6.9. In contrast, the complexes with less steric bulk on nitrogen 
are more difficult to ring-open, and complexes cis-[Pt(Me-
(H)N(CH2)2PPh2-P,N)2]C12 and cis-[Pt(H2 N(CH 2)3 PPh2-P,til)2]-
Cl2 had associated pK values of 2.1 and 2.9, respectively. X-Ray 
crystallographic studies show that these aminophosphine com-
plexes exhibit square-planar geometries with varying degrees of 
distortion and relatively long metal-nitrogen bond distances. 
Some of the complexes are cytotoxic to cancer cells and may 
be promising new antitumour agents. 12  In chelate-ring-closed 
form they can act as antimitochondrial agents and destroy 
membrane potentials, whereas in the ring-opened form they can 
bind to nucleobases on DNA. 
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